<SEC-DOCUMENT>0001711279-23-000029.txt : 20230508
<SEC-HEADER>0001711279-23-000029.hdr.sgml : 20230508
<ACCEPTANCE-DATETIME>20230508082512
ACCESSION NUMBER:		0001711279-23-000029
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230508
DATE AS OF CHANGE:		20230508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Krystal Biotech, Inc.
		CENTRAL INDEX KEY:			0001711279
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				821080209
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38210
		FILM NUMBER:		23895953

	BUSINESS ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		(412) 586-5830

	MAIL ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>krys-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:451658bd-d88f-4282-9c6a-c1dd52cf3f31,g:9c0f2f52-9e92-4a03-8bd1-6f7b5787d327,d:2bdcf3ebe02d404d9f9330c0d4eecb0d--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:krys="http://www.krystalbio.com/20230331" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>krys-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80L2ZyYWc6OTZlZTRiODQxMmQyNDU3NGEwMWZmZTMwNzFhMmY5MDAvdGFibGU6YmE2YjIxODRhZjdhNGQ5Yzk1YWE5OTQ3MGYxZGFjODYvdGFibGVyYW5nZTpiYTZiMjE4NGFmN2E0ZDljOTVhYTk5NDcwZjFkYWM4Nl8zLTEtMS0xLTUxMzA3_0630ae97-758b-4309-8e54-99e01f9956fe">false</ix:nonNumeric><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80L2ZyYWc6OTZlZTRiODQxMmQyNDU3NGEwMWZmZTMwNzFhMmY5MDAvdGFibGU6YmE2YjIxODRhZjdhNGQ5Yzk1YWE5OTQ3MGYxZGFjODYvdGFibGVyYW5nZTpiYTZiMjE4NGFmN2E0ZDljOTVhYTk5NDcwZjFkYWM4Nl81LTEtMS0xLTUxMzA3_6f90c0a9-e50d-4301-a006-4f16706fb888">2023</ix:nonNumeric><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80L2ZyYWc6OTZlZTRiODQxMmQyNDU3NGEwMWZmZTMwNzFhMmY5MDAvdGFibGU6YmE2YjIxODRhZjdhNGQ5Yzk1YWE5OTQ3MGYxZGFjODYvdGFibGVyYW5nZTpiYTZiMjE4NGFmN2E0ZDljOTVhYTk5NDcwZjFkYWM4Nl82LTEtMS0xLTUxMzA3_75d36a49-2797-483d-8a3d-8501437683df">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80L2ZyYWc6OTZlZTRiODQxMmQyNDU3NGEwMWZmZTMwNzFhMmY5MDAvdGFibGU6YmE2YjIxODRhZjdhNGQ5Yzk1YWE5OTQ3MGYxZGFjODYvdGFibGVyYW5nZTpiYTZiMjE4NGFmN2E0ZDljOTVhYTk5NDcwZjFkYWM4Nl85LTEtMS0xLTUxMzA3_23884cec-4620-4f75-97f2-0d70ff1e01fa">0001711279</ix:nonNumeric><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80L2ZyYWc6OTZlZTRiODQxMmQyNDU3NGEwMWZmZTMwNzFhMmY5MDAvdGFibGU6YmE2YjIxODRhZjdhNGQ5Yzk1YWE5OTQ3MGYxZGFjODYvdGFibGVyYW5nZTpiYTZiMjE4NGFmN2E0ZDljOTVhYTk5NDcwZjFkYWM4Nl8xMC0xLTEtMS01MTMwNw_f2800e32-95f4-40a0-a8f6-ae841cab1315">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="iab062c8a7a8c411fa82f2d7c0deec53b_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTExNQ_1ff19d5b-7ebe-44d5-815e-fa8e50130fbf">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i99bf40e31c9c43caaa925da542ea4133_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTE0Nw_06c5c353-58b3-42d1-85b7-6f88da10a8be">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i91dfabdbc99a482ca88701984073bc51_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTc3_6f3f7115-1588-4f4d-bb1c-32086269f4cb">P4Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="krys-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie832448b6e8a4a0395ec135879c734ce_I20230501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65fbf7b333674008878005497a15d13f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ac3e0fd9317440dac10b07c59703d04_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia96e3d34d40c48289e74f96e776c6ed1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3896475111104dd6abbb477aef133548_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d9b884d4558463fa0d98791f90f9606_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabc9e0eb98364fb3ad07b8cf7150e319_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic94d5fe5213a4f26a3256b3f0bfc26d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5450c8199b9e4fd5afb2a7b09a42d9f0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0494490052724969ad4dda9da8c25266_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b0f3dfb98b42caa153a99313d719d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida72ac9ff53040f28071df8ab44a4388_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1c089ca6dbf4946b9175e1adec58907_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f638a7b209c4dacaa94a230ca55e1ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id70922e6d9374781a321436c00157066_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id41bc98a3a7d4b52bf0e3a53731fb357_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6f630d3e1e44ce5aa3f5e2ff715bbfb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d637ac1bef94cb39b5dba2d17d51f98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia05e2f5705fb414dae7eddeea359d8c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i344d0fb131be4470b723a325e38905bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff9d64d433fc4c8581724468d59dc4ca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcfa5a617a40436f9e9057caaa0a86ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i241ffd0cd8bc4e4f8afe5a3a324b02c1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76bbae0d55ce463db494ea5540773374_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56232f71838b463888f902e03c7adab8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib576e67237ad45acaa64f5f64e381e6f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id93c5ffaa22a4251b0b179d55468758a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>krys:segment</xbrli:measure></xbrli:unit><xbrli:context id="i3d5858b254a74055947c9db86b18c8a3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98497d61c2dc4015859731c29c4a5191_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5a1d7d6d3b45cc86f55259988312d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ad7d5c593e74fa481f25d0584ed5bb3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff57f58cd1564684a2781fa990333e72_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96507c2336ed410dba27455fd3d47784_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab72ff6d793d4c95b00695f6313daf97_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4634ec644b074dc2a73fb4d688425c09_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a98446c7d2a422cb8484c551d8569e1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c577603e2e64c98b5ecf7704120a266_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib56d0e98532345689136cfae336cfbd6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacdb4dc62a9b4428bdc804b7838f7fdc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i254b57e74219457a9976070bb3f01cca_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4bcbb3bbdfb443c9dc1d6277b193724_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93a24294ea254807b3a01f15a488820e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia679ddbe0c9148b596ce5d22d0a1c72d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie55cf1b68f5343cd983d4229a5bf466c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia810a7f2836b4a4c8b9329aa2c255208_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cd9dad418b8488cb10071f2be3a4912_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0bea5cf40f844f38d74969a8559b2c5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199b309fe28245b5b261791cfe807797_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i821aef589ece4731b6e9f4ebc1acba43_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia170328c9e7e4a0ca886658a03a5bf79_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f5f311477c243739da11f1d6cf25133_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e4f7f10a1f943dba2eb0d494342e180_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25bc3c11b7b447f38c5ac9085cb16011_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7dabfb39094405ea129e230c5fea918_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc0dea8cd85c4b10a8ca0270bc96ca37_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db97cf4a1ee43798607ccb440a0c691_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19390a3c5c074f8cb033de62ea4926ba_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i955d93f6b8e8480aac09b577bc03fd18_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a9e54233c0c409fbb144f9054234dc7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3253f0426d1b464d823eff67b81326d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabfee1fcc75f4f5cb247fc8dcaa4469f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd001999a79b40e58c92b5976170c12c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i558055bb178d47cf8d6907260c65860d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848d726cc7ea4e92bb8c216498e171d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708d874019134729a370416147542b1e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if91c8903d66e47ed89c8a8a928e0ad19_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04d0048badcd4c6aa1082f735dda5fa5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fd54f5b9a434b3b9b37bebfcedd8570_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54381d9b7697447d972984381f5addb6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe9d0765d4040a88c16e531654af652_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dad77b16170425f951687a001a58cf7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09632b1d13f447d83cab24d09f19673_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36bffbb608004cf7bd1c29662284954f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1642cf0b875e42d18be7877570ce84d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id90668d113b34bf0b03c32cdd534454d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26fb1563e4c745bcb1ecf87c332f3971_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b41653db9f6419aab13fd18aaffc538_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e884919c2f4f82a2242d01a6e29dba_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63f3f336a5e844e5b596e41d4095f2d6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3336d8df96f44c03b0edde5a7b3f3f1a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e13fb41138141a8a45f22e1363c6694_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95624b73ce524801a03f62c6d6488c4d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70f55b22e3c64c36aa9d32e22506ddb0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib70c320c8793401f8ad427840ed747f4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7c0541a8fd74c0fab5d9a8c2a1fb295_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1679847f2284f818043b46f19f6d0fe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9eb878f8f5476899e4bdc1684dbc88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc7771852e944942a97a47f105d3ddb4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1402d218b7f411a89c2d0a991370111_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c4f65d06694451b7c17b1d48fc362e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc58ce8deb464b0999c8eba8a23d5170_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c8785f3fae3400a93aa066e59ff0830_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i788e335dd01542c6877956cecd45ef64_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa1cfbf80d374c378d2f9b338ebb5deb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77d7d7ecd78845e5bd5596242784b33d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc4c065296114490bb18d3287e10eee4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d538d178644369ac955f83b6d3c6cb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ccbd4c24004f7c9a76c78c77580c61_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38665521367949c5a5b7b6f4a45a6367_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>krys:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i3a63fc072ee84250a08db24153192cce_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac262c9c6f0f403486081e497b2c7281_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4243169cc3fd4a5b9a86b7ea453f05f5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34cbc871f0d741f2a78e2f78568df717_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa962a4885f645e19feb14d38de37c30_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i450e68ee6678498fa0a8d69ede89d91d_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id69a8a353b3642439f10c5a61f8f2f64_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6d80521c426d495a9687ea96ad9ca399_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4eb18cd516042b7aab83e20049963ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i204fc13707f54377a36f6695aa4c916f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if019f17b70c645eab7cf5f73638d1837_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i514f2cde4cee40baaa8b763c557430ae_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:A2017IPOStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab062c8a7a8c411fa82f2d7c0deec53b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99bf40e31c9c43caaa925da542ea4133_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2264b9c9914e3abaee4de6745b7cf8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id23450f1c26144fca1df4aefaa3a147d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i228ec404a39040e2a3b2cf301e832687_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedcfd366e93c4c2d8c5b5452e2b1caf3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id58086907cf445e3b68de6647460560d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib13481cdbf0441e49f4f32596d741801_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2350fa2df2594c7d83ae40618dfdbd3f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65adaea3f9a54843afd31a5010fe66a3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f30b015d0b54cef9f1f1fe7e1c87a6b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91dfabdbc99a482ca88701984073bc51_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f8fe089ab942b2b54a2474e590165e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i645b28bb0a98487cb270051dfc6fdcfe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ef87a5ae2a4962839a23c59b1310dc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc7538673d38443ba7514e523de7d067_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if52d01079bea47b58f76c834f2bd69aa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef73c4961e74f54a77c41e6d1e60853_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af32a972cdb4a749407af929c2d1837_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide792579d6fa48f0b86d34c66b1032f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfcec0e0e32c41ff965b11623a8537b6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b071d986514acea476f82fe822eeb2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67805b5822e040868da524c3ac650689_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib38669f3d3714bb9a64a611f418227d2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8865efa296147f4b6d4959a17d55e59_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b2e6b1732847ebb483c440b3b816ea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bce8d3bcf1140e8aceb74a97f62d71a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8817887d7f81412584905713f1293a84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0633520e282645f49e4915cae45e1e31_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a5c357849b34fb4847ad068877525ca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447050dc5b89452bb373864b41c4e5ab_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib03c89f358de41aba14e7922b0f06df8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_1"></div><div style="min-height:27pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDcw_27cfe17b-2453-44e5-8139-4fb43befdd3b">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6OTA1YmU5ZDJmOGQ0NDAwMmI2NjAyNjdiMGE2MDAxMWMvdGFibGVyYW5nZTo5MDViZTlkMmY4ZDQ0MDAyYjY2MDI2N2IwYTYwMDExY18wLTAtMS0xLTUxMzA3_bb465fa9-9b0c-4023-ba0e-2754ceb1c56c">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDI_eb354631-0132-43f6-ae6a-22f156abaf2c">March&#160;31, 2023</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6YWY3ZmRiMzIzNTdjNGM5MjliNGY1NjJkYTkzZjE4YmYvdGFibGVyYW5nZTphZjdmZGIzMjM1N2M0YzkyOWI0ZjU2MmRhOTNmMThiZl8wLTAtMS0xLTUxMzA3_12eb106f-464a-4cc7-9ac1-cd7b0cd79d25">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDcx_8bc12d30-ab75-4b7e-a780-5c840593a039">001-38210</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDYy_0a43febc-4f16-44d1-baa1-7f9612fe3797">Krystal Biotech, Inc.</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-align:center;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6Yzg4MDlhYWNjOTgwNGI3NDg1ZTA0OGVmN2JjNTFlODUvdGFibGVyYW5nZTpjODgwOWFhY2M5ODA0Yjc0ODVlMDQ4ZWY3YmM1MWU4NV8wLTAtMS0xLTUxMzA3_c3da81b3-18a1-4d3c-bb32-f71dd65554ab">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6Yzg4MDlhYWNjOTgwNGI3NDg1ZTA0OGVmN2JjNTFlODUvdGFibGVyYW5nZTpjODgwOWFhY2M5ODA0Yjc0ODVlMDQ4ZWY3YmM1MWU4NV8wLTItMS0xLTUxMzA3_a02e247b-9593-4d31-882a-226420c6809e">82-1080209</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDYz_b383172f-e0b6-4ebe-8b31-b051d1c1e05e">2100 Wharton Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDU4_1bc9069a-1248-4c33-91e8-b73d30a2174c">Suite 701</ix:nonNumeric></span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDcy_7a7d66db-13d5-4de8-9185-ad92cbcc55ce">Pittsburgh</ix:nonNumeric>, <ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDcz_0f6100bb-fc72-453f-b251-aec29e74e6fb">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl81OTk_86439a48-4970-411f-af0e-2e22d31d766d">15203</ix:nonNumeric></span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDc0_30f5cc36-269e-47bd-aa7a-0774f099dc24">412</ix:nonNumeric>) <ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDU5_06f933a5-dc34-42cf-87da-233af33ffc92">586-5830</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6N2FlYjBhYjM5ZWY5NDVjNWJjNGRkZGUwMmM3MjkyZGUvdGFibGVyYW5nZTo3YWViMGFiMzllZjk0NWM1YmM0ZGRkZTAyYzcyOTJkZV8xLTAtMS0xLTUxMzA3_a45bcd25-a58d-4597-9b12-4eaf8ae15fa2">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6N2FlYjBhYjM5ZWY5NDVjNWJjNGRkZGUwMmM3MjkyZGUvdGFibGVyYW5nZTo3YWViMGFiMzllZjk0NWM1YmM0ZGRkZTAyYzcyOTJkZV8xLTEtMS0xLTUxMzA3_2751ea7c-9180-472f-8101-032e56575948">KRYS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6N2FlYjBhYjM5ZWY5NDVjNWJjNGRkZGUwMmM3MjkyZGUvdGFibGVyYW5nZTo3YWViMGFiMzllZjk0NWM1YmM0ZGRkZTAyYzcyOTJkZV8xLTItMS0xLTUxMzA3L3RleHRyZWdpb246ZmQ1NWZhNmY4MjhiNGIyMGE0NjkyYzhkNDY5M2I3NDdfNA_00db8dd3-a29e-45f4-87b0-ec3828ac38fa">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     <ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDY1_a0da9f0b-7c25-4b39-9d0b-705066e128fd">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDY2_c76f9aa0-555a-44e2-8323-de5f4f9f3e47">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6MWRmMDI1NWM1ZGM1NGZkZTkxMDAwYThjM2EzNDM1NTAvdGFibGVyYW5nZToxZGYwMjU1YzVkYzU0ZmRlOTEwMDBhOGMzYTM0MzU1MF8wLTAtMS0xLTUxMzA3_21cf53b9-b808-4dc9-89a1-28b66182c8c0">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6MWRmMDI1NWM1ZGM1NGZkZTkxMDAwYThjM2EzNDM1NTAvdGFibGVyYW5nZToxZGYwMjU1YzVkYzU0ZmRlOTEwMDBhOGMzYTM0MzU1MF8xLTYtMS0xLTUxMzA3_faefbae9-e215-4911-8a40-3af5579ab677">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;&#160;&#160;            </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDYw_35808663-5ebb-4af4-a0d5-062377101ac9">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDYx_d1314b17-62fc-4882-a6ff-6f2b099cc74d">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of May&#160;1, 2023, there were <ix:nonFraction unitRef="shares" contextRef="ie832448b6e8a4a0395ec135879c734ce_I20230501" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yMzkw_2ec91c25-1832-4610-8016-f0956b483135">25,799,738</ix:nonFraction> shares of the registrant&#8217;s common stock issued and outstanding.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_16">Condensed Consolidated Balance Sheets as of </a>March&#160;31, 2023<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_16"> and </a>December&#160;31, 2022 (unaudited)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the </a>Three<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_19"> Months Ended </a>March&#160;31, 2023<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_19"> and </a>2022 (unaudited)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_22">Condensed Consolidated Statements of Stockholders&#8217; Equity for the </a>Three<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_22"> Months Ended </a>March&#160;31, 2023<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_22"> and </a>2022 (unaudited)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_25">Condensed Consolidated Statements of Cash Flows for the </a>Three Months Ended<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_25"> </a>March&#160;31, 2023<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_25">  and </a>2022 (unaudited)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_28">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_58">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_58">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_58">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_73">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_73">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_73">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_76">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_76">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_79">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_82">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_82">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_85">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_85">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_88">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_88">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_88">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_91">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_91">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_91">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_94">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_94">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_94">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_97">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_97">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_97">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_100">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_100">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_100">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_103">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2bdcf3ebe02d404d9f9330c0d4eecb0d_103">34</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_16"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNC0xLTEtMS01MTMwNw_57dc8e87-ae08-47bd-be1c-bb7690fa9e81">140,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNC0zLTEtMS01MTMwNw_c51913db-e3a2-4ca3-9300-2a0c82600ef1">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNS0xLTEtMS01MTMwNw_a87e3408-abbb-493a-9b2f-6cb84380085d">209,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNS0zLTEtMS01MTMwNw_d3b8313b-163a-4ee3-82d8-8e3a685b9961">217,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNi0xLTEtMS01MTMwNw_29e01e24-1efd-465b-9b4e-3936e9e69aaa">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNi0zLTEtMS01MTMwNw_745950ed-b600-4f06-ae56-0c21e3354a58">4,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNy0xLTEtMS01MTMwNw_da0a1302-7131-47ec-8605-209900f6176a">355,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNy0zLTEtMS01MTMwNw_27db1d29-bd57-49b0-943c-4d6c8a91637a">383,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfOC0xLTEtMS01MTMwNw_981cc80c-0fc5-4b8f-8ee1-ebee7e6833ef">163,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfOC0zLTEtMS01MTMwNw_e257d66f-18be-4ecb-a9e5-38f328fd4358">161,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfOS0xLTEtMS01MTMwNw_dcf7ea40-206f-4582-8399-afc51fffea15">5,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfOS0zLTEtMS01MTMwNw_770bde68-7319-4858-bfaf-77bd6000d7c8">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTAtMS0xLTEtNTEzMDc_aa471eef-4f4f-40a8-b832-bf5aef90d859">7,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTAtMy0xLTEtNTEzMDc_bfbe311b-8a84-4b80-952e-d6ce2568f69f">8,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTEtMS0xLTEtNTEzMDc_d6a6bf34-fe10-4a0f-9f77-3b8cd5fb7761">402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTEtMy0xLTEtNTEzMDc_70344ef0-b5d0-44f8-841d-63cdce9be4d3">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTItMS0xLTEtNTEzMDc_7b895697-b3aa-4f0a-a2c1-c0235a34a6e3">531,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTItMy0xLTEtNTEzMDc_ff0f1164-0445-47d5-adb0-60e6d2a99513">558,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTUtMS0xLTEtNTEzMDc_69503879-bf8f-4310-b185-6d9af579bb11">4,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTUtMy0xLTEtNTEzMDc_b2ea3b35-4464-408a-9999-5a262684ad43">3,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTYtMS0xLTEtNTEzMDc_5b3e48e0-0d7b-4b96-b8ad-9ca89f489530">1,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTYtMy0xLTEtNTEzMDc_a8a04e94-471d-409d-a720-9dd78beca57f">1,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTctMS0xLTEtNTEzMDc_bbebbbc4-7930-41e1-a50c-417eaf55c674">29,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTctMy0xLTEtNTEzMDc_d9ccbce6-64cd-426c-8bd3-f5addf12ff20">23,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTktMS0xLTEtNTEzMDc_e0a3f95c-899e-400b-85b1-8dced13e7649">35,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTktMy0xLTEtNTEzMDc_3a513b01-5045-4289-b274-29d6e499b938">28,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjAtMS0xLTEtNTEzMDc_8c4bd913-a9a2-4e45-bdda-ea9c0e20439c">7,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjAtMy0xLTEtNTEzMDc_83635f99-42fa-478b-9c23-4000c297a4a5">7,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjEtMS0xLTEtNTEzMDc_618cf14b-17c1-4ab1-8a7b-ac9c82c9ca56">42,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjEtMy0xLTEtNTEzMDc_46bb6374-4bd3-4e2b-b8cd-294e4d2d1a4e">36,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjItMS0xLTEtNTEzMDc_943bde5c-7a3c-4ae7-bd3a-e0195053b442"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjItMy0xLTEtNTEzMDc_4f199416-008f-4d56-9b80-d09738d43c17"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8xOA_3855e2cf-c90f-4744-9d6f-9c4564769ba9"><ix:nonFraction unitRef="usdPerShare" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8xOA_d1b21de7-0312-496d-808a-9d389c04df39">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8zMg_ca57cd85-654f-4a5b-a581-e5f8c0912ac9"><ix:nonFraction unitRef="shares" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8zMg_eab650f5-ae4d-4b3b-88b8-e903e6fea51a">80,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV82Nw_2c5518b8-82de-4258-a2f3-e8e4647d2727"><ix:nonFraction unitRef="shares" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV82Nw_b95f7f58-d99e-447e-8596-367f022b9956">25,796,213</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023; and <ix:nonFraction unitRef="shares" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8xMTE_0493a3ab-2ec3-4a9c-8ac0-76560b24414d"><ix:nonFraction unitRef="shares" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8xMTE_759d8ef2-31c4-4a74-9870-12aa18173ef0">25,763,743</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMS0xLTEtNTEzMDc_066922ee-2d61-4396-95fa-93a278660586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMy0xLTEtNTEzMDc_4795b4a7-ac39-47f5-855b-af514e61769a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjYtMS0xLTEtNTEzMDc_34c5b21d-9e7a-400c-aadf-5f3d6fbfacc5">815,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjYtMy0xLTEtNTEzMDc_8df3ce49-2498-4ed1-8abb-18cd1c7c4c9e">803,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjctMS0xLTEtNTEzMDc_71831431-037f-469a-8e0c-09bbfad44975">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjctMy0xLTEtNTEzMDc_5a5eb667-7d5b-456a-a745-78fddff40a53">728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjgtMS0xLTEtNTEzMDc_5a226711-6850-45cb-9244-5f1745142b88">326,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjgtMy0xLTEtNTEzMDc_aa4566ae-61ba-461b-afc7-22ad06538e06">280,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjktMS0xLTEtNTEzMDc_15e8d3a0-e699-4fff-99ad-ae1ce1de193e">489,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjktMy0xLTEtNTEzMDc_32448fbd-d682-4355-afff-9717619c1815">522,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMzAtMS0xLTEtNTEzMDc_30d43000-8fab-428b-ba55-0bf82fd809a3">531,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMzAtMy0xLTEtNTEzMDc_3b828344-3517-4b60-a0c9-e7e7ba440010">558,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMy0xLTEtMS01MTMwNw_da25850e-a37e-4a49-9995-ad0c80ef67a7">12,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMy0zLTEtMS01MTMwNw_78f295f4-325d-476d-a146-9c4ba5bdb134">9,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNC0xLTEtMS01MTMwNw_52317d78-02ad-497e-b19c-58086ff715a2">24,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNC0zLTEtMS01MTMwNw_1446b987-2c3b-47cc-8218-4c351624bed3">15,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNS0xLTEtMS01MTMwNw_78eb8645-a9a2-45b2-aacf-f549f73f67fd">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNS0zLTEtMS01MTMwNw_7907f6f3-9025-4f5b-acb0-87ad42c120ce">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNi0xLTEtMS01MTMwNw_9177abcb-8a41-42a8-ab66-e5e24eaee44c">48,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNi0zLTEtMS01MTMwNw_cdf69cc7-c42e-42d9-a574-8b64da4e9f97">50,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNy0xLTEtMS01MTMwNw_68b4a24e-f6d3-42fe-a71f-b0f86f701fae">48,823</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNy0zLTEtMS01MTMwNw_7f13bd2d-a538-42bc-9844-7b14ce817c3a">50,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfOS0xLTEtMS01MTMwNw_a303a687-df91-45e8-b0d6-a029305275af">3,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfOS0zLTEtMS01MTMwNw_b09a17c6-86c2-4c6e-8c13-c070028b0af2">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTEtMS0xLTEtNTEzMDc_d36b2a9a-3231-44fb-a502-c1cc3619127c">45,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTEtMy0xLTEtNTEzMDc_384e3bc4-5b89-428e-8b46-5707eae361e8">49,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale securities and currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTItMS0xLTEtNTEzMDc_ca871dcc-0bdd-47f8-9adc-841a8db30297">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTItMy0xLTEtNTEzMDc_0826f4b0-031b-4a14-9ace-1e39b17dc00b">1,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTMtMS0xLTEtNTEzMDc_83c7fa04-0742-486c-8cfe-bf9f82ee6594">44,723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTMtMy0xLTEtNTEzMDc_a8eb94df-bf47-4ccb-af28-597431da0253">50,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share:<br/>&#160;&#160; Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTUtMS0xLTEtNTEzMDc_2263bcd1-914b-4bbe-9a3f-972377552aa2"><ix:nonFraction unitRef="usdPerShare" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTUtMS0xLTEtNTEzMDc_f9e646be-8de7-45b2-9cc7-00cfba285036">1.76</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTUtMy0xLTEtNTEzMDc_6f69f59c-f452-4f98-8e89-c52ae8d7a4d6"><ix:nonFraction unitRef="usdPerShare" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTUtMy0xLTEtNTEzMDc_9fc88a79-bc67-475b-86f3-a2a668972fd8">1.99</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:<br/>&#160;&#160; Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTctMS0xLTEtNTEzMDc_36622f4f-7e72-42f8-bfe6-b4eae7d249d8"><ix:nonFraction unitRef="shares" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTctMS0xLTEtNTEzMDc_7dbae351-fed3-4e71-9bd4-e7b6722b5752">25,712,220</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTctMy0xLTEtNTEzMDc_67cacb9a-ca46-4ae3-9c56-b357b5f9f6c1"><ix:nonFraction unitRef="shares" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTctMy0xLTEtNTEzMDc_f95a6ee1-67d9-4c28-9367-ed872d3ea722">25,114,453</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:2pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.943%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at January 1, 2023</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65fbf7b333674008878005497a15d13f_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy0xLTEtMS01MTMwNw_40ee573d-8193-487f-8e28-6dca4fde676f">25,763,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65fbf7b333674008878005497a15d13f_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy0zLTEtMS01MTMwNw_d757c2cf-98a4-4011-a11e-db1a481900ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac3e0fd9317440dac10b07c59703d04_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy01LTEtMS01MTMwNw_fa178cd5-7132-4686-a1b4-9ff04cacc1ae">803,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia96e3d34d40c48289e74f96e776c6ed1_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy03LTEtMS01MTMwNw_54376fdf-8c0b-436d-8c23-76adadc67e64">728</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3896475111104dd6abbb477aef133548_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy05LTEtMS01MTMwNw_609332bc-92c8-417f-89df-7ab6315dfd45">280,759</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy0xMS0xLTEtNTEzMDc_4e10e79d-ce54-427d-909c-111b4f9ddb01">522,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d9b884d4558463fa0d98791f90f9606_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNC0xLTEtMS01MTMwNw_c4923ded-c6b2-4c1a-891d-760e77d0755a">42,021</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc9e0eb98364fb3ad07b8cf7150e319_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNC01LTEtMS01MTMwNw_5787f89b-946b-4c31-8f37-14e63b04fba0">2,208</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNC0xMS0xLTEtNTEzMDc_3d002a05-ff6c-4a5c-95ad-22a9c6918ea8">2,208</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares surrendered for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0d9b884d4558463fa0d98791f90f9606_D20230101-20230331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNS0xLTEtMS01MTMwNw_c583a5a8-efc5-4d15-aba0-5703272e79b7">9,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabc9e0eb98364fb3ad07b8cf7150e319_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNS01LTEtMS01MTMwNw_e31a4688-4a45-431f-b67c-1abc5be8f507">749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNS0xMS0xLTEtNTEzMDc_d6060089-dcc0-4bc8-88e6-c7291601b1ed">749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc9e0eb98364fb3ad07b8cf7150e319_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNi01LTEtMS01MTMwNw_b2cac571-0708-4820-b679-ba455017e146">10,599</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNi0xMS0xLTEtNTEzMDc_b135efcc-5b48-4975-88bc-da4051bb3d6c">10,599</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on investments and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94d5fe5213a4f26a3256b3f0bfc26d1_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNy03LTEtMS01MTMwNw_878b2486-e791-49a4-bbb6-a7391f2ba8e7">574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNy0xMS0xLTEtNTEzMDc_ac41ab49-d388-454a-abfb-6467b6647e29">574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5450c8199b9e4fd5afb2a7b09a42d9f0_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOC05LTEtMS01MTMwNw_a1d45122-e4fb-45c8-b2d2-eabf1af1fb48">45,297</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOC0xMS0xLTEtNTEzMDc_0d3d6c96-0c54-4eb7-88bf-b5334804c960">45,297</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0494490052724969ad4dda9da8c25266_I20230331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS0xLTEtMS01MTMwNw_5aadbd94-1a6a-4902-b43c-d27ef2b32135">25,796,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0494490052724969ad4dda9da8c25266_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS0zLTEtMS01MTMwNw_60bbd574-04b0-40c9-8f98-e4cf32864468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b0f3dfb98b42caa153a99313d719d9_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS01LTEtMS01MTMwNw_724bbb81-6e85-4c41-993d-13d89b4f977b">815,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida72ac9ff53040f28071df8ab44a4388_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS03LTEtMS01MTMwNw_86880be3-5d7e-45d0-91ff-78284bfdb5b0">154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1c089ca6dbf4946b9175e1adec58907_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS05LTEtMS01MTMwNw_9ad1f215-a044-4497-947c-06a017c77ab3">326,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS0xMS0xLTEtNTEzMDc_32be236f-43b4-4224-bfce-dba75d130e4f">489,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.943%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f638a7b209c4dacaa94a230ca55e1ce_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy0xLTEtMS01MTMwNw_f6165fe0-8f56-4bff-819d-6460ac9ed3f7">25,207,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f638a7b209c4dacaa94a230ca55e1ce_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy0zLTEtMS01MTMwNw_7d0825d7-42ef-47bc-a254-94a57667cd47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70922e6d9374781a321436c00157066_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy01LTEtMS01MTMwNw_5c365ba7-3fcb-4446-a5b9-00d466644a30">734,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id41bc98a3a7d4b52bf0e3a53731fb357_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy03LTEtMS01MTMwNw_e7c93519-45ec-494b-a478-9675c136583f">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f630d3e1e44ce5aa3f5e2ff715bbfb_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy05LTEtMS01MTMwNw_a5a29472-18a7-40a0-8943-9beb39d1360f">140,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d637ac1bef94cb39b5dba2d17d51f98_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy0xMS0xLTEtNTEzMDc_438a8703-d51d-4ff5-a802-a1e27973407f">593,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia05e2f5705fb414dae7eddeea359d8c8_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNC0xLTEtMS01MTMwNw_41480cbe-afa7-48c7-9153-1d607b1e488f">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344d0fb131be4470b723a325e38905bf_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNC01LTEtMS01MTMwNw_de4f8fb1-b5cb-4f04-a489-23a02f1e34a3">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNC0xMS0xLTEtNTEzMDc_0060b719-c276-40fe-be84-b029b0d4e10f">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares surrendered for taxes and forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia05e2f5705fb414dae7eddeea359d8c8_D20220101-20220331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNS0xLTEtMS03NTQ3MQ_e88b9a61-ca99-4a27-8265-d57136d77ee4">10,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i344d0fb131be4470b723a325e38905bf_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNS01LTEtMS03NTQ2NQ_92d24094-c730-4e34-8529-16d8b240039c">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNS0xMS0xLTEtNzU0NzE_1d020ff1-f520-4b96-9793-728489428632">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344d0fb131be4470b723a325e38905bf_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNS01LTEtMS01MTMwNw_601d80b7-da62-46f3-92bd-1ad388662231">6,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNS0xMS0xLTEtNTEzMDc_1e6ce29d-fee8-4996-9bbf-a3d6be52d82e">6,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (loss) on investments and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff9d64d433fc4c8581724468d59dc4ca_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNi03LTEtMS01MTMwNw_b1d97e39-7aed-47c1-bfea-47adb94f8245">1,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNi0xMS0xLTEtNTEzMDc_0a5e9076-5d19-40df-b67c-a7062eb6b534">1,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcfa5a617a40436f9e9057caaa0a86ab_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNy05LTEtMS01MTMwNw_19338bbd-c1b3-4d59-ae3f-12c19d3d4e65">49,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNy0xMS0xLTEtNTEzMDc_b304421f-95bc-4989-b056-c5b5d4aab986">49,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i241ffd0cd8bc4e4f8afe5a3a324b02c1_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC0xLTEtMS01MTMwNw_1a9ea3e9-a652-4a68-a5cd-398bb0649efc">25,199,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i241ffd0cd8bc4e4f8afe5a3a324b02c1_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC0zLTEtMS01MTMwNw_059bf86f-8dbb-4c53-b4a8-ea343891fefd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76bbae0d55ce463db494ea5540773374_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC01LTEtMS01MTMwNw_805d8169-c0c0-4e67-813f-b63d2026021c">740,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56232f71838b463888f902e03c7adab8_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC03LTEtMS01MTMwNw_983e5ec0-5409-444f-b56c-ca1afbef2f14">1,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib576e67237ad45acaa64f5f64e381e6f_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC05LTEtMS01MTMwNw_bbde1857-357b-47ca-887d-a9b84acd5709">190,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93c5ffaa22a4251b0b179d55468758a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC0xMS0xLTEtNTEzMDc_c3c8461d-45a4-4313-8029-ee17d2ae64a7">548,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:12pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMy0xLTEtMS01MTMwNw_f2bb617e-730d-4c22-9844-83133453ccdc">45,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMy0zLTEtMS01MTMwNw_3c3dc8ab-1b10-4e31-98d7-90312d99e847">49,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNS0xLTEtMS01MTMwNw_70da3dd4-0492-41ba-8b08-988079935d9d">705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNS0zLTEtMS01MTMwNw_a64095e4-e944-422a-8b41-99ac1bcebce4">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNi0xLTEtMS01MTMwNw_36408d0a-1fdc-44ad-bc2e-6a8e1f914e72">10,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNi0zLTEtMS01MTMwNw_5f0c2550-03bc-4d5b-9158-d51228c4b8c7">6,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTAtMS0xLTEtNTEzMDc_0a77ca16-dec1-4fab-a2e8-fa08b05c6eac">605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTAtMy0xLTEtNTEzMDc_efc6e60c-ffbe-4a8e-aed4-32ae03cbd5c8">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTItMS0xLTEtNTEzMDc_604cd620-e13f-4f8e-9fb8-968150aecdfb">327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTItMy0xLTEtNTEzMDc_868cf330-54ae-4d7b-8535-917308dd7967">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTQtMS0xLTEtNTEzMDc_d4f08d96-e0a8-4ae3-a2e4-98a0f8a3ccae">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTQtMy0xLTEtNTEzMDc_8e465cce-84f7-4f70-be04-60f36f0cb90b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTUtMS0xLTEtNTEzMDc_7eae9a68-c0b1-4946-9774-be240492012d">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTUtMy0xLTEtNTEzMDc_21f1826a-09fe-443a-b60f-0f8e77ef462d">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTYtMS0xLTEtNTEzMDc_dec49bc0-6d35-4ec5-a494-353774f5f005">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTYtMy0xLTEtNTEzMDc_d0fa41e7-3029-4ff9-b20f-955e62651923">554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTctMS0xLTEtNTEzMDc_2d822262-d0f8-4888-832f-2addcb339f57">3,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTctMy0xLTEtNTEzMDc_a66581e0-a786-4689-b065-70e09df55390">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTgtMS0xLTEtNTEzMDc_411c1c98-0913-49f2-acfe-6b610f866f8e">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTgtMy0xLTEtNTEzMDc_4da5d988-1e45-45e6-85a3-55609e5d5e6f">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTktMS0xLTEtNTEzMDc_5ea383ca-3189-42cd-89a2-f74e4c4c174a">26,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTktMy0xLTEtNTEzMDc_7181c2c1-9986-4f10-a452-3f7f3019c6f5"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTktMy0xLTEtNTEzMDc_bb1f5e30-bac0-44e7-b9ba-370f8533aedf">15,493</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjItMS0xLTEtNTEzMDc_2cd3e256-dc2f-497e-b321-61fa0680e326">5,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjItMy0xLTEtNTEzMDc_f44aa005-ea36-43df-9c36-6b8157e1c430">17,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjMtMS0xLTEtNTEzMDc_7f0e3178-e2c7-4578-9423-b491e88e734f">145,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjMtMy0xLTEtNTEzMDc_10d265c0-45db-4e30-8bbc-2e626044379e">62,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjQtMS0xLTEtNTEzMDc_7e3b5d5c-69ac-402d-9908-269402eafadd">154,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjQtMy0xLTEtNTEzMDc_9e288101-1bf4-4dcc-8579-8d81b3327b32">24,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjYtMS0xLTEtNTEzMDc_65973937-5dbd-4579-8099-ad3f0b8a02f8">3,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjYtMy0xLTEtNTEzMDc_786c15c7-242d-4c46-8d9d-1ad5b6cc9b67">55,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjktMS0xLTEtNTEzMDc_3eb83b1d-a2b8-42e3-9046-d25a6d3ab549">2,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjktMy0xLTEtNTEzMDc_6468b43d-16c9-4802-926e-20fc12efae8b">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to settlement of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzAtMS0xLTEtNTEzMDc_58f29c6f-25d2-42f3-9da6-f67a4ce5f0e9">749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzAtMy0xLTEtNTEzMDc_7ca83459-009d-4366-a11e-68f72a441ab1">649</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzItMS0xLTEtNTEzMDc_2d57e89a-7553-4751-a695-22c291295d72">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzItMy0xLTEtNTEzMDc_1e6c2c0b-3d36-4e85-9085-fe24a3d7a0a8">542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzQtMS0xLTEtODEwNzc_636c7f34-ed34-4c0d-a51b-86e7c2f5e1f3">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzQtMy0xLTEtODE4NjM_25189e8f-b88c-4778-af83-b1adf95287e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzQtMS0xLTEtNTEzMDc_2079312a-fd70-4087-adb3-c138c080bcdf">21,155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzQtMy0xLTEtNTEzMDc_11f089f8-8904-41c0-8094-97d5ed9f0e5b">71,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzYtMS0xLTEtNTEzMDc_8e6f1a0f-2689-4139-89d5-7a2ce8fd5d18">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d637ac1bef94cb39b5dba2d17d51f98_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzYtMy0xLTEtNTEzMDc_7b6d3afa-bd7e-45f0-9abe-9fc1cdf71bf2">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzctMS0xLTEtNTEzMDc_6cd1ea02-b178-4ad1-b5ef-03b84d74a817">140,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93c5ffaa22a4251b0b179d55468758a_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzctMy0xLTEtNTEzMDc_70d45dad-c789-4fd5-8786-0f027532c13e">269,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNDAtMS0xLTEtNTEzMDc_ccd98aeb-e060-42e2-9447-e67c826171b9">11,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNDAtMy0xLTEtNTEzMDc_1126a1a9-0f63-4f92-b804-b91790cda07e">14,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial recognition of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNDMtMS0xLTEtNzc2Njc_7e03f979-0ac8-44e9-bbeb-0d1279156fbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNDMtMy0xLTEtNzc2Njc_04055a3a-5e8b-4d19-a095-9ae730936978">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zMS9mcmFnOjljZjc0MTdmZDdlMDQzOGNhZmRkYWM3NTcyNTY5YTE5L3RleHRyZWdpb246OWNmNzQxN2ZkN2UwNDM4Y2FmZGRhYzc1NzI1NjlhMTlfMjcxNQ_a31cbe2e-7943-4960-862d-19f10539fffe" continuedAt="i4297a6c1a8df4ed8bc143ef7bff80b89" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i4297a6c1a8df4ed8bc143ef7bff80b89" continuedAt="ia58148b1f08a468c915c1789747f11fa"><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations in April 2016. In March 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. In June 2018, the Company incorporated a wholly-owned subsidiary in Australia for the purpose of undertaking preclinical and clinical studies in Australia. In April 2019, the Company incorporated Jeune Aesthetics Inc ("Jeune Aesthetics"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. In January 2022, August 2022, and December 2022, the Company incorporated wholly-owned subsidiaries in Switzerland, Netherlands, and France, respectively, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's product pipeline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale Current Good Manufacturing Practices ("CGMP") manufacturing capabilities.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zMS9mcmFnOjljZjc0MTdmZDdlMDQzOGNhZmRkYWM3NTcyNTY5YTE5L3RleHRyZWdpb246OWNmNzQxN2ZkN2UwNDM4Y2FmZGRhYzc1NzI1NjlhMTlfMTIwMA_7d1c2db0-f216-4ec0-ae01-838d5cb1b95d">326.1</ix:nonFraction> million. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through its on hand cash and cash equivalents, the sale of equity, debt financings, and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia58148b1f08a468c915c1789747f11fa">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to commercialize product candidates. The Company expects to incur significant costs to expand its commercialization capabilities in advance of the potential global regulatory approvals of its lead product, beremagene geperpavec (&#8220;B-VEC&#8221;). The Company believes that its cash, cash equivalents and short-term investments of approximately $<ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zMS9mcmFnOjljZjc0MTdmZDdlMDQzOGNhZmRkYWM3NTcyNTY5YTE5L3RleHRyZWdpb246OWNmNzQxN2ZkN2UwNDM4Y2FmZGRhYzc1NzI1NjlhMTlfNTQ5NzU1ODE4NDQ5_a4de5d2d-1b1b-4ddd-bc9c-e1f26464d3ef">350.4</ix:nonFraction> million as of March&#160;31, 2023 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q.</ix:continuation> </span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0Mzg_d2160ae5-967b-4df7-86c2-07f70df4e403" continuedAt="id287f551571f44b08d35404e0e42782d" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="id287f551571f44b08d35404e0e42782d" continuedAt="i127c2c6f01f84333ae15baf28777cafd"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDg_04bee15d-322f-49b6-9fe2-b783d218a70e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022, as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on February 27, 2023.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i127c2c6f01f84333ae15baf28777cafd" continuedAt="i6a855229869b4f1692e72f96671b4748"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NTA_4b734a10-9aa7-49b8-a750-bb07bc3b4854" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDQ_0a479ff4-2b6d-4864-9d1b-96f707d505ba" continuedAt="i378d30d423654c32873cc87de451ca83" escape="true">Segment and Geographical Information</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i378d30d423654c32873cc87de451ca83">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in <ix:nonFraction unitRef="segment" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMzk1Nw_8ba93aad-0e58-4707-8b6a-59512165925c">one</ix:nonFraction> operating segment, which is the business of developing and commercializing pharmaceutical products.</ix:continuation> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDY_92425d09-f5c1-462f-a370-a98ad89ad8f0" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NTE_20242550-f2fd-4d63-bbc1-1365375e93dc" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of less than one year are classified as short-term investments on the condensed consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the condensed consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on investments is also classified as short-term investments on the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the condensed consolidated balance sheets. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest and other income, net, in the consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDU_24b73128-e110-4e96-95a9-23d1dab9324d" continuedAt="i48211e2a1ecf4b079255ed2768af388b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i6a855229869b4f1692e72f96671b4748" continuedAt="i28e687b231824f1a8f404a8b13c53b9b"><ix:continuation id="i48211e2a1ecf4b079255ed2768af388b"><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s condensed consolidated financial statements, approximate fair value, primarily due to their short maturities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 financial instruments. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div></ix:continuation><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0Mzk_38ff6f4f-e87f-4c7f-842e-74f436144c85" continuedAt="if36affdedadd42dc8b0fd70aa1f8b801" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. <ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="krys:EstimatedUsefulLivesOfAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDc_5deb2460-16dc-4672-830c-62b2ffa4b79f" continuedAt="i5c27340c8c864cdcb0d9fda0efaf02bc" escape="true">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><ix:continuation id="i5c27340c8c864cdcb0d9fda0efaf02bc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3d5858b254a74055947c9db86b18c8a3_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMC0xLTEtMS04MjQwMS90ZXh0cmVnaW9uOjlmNjJiYmRjN2VkYzRiYWI4OTBjMGVmNjk4ODQxOGJhXzU0OTc1NTgxMzkyNw_7fe5cd98-852d-4d1f-ab60-c3ae7f161fd3">7</ix:nonNumeric> - <ix:nonNumeric contextRef="i98497d61c2dc4015859731c29c4a5191_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMC0xLTEtMS04MjQwMS90ZXh0cmVnaW9uOjlmNjJiYmRjN2VkYzRiYWI4OTBjMGVmNjk4ODQxOGJhXzU0OTc1NTgxMzkxNg_4d19d2d1-a8bb-44d2-8408-176eec963d42">47</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4d5a1d7d6d3b45cc86f55259988312d1_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMC0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOmRhYjQ2OWYyNjJhMzQyMTg4OWNhMzk1MTBjYzQyYTcwXzQ_a72cd3a9-10ad-45c5-b5b9-093e0c680e3a">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i1ad7d5c593e74fa481f25d0584ed5bb3_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMC0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOmRhYjQ2OWYyNjJhMzQyMTg4OWNhMzk1MTBjYzQyYTcwXzk_be98d1b8-e8f8-46de-9c9d-33266fdf83d0">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff57f58cd1564684a2781fa990333e72_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMi0xLTEtMS04NTE4Ny90ZXh0cmVnaW9uOmZhZTYyZmUzMjhkNTQxNGJhYTNmN2MwMzU3Y2I5MmFkXzU0OTc1NTgxMzg5Mg_371c3721-765b-4217-98e9-f71cf0db6e4d">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i96507c2336ed410dba27455fd3d47784_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMi0xLTEtMS04NTE4Ny90ZXh0cmVnaW9uOmZhZTYyZmUzMjhkNTQxNGJhYTNmN2MwMzU3Y2I5MmFkXzU0OTc1NTgxMzg5Ng_98570ac0-38f5-4720-9c63-d84604a0b5e4">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iab72ff6d793d4c95b00695f6313daf97_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMS0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOmMwNWE4ODFkNmIzMjQ2ZDRhNGRkOGY5N2M1M2M1OTA5XzQ_4cfaa986-f7f4-44fd-9a06-0324261e440d">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i4634ec644b074dc2a73fb4d688425c09_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMS0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOmMwNWE4ODFkNmIzMjQ2ZDRhNGRkOGY5N2M1M2M1OTA5Xzk_03c01a90-4016-4722-9428-8ca609038913">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3a98446c7d2a422cb8484c551d8569e1_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMi0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOjdkNWYwOGZhZjlkNzQ3OWZiZGY3ODU2N2VhMzUyMTdmXzQ_a8747b76-f0fe-4001-a94f-03868739f3bb">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i7c577603e2e64c98b5ecf7704120a266_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMi0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOjdkNWYwOGZhZjlkNzQ3OWZiZGY3ODU2N2VhMzUyMTdmXzk_f8a472e5-98ff-4ada-ab4a-c6fb862b9443">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of useful life or remaining life of lease</span></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if36affdedadd42dc8b0fd70aa1f8b801">Construction in progress is not depreciated until the asset is placed in service.</ix:continuation> </span></div><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0MzY_859515ab-7a9d-42b5-95dc-93806c02167c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition.  In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to an amount by which the net book value exceeds the fair value of the asset.  Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company has <ix:nonFraction unitRef="usd" contextRef="ib56d0e98532345689136cfae336cfbd6_D20230101-20230331" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTA5ODY_6e5cb831-0317-4d59-bd5d-7ad873a4d301"><ix:nonFraction unitRef="usd" contextRef="iacdb4dc62a9b4428bdc804b7838f7fdc_D20220101-20220331" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTA5ODY_82f448a3-5f35-4b97-b3ae-e55c149d27ab">no</ix:nonFraction></ix:nonFraction>t identified any triggering events or recognized any impairment losses for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i28e687b231824f1a8f404a8b13c53b9b" continuedAt="i28e8b3c8101648b7a8b878bb9a1ac99f"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0Mzc_3d3cea22-c2de-4849-b54a-25e25c889f51" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease liabilities represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its condensed consolidated balance sheets and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain sale-leaseback criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDA_83f21c49-8f45-401a-a3ca-2026d8bb6ffa" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with third-party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDE_633aba07-2846-4ec6-9d5f-cf002456ab18" continuedAt="i9fa3bc4de8ee4df1ae785a1504e0a8ce" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to equity awards granted are based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense for stock options, restricted stock awards, and restricted stock units is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense for performance-based restricted stock units is recognized for the awards that are probable of vesting over the service period of the award. On a quarterly basis, management estimates the probable number of performance-based restricted stock units that would vest until such time that the ultimate achievement of the performance criteria are known. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates stock price volatility by using its own historical data. The expected term of the Company&#8217;s stock options is estimated using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i28e8b3c8101648b7a8b878bb9a1ac99f"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9fa3bc4de8ee4df1ae785a1504e0a8ce">to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</ix:continuation> </span></div><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDI_b1181981-648d-4ea6-ab54-19097804a449" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We record reclassifications from other comprehensive gains or losses to interest and other income, net on the condensed consolidated statements of operations related to realized gains on sales of available-for-sale securities.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its securities quarterly to determine whether an other-than-temporary impairment has occurred. The Company determined that there were no other-than-temporary impairments during the three months ended March&#160;31, 2023 and 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDM_a9eb8dc0-9957-41bc-b866-ff02d420a8e6" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB that the Company adopts as of the specified effective date. There were no recently adopted accounting pronouncements that had a material impact on the Company&#8217;s condensed consolidated financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company&#8217;s condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RleHRyZWdpb246MDE4NzZjYjFmYmVkNGRjNmFiMzkxMDU3NWZhYTg2MzlfOTU4_3a77733b-c936-4309-8271-661b460b6539" continuedAt="i12578ed9b7c54929aaba36c2bced7db1" escape="true">Net Loss Per Share Attributable to Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="i12578ed9b7c54929aaba36c2bced7db1"><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were <ix:nonFraction unitRef="shares" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RleHRyZWdpb246MDE4NzZjYjFmYmVkNGRjNmFiMzkxMDU3NWZhYTg2MzlfNjYz_cf7f74c7-8b1d-4e64-911e-2190cde3dc58">3,829,535</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RleHRyZWdpb246MDE4NzZjYjFmYmVkNGRjNmFiMzkxMDU3NWZhYTg2MzlfNjcw_d73ac615-41f1-4105-a766-7067c7e6fc59">3,226,962</ix:nonFraction> common share equivalents outstanding as of March&#160;31, 2023 and 2022, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RleHRyZWdpb246MDE4NzZjYjFmYmVkNGRjNmFiMzkxMDU3NWZhYTg2MzlfOTU5_7fbb6e88-09b9-4ecc-a795-bfa4853f9287" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.589%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNC0xLTEtMS01MTMwNw_e8179e0a-c0ca-410c-ae91-ddaecef135c0">45,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNC0zLTEtMS01MTMwNw_f0635654-2e79-4752-8814-0d5a43a02aaa">49,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNi0xLTEtMS01MTMwNw_692beee2-ba12-4681-b310-16afc01c5e46"><ix:nonFraction unitRef="shares" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNi0xLTEtMS01MTMwNw_f2e413e0-70b2-4c21-9383-dd44b154d77a">25,712,220</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNi0zLTEtMS01MTMwNw_37f821fb-f040-4864-9566-4dcf4a8e58b5"><ix:nonFraction unitRef="shares" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNi0zLTEtMS01MTMwNw_7017b58b-2e80-4783-af81-73d3f754e596">25,114,453</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNy0xLTEtMS01MTMwNw_30c32ccb-7e44-4cd5-9a62-a416b611495c"><ix:nonFraction unitRef="usdPerShare" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNy0xLTEtMS01MTMwNw_7420f32c-3557-4b00-b509-cf26d98bc851">1.76</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNy0zLTEtMS01MTMwNw_220675fd-c4e5-496e-bf52-08bdf081b989"><ix:nonFraction unitRef="usdPerShare" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNy0zLTEtMS01MTMwNw_be8b50a4-7a31-4599-b7f9-853ac107decb">1.99</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RleHRyZWdpb246MWU0NDhlNTgwNjc0NDBlNjkzMjUxMDkxZDYzMmQ4NGNfNTA0_e356d8bb-626e-453e-bf34-248dfc1dbfac" continuedAt="i8f910b7a21b74d9ca2f40379e1fe22fa" escape="true">Fair Value Instruments</ix:nonNumeric></span></div><ix:continuation id="i8f910b7a21b74d9ca2f40379e1fe22fa"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RleHRyZWdpb246MWU0NDhlNTgwNjc0NDBlNjkzMjUxMDkxZDYzMmQ4NGNfNTA1_fa02d024-8790-48cb-b66f-d07d53794cdd" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of March&#160;31, 2023 and December&#160;31, 2022, respectively (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:24.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.032%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i254b57e74219457a9976070bb3f01cca_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNC0xLTEtMS01MTMwNw_1f0446c3-f103-4b6b-ba42-918f4886361f">140,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i254b57e74219457a9976070bb3f01cca_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNC03LTEtMS01MTMwNw_d93d1687-f2eb-466e-869e-99d49e7f523b">140,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4bcbb3bbdfb443c9dc1d6277b193724_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNC05LTEtMS01MTMwNw_01f63e93-6b45-4f70-8b61-8771e53e6248">140,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a24294ea254807b3a01f15a488820e_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNS0xLTEtMS01MTMwNw_183efadb-dcd1-4814-9cf2-162451da2c62">140,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a24294ea254807b3a01f15a488820e_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNS03LTEtMS01MTMwNw_3556263a-a31e-49cd-9033-7e2cbc23ae69">140,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia679ddbe0c9148b596ce5d22d0a1c72d_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNS05LTEtMS01MTMwNw_3c8726da-bb68-40f4-9dd7-264347f9730d">140,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie55cf1b68f5343cd983d4229a5bf466c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC0xLTEtMS01MTMwNw_5477e92b-7440-4889-bbd0-d6c48f96119a">97,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie55cf1b68f5343cd983d4229a5bf466c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC0zLTEtMS01MTMwNw_5f82dc18-d253-4879-9484-496ebe5180a3">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie55cf1b68f5343cd983d4229a5bf466c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC01LTEtMS01MTMwNw_218cf31c-52e6-4135-9b18-a0b94804e230">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie55cf1b68f5343cd983d4229a5bf466c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC03LTEtMS01MTMwNw_52561489-cd5c-43f0-af7b-3a43a3568752">97,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia810a7f2836b4a4c8b9329aa2c255208_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC0xMS0xLTEtNTEzMDc_421d355c-4d16-42e6-a980-d5ffa589f8ce">97,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd9dad418b8488cb10071f2be3a4912_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC0xMy0xLTEtNTEzMDc_17bdaf8c-81ab-4317-9749-9abe86325124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0bea5cf40f844f38d74969a8559b2c5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS0xLTEtMS01MTMwNw_d3b0a28c-9bfe-4fed-a206-f9845b9d1326">49,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0bea5cf40f844f38d74969a8559b2c5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS0zLTEtMS01MTMwNw_97540618-74a2-427f-aaf5-6b2899ba8c66">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0bea5cf40f844f38d74969a8559b2c5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS01LTEtMS01MTMwNw_ac41b602-fc9d-486a-9cd9-572344012a47">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0bea5cf40f844f38d74969a8559b2c5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS03LTEtMS01MTMwNw_64ec3f1c-9c6c-4c2e-a235-d15e8280f432">49,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199b309fe28245b5b261791cfe807797_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS0xMS0xLTEtNTEzMDc_e22d542f-89d6-4f48-8308-cbe6fc939105">45,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821aef589ece4731b6e9f4ebc1acba43_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS0xMy0xLTEtNTEzMDc_7b8d4aab-d2a8-4c90-9d4f-df658ba025fc">4,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia170328c9e7e4a0ca886658a03a5bf79_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtMS0xLTEtNTEzMDc_dd4f4943-8cf0-44ce-a3fc-0cb2bd958d62">67,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia170328c9e7e4a0ca886658a03a5bf79_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtMy0xLTEtNTEzMDc_0b0b1ac8-a231-4fb7-8591-d9654fd8ce33">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia170328c9e7e4a0ca886658a03a5bf79_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtNS0xLTEtNTEzMDc_53356420-285c-4525-bf51-a5ae20996485">190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia170328c9e7e4a0ca886658a03a5bf79_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtNy0xLTEtNTEzMDc_111eebb3-8d26-4612-b486-df431a7e5885">67,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5f311477c243739da11f1d6cf25133_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtMTEtMS0xLTUxMzA3_0515fd53-96ae-4336-a9bf-e90b59759d8c">66,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4f7f10a1f943dba2eb0d494342e180_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtMTMtMS0xLTUxMzA3_a6b228e9-ca7f-45ca-a58e-476cdc8105a0">967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bc3c11b7b447f38c5ac9085cb16011_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtMS0xLTEtNTEzMDc_fb53f1d6-7177-401b-8483-0909362929ee">214,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bc3c11b7b447f38c5ac9085cb16011_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtMy0xLTEtNTEzMDc_eef0742a-49ca-48ca-85dc-ca145d125a4a">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25bc3c11b7b447f38c5ac9085cb16011_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtNS0xLTEtNTEzMDc_7c2568c1-5e16-43d8-b70a-f29908ac6083">314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bc3c11b7b447f38c5ac9085cb16011_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtNy0xLTEtNTEzMDc_7766aefe-6d04-4e97-844a-64ac50274eab">214,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7dabfb39094405ea129e230c5fea918_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtMTEtMS0xLTUxMzA3_57bbc433-a52d-4cca-a212-8d825192080e">209,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0dea8cd85c4b10a8ca0270bc96ca37_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtMTMtMS0xLTUxMzA3_b3c762ca-3240-45cf-86d6-9835e188fc05">5,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItMS0xLTEtNTEzMDc_217083aa-0fe7-46bb-971d-75735dda77ca">355,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItMy0xLTEtNTEzMDc_b7cdda35-d50f-40ee-9d1a-8e89482b60ea">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItNS0xLTEtNTEzMDc_eaae2bec-3872-40d1-914a-9af7c5ecf2c3">314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItNy0xLTEtNTEzMDc_baea3687-902d-42e6-b311-d52bc435fa50">355,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db97cf4a1ee43798607ccb440a0c691_I20230331" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItOS0xLTEtNTEzMDc_9b10f525-0300-4758-9cc5-a2e7634fa7bb">140,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19390a3c5c074f8cb033de62ea4926ba_I20230331" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItMTEtMS0xLTUxMzA3_289912e3-8b37-4923-b6e2-855955b8c389">209,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955d93f6b8e8480aac09b577bc03fd18_I20230331" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItMTMtMS0xLTUxMzA3_81573c19-452b-4f36-857e-2dd0d2d9a739">5,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.100%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9e54233c0c409fbb144f9054234dc7_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMy0xLTEtMS01MTMwNw_b57954cd-667c-4202-b092-0ecf86bc1a42">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9e54233c0c409fbb144f9054234dc7_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMy03LTEtMS01MTMwNw_be00766c-e852-4364-ab1e-cccda38d8c97">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3253f0426d1b464d823eff67b81326d7_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMy05LTEtMS01MTMwNw_b4b0b54e-1c91-45cd-bac7-95b9ad50fee2">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabfee1fcc75f4f5cb247fc8dcaa4469f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNS0xLTEtMS01MTMwNw_3c03e55a-19ba-41b3-a45a-2be35ae4f5c4">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabfee1fcc75f4f5cb247fc8dcaa4469f_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNS03LTEtMS01MTMwNw_34399be3-8efb-4314-b1e0-79e63214ae08">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd001999a79b40e58c92b5976170c12c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNS05LTEtMS01MTMwNw_51011ffb-bfd9-4374-a04b-c89d8e2cdfbf">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558055bb178d47cf8d6907260c65860d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy0xLTEtMS01MTMwNw_8e98d7c6-4bc3-428f-8879-2223c37e3f1e">63,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558055bb178d47cf8d6907260c65860d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy0zLTEtMS01MTMwNw_31b15f3c-6b62-4db5-9591-2af768f51701">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i558055bb178d47cf8d6907260c65860d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy01LTEtMS01MTMwNw_0e28fb19-07c2-4d82-8e64-e2db2561405b">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558055bb178d47cf8d6907260c65860d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy03LTEtMS01MTMwNw_d433e627-32eb-4296-96df-7d0370b19cdd">63,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848d726cc7ea4e92bb8c216498e171d6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy0xMS0xLTEtNTEzMDc_e723e8fd-5d67-4449-a293-9ea09b7a6d98">63,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708d874019134729a370416147542b1e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy0xMy0xLTEtNTEzMDc_c7bee97f-c38f-4be3-b648-fa181460e127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if91c8903d66e47ed89c8a8a928e0ad19_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC0xLTEtMS01MTMwNw_f734869f-e106-4697-8a3c-243785f03758">82,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if91c8903d66e47ed89c8a8a928e0ad19_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC0zLTEtMS01MTMwNw_3455c190-3f5e-4a01-9bcf-25b986caf8b6">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if91c8903d66e47ed89c8a8a928e0ad19_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC01LTEtMS01MTMwNw_fdfc340b-7d63-4c0e-b990-5469c9c5059c">419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if91c8903d66e47ed89c8a8a928e0ad19_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC03LTEtMS01MTMwNw_b7c8ba08-090c-4633-947b-bb493164a368">81,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04d0048badcd4c6aa1082f735dda5fa5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC0xMS0xLTEtNTEzMDc_7fc3bb8e-20fc-432b-843d-444c90e8b424">77,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd54f5b9a434b3b9b37bebfcedd8570_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC0xMy0xLTEtNTEzMDc_d4660052-f0f5-4e57-be11-8c1c4dbb3bf6">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54381d9b7697447d972984381f5addb6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS0xLTEtMS01MTMwNw_b8ada7a6-137e-4683-85a2-aaab5c14462c">76,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54381d9b7697447d972984381f5addb6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS0zLTEtMS01MTMwNw_9c4a037d-1648-4d9f-b351-8fdd3a90e2e6">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54381d9b7697447d972984381f5addb6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS01LTEtMS01MTMwNw_10aead66-8f8f-49e8-9d1b-a32cb6207663">393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54381d9b7697447d972984381f5addb6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS03LTEtMS01MTMwNw_c7884a85-1bcb-483d-981e-f1262f7ecdc9">76,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe9d0765d4040a88c16e531654af652_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS0xMS0xLTEtNTEzMDc_4ae680f0-1549-4eb6-bfe8-bd5430cfaf10">76,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dad77b16170425f951687a001a58cf7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS0xMy0xLTEtNTEzMDc_3c34d47f-e2a0-4003-b61e-18aa250f946f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09632b1d13f447d83cab24d09f19673_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtMS0xLTEtNTEzMDc_99d0c699-97e7-4219-a489-d3ed49ea5d15">222,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09632b1d13f447d83cab24d09f19673_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtMy0xLTEtNTEzMDc_b49f94f0-ccb5-499e-bf3b-e6b6ee9f3bde">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie09632b1d13f447d83cab24d09f19673_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtNS0xLTEtNTEzMDc_430eec76-6958-4601-b4aa-7dd31b647144">835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09632b1d13f447d83cab24d09f19673_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtNy0xLTEtNTEzMDc_2c6e489d-cd62-4c6b-9681-45d48843863f">221,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36bffbb608004cf7bd1c29662284954f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtMTEtMS0xLTUxMzA3_a9908fc8-b037-473f-8ed6-ee544b027e3b">217,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1642cf0b875e42d18be7877570ce84d9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtMTMtMS0xLTUxMzA3_c5f3cf68-d2ae-4e83-bb90-3af48bd16a70">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtMS0xLTEtNTEzMDc_ce3e4ad1-97d8-4bac-a879-dea798f64234">384,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtMy0xLTEtNTEzMDc_956859cf-4f22-4f8f-98eb-e89777c1ae7a">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtNS0xLTEtNTEzMDc_d72d532a-9d87-4784-a748-acdd7b243231">835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtNy0xLTEtNTEzMDc_d90424e5-f8e2-486a-94c5-7b568cd83615">383,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90668d113b34bf0b03c32cdd534454d_I20221231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtOS0xLTEtNTEzMDc_330f3e15-7950-4416-b3bc-6fa4412c2504">161,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26fb1563e4c745bcb1ecf87c332f3971_I20221231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtMTEtMS0xLTUxMzA3_7d05d51c-ba93-45ff-89c5-c5b206b71be2">217,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b41653db9f6419aab13fd18aaffc538_I20221231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtMTMtMS0xLTUxMzA3_7a2d3cc8-4fe0-4537-9d4c-597ac697e8ac">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company&#8217;s short-term marketable securities mature in <ix:nonNumeric contextRef="ib7dabfb39094405ea129e230c5fea918_I20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RleHRyZWdpb246MWU0NDhlNTgwNjc0NDBlNjkzMjUxMDkxZDYzMmQ4NGNfMjcz_060d0e53-60fb-4a4e-a3ae-99e749e8a490">one year</ix:nonNumeric> or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company's long-term marketable securities mature between <ix:nonNumeric contextRef="id9e884919c2f4f82a2242d01a6e29dba_I20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RleHRyZWdpb246MWU0NDhlNTgwNjc0NDBlNjkzMjUxMDkxZDYzMmQ4NGNfMzQ2_3ca4f886-2f1f-4009-8329-3f74c2264ee6">one year</ix:nonNumeric> and <ix:nonNumeric contextRef="i63f3f336a5e844e5b596e41d4095f2d6_I20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RleHRyZWdpb246MWU0NDhlNTgwNjc0NDBlNjkzMjUxMDkxZDYzMmQ4NGNfMzUz_35d59bc9-ee11-4ff3-8930-174de46cf13f">two years</ix:nonNumeric>.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RleHRyZWdpb246MmE2YmI4M2I1ZGZiNDQ5NTgxMzkyNDNlYjUzYTQ1ZTdfMzg4_877e001e-6184-4cfb-8e85-4841cd288eab" continuedAt="ia06708a1ecda40c89003101bf7a3c76b" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ia06708a1ecda40c89003101bf7a3c76b"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RleHRyZWdpb246MmE2YmI4M2I1ZGZiNDQ5NTgxMzkyNDNlYjUzYTQ1ZTdfMzg5_e79b1149-e13d-4174-b37c-b05fc299987c" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3336d8df96f44c03b0edde5a7b3f3f1a_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfMi0xLTEtMS01MTMwNw_243afc9e-333c-4485-97de-bb0c21a45147">122,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e13fb41138141a8a45f22e1363c6694_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfMi0zLTEtMS01MTMwNw_51893789-dcaa-446d-a5ab-6fb4704e3181">131,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95624b73ce524801a03f62c6d6488c4d_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfMy0xLTEtMS01MTMwNw_e6169e47-92c6-4daa-bc6c-3e06cbf80d35">24,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70f55b22e3c64c36aa9d32e22506ddb0_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfMy0zLTEtMS01MTMwNw_18c329ee-6195-420a-8106-6170081e80b4">24,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib70c320c8793401f8ad427840ed747f4_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNS0xLTEtMS04Njk4OA_523946e7-3dd0-4e2b-8eef-08cd970cf461">10,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c0541a8fd74c0fab5d9a8c2a1fb295_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNS0zLTEtMS04Njk4OA_91c1ccf2-33ba-4350-b671-f11c0233124a">9,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1679847f2284f818043b46f19f6d0fe_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNi0xLTEtMS04NzUxOA_da84b89d-9391-4052-8f7a-05a75c157d08">9,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9eb878f8f5476899e4bdc1684dbc88_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNi0zLTEtMS04NzUxOA_cd99d24e-e637-4b34-88ae-63a15d923c80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc7771852e944942a97a47f105d3ddb4_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNi0xLTEtMS04MzY1Mg_8a1a7806-41c1-4017-8965-94b9225a375e">2,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1402d218b7f411a89c2d0a991370111_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNi0zLTEtMS04MzY1Mg_7f1673b3-746f-4a9d-ac5d-5ae9d3a95b3d">2,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c4f65d06694451b7c17b1d48fc362e_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNC0xLTEtMS01MTMwNw_7c8fb942-84f3-43c8-b1d5-3149f4860dff">1,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc58ce8deb464b0999c8eba8a23d5170_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNC0zLTEtMS01MTMwNw_d9c74e94-7f8e-42ce-aeaa-e87309a4056e">957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8785f3fae3400a93aa066e59ff0830_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNS0xLTEtMS01MTMwNw_8eb4bb43-a175-4a27-9dbc-ee5d75d23d26">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i788e335dd01542c6877956cecd45ef64_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNS0zLTEtMS01MTMwNw_31bf68b4-2e2a-4dc0-8a33-09082c217693">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNy0xLTEtMS01MTMwNw_0a1afe49-e32e-483f-9511-dbbcda2f35ce">170,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNy0zLTEtMS01MTMwNw_61a01b18-7e98-42e2-aed9-b16550739a43">168,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfOC0xLTEtMS01MTMwNw_917f1619-5eb1-410e-b8f0-c5870ef0ac82">7,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfOC0zLTEtMS01MTMwNw_03adbfc2-9592-4aaa-b3d4-9e9c2695ac24">6,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfOS0xLTEtMS01MTMwNw_27bef250-fd5e-4473-84af-cdb0046d441b">163,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfOS0zLTEtMS01MTMwNw_fa1d34ed-21c0-4cfc-ab12-a00f29080e34">161,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RleHRyZWdpb246MmE2YmI4M2I1ZGZiNDQ5NTgxMzkyNDNlYjUzYTQ1ZTdfMTU3_c86af8ed-c7e3-4369-883a-5fa34250a0af">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RleHRyZWdpb246MmE2YmI4M2I1ZGZiNDQ5NTgxMzkyNDNlYjUzYTQ1ZTdfNTQ5NzU1ODE0MzA1_f16bc821-f913-4b02-8506-abdb422abf96">462</ix:nonFraction> thousand for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company placed a portion of its second commercial scale CGMP facility, ASTRA, into service during the three months ended March&#160;31, 2023 as it was determined that certain assets were ready for their intended use. On March 27, 2023, the Company received the permanent occupancy permit for ASTRA which allowed the Company to begin utilizing certain portions of the building.  As a result, assets relating to ASTRA were reclassified from construction in progress to leasehold improvements, manufacturing equipment, buildings and building improvements, furniture and fixtures, or computer equipment and software as of March&#160;31, 2023. As certain building improvements are not yet complete and certain qualification activities are still underway, the Company will continue to hold the remaining assets within construction in progress until validation has been completed and the assets are ready for their intended use. Validation of the facility is expected to be completed in 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RleHRyZWdpb246MmE2YmI4M2I1ZGZiNDQ5NTgxMzkyNDNlYjUzYTQ1ZTdfMzg3_5243e101-d9a4-4a3d-90f4-be4006e49c97" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMy0xLTEtMS04Mjc5OA_b969d587-1da4-4099-921c-0f4538bbdf85">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMy0zLTEtMS04Mjc5OA_bd6a186f-a086-441d-bafe-2a54c911eafc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="krys:AccruedConstructionInProgressCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMi0xLTEtMS01MTMwNw_88aa61f0-da27-48a8-9a0d-13b98253416c">8,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="krys:AccruedConstructionInProgressCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMi0zLTEtMS01MTMwNw_2be75908-8a05-4a17-93ac-bbf603fb3e1f">11,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMy0xLTEtMS01MTMwNw_8c5ab509-ceb8-4cde-842f-64114ba79c2f">3,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMy0zLTEtMS01MTMwNw_5c56b3c8-65ad-4605-bbc6-95267b70b0f9">3,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="krys:AccruedPayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNC0xLTEtMS01MTMwNw_77443f8d-0cbe-4fd2-a760-5e50c06587ce">2,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="krys:AccruedPayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNC0zLTEtMS01MTMwNw_ed38fb8e-32a0-41d7-b8f9-16f54cb0f61e">6,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="krys:AccruedPreclinicalAndClinicalExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNS0xLTEtMS01MTMwNw_a39f1aa7-2732-445d-bb2e-f1160d1fe5be">1,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="krys:AccruedPreclinicalAndClinicalExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNS0zLTEtMS01MTMwNw_2fbb1963-862e-4b68-a424-2bbc788c71c8">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNy0xLTEtMS01MTMwNw_56525cb5-09b2-4e2e-9d68-077be725adf6">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNy0zLTEtMS01MTMwNw_603cf2f8-c3f6-496d-8fdf-41d094f89cf6">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfOC0xLTEtMS01MTMwNw_8749498e-8922-443a-a461-08baf651ff45">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfOC0zLTEtMS01MTMwNw_19574c77-14a7-4218-8110-fd59ea4d34d6">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="krys:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMTAtMS0xLTEtNTEzMDc_1a6f517e-2580-417c-afe2-8f073e07447a">29,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="krys:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMTAtMy0xLTEtNTEzMDc_59421324-ba83-407f-b6cf-0adf4ea6ae86">23,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_890"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzcxNDY4MjU1OTY2NjY_ee617311-0de2-4004-8745-0c2e7218579c" continuedAt="i4edc1756453c44228cb63d1ca2d69504" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i4edc1756453c44228cb63d1ca2d69504" continuedAt="i32107e5734e048d7a969ff4de3d25853"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Research Organizations and Contract Manufacturing Organizations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs primarily relate to the manufacturing of our cell and virus banks and for the manufacturing of our sterile gel that is mixed with in-house produced vectors as part of the final drug product for B-VEC. Agreements with third parties may also include research and development consulting activities, clinical-</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i32107e5734e048d7a969ff4de3d25853"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial agreements, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage or pre-commercial products. The Company is obligated to make milestone payments under certain of these contracts. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The estimated remaining commitment as of March&#160;31, 2023 under these agreements is approximately $<ix:nonFraction unitRef="usd" contextRef="iaa1cfbf80d374c378d2f9b338ebb5deb_I20230331" decimals="-5" name="krys:RemainingCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzkwMw_009b3332-9e79-4b17-9fc4-546877249fdd">2.0</ix:nonFraction> million. The Company has incurred research and development expenses under these agreements of $<ix:nonFraction unitRef="usd" contextRef="i77d7d7ecd78845e5bd5596242784b33d_D20230101-20230331" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzExMTM_c5cbb135-24fc-4877-944d-42dde3e6fc8f">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc4c065296114490bb18d3287e10eee4_D20220101-20220331" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU0OTc1NTgyMjI2MA_f1b322f7-5520-4106-9403-1a686996afa1">1.8</ix:nonFraction> million for the three months ended March&#160;31, 2023 and  2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to complete the interior build-out of our second CGMP facility, ASTRA. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of March&#160;31, 2023 is $<ix:nonFraction unitRef="usd" contextRef="i59d538d178644369ac955f83b6d3c6cb_I20230331" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzIyMzM_1ab1d652-8721-406e-a5e0-8c3fbedb6286">11.9</ix:nonFraction> million and primarily relates to the remaining building improvements and certain qualification activities of the facility. The Company has included costs incurred to-date associated with the ongoing build-out of ASTRA within construction in progress. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, Substantial Completion, as defined in the Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (the &#8220;Agreement&#8221;) with Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), the construction manager for ASTRA, had not been achieved. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement may not equate to the date of completion of ASTRA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, the Company entered into a binding term sheet to settle the dispute.  On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic7ccbd4c24004f7c9a76c78c77580c61_D20220428-20220428" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU0NTY_df51a786-b483-4002-beea-7bfd4432fbd5">25.0</ix:nonFraction>&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.  Upon approval of the Company's first product by the U.S. Food and Drug Administration, the Company will pay PeriphaGen an additional $<ix:nonFraction unitRef="usd" contextRef="i38665521367949c5a5b7b6f4a45a6367_D20230101-20230331" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU4MjU_6ff2f47e-dc7f-407f-bfaf-39021497db41">12.5</ix:nonFraction>&#160;million, followed by <ix:nonFraction unitRef="milestone" contextRef="i38665521367949c5a5b7b6f4a45a6367_D20230101-20230331" decimals="INF" name="krys:NumberOfMilestones" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU4NDE_377fb2ee-eaa8-451f-893f-c683700e977c">three</ix:nonFraction> additional $<ix:nonFraction unitRef="usd" contextRef="i3a63fc072ee84250a08db24153192cce_D20230101-20230331" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU4NTU_34a37769-6de7-4a00-a4ed-faebbca5bf3b"><ix:nonFraction unitRef="usd" contextRef="iac262c9c6f0f403486081e497b2c7281_D20230101-20230331" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU4NTU_3c573956-1f7d-494e-ab40-737ac53500aa"><ix:nonFraction unitRef="usd" contextRef="i4243169cc3fd4a5b9a86b7ea453f05f5_D20230101-20230331" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU4NTU_9c098b6a-3ca8-4489-b966-5c3d9052ac0a">12.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million contingent milestone payments upon reaching $<ix:nonFraction unitRef="usd" contextRef="i34cbc871f0d741f2a78e2f78568df717_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU5MDI_55457818-260a-4790-b7b6-b56567f2f791">100.0</ix:nonFraction>&#160;million in total cumulative sales, $<ix:nonFraction unitRef="usd" contextRef="iaa962a4885f645e19feb14d38de37c30_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU5MzI_17d455d5-a050-4c1c-a85b-da36db39ebca">200.0</ix:nonFraction>&#160;million in total cumulative sales and $<ix:nonFraction unitRef="usd" contextRef="i450e68ee6678498fa0a8d69ede89d91d_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU5NjU_293c9aec-e720-4b87-9a4a-6b32e4418431">300.0</ix:nonFraction>&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of the Company products by the Company and its affiliates and licensees, as reported by the Company in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $<ix:nonFraction unitRef="usd" contextRef="id69a8a353b3642439f10c5a61f8f2f64_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementTotalConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzYzODA_d9c5f5a2-1920-4ef1-8eb9-a7de4fe221d7">75.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the upfront settlement payment of $<ix:nonFraction unitRef="usd" contextRef="i38665521367949c5a5b7b6f4a45a6367_D20230101-20230331" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzY0MDk_e6d16fbe-9505-4785-9bb1-e5e18eeb46e6">25.0</ix:nonFraction>&#160;million under litigation settlement expense on the condensed consolidated statements of operations for the three months ended March&#160;31, 2022. In accordance with ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has determined that FDA approval of B-VEC is now probable, and accordingly has accrued for an additional $<ix:nonFraction unitRef="usd" contextRef="i38665521367949c5a5b7b6f4a45a6367_D20230101-20230331" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU0OTc1NTgyMTg5NQ_6ff2f47e-dc7f-407f-bfaf-39021497db41">12.5</ix:nonFraction>&#160;million litigation settlement liability as of March&#160;31, 2023. The remaining contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of March&#160;31, 2023, and therefore no additional accrual has been recorded.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received $<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzY3NDk_427ac81f-797c-4398-9cb1-92cc0c36f1bf">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzY3NTY_cd6c4435-2023-418d-a370-c53177080ca1">768</ix:nonFraction>&#160;thousand of insurance proceeds during the three months ended March&#160;31, 2023 and 2022, respectively. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RleHRyZWdpb246ZTllNzMwYzY0MzRhNDg3ZGEwMDExZWE4MTE0ODJmMzdfMTI3NzE_a84eebb3-9806-4d5f-9f77-757451ea492b" continuedAt="ic93dea0997f04e0cad92f09fe6e954e6" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ic93dea0997f04e0cad92f09fe6e954e6"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RleHRyZWdpb246ZTllNzMwYzY0MzRhNDg3ZGEwMDExZWE4MTE0ODJmMzdfMTI3NzA_76c18255-8e9d-4a14-8b13-54b152fb633c" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future minimum commitments under the Company&#8217;s operating leases with lease terms in excess of 12 months were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfMS0xLTEtMS01MTMwNw_9bfab988-9dae-4a59-bfe0-ba4f74e5b366">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfMi0xLTEtMS01MTMwNw_e6700e1f-7cab-4a25-9dcd-df40055bb8a0">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfMy0xLTEtMS01MTMwNw_b43862ea-5815-487e-ab1f-63bf980c1b13">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfNC0xLTEtMS01MTMwNw_255aa9ec-7f9f-465c-b1b6-26090a0dbca9">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfNS0xLTEtMS01MTMwNw_d73ab51d-9b5c-4b1a-8362-c5f0d8b85e12">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfNi0xLTEtMS01MTMwNw_f391b363-e2cc-46ca-8295-5e04c31a04cc">10,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfNy0xLTEtMS01MTMwNw_6c201861-3617-4c95-b41b-06b2a2c8275f">17,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfOC0xLTEtMS01MTMwNw_55af7e4b-fb7d-4bcd-b9f6-a57a7ef228a4">8,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfOS0xLTEtMS01MTMwNw_939cba47-69d5-4078-bd5d-716ec2e8f06a">8,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RleHRyZWdpb246ZTllNzMwYzY0MzRhNDg3ZGEwMDExZWE4MTE0ODJmMzdfMTI3NzI_160daf24-9986-4192-8639-45e0a38ed215" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfMy0xLTEtMS01MTMwNw_10e85699-7672-446d-83e0-7ab5ae43c0fc">7,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfMy0zLTEtMS01MTMwNw_3c4aead0-b814-4602-9577-0c35d34979df">8,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNC0xLTEtMS01MTMwNw_24bd9991-0aa6-48c0-9b1f-41fea92716bb">1,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNC0zLTEtMS01MTMwNw_fd23dea4-312c-4ee3-854e-d2dcde7748c6">1,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNS0xLTEtMS01MTMwNw_a276b849-bb7b-412c-b31a-67def0739aed">7,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNS0zLTEtMS01MTMwNw_1cdb9bd9-78f2-47c2-b6ee-e7ba48ae98ad">7,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNi0xLTEtMS01MTMwNw_70469166-5667-4f61-b54f-7e86308c0e41">8,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNi0zLTEtMS01MTMwNw_7f39f9e3-e69d-412f-8580-1ddfa190e026">8,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNy0xLTEtMS01MTMwNw_ad6fd445-e602-4388-b5bc-103c3115e111">12.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNy0zLTEtMS01MTMwNw_aea51ab0-b918-472c-b549-990e4d6db81b">12.5</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfOC0xLTEtMS01MTMwNw_ae3694dd-dacc-4b2f-ba97-46f2e3ab7527">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfOC0zLTEtMS01MTMwNw_d76e155e-bf9a-47ad-8031-cf494b5b689d">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RleHRyZWdpb246ZTllNzMwYzY0MzRhNDg3ZGEwMDExZWE4MTE0ODJmMzdfMTI3NzM_faa78c5d-6866-4466-8dc6-e96ab4613f27" escape="true"><div style="margin-top:2pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's lease expense are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNC0xLTEtMS01MTMwNw_02a8cae1-4e45-45f5-850f-f791922a4904">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNC0zLTEtMS01MTMwNw_418183df-1201-4217-bae0-0c7200811846">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNS0xLTEtMS01MTMwNw_e57abad2-ff8b-4707-80a3-56ac739844f7">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNS0zLTEtMS01MTMwNw_10c7ee5c-910c-426b-9982-b308967cc9f3">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNi0xLTEtMS01MTMwNw_8bb48221-dfd1-4d72-91e5-8f2eac4e4aee">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNi0zLTEtMS01MTMwNw_a18fc096-00ae-46c5-b4b3-d39b21f299a9">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80OS9mcmFnOmU5MDJkOGU4NDU3ODQ2YmVhMWFhYTk4MzViNTRlZWIyL3RleHRyZWdpb246ZTkwMmQ4ZTg0NTc4NDZiZWExYWFhOTgzNWI1NGVlYjJfMjA0Nw_d65cada0-c970-4f33-8d92-b4078fd5cf67" continuedAt="if8557966cda347449bb5af5bd62ff1c2" escape="true">Capitalization</ix:nonNumeric></span></div><ix:continuation id="if8557966cda347449bb5af5bd62ff1c2"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Program</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sold shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acted as the Company's agent and/or principal and could issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $<ix:nonFraction unitRef="usd" contextRef="i6d80521c426d495a9687ea96ad9ca399_I20211231" decimals="-5" name="krys:SaleOfStockAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80OS9mcmFnOmU5MDJkOGU4NDU3ODQ2YmVhMWFhYTk4MzViNTRlZWIyL3RleHRyZWdpb246ZTkwMmQ4ZTg0NTc4NDZiZWExYWFhOTgzNWI1NGVlYjJfNTMx_04b00116-b80a-4b27-94f9-b025d06e4e24">150.0</ix:nonFraction>&#160;million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement were made pursuant to the Company's effective "shelf" registration statement on Form S-3. There were <ix:nonFraction unitRef="shares" contextRef="ia4eb18cd516042b7aab83e20049963ed_D20220101-20220331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80OS9mcmFnOmU5MDJkOGU4NDU3ODQ2YmVhMWFhYTk4MzViNTRlZWIyL3RleHRyZWdpb246ZTkwMmQ4ZTg0NTc4NDZiZWExYWFhOTgzNWI1NGVlYjJfNzE0NjgyNTU4NTU0Nw_86d38bd0-8877-4b36-a61e-1fe44c7858e9"><ix:nonFraction unitRef="shares" contextRef="i204fc13707f54377a36f6695aa4c916f_D20230101-20230331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80OS9mcmFnOmU5MDJkOGU4NDU3ODQ2YmVhMWFhYTk4MzViNTRlZWIyL3RleHRyZWdpb246ZTkwMmQ4ZTg0NTc4NDZiZWExYWFhOTgzNWI1NGVlYjJfNzE0NjgyNTU4NTU0Nw_fd3a9219-441e-40bd-aaae-185ff756713b">no</ix:nonFraction></ix:nonFraction> shares issued under the ATM Program during the three months ended March&#160;31, 2023 and 2022. As of March&#160;31, 2023, there was a remaining $<ix:nonFraction unitRef="usd" contextRef="if019f17b70c645eab7cf5f73638d1837_D20230101-20230331" decimals="-5" name="krys:SaleOfStockRemainingAvailableIssuanceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80OS9mcmFnOmU5MDJkOGU4NDU3ODQ2YmVhMWFhYTk4MzViNTRlZWIyL3RleHRyZWdpb246ZTkwMmQ4ZTg0NTc4NDZiZWExYWFhOTgzNWI1NGVlYjJfNTAwMA_aa90b0b4-e6e1-436e-853d-7063b466fe09">102.5</ix:nonFraction>&#160;million available for issuance under the ATM Program. The ATM Program expired on May 4, 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIwMw_84440eb3-5d1d-4981-8bfe-bae6fec48c45" continuedAt="ie7afd8677f0644d49a21f3fda88be3b1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ie7afd8677f0644d49a21f3fda88be3b1" continuedAt="ibe9d5ffb55b2433a99944e7d40cb0d2f"><div style="margin-top:9pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company adopted the 2017 IPO Stock Plan (the &#8220;Plan&#8221;), which governs the issuance of stock options and restricted stock to employees, certain non-employee consultants, and directors. Initially, the Company reserved <ix:nonFraction unitRef="shares" contextRef="i514f2cde4cee40baaa8b763c557430ae_I20171231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTA5OTUxMTYzMTk1MjY_3d57bc9a-2ca9-45c0-b920-404b9b6e1a7a">900</ix:nonFraction>&#160;thousand shares for issuance under the Plan with an initial sublimit for incentive stock options of <ix:nonFraction unitRef="shares" contextRef="i514f2cde4cee40baaa8b763c557430ae_I20171231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNzE0NjgyNTYyMjI4Mw_9607b19c-7602-486b-9d14-0567bf32c3e0">900</ix:nonFraction>&#160;thousand shares. On an annual basis, the amount of shares available for issuance under the Plan increases by an amount equal to <ix:nonFraction unitRef="number" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNzE0NjgyNTYyMjQxMw_747e6891-b2e0-402d-a28a-4a34d17bc4ed">four</ix:nonFraction> percent of the total outstanding shares as of the last day of the preceding calendar year. The sublimit of incentive stock options is not subject to the increase. The Company has historically granted stock options and restricted stock awards to its employees. In February 2023, the Company began issuing restricted stock units and performance-based restricted stock units to certain employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and non-employees vest ratably over a <ix:nonNumeric contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIwNA_8062a912-6ecb-49fd-810a-3c353bc05fa4">four-year</ix:nonNumeric> period and stock options granted to directors of the Company vest ratably over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTExNQ_1ff19d5b-7ebe-44d5-815e-fa8e50130fbf">one</span>-year to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTE0Nw_06c5c353-58b3-42d1-85b7-6f88da10a8be">three</span>-year periods. Stock options have a life of <ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMjU3_1d634cb3-d48b-49e2-98d5-3e7ca8d77bb2">ten years</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="i0b2264b9c9914e3abaee4de6745b7cf8_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMjgy_5585bbed-5791-40f6-87e7-c2a55eb04d81">287,600</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id23450f1c26144fca1df4aefaa3a147d_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTc3OA_7a437c4b-63b2-4e1c-9dc0-58c240c7b726">1,179,500</ix:nonFraction> stock options to employees, non-employees, and directors of the Company during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIxMA_ed377766-3c1a-4dd5-b29d-e1f2ae89441f" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMS0xLTEtMS01MTMwNw_74d629c9-93bc-4fc5-ab24-5209502fb40c">3,582,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMS0zLTEtMS01MTMwNw_722b08a2-a5f2-4bc9-ba0a-e289a4b4d3c6">61.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CCECFF;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i228ec404a39040e2a3b2cf301e832687_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMS01LTEtMS01MTMwNw_08c2edd0-d599-409d-9596-a04f52609910">8.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMS03LTEtMS01MTMwNw_0230f9b9-389d-4a34-98a1-b2fdb84e8f11">64,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMi0xLTEtMS01MTMwNw_94086e2b-483b-418f-89c5-7adead538266">287,600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMi0zLTEtMS01MTMwNw_e40facbb-b65b-4876-a0c3-a3cfece7459e">81.83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMy0xLTEtMS01MTMwNw_d375aca1-551a-4ec1-a1f8-f812867d08a1">42,021</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMy0zLTEtMS01MTMwNw_ec6574f3-e588-4b93-b8a3-ea2845e81076">53.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNC0xLTEtMS01MTMwNw_6dbf77f9-b6fe-4a0a-b983-1a9193c3e529">42,625</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNC0zLTEtMS01MTMwNw_b7fb86b8-6422-432e-bc83-c22a6a0d3675">65.59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNS0xLTEtMS01MTMwNw_9c86c055-69bf-4570-b86e-2446e0435b87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNS0zLTEtMS01MTMwNw_730cc662-61cc-4f47-9ef3-dcd02ea0a08b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNi0xLTEtMS01MTMwNw_c394b7c6-c09a-460f-ab9c-c0b74a331157">3,785,135</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNi0zLTEtMS01MTMwNw_8bf5a720-4817-40dd-a4d3-d6fe22116771">62.75</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNi01LTEtMS01MTMwNw_13a1a7fb-a558-4481-a0bf-d90dd1412414">8.5</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNi03LTEtMS01MTMwNw_8edfdcba-69ce-429c-aceb-8620c7869a17">66,066</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNy0xLTEtMS01MTMwNw_f40c4747-25e9-4927-a022-8642ba03ab68">961,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNy0zLTEtMS01MTMwNw_73abdd3b-ae1d-4485-8e70-8bf76a196194">55.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNy01LTEtMS01MTMwNw_063f71f3-7aa8-430a-818a-e7317014b91e">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNy03LTEtMS01MTMwNw_56145de0-a085-45ed-a3fc-01222c954666">24,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March&#160;31, 2023 and the exercise price of outstanding in-the-money options.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTA5OA_6fb2a0a3-d744-4f71-8f86-595d618e61dd">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MjEwMA_a6b8e8b4-7def-48b4-a26c-d47d33284e8f">36</ix:nonFraction>&#160;thousand, respectively </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTMzNQ_99b58857-6261-4aea-891b-6ea34290a115">56.86</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTM5OA_3ae080b3-a808-41ac-a403-57c05d1bfe52">43.09</ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="iedcfd366e93c4c2d8c5b5452e2b1caf3_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTM0_5d1af1a8-36c0-47f9-a6ad-b9286bc4d298">109.2</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to employees', non-employees', and directors&#8217; option awards that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="id58086907cf445e3b68de6647460560d_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTQ1_80133a9f-8583-4103-8852-4d9b36a44d58">2.8</ix:nonNumeric> years as of March&#160;31, 2023.</span></div><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIwOA_df46618b-940f-4f04-8f10-6bc5369be330" continuedAt="i3062ceb9b85741d3bd0193be2563f7f9" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib13481cdbf0441e49f4f32596d741801_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfMy0xLTEtMS01MTMwNw_53342617-6ec9-47d1-bfe7-34037b46cdc4">2,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2350fa2df2594c7d83ae40618dfdbd3f_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfMy0zLTEtMS01MTMwNw_dc7a1ec9-5963-483f-9332-12136e37a2a0">1,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65adaea3f9a54843afd31a5010fe66a3_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfNC0xLTEtMS01MTMwNw_3c637d6f-3b11-4c1f-9181-e3816d2b1a71">7,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f30b015d0b54cef9f1f1fe7e1c87a6b_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfNC0zLTEtMS01MTMwNw_dec3f8a2-46aa-4656-a14b-0c15e45d9e1a">4,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfNS0xLTEtMS01MTMwNw_e51c73df-6ee0-40ef-a889-f4f5a011ae59">9,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfNS0zLTEtMS01MTMwNw_c1659f70-9912-426c-9d97-d507dd1fd8de">5,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIwOQ_4f24c38e-46e9-4f85-88fe-2b903023fe72" continuedAt="i2cc469e840df400b837841bd687f7e31" escape="true">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three months ended March&#160;31, 2023 and 2022:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="ibe9d5ffb55b2433a99944e7d40cb0d2f" continuedAt="i67d15b5297414eaf92f6ffd58f9423dd"><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><ix:continuation id="i2cc469e840df400b837841bd687f7e31"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfMi0xLTEtMS01MTMwNw_bf5aec04-9106-45e9-8754-a0b552a88b48">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfMi0zLTEtMS01MTMwNw_31d8cab2-b8d1-469d-8f9f-d5e97f78aa32">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfMy0xLTEtMS01MTMwNw_750777b9-8a93-4746-b7e8-fa014c10574e">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfMy0zLTEtMS01MTMwNw_b622e41c-93ab-442e-aa4d-50055b5da0a2">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNC0xLTEtMS01MTMwNw_c1133274-2c96-445b-a31c-5120884f79eb">4.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNC0zLTEtMS01MTMwNw_4cdaec58-3bb4-4a81-969a-e590f1fe67eb">1.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNS0xLTEtMS01MTMwNw_9675c642-0b20-419d-a86e-b4bc16add690">81.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNS0zLTEtMS01MTMwNw_4486a1d9-79b7-4d3f-a493-ca58d78e9762">62.53</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNi0xLTEtMS01MTMwNw_336ac167-f910-41c5-96b6-7f5d8bb0105e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNi0zLTEtMS01MTMwNw_f5658619-b6d3-4bad-890d-c41216e8a8f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNy0xLTEtMS04NzA1MA_36cfed79-5fff-4b77-8757-a127082a64d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNy0zLTEtMS04NzA1MA_97177a32-a0ac-4050-ad8c-dbb9c441fbf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIxMQ_6f1db7ed-7b11-47b8-a107-44623c6125ff" continuedAt="i76c1ce3f8fc04ce6802d076e8adae5e1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTc3_6f3f7115-1588-4f4d-bb1c-32086269f4cb">four</span>-year period. The Company granted <ix:nonFraction unitRef="shares" contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTgy_873a3897-51c5-4d24-bfd1-52334380a759"><ix:nonFraction unitRef="shares" contextRef="i29f8fe089ab942b2b54a2474e590165e_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTgy_d35bc165-d391-4fad-acf3-bb38c5e89437">zero</ix:nonFraction></ix:nonFraction> RSAs to employees of the Company during each of the three months ended March&#160;31, 2023 and March&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i645b28bb0a98487cb270051dfc6fdcfe_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMS0xLTEtMS01MTMwNw_2fa9a972-4cd3-4359-a2bf-3f2a892f1e95">66,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i645b28bb0a98487cb270051dfc6fdcfe_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMS0zLTEtMS01MTMwNw_893061cf-851a-415b-8e67-02ca111d9847">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMi0xLTEtMS01MTMwNw_4df37eef-ba39-4507-9f55-0bae170ade35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMi0zLTEtMS01MTMwNw_10dfc2d0-5eaf-4f67-a1ea-6ca1022db496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMy0xLTEtMS01MTMwNw_3fa69c4f-ef7d-4e78-88e9-334ea4ef0590">12,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMy0zLTEtMS01MTMwNw_a0cce921-112f-47aa-aa95-6939726e95d7">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfNC0xLTEtMS01MTMwNw_820cccdf-d089-4b7d-981e-47fb0557af79">9,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfNC0zLTEtMS01MTMwNw_df0afb8d-0c7a-4b84-b3b8-01ff72062b05">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49ef87a5ae2a4962839a23c59b1310dc_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfNS0xLTEtMS01MTMwNw_6f874aeb-2854-4a1f-a9e4-631c86c26a01">44,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i49ef87a5ae2a4962839a23c59b1310dc_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfNS0zLTEtMS01MTMwNw_4e349a2e-f965-4fc0-9592-6c6f3b822b79">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i49ef87a5ae2a4962839a23c59b1310dc_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDA2_6b375db8-06e2-4f03-8d99-dc33af38a9cc">3.3</ix:nonFraction> million of unrecognized stock-based compensation expense related to employees&#8217;&#160;RSAs that is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDc2_044c8535-4b8d-4a70-8773-f32fd2ebf255">1.9</ix:nonNumeric> years as of March&#160;31, 2023.</span></div><ix:continuation id="i3062ceb9b85741d3bd0193be2563f7f9" continuedAt="i734604c5e22e462584afadb1d4fcc11c"><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7538673d38443ba7514e523de7d067_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmVkMzEyNGMxYTU5ZTQzNWI4YjZhMDMzZjljYWNjYmI5L3RhYmxlcmFuZ2U6ZWQzMTI0YzFhNTllNDM1YjhiNmEwMzNmOWNhY2NiYjlfMy0xLTEtMS01MTMwNw_30f7c728-5cc1-44f5-84c6-cb4046e7ffb8">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52d01079bea47b58f76c834f2bd69aa_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmVkMzEyNGMxYTU5ZTQzNWI4YjZhMDMzZjljYWNjYmI5L3RhYmxlcmFuZ2U6ZWQzMTI0YzFhNTllNDM1YjhiNmEwMzNmOWNhY2NiYjlfMy0zLTEtMS01MTMwNw_55786195-6ce1-45d3-a3ee-9dfdb5bf27f3">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmVkMzEyNGMxYTU5ZTQzNWI4YjZhMDMzZjljYWNjYmI5L3RhYmxlcmFuZ2U6ZWQzMTI0YzFhNTllNDM1YjhiNmEwMzNmOWNhY2NiYjlfNC0xLTEtMS01MTMwNw_b7aef16c-375d-463f-95c4-55d0d26ccae7">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f8fe089ab942b2b54a2474e590165e_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmVkMzEyNGMxYTU5ZTQzNWI4YjZhMDMzZjljYWNjYmI5L3RhYmxlcmFuZ2U6ZWQzMTI0YzFhNTllNDM1YjhiNmEwMzNmOWNhY2NiYjlfNC0zLTEtMS01MTMwNw_75e4937b-5463-4a9a-a3c1-618e67541e3a">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;) granted to employees vest ratably over a <ix:nonNumeric contextRef="idef73c4961e74f54a77c41e6d1e60853_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNzE0NjgyNTYyMjM4Mw_6a1ab800-c77f-4c21-898e-50a1dac11b30">four-year</ix:nonNumeric> period. <ix:continuation id="i76c1ce3f8fc04ce6802d076e8adae5e1" continuedAt="i25b7393b433b429f8bdb47b00a5b5354">The Company granted <ix:nonFraction unitRef="shares" contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MjA4_0f9e9232-2669-4d94-988c-6bf46a86938a">186,900</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7af32a972cdb4a749407af929c2d1837_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MjE3_dd9fa0e4-382e-422b-a166-b19494d93393">zero</ix:nonFraction> RSUs to employees of the Company during the three months ended March&#160;31, 2023, and 2022, respectively.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i25b7393b433b429f8bdb47b00a5b5354"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:65.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide792579d6fa48f0b86d34c66b1032f8_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMS0xLTEtMS04MTM2OA_9008707e-5e0a-4fa8-81cb-454493c92a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="ide792579d6fa48f0b86d34c66b1032f8_I20221231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMS0zLTEtMS04NDg5Mw_3bf84df5-5449-4faa-b7d4-c8ff989c9fa9"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMi0xLTEtMS04MTM2OA_bc19db5e-938a-4ff0-a2e8-74dd02415a59">186,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMi0zLTEtMS04MTM3OA_5eb38850-1a3e-4b5d-8004-4263b4b5827b">81.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMy0xLTEtMS04MTM2OA_46dedfeb-5c18-48fb-ab17-8b5dd6ef3fd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMy0zLTEtMS04NDg5Mw_608b5a8a-f22d-44d9-add7-3f7c78b9f570"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfNC0xLTEtMS04MTM2OA_57a80fb9-1ea2-4f9e-a6e3-f716abc12ff2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfNC0zLTEtMS04NDg5Mw_3d94953e-ad09-46d2-9db0-daa2064b4445"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfcec0e0e32c41ff965b11623a8537b6_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfNS0xLTEtMS04MTM2OA_5f8440fa-5f6e-43b3-87b8-5500c00bc811">186,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibfcec0e0e32c41ff965b11623a8537b6_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfNS0zLTEtMS04MTM3OA_b6b26302-eab6-44b5-a9e7-253c8bef4807">81.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="ibfcec0e0e32c41ff965b11623a8537b6_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDY0_80ec366c-876d-4068-9d73-c37d99db7db9">15.0</ix:nonFraction> million of unrecognized stock-based compensation expense related to employees&#8217;&#160;RSU awards that is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDgz_808c97bc-0580-4223-9fca-aa2ddff1078d">3.9</ix:nonNumeric> years as of March&#160;31, 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i67d15b5297414eaf92f6ffd58f9423dd"><ix:continuation id="i734604c5e22e462584afadb1d4fcc11c" continuedAt="i7edc57d5f2714d35b97f6802c01b1338"><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSUs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b071d986514acea476f82fe822eeb2_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfMi0xLTEtMS04MTUzMA_3f9283d2-1d4f-48a4-a11d-42e3453ae891">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67805b5822e040868da524c3ac650689_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfMi0zLTEtMS04NDkxMA_1a995d12-ca00-4bdf-9a1a-5dac09886c8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38669f3d3714bb9a64a611f418227d2_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfMi0xLTEtMS03ODYxMg_545b5b31-f399-4008-ab8f-975f57660fbb">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8865efa296147f4b6d4959a17d55e59_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfMi0zLTEtMS03ODYxMg_56d99efa-37f4-4fac-9c9f-e56485b82a13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfNC0xLTEtMS04NDkxMA_723d3184-1233-4121-b82e-6d3067d2da6f">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af32a972cdb4a749407af929c2d1837_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfNC0zLTEtMS04NDkxMA_c07ec363-5297-4d0f-86c3-5aae743169a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based restricted stock units (&#8220;PSUs&#8221;) granted to employees vest ratably over two years based upon continued service through the vesting date and the achievement of specific regulatory and commercial performance criteria as determined by the Compensation Committee of the Company&#8217;s Board of Directors. The performance criteria are to be completed by the end of the year in which the PSU awards were granted. Each PSU represents the right to receive one share of the Company's common stock upon vesting. The Company recognizes stock-based compensation expense for the fair value of the PSU awards relating to the portion of the awards that are probable of vesting over the service period. On a quarterly basis, management estimates the probable number of PSU&#8217;s that would vest until such time that the ultimate achievement of the performance criteria are known.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023, the Company estimates that <ix:nonFraction unitRef="number" contextRef="i89b2e6b1732847ebb483c440b3b816ea_I20230331" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTA5OTUxMTYzMTk1MTc_d613485e-629d-41eb-8da6-5b4c8c10fc3a">100</ix:nonFraction>% of the PSUs granted will be eligible to vest.</span></div><ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTA5OTUxMTYzMTk1MjI_7b0014a6-0da5-453d-961d-67d7de1f148b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MzAz_6547b7d9-2530-4721-85b3-3002c05652ca">60,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7bce8d3bcf1140e8aceb74a97f62d71a_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MzEz_b74d8e06-3c18-41e8-894d-d5219d42bafa">zero</ix:nonFraction> PSUs to employees of the Company during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:65.126%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested PSUs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8817887d7f81412584905713f1293a84_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMS0xLTEtMS04MTQzNw_3a4ceaa1-a28f-4772-898a-dadd7ca1e926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i8817887d7f81412584905713f1293a84_I20221231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMS0zLTEtMS04NDk1Ng_a906b509-03a2-4445-a8e1-a49284a9638c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMi0xLTEtMS04MTQzNw_9189815c-8714-4a72-bd14-1c6421eb2569">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMi0zLTEtMS04MTQzNw_a5ac915b-5926-41b8-b0b0-f3f824ded86d">81.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMy0xLTEtMS04MTQzNw_93ef014e-578c-4fc3-a5f6-d112fe35fa37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMy0zLTEtMS04NDk1Ng_7c13e2b6-515e-4a2d-8855-df81757f526d"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfNC0xLTEtMS04MTQzNw_acb95d06-86ad-4fae-b72e-c91ad9d6d10d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfNC0zLTEtMS04NDk1Ng_b4fad009-99c9-4915-8d2d-60f84e97a32c"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested PSUs as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89b2e6b1732847ebb483c440b3b816ea_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfNS0xLTEtMS04NDk1Ng_060ae162-4a91-471d-beef-88777309f030">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i89b2e6b1732847ebb483c440b3b816ea_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfNS0zLTEtMS04MTQ0NQ_64d670ad-0af7-4efb-8c2f-301c73a7c11b">81.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i89b2e6b1732847ebb483c440b3b816ea_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDI0_c3317e54-ed20-4f2b-9075-e3292670f084">4.7</ix:nonFraction> million of unrecognized stock-based compensation expense related to employees&#8217;&#160;PSU awards that is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDkw_b884fe01-b0e1-4d8f-9dfa-5aaabca7ec35">1.9</ix:nonNumeric> years as of March&#160;31, 2023.</span></div><ix:continuation id="i7edc57d5f2714d35b97f6802c01b1338"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to PSUs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0633520e282645f49e4915cae45e1e31_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc5MTdhYmJlNGJjMDRjZjg5MDJjZTI4YTkzMWRlMjA2L3RhYmxlcmFuZ2U6NzkxN2FiYmU0YmMwNGNmODkwMmNlMjhhOTMxZGUyMDZfMi0xLTEtMS04NDk2MA_c7daea82-2933-4082-a30f-e5c9e39cb4bd">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a5c357849b34fb4847ad068877525ca_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc5MTdhYmJlNGJjMDRjZjg5MDJjZTI4YTkzMWRlMjA2L3RhYmxlcmFuZ2U6NzkxN2FiYmU0YmMwNGNmODkwMmNlMjhhOTMxZGUyMDZfMi0zLTEtMS04NDk2MA_bbb85b81-f3b0-401a-8ab4-4b936358bf43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc5MTdhYmJlNGJjMDRjZjg5MDJjZTI4YTkzMWRlMjA2L3RhYmxlcmFuZ2U6NzkxN2FiYmU0YmMwNGNmODkwMmNlMjhhOTMxZGUyMDZfMy0xLTEtMS04NDk2MA_3b546d82-edfc-48a9-892a-5aeeb6113208">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bce8d3bcf1140e8aceb74a97f62d71a_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc5MTdhYmJlNGJjMDRjZjg5MDJjZTI4YTkzMWRlMjA2L3RhYmxlcmFuZ2U6NzkxN2FiYmU0YmMwNGNmODkwMmNlMjhhOTMxZGUyMDZfMy0zLTEtMS04NDk2MA_f1b86f5c-9d85-4a5e-913c-ad0fe0d5b413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares remaining available for grant under the Company&#8217;s stock incentive plan were <ix:nonFraction unitRef="shares" contextRef="i447050dc5b89452bb373864b41c4e5ab_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTYw_8ab18a81-5f2d-4845-9108-4444fc4a20f0">1,005,626</ix:nonFraction>, with a sublimit for incentive stock options of <ix:nonFraction unitRef="shares" contextRef="ib03c89f358de41aba14e7922b0f06df8_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTY4_7d449634-0338-4935-8a9e-3431da8be903">2,629</ix:nonFraction>, at March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of manufacturing facilities. There was $<ix:nonFraction unitRef="usd" contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1Mjc0MA_23549d6e-4221-4089-92e4-883a80cccb42">162</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1Mjc0OQ_b66d261c-0cff-483d-86d2-f3a93f55fea4">141</ix:nonFraction>&#160;thousand of stock-based compensation that was capitalized in the three months ended March&#160;31, 2023 and 2022, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81NS9mcmFnOmJkOTk3YWE1MGNkNjRhNjhiNDY4OWQ4YzZkMzJmMmQxL3RleHRyZWdpb246YmQ5OTdhYTUwY2Q2NGE2OGI0Njg5ZDhjNmQzMmYyZDFfMzcw_9e1f24b7-cd1c-4058-88d0-5692e4ca4dbf" continuedAt="ife4eb73cd4b1437ea16acb1f43855e9f" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ife4eb73cd4b1437ea16acb1f43855e9f">The Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require recognition or disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on February 27, 2023.</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Some of such factors include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, cost, progress and results, of our research and development activities, preclinical studies and clinical trials for B-VEC (previously &#8220;KB103&#8221; and now known as Vyjuvek</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and our other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope or results of regulatory filings and approvals, including timing of final U.S. Food and Drug Administration (&#8220;FDA&#8221;) and other regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve certain accelerated or orphan drug designations from the FDA;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our estimates regarding the potential market opportunity for B-VEC and our other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise capital to fund our operations;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in costs associated with our research and development programs for our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our general and administrative expenses;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ability to successfully develop and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and develop new product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, recruit and retain key personnel;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our marketing and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our business model and strategic plans for our business, product candidates and technology;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of building a medical affairs and commercial organization, including a sales force in anticipation of commercialization of any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our product candidates and gene therapy, in general;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position and the success of competing therapies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position and our ability to protect and enforce our intellectual property;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully avoid or resolve any litigation, intellectual property or other claims, that may be brought against us;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global economic conditions, including the recent rise in inflation and interest rates and recent bank failures; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in laws and regulations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in other filings we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">make with the SEC from time to time. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Quarterly Report. You should read this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Form 10-Q, unless the context requires otherwise, all references to &#8220;Krystal,&#8221; &#8220;the Company,&#8221; we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to Krystal Biotech, Inc., together with its consolidated subsidiaries. Web links throughout this document are provided for convenience only and are not intended to be active hyperlinks to the referenced websites. No content on the referenced websites shall be deemed incorporated by reference into this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale CGMP manufacturing capabilities.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our product candidates in various stages of clinical and preclinical development:</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><img src="krys-20230331_g1.jpg" alt="Pipeline Chart Q1 23.jpg" style="height:819px;margin-bottom:5pt;vertical-align:text-bottom;width:648px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the upcoming milestones will be met on the expected timeline or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Highlights and Recent Developments</span></div><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dermatology</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beremagene geperpavec ("B-VEC") is a topical gel containing our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL7A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of dystrophic epidermolysis bullosa (&#8220;DEB&#8221;), a serious rare skin disease caused by missing or mutated COL7 protein. We submitted a Biologics License Application (&#8220;BLA&#8221;) to the FDA for B-VEC for the treatment of DEB in June 2022. The FDA accepted the BLA in August 2022 granting B-VEC a Priority Review Designation. The action date for B-VEC is May 19, 2023. We submitted a request for a Marketing Authorization Application (&#8220;MAA&#8221;) with the European Medicines Agency (&#8220;EMA&#8221;) in November 2022 for B-VEC for the treatment of DEB in patients 6 months and older. The Company was informed by the EMA in January 2023 to modify the Pediatric Investigation Plan (&#8220;PIP&#8221;) waiver request to include patients between birth and 6 months. The Company has modified and submitted the PIP waiver so that the MAA procedure can officially start in the second half of 2023 with an approval expected in early 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB105 is a topical gel containing our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TGM1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of TGM1-deficient autosomal recessive congenital ichthyosis ("TGM1-ARCI"), a serious rare skin disorder caused by missing or mutated TGM1 protein. A randomized, placebo-controlled Phase 1/2 study is ongoing. In July 2021, we announced complete data from the Phase 1 trial, showing repeat topical KB105 dosing continued to be well tolerated with no adverse events or evidence of immune response. Details of the Phase 1/2 study can be found at www.clinicaltrials.gov under NCT identifier NCT04047732. We plan to initiate a Phase 2 study in the first half of 2023.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB104 is a topical gel formulation of our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINK5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of Netherton Syndrome, a debilitating autosomal recessive skin disorder caused by missing or mutated SPINK5 protein. The FDA has granted KB104 rare pediatric designation for the treatment of Netherton Syndrome. We plan to file an Investigational New Drug (&#8220;IND&#8221;) application and initiate a clinical trial of KB104 to treat patients with Netherton Syndrome in 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Respiratory</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB407 is an inhaled (nebulized) formulation of our novel vector designed to deliver two copies of the full-length cystic fibrosis transmembrane conductance regulator ("CFTR") transgene for the treatment of cystic fibrosis, a serious rare lung disease caused by missing or mutated CFTR protein.  In September 2021, we announced that the Bellberry Human Research Ethics Committee in Australia granted approval to conduct a Phase 1 clinical study of inhaled KB407 in patients with cystic fibrosis, and trial initiation is anticipated in the first half of 2023. Details of the Phase 1 study can be found at www.clinicaltrials.gove under NCT identifier NCT05095246. In August 2022, we announced that the FDA had accepted our IND application to evaluate KB407 in a clinical trial to treat patients with cystic fibrosis. Details of the Phase 1 study can be found at www.clinicaltrials.gov under NCT identifier NCT05504837. We are closely working with the Therapeutics Development Network of the Cystic Fibrosis Foundation to validate our Phase 1 clinical protocol. We plan to initiate a Phase 1 clinical trial in the U.S. in the first half of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB408 is an inhaled (nebulized) formulation of our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SERPINA1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene, that encodes for normal human alpha-1 antitrypsin protein, for the treatment of alpha-1 antitrypsin deficiency ("AATD"). We presented preclinical pharmacology data for KB408 at the European Society of Gene &amp; Cell Therapy Virtual Congress that was held October 19-22, 2021. We are planning to file an IND for KB408 to treat AATD patients in the second half of 2023.   </span></div><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aesthetics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also leveraging the ability of our platform to deliver proteins of interest to cells in the skin in the context of aesthetic medicine via our wholly-owned subsidiary, Jeune Aesthetics, Inc. ("Jeune"). KB301 is a solution formulation of our novel vector for intradermal injection designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL3A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene to address signs of aging or damaged skin caused by declining levels of, or damaged proteins within the extracellular matrix, including type III collagen.  In March 2021, Jeune announced that data from the safety cohort of a Phase 1 clinical trial, the PEARL-1 trial, for the treatment of aesthetic skin conditions, showed the safety and tolerability of repeat KB301 injections. Complete results from the safety cohort of the PEARL-1 trial were presented at the 2021 Society for Investigative Dermatology Annual Meeting. In 2022, we completed efficacy and durability cohorts of the PEARL-1 trial. In March 2022, Jeune announced positive proof-of-concept, safety and efficacy data with respect to improvement of fine lines and wrinkles from the efficacy cohort of the PEARL-1 trial. In November 2022, Jeune announced data from the PEARL-1 extension cohort showing up to nine-month durability of effect following administration of high dose KB301.  Details of the Phase 1 study can be found at www.clinicaltrials.gov under NCT identifier (NCT04540900).   </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeune has several other aesthetic medicine product candidates in various stages of preclinical development as reflected in the chart above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Highlights and Recent Developments</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">In April 2023, the Company presented new data on the compassionate use of topical B-VEC to treat a patient with DEB with recurrent cicatrizing conjunctivitis at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting. The patient underwent surgical symblepharon lysis with pannus removal in the right eye. B-VEC was administered to the patient&#8217;s right eye at regular intervals following surgery in addition to routine post-surgical management. B-VEC was well tolerated and associated with full corneal healing by 3 months as well as significant visual acuity improvement from hand motion to 20/40 at 7 months, the latest time point of the on-going treatment effect evaluation.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">In April 2023, the Company was informed by the Ministry of Health, Labour and Welfare (MHLW) of Japan that B-VEC was confirmed as safe for importation under the Cartagena Act. With the approval for importation of B-VEC under the Cartagena Act, we intend to start a small open label extension (&#8220;OLE&#8221;) study of B-VEC in Japan with an approval in Japan expected in early 2025.  </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">In April 2023, Jeune treated the first subject in the Phase 1, Cohort 3 study of KB301 for the improvement of lateral canthal lines at rest. The Phase 1, Cohort 3 study is being conducted at a single center as an open label study to evaluate two different doses of KB301 in up to 20 subjects. Improvement of lateral canthal lines at rest (&#8220;LCL&#8221;) was selected as a target indication for KB301 based upon the Phase 1 safety, efficacy and durability studies, which evaluated KB301 in the lower and upper cheek, including the lateral canthal region. Subjects will be followed for three months after KB301 treatment, and the study is expected to be completed in the second half of 2023. Following completion of this study, Jeune plans to initiate a Phase 2 study of KB301 in LCL.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date the impact of the COVID-19 pandemic on our business and clinical trials in the U.S. has been minimal.  Outside of the U.S., we experienced pandemic-related delays in clinical trial initiation in Australia. We will closely monitor any potential impact that future public health crises may have on our clinical trials. For additional information, please see "The effect of the COVID-19 pandemic or similar public health crises on our operations and the operations of our third-party partners could cause a disruption of the development efforts for our product candidates and adversely impact our business" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. </span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no approved products for commercial marketing or sale and have not generated any revenue from the sale of products or other sources to date. In the future, we may generate revenue from product sales, royalties on product sales, or license fees, milestones, or other upfront payments if we enter into any collaborations or license agreements. We expect that our future revenue will fluctuate from quarter to quarter for many reasons, including the uncertain timing and amount of any such sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred to advance our preclinical and clinical candidates, which include:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract manufacturing organizations, contract research organizations, consultants and other vendors that conduct our preclinical activities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of acquiring, developing and manufacturing clinical trial materials and lab supplies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility costs, depreciation and other expenses, which include direct expenses for rent and maintenance of facilities and other supplies; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payroll related expenses, including stock-based compensation expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense internal research and development costs to operations as incurred. We expense third-party costs for research and development activities, such as the manufacturing of preclinical and clinical materials, based on an evaluation of the progress to completion of specific tasks such as manufacturing of drug substance, fill/finish and stability testing, which is provided to us by our vendors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses will increase as we continue the manufacturing of preclinical and clinical materials and manage the clinical trials of, and seek regulatory approval for, our product candidates and expand our product portfolio. In the near term, we expect that our research and development expenses will increase as we continue our open label extension study for B-VEC, resume dosing with KB105 Phase&#160;1/2 clinical trial, continue the Phase 1, Cohort 3 study and initiate a Phase 2 trial for KB301, initiate Phase 1 trials for KB407, initiate a Phase 1 trial for KB104, and incur preclinical expenses for our other product candidates. Due to the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration, costs and timing of clinical trials, and, as a result, the actual costs to complete clinical trials may exceed the expected costs.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist principally of salaries and other related costs, including stock-based compensation for personnel in our executive, commercial, business development and other administrative functions. General and administrative expenses also include professional fees associated with corporate and intellectual property-related legal expenses, consulting and accounting services, facility-related costs and expenses associated with obtaining and maintaining patents. Other general and administrative costs include travel expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future to support the continued research and development of our product candidates and our commercial and operational goals. These increases will likely include increased costs for insurance, costs related to the hiring of additional personnel and payments to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate that we will continue to increase our salary and personnel costs and other expenses as a result of our preparation for commercial operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASTRA Capital Expenditures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we closed on the purchase of the building that was constructed to house our second CGMP facility, ASTRA. We are currently in the process of constructing the interior build-out of this facility and we have entered into a contract with Whiting-Turner who manages the construction of ASTRA. The Company placed a portion of ASTRA into service during the three months ended March&#160;31, 2023 as it was determined that certain assets were ready for their intended use. On March 27, 2023, the Company received the permanent occupancy permit for ASTRA which allowed the Company to begin utilizing certain portions of the building. As certain building improvements and certain qualification activities are still underway, the Company will continue to hold the remaining assets within construction in progress until validation has been completed and the assets are ready for their intended use. Validation of the facility is expected to be completed in 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income&#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income consists primarily of income earned from our cash, cash equivalents and investments.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, and Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes during the three months ended March&#160;31, 2023 to our critical accounting policies, significant judgments and estimates as disclosed in our management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2023 and 2022</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:56.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,399)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,823)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,222)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,297)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,965)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development expenses increased $3.0 million in the three months ended March&#160;31, 2023 compared to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2022. The increase was primarily due to increased payroll related expenses of $2.4 million, which were primarily driven by an increase in headcount to support overall growth, and includes a $1.1 million increase in stock-based compensation, an increase in outsourced research and development activities of $432 thousand, and increased other research and development expenses of $1.2 million, primarily due to depreciation, facilities expenses, license and regulatory fees, and software related costs. The increase was partially offset by decreases in preclinical, clinical and pre-commercial manufacturing expenses of $1.0 million, due to fewer receipts of raw materials and lab supplies period over period that were purchased for planned manufacturing runs of the Company&#8217;s products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs relating to the preclinical and clinical development of our product candidates and preclinical programs. Direct research and development expenses associated with our product candidates or development programs consist of compensation related expenses for our internal resources conducting research and development activities, fees paid to external consultants, contract research organizations, or for costs to support our clinical trials. Indirect research and development expenses that are allocated to our product candidates or programs consist of lab supplies and software fees. A significant portion of our research and development expenses are not allocated to individual product candidates and preclinical programs, as certain expenses benefit multiple product candidates and pre-clinical programs. For example, we do not allocate costs associated with stock-based compensation, manufacturing of preclinical or clinical development products or costs relating to facilities and equipment to individual product candidates and preclinical programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expense by product candidate or program, and for unallocated expenses, by type, for the quarters ended March&#160;31, 2023 and 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.391%"><tr><td style="width:1.0%"></td><td style="width:54.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B-VEC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387</span></td><td colspan="3" style="background-color:#cceeff;padding:0 3.77pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KB105</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KB407</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KB301</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other dermatology programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other respiratory programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other aesthetics programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated manufacturing expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(583)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,288</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 3.77pt 0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,314</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,974</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:14.492%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Unallocated manufacturing expenses consist of shared pre-commercial manufacturing costs, primarily relating to raw materials, contract manufacturing, contract testing, process development, quality control and quality assurance activities and other manufacturing costs which support the development of multiple product candidates in our preclinical and clinical development programs. </span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other unallocated expenses include rental, storage, depreciation, and other facility related costs that we do not allocate to our individual product candidates.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, research and development expense increased </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.0 million in the three months ended March&#160;31, 2023 compared to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2022. Expenses for B-VEC increased $844 thousand, due to increased payroll related expenses to support pre-approval activities, clinical trial costs, license and regulatory costs and increased allocated research and development expenses. KB105 and other development programs spending increased primarily due to payroll related costs. Spending on other research programs increased by $385 thousand due primarily to increased internal resources and other payroll related costs and an increase from allocated research and development expenses. Stock-based compensation increased $1.1 million due to an increase in internal resources to support overall research and development growth. Additionally, other unallocated expenses increased $682 thousand primarily related to increases in depreciation expense. These increases were offset by a decrease in other unallocated manufacturing expenses of $583 thousand due to fewer receipts of raw materials period over period that were purchased for planned manufacturing runs of the Company&#8217;s products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $8.1 million in the three months ended March&#160;31, 2023 as compared to the three months ended March&#160;31, 2022. Higher general and administrative spending was due largely to increases in payroll related expenses of approximately $7.0 million, which was primarily driven by an increase in headcount in our commercial and other administrative functions to support overall growth and preparation for commercialization, and includes a $2.9 million increase in stock-based compensation, increased marketing costs of $919 thousand, increased software-related costs of $253 thousand, increased travel related costs of $232 thousand, and an increase in other general and administrative expenses of $456 thousand, which consisted primarily of increased information technology costs and utilities costs. These increases were partially offset by a net decrease of legal costs of $434 thousand, which consists of decreased legal and professional fees of $943 thousand offset by a decrease in litigation related insurance proceeds of approximately $509 thousand, due primarily to the settlement of the PeriphaGen litigation, and a decrease in medical affairs costs of $277 thousand.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Settlement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation settlement for the three months ended March&#160;31, 2023 and 2022 was $12.5 million and $25.0 million, respectively, and consisted of amounts related to the settlement of litigation with PeriphaGen.  For the three months ended March&#160;31, 2023, in accordance with ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we determined that FDA approval of B-VEC was probable, and recorded expense relating to the first milestone payment, which becomes payable upon the approval of our first product by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FDA. See "Legal Proceedings" in Note 6 of the notes to condensed consolidated financial statements included in this Form 10-Q for more information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and Other Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income for the three months ended March&#160;31, 2023 and 2022 was $3.5 million and $257 thousand, respectively, and consisted of interest and dividend income earned from our cash, cash equivalents and investments. The increase in interest and dividend income is the result of increased investment activity and more favorable interest rates as compared to the prior period.</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_70"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2023, our cash, cash equivalents and short-term investments balance was approximately $350.4 million. Since operations began, we have incurred operating losses. Our net losses were $45.3 million and $50.0 million for the three months ended March&#160;31, 2023 and 2022, respectively. At March&#160;31, 2023, we had an accumulated deficit of $326.1&#160;million. We believe that our cash, cash equivalents and short-term investments as of March&#160;31, 2023 will be sufficient to allow us to fund operations for at least 12 months from the filing date of this Quarterly Report on Form 10-Q. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of our product candidates and the achievement of a level of revenues adequate to support our cost structure. Furthermore, we expect to incur increasing costs associated with satisfying regulatory and quality standards, maintaining product and clinical trials, and furthering our efforts around our current and future product candidates. We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital or obtain financing from other sources. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to clinical trials can be unpredictable and therefore there can be no guarantee that we will have sufficient capital to fund our continued clinical studies of B-VEC, KB105, KB407, KB301 or our planned clinical and preclinical studies for our other product candidates, or our operations.  Further, we do not expect to generate any product revenues until 3Q 2023, at the earliest, assuming we receive marketing approval for B-VEC on the schedule we currently contemplate. While we are in the process of building out our internal vector manufacturing capacity, some of our manufacturing activities will be contracted out to third parties. Additionally, we currently utilize third-party contract research organizations to carry out some of our clinical development activities. As we seek to obtain regulatory approval for our product candidates, we expect to continue to incur significant manufacturing and commercialization expenses as we prepare for product sales, marketing, commercial manufacturing, packaging, labeling and distribution. Furthermore, pursuant to our settlement agreement with PeriphaGen, we will be required to pay $12.5 million upon the approval of our first product by the FDA, followed by three additional $12.5 million contingent milestone payments upon reaching $100.0 million in total cumulative sales, $200.0 million in total cumulative sales and $300.0 million in total cumulative sales.  Our funds may not be sufficient to enable us to conduct pivotal clinical trials for, seek marketing approval for or commercially launch B-VEC, KB105, KB407, KB301 or any other product candidate. Accordingly, to obtain marketing approval for and to commercialize these or any other product candidates, we may be required to obtain further funding through public or private equity offerings, debt financings, collaboration and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, if at all. Our failure to raise capital when needed could have a negative effect on our financial condition and our ability to pursue our business strategy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be for the near future, compensation and related expenses, manufacturing costs for preclinical and clinical materials, third-party clinical trial research and development services, laboratory and related supplies, pre-commercialization costs, legal and other regulatory expenses, payments of settlement amounts to PeriphaGen and general overhead costs.  In order to complete the process of obtaining regulatory approval for any of our product candidates and to build the sales, manufacturing, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we may require substantial additional funding.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timeline and cost of our OLE study for B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and costs of our ongoing Phase 1/2 clinical trials for KB105;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and costs of our Phase 1, Cohort 3 study and Phase 2 clinical trials for KB301;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and costs of our KB407 clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and costs of manufacturing of B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued development and the filing of an IND application for current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, progress, timing, costs and results of drug discovery, laboratory testing, manufacturing, preclinical studies and clinical trials for any other product candidates that we may pursue in the future, if any;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of maintaining our own commercial-scale CGMP manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and costs of seeking regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the manufacturing process development and evaluation of third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the costs of our product candidates, if approved, will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities for our current and future product candidates if we receive marketing approval for such product candidates we may develop, including the costs and timing of establishing product sales, medical affairs, marketing, distribution and manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to receipt of marketing approval, if any, revenue received from commercial sale of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or other intellectual property rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current license agreements remaining in effect and our achievement of milestones under those agreements;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and licenses on favorable terms, if at all; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we&#160;acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain substantial additional funding in order to receive regulatory approval and to commercialize our product candidates. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely affect our ability to conduct our business. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back or discontinue the development or commercialization of our product candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to our product candidates that we otherwise would seek to develop or commercialize ourselves.&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for the three months ended March&#160;31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.985%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,156)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,155)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,943)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2023 was $26.2&#160;million and consisted primarily of a net loss of $45.3&#160;million adjusted for non-cash items primarily comprised of stock-based compensation expense of $10.4&#160;million and depreciation and amortization of $705 thousand, and cash provided by decreases in net working capital of approximately $8.6&#160;million which includes an increase in accrued legal settlement of $12.5 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March 31, 2022 was $15.5 million and consisted primarily of a net loss of $50.0 million adjusted for non-cash items primarily of depreciation and amortization and stock-based compensation expense of $7.3 million, and cash provided by decreases in net working capital of approximately $27.2 million which includes an increase in accrued legal settlement of $25.0 million.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March&#160;31, 2023 was $3.6&#160;million and consisted primarily of  proceeds of $154.5&#160;million received from the maturities of short-term investments, partially offset by expenditures of $5.4&#160;million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, and $145.6 million on the purchase of short-term and long-term investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March 31, 2022 was $55.9 million and consisted primarily of expenditures of $17.2 million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, $62.8 million on the purchase of short-term and long-term investments, partially offset by proceeds of $24.0 million received from the maturities of short-term investments.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2023 was $1.5&#160;million and consisted primarily of proceeds of $2.2&#160;million received from exercises of stock options and partially offset by $749&#160;thousand used for the employee tax withholding payment for settlement of vested restricted stock awards. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used by financing activities for the three months ended March 31, 2022 was $542 thousand and consisted primarily of proceeds of $107 thousand received from exercises of stock options and offset by $649 thousand used for the employee tax withholding payment for settlement of vested restricted stock awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Qualitative and Quantitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and short-term investments of $350.4 million at March&#160;31, 2023, which consist primarily of money market, bank deposits, commercial paper, corporate bonds, and government agency securities. The investments in these financial instruments are made in accordance with an investment policy which specifies the categories, allocations and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments in which we invest could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. To minimize this risk, we intend to maintain a portfolio which may include cash, cash equivalents and short and long-term investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates. Based on our current investment portfolio, we do not believe that our results of operations or our financial position would be materially affected by an immediate change of 10% in interest rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and short-term investments have a significant risk of default or illiquidity. While we believe our cash, cash equivalents and short-term investments do not contain excessive risk, we cannot provide absolute assurance that the investments we make in the future will not be subject to adverse changes in market value. Our cash, cash equivalents and short and long-term investments are recorded at fair value.</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and our Chief Accounting Officer, with the participation of other members of the Company&#8217;s management, have evaluated the effectiveness of the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;)) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Accounting Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting during the quarter ended March&#160;31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_82"></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under the heading &#8220;Legal Proceedings&#8221; in Note 6 of the notes to condensed consolidated financial statements included in Item 1 of Part I of this Form 10-Q is incorporated by reference in response to this item.</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in "Summary Risk Factors" and "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on February 27, 2023, there are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. There have been no material changes from the risk factors previously disclosed in such filing.</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information with respect to purchases of our equity securities during the quarter ended March 31, 2023:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of shares (or units) purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average price paid per share (or unit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of shares (or units) purchased as part of publicly announced plans or programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maximum number                                    (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2023 - January 31,2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1, 2023 - February 28, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2023 - March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    Represents shares withheld from employees for taxes resulting from the vesting of restricted stock awards.</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20230331ex101rsu.htm">Form of Time-Based Restricted Stock Unit Award Agreement under the 2017 IPO Stock Incentive Plan</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20230331ex102psu.htm">Form of Performance-Based Restricted Stock Unit Award Agreement under the 2017 IPO Stock Incentive Plan</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20230331ex311.htm">Certification of Periodic Report by Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20230331ex312.htm">Certification of Periodic Report by Chief Accounting Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20230331ex321.htm">Certification of Chief Executive Officer and Chief Accounting Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL (Extensible Business Reporting Language). The following materials from this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2023, are formatted in Inline XBRL: (i) consolidated balance sheets of Krystal Biotech, Inc., (ii) consolidated statements of operations of Krystal Biotech, Inc., (iii) consolidated statements of comprehensive income/(loss) of Krystal Biotech, Inc., (iv) consolidated statements of changes in equity of Krystal Biotech, Inc., (v) consolidated statements of cash flows of Krystal Biotech, Inc. and (vi) notes to consolidated financial statements of Krystal Biotech, Inc. The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL. </span></div></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#    Indicates a management contract or compensatory plan or arrangement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i2bdcf3ebe02d404d9f9330c0d4eecb0d_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.240%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KRYSTAL BIOTECH, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;8, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal executive officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial and accounting officer)</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>krys-20230331ex101rsu.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i46193278230c45ffacc3b5213a12153c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="padding-left:24.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.743%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KRYSTAL BIOTECH, INC. 2017 IPO STOCK INCENTIVE PLAN<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NOTICE OF RESTRICTED STOCK UNIT AWARD</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grantee&#8217;s Name and Address&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You (the &#8220;Grantee&#8221;) have been granted an award of Restricted Stock Units (the &#8220;RSUs&#8221;), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the &#8220;Notice&#8221;), the Krystal Biotech, Inc. 2017 IPO Stock Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;), and the Restricted Stock Unit Award Agreement (the &#8220;Agreement&#8221;) attached hereto, as follows.  Unless otherwise provided herein, the terms in this Notice shall have the same meaning as those defined in the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Award Number&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of Award&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting Commencement Date&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Number of RSUs&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the Grantee&#8217;s Continuous Service and other limitations set forth in this Notice, the Agreement and the Plan, the RSUs will &#8220;vest&#8221; in accordance with the following schedule (the &#8220;Vesting Schedule&#8221;)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The unvested RSUs shall vest ratably over a four year period with one-fourth of the unvested RSUs vesting on the Vesting Commencement Date and one-fourth vesting on each anniversary thereafter until all unvested RSUs have vested.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During any authorized leave of absence, the vesting of the RSUs as provided in this schedule shall be suspended after the leave of absence exceeds a period of three (3) months.  Vesting of the RSUs shall resume upon the Grantee&#8217;s termination of the leave of absence and return to service to the Company or a Related Entity.  The Vesting Schedule of the RSUs shall be extended by the length of the suspension.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event of the Grantee&#8217;s change in status from Employee, Director or Consultant to any other status of Employee, Director or Consultant, the RSUs shall continue to vest in accordance with the Vesting Schedule set forth above.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Grantee would become vested in a fraction of an RSU, such RSU shall not vest until the Grantee becomes vested in the entire RSU.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting shall cease upon the date of termination of the Grantee&#8217;s Continuous Service for any reason, including death or Disability.  In the event the Grantee&#8217;s Continuous Service is terminated for any reason, including death or Disability, all unvested RSUs will be forfeited to the Company, and all rights of the Grantee to such RSUs will immediately terminate without payment of any consideration to the Grantee.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The RSUs shall be subject to the provisions of Section 11 of the Plan in the event of a Corporate Transaction or Change in Control.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Company and the Grantee have executed this Notice and agree that the RSUs are to be governed by the terms and conditions of this Notice, the Plan and the Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krystal Biotech, Inc.,<br>a Delaware corporation</font></div><div style="margin-top:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THE GRANTEE ACKNOWLEDGES AND AGREES THAT THE RSUS SHALL VEST, IF AT ALL, ONLY DURING THE PERIOD OF THE GRANTEE&#8217;S CONTINUOUS SERVICE OR AS OTHERWISE SPECIFICALLY PROVIDED HEREIN (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THESE RSUS OR ACQUIRING SHARES HEREUNDER).  THE GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS NOTICE, THE AGREEMENT, OR THE PLAN SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH RESPECT TO FUTURE AWARDS OR CONTINUATION OF THE GRANTEE&#8217;S CONTINUOUS SERVICE, NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE&#8217;S RIGHT OR THE RIGHT OF THE COMPANY OR RELATED ENTITY TO WHICH THE GRANTEE PROVIDES SERVICES TO TERMINATE THE GRANTEE&#8217;S CONTINUOUS SERVICE AT ANY TIME, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT NOTICE.  THE GRANTEE ACKNOWLEDGES THAT UNLESS THE GRANTEE HAS A WRITTEN EMPLOYMENT AGREEMENT WITH THE COMPANY TO THE CONTRARY, THE GRANTEE&#8217;S STATUS IS AT WILL.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Grantee acknowledges receipt of a copy of the Plan and the Agreement and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts the RSUs subject to all of the terms and provisions hereof and thereof.  The Grantee has reviewed this Notice, the Agreement and the Plan in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Notice and fully understands all provisions of this Notice, the Agreement and the Plan.  The Grantee hereby agrees that all questions of interpretation and administration relating to this Notice, the Plan and the Agreement shall be resolved by the Administrator in accordance with Section 10 of the Agreement.  The Grantee further agrees to the venue selection and waiver of a jury trial in accordance with Section 11 of the Agreement.  The Grantee further agrees to notify the Company upon any change in the residence address indicated in this Notice.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver this Notice, the Agreement, the Plan and the Plan prospectus (collectively, the &#8220;Plan Documents&#8221;) to the Grantee by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  The Grantee hereby agrees to Company&#8217;s provision to the Grantee of these documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">If the Grantee does not accept or decline this RSU award within 90 days of the Date of Award or by such other date that may be communicated the Grantee by the Company, the Company will accept this RSU award on the Grantee&#8217;s behalf and Grantee will be deemed to have accepted the terms and conditions of the RSUs set forth in the Plan and the Award Agreement. If the Grantee wishes to decline this RSU award, the Grantee should promptly notify the Company at 412-586-5830. If Grantee declines this RSU award, the RSUs will be cancelled and no benefits from the RSUs nor any compensation or benefits in lieu of the RSUs will be provided to Grantee.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Grantee acknowledges that the Grantee has access to the Company&#8217;s intranet and has either received electronic or paper copies of the Plan Documents.</font></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Signed&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KRYSTAL BIOTECH, INC. 2017 IPO STOCK INCENTIVE PLAN<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Grant of RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Krystal Biotech, Inc., a Delaware corporation (the &#8220;Company&#8221;), hereby grants to the Grantee (the &#8220;Grantee&#8221;) named in the Notice of Restricted Stock Unit Award (the &#8220;Notice&#8221;), the Total Number of RSUs set forth in the Notice, subject to the Notice, this Restricted Stock Unit Award Agreement (the &#8220;Agreement&#8221;) and the terms and provisions of the Company&#8217;s 2017 IPO Stock Incentive Plan (the &#8220;Plan&#8221;), as amended from time to time, which are incorporated herein by reference. An RSU is a non-voting unit of measurement which is deemed solely for bookkeeping purposes to be equivalent to one outstanding Share.  The RSUs are used solely as a device to determine the number of Shares to eventually be issued to Grantee if such RSUs vest. The RSUs shall not be treated as property or as a trust fund of any kind. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Agreement.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">On or as soon as administratively practical (and within thirty (30) days) following the applicable date of vesting under the Vesting Schedule set forth in the Notice (a &#8220;Vesting Date&#8221;), the Company will deliver to Grantee a number of Shares (either by delivering one or more certificates for such Shares or by entering such Shares in book entry form, as determined by the Company in its discretion) equal to the number of RSUs that vest on the applicable Vesting Date, subject to the satisfaction of any applicable tax withholding obligations. No fractional RSUs or rights for fractional Shares shall be created pursuant to this Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The Company reserves the right to issue to the Grantee the cash equivalent of Shares, in part or in full satisfaction of the delivery of Shares, upon vesting of the RSUs, and to the extent applicable, references in the Agreement to Shares issuable in connection with the RSUs will include the potential issuance of its cash equivalent pursuant to such right.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividend and Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless and until such time as Shares are issued in settlement of vested RSUs, the Grantee will have no ownership of the Shares allocated to the RSUs, and will have no rights to vote such Shares and no rights to dividends.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Transfer Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The RSUs and any interest therein may not be sold, transferred by gift, pledged, hypothecated, or otherwise transferred or disposed of in any manner other than by will or the laws of descent or distribution or court order. The terms of the RSUs shall be binding upon the executors, administrators, heirs, successors and assigns of the Grantee.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Termination of Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If the Grantee&#8217;s Continuous Service terminates for any reason, including death or Disability, all unvested RSUs will be forfeited to the Company, and all rights of the Grantee to such RSUs will immediately terminate without payment of any consideration to the Grantee. The Administrator shall have the exclusive discretion to determine when the Grantee is no longer actively providing services for purposes of his or her RSU grant (including whether the Grantee may still be considered to be providing services while on a leave of absence).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt;text-decoration:underline">Tax Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Grantee is ultimately liable and responsible for all taxes owed by the Grantee in connection with the RSUs, regardless of any action the Company or any Related Entity takes with respect to any tax withholding obligations that arise in connection with the RSUs.  Neither the Company nor any Related Entity makes any representation or undertaking regarding the treatment of any tax withholding in connection with the grant or vesting of the RSUs or the subsequent sale of Shares issued in settlement of the RSUs.  The Company and its Related Entities do not commit and are under no obligation to structure the RSUs to reduce or eliminate the Grantee&#8217;s tax liability.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Payment of Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Prior to any event in connection with the RSUs that the Company determines may result in any tax withholding obligation, whether United States federal, state, local or non-U.S., including any social insurance, employment tax, payment on account or other tax-related obligation (the &#8220;Tax </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Withholding Obligation&#8221;), the Grantee must arrange for the satisfaction of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.57pt">By Share Withholding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding Section 7(c) of the Plan, if permissible under Applicable Law, the Administrator may permit the Grantee to elect to authorize the Company to withhold from those Shares otherwise issuable upon settlement of the RSUs to the Grantee the whole number of Shares sufficient to satisfy up to the maximum applicable Tax Withholding Obligation.  The maximum applicable Tax Withholding Obligation is based on the applicable rates of the relevant tax authorities (for example, federal, state and local), including the Grantee&#8217;s share of payroll or similar taxes, as provided in the tax law, regulations or the authority&#8217;s administrative practices, not to exceed the highest statutory rate in that jurisdiction.  Any elections to have Shares withheld or sold for this purpose will be made in accordance with the requirements established by the Administrator for such elections and be in writing in a form acceptable to the Administrator.  Further, if permissible under Applicable Law, the Grantee hereby authorizes the Company to, upon the exercise of its sole discretion, withhold from those Shares otherwise issuable to the Grantee the whole number of Shares sufficient to satisfy the minimum applicable Tax Withholding Obligation.  The Grantee acknowledges that the withheld Shares may still not be sufficient to satisfy the Grantee&#8217;s minimum Tax Withholding Obligation.  Accordingly, the Grantee agrees to pay to the Company or any Related Entity as soon as practicable, including through additional payroll withholding, any amount of the Tax Withholding Obligation that is not satisfied by the withholding of Shares described above.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:23.8pt">By Check, Wire Transfer or Other Means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  At any time not less than five (5) business days (or such fewer number of business days as determined by the Administrator) before any Tax Withholding Obligation arises (e.g., a vesting date), the Grantee may elect to satisfy the Grantee&#8217;s Tax Withholding Obligation by delivering to the Company an amount that the Company determines is sufficient to satisfy the Tax Withholding Obligation by (x) wire transfer to such account as the Company may direct, (y) delivery of a certified check payable to the Company, or (z) such other means as specified from time to time by the Administrator.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, the Company or a Related Entity also may satisfy any Tax Withholding Obligation by offsetting any amounts (including, but not limited to, salary, bonus and severance payments) payable to the Grantee by the Company and&#47;or a Related Entity.  Furthermore, in the event of any determination that the Company and&#47;or a Related Entity has failed to withhold a sum sufficient to pay all withholding taxes due in connection with the RSUs, the Grantee agrees to pay the Company and&#47;or the Related Entity the amount of such deficiency in cash within five (5) days after receiving a written demand from the Company and&#47;or the Related Entity to do so, whether or not the Grantee is an employee of the Company and&#47;or the Related Entity at that time.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Stop-Transfer Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In order to ensure compliance with the restrictions on transfer set forth in this Agreement, the Notice or the Plan, the Company may issue appropriate &#8220;stop transfer&#8221; instructions to its transfer agent, if any, and, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records.  The Company may issue a &#8220;stop transfer&#8221; instruction if the Grantee fails to satisfy any Tax Withholding Obligations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Entire Agreement&#58; Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Notice, the Plan and this Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Grantee with respect to the subject matter hereof, and may not be modified adversely to the Grantee&#8217;s interest except by means of a writing signed by the Company and the Grantee.  These agreements are to be construed in accordance with and governed by the internal laws of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of Delaware to the rights and duties of the parties.  Should any provision of the Notice or this Agreement be determined to be illegal or unenforceable, the other provisions shall nevertheless remain effective and shall remain enforceable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The captions used in the Notice and this Agreement are inserted for convenience and shall not be deemed a part of the RSU award for construction or interpretation.  Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.  Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Administration and Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any question or dispute regarding the administration or interpretation of the Notice, the Plan or this Agreement shall be submitted by the Grantee or by the Company to the Administrator.  The resolution of such question or dispute by the Administrator shall be final and binding on all persons.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Venue and Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The parties agree that any suit, action, or proceeding arising out of or relating to the Notice, the Plan or this Agreement shall be brought in the United States District Court for Delaware (or should such court lack jurisdiction to hear such action, suit or proceeding, in a Delaware state court) and that the parties shall submit to the jurisdiction of such court.  The parties irrevocably waive, to the fullest extent permitted by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">law, any objection the party may have to the laying of venue for any such suit, action or proceeding brought in such court.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">THE PARTIES ALSO EXPRESSLY WAIVE ANY RIGHT THEY HAVE OR MAY HAVE TO A JURY TRIAL OF ANY SUCH SUIT, ACTION OR PROCEEDING.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If any one or more provisions of this Section 11 shall for any reason be held invalid or unenforceable, it is the specific intent of the parties that such provisions shall be modified to the minimum extent necessary to make it or its application valid and enforceable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery, upon deposit for delivery by an internationally recognized express mail courier service or upon deposit in the United States mail by certified mail (if the parties are within the United States), with postage and fees prepaid, addressed to the other party at its address as shown in these instruments, or to such other address as such party may designate in writing from time to time to the other party.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If the Grantee has received this Agreement or any other document related to the Plan translated into a language other than English and if the translated version is different than the English version, the English version will control, unless otherwise prescribed by Applicable Law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Nature of RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In accepting the RSUs, the Grantee acknowledges and agrees that&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, unless otherwise provided in the Plan and this Agreement&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the RSU award is voluntary and occasional and does not create any contractual or other right to receive future awards, or benefits in lieu of awards, even if awards have been awarded repeatedly in the past&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">the Grantee&#8217;s participation in the Plan shall not create a right to any employment with the Grantee&#8217;s employer and shall not interfere with the ability of the Company or the employer to terminate the Grantee&#8217;s employment relationship, if any, at any time&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.01pt">the RSU is not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company or any Related Entity&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">in the event that the Grantee is not an Employee of the Company or any Related Entity, the RSU award and the Grantee&#8217;s participation in the Plan will not be interpreted to form an employment or service contract or relationship with the Company or any Related Entity&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the future value of the underlying Shares is unknown and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">in consideration of the RSUs, no claim or entitlement to compensation or damages shall arise from termination of the RSUs or diminution in value of the RSUs or Shares acquired upon vesting of the RSUs, resulting from termination of the Grantee&#8217;s Continuous Service by the Company or any Related Entity (for any reason whatsoever and whether or not in breach of local labor laws) and in consideration of the grant of the RSUs, the Grantee irrevocably releases the Company and any Related Entity from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing the Notice, the Grantee shall be deemed irrevocably to have waived his or her right to pursue or seek remedy for any such claim or entitlement&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">in the event of termination of the Grantee&#8217;s Continuous Service (whether or not in breach of local labor laws), the Grantee&#8217;s right to receive RSUs under the Plan and to vest in such RSUs, if any, will (except as otherwise provided in the Notice or herein) terminate effective as of the date that the Grantee is no longer providing services and will not be extended by any notice period mandated under local law (e.g., providing services would not include a period of &#8220;garden leave&#8221; or similar period pursuant to local law)&#59; furthermore, in the event of termination of the Grantee&#8217;s Continuous Service (whether or not in breach of local labor laws), the Administrator shall have the exclusive discretion to determine when the Grantee is no longer providing services for purposes of the RSUs&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of Shares&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">the Grantee is hereby advised to consult with the Grantee&#8217;s own personal tax, legal and financial advisers regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.91pt">The Grantee hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Grantee&#8217;s personal data as described in the Notice and this Agreement by and among, as applicable, the Grantee&#8217;s employer, the Company and any Related Entity for the exclusive purpose of implementing, administering and managing the Grantee&#8217;s participation in the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.34pt">The Grantee understands that the Company and the Grantee&#8217;s employer may hold certain personal information about the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, date of birth, social insurance or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, vested, unvested or outstanding in the Grantee&#8217;s favor, for the exclusive purpose of implementing, administering and managing the Plan (&#8220;Data&#8221;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">The Grantee understands that Data will be transferred to any third party assisting the Company with the implementation, administration and management of the Plan.  The Grantee understands that the recipients of the Data may be located in the Grantee&#8217;s country, or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than the Grantee&#8217;s country.  The Grantee understands that the Grantee may request a list with the names and addresses of any potential recipients of the Data by contacting the Grantee&#8217;s local human resources representative.  The Grantee authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Grantee&#8217;s participation in the Plan.  The Grantee understands that Data will be held only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan.  The Grantee understands that the Grantee may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Grantee&#8217;s local human resources representative.  The Grantee understands, however, that refusal or withdrawal of consent may affect the Grantee&#8217;s ability to participate in the Plan.  For more information on the consequences of the Grantee&#8217;s refusal to consent or withdrawal of consent, the Grantee understands that the Grantee may contact the Grantee&#8217;s local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">END OF AGREEMENT</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>krys-20230331ex102psu.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i98a17251f35c4ebd9eff99cd4ab5d2b9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div></div><div style="padding-left:24.35pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.743%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KRYSTAL BIOTECH, INC. 2017 IPO STOCK INCENTIVE PLAN<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NOTICE OF PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grantee&#8217;s Name and Address&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You (the &#8220;Grantee&#8221;) have been granted an award of performance-based Restricted Stock Units (the &#8220;RSUs&#8221;), subject to the terms and conditions of this Notice of Performance-Based Restricted Stock Unit Award (the &#8220;Notice&#8221;), the Krystal Biotech, Inc. 2017 IPO Stock Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;), and the Performance-Based Restricted Stock Unit Award Agreement (the &#8220;Agreement&#8221;) attached hereto, as follows.  Unless otherwise provided herein, the terms in this Notice shall have the same meaning as those defined in the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Award Number&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of Award&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant Date&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Number of RSUs&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to the Grantee&#8217;s Continuous Service and other limitations set forth in this Notice, the Agreement and the Plan, the RSUs will &#8220;vest&#8221; in accordance with the following vesting conditions&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The RSUs are subject to both a performance condition (the &#8220;Performance Condition&#8221;) and a time-based condition (the &#8220;Service Condition&#8221;), which both must be satisfied for the RSUs to vest. Each installment of RSUs that become vested is a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.5pt">Performance Condition&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The satisfaction of the Performance Goals set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If the Performance Goals, or a portion of the Performance Goals, are not satisfied, then the corresponding RSUs will be forfeited, unvested (regardless of the Grantee&#8217;s satisfaction of the Service Condition), as of the determination by the Administrator that the Performance Goals were not satisfied. </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.5pt">Service Condition&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Service Condition shall be satisfied with respect to one-half of the RSUs on the one-year anniversary of the Grant Date and with respect to an additional one-half of the RSUs on the second anniversary of the Grant Date (the &#8220;Service Vesting Schedule&#8221;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During any authorized leave of absence, the Service Condition vesting of the RSUs as provided in this schedule shall be suspended after the leave of absence exceeds a period of three (3) months.  Service Condition vesting of the RSUs shall resume upon the Grantee&#8217;s termination of the leave of absence and return to service to the Company or a Related Entity.  The Service Vesting Schedule of the RSUs shall be extended by the length of the suspension.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event of the Grantee&#8217;s change in status from Employee, Director or Consultant to any other status of Employee, Director or Consultant, the RSUs shall continue to vest in accordance with the Service Vesting Schedule set forth above.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Grantee would become vested in a fraction of an RSU, such RSU shall not vest until the Grantee becomes vested in the entire RSU.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting shall cease upon the date of termination of the Grantee&#8217;s Continuous Service for any reason, including death or Disability.  In the event the Grantee&#8217;s Continuous Service is terminated for any reason, including death or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disability, all unvested RSUs will be forfeited to the Company, including, for the avoidance of doubt, any RSUs for which the Performance Condition has been achieved but the Service Condition has not been achieved, and all rights of the Grantee to such RSUs will immediately terminate without payment of any consideration to the Grantee.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The RSUs shall be subject to the provisions of Section 11 of the Plan in the event of a Corporate Transaction or Change in Control.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Company and the Grantee have executed this Notice and agree that the RSUs are to be governed by the terms and conditions of this Notice, the Plan and the Agreement.</font></div><div style="margin-top:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krystal Biotech, Inc.,<br>a Delaware corporation</font></div><div style="margin-top:24pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THE GRANTEE ACKNOWLEDGES AND AGREES THAT THE RSUS SHALL VEST, IF AT ALL, ONLY DURING THE PERIOD OF THE GRANTEE&#8217;S CONTINUOUS SERVICE OR AS OTHERWISE SPECIFICALLY PROVIDED HEREIN (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THESE RSUS OR ACQUIRING SHARES HEREUNDER).  THE GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS NOTICE, THE AGREEMENT, OR THE PLAN SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH RESPECT TO FUTURE AWARDS OR CONTINUATION OF THE GRANTEE&#8217;S CONTINUOUS SERVICE, NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE&#8217;S RIGHT OR THE RIGHT OF THE COMPANY OR RELATED ENTITY TO WHICH THE GRANTEE PROVIDES SERVICES TO TERMINATE THE GRANTEE&#8217;S CONTINUOUS SERVICE AT ANY TIME, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT NOTICE.  THE GRANTEE ACKNOWLEDGES THAT UNLESS THE GRANTEE HAS A WRITTEN EMPLOYMENT AGREEMENT WITH THE COMPANY TO THE CONTRARY, THE GRANTEE&#8217;S STATUS IS AT WILL.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Grantee acknowledges receipt of a copy of the Plan and the Agreement and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts the RSUs subject to all of the terms and provisions hereof and thereof.  The Grantee has reviewed this Notice, the Agreement and the Plan in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Notice and fully understands all provisions of this Notice, the Agreement and the Plan.  The Grantee hereby agrees that all questions of interpretation and administration relating to this Notice, the Plan and the Agreement shall be resolved by the Administrator in accordance with Section 10 of the Agreement.  The Grantee further agrees to the venue selection and waiver of a jury trial in accordance with Section 11 of the Agreement.  The Grantee further agrees to notify the Company upon any change in the residence address indicated in this Notice.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company may, in its sole discretion, decide to deliver this Notice, the Agreement, the Plan and the Plan prospectus (collectively, the &#8220;Plan Documents&#8221;) to the Grantee by electronic means or request the Grantee&#8217;s consent to participate in the Plan by electronic means.  The Grantee hereby agrees to Company&#8217;s provision to the Grantee of these documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">If the Grantee does not accept or decline this RSU award within 90 days of the Date of Award or by such other date that may be communicated the Grantee by the Company, the Company will accept this RSU award on the Grantee&#8217;s behalf and Grantee will be deemed to have accepted the terms and conditions of the RSUs set forth in the Plan and the Award Agreement. If the Grantee wishes to decline this RSU award, the Grantee should promptly notify the Company at 412-586-5830. If Grantee declines this RSU award, the RSUs will be cancelled and no benefits from the RSUs nor any compensation or benefits in lieu of the RSUs will be provided to Grantee.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Grantee acknowledges that the Grantee has access to the Company&#8217;s intranet and has either received electronic or paper copies of the Plan Documents.</font></div><div style="margin-top:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Signed&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KRYSTAL BIOTECH, INC. 2017 IPO STOCK INCENTIVE PLAN<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Grant of RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Krystal Biotech, Inc., a Delaware corporation (the &#8220;Company&#8221;), hereby grants to the Grantee (the &#8220;Grantee&#8221;) named in the Notice of Performance-Based Restricted Stock Unit Award (the &#8220;Notice&#8221;), the Total Number of RSUs set forth in the Notice, subject to the Notice, this Performance-Based Restricted Stock Unit Award Agreement (the &#8220;Agreement&#8221;) and the terms and provisions of the Company&#8217;s 2017 IPO Stock Incentive Plan (the &#8220;Plan&#8221;), as amended from time to time, which are incorporated herein by reference. An RSU is a non-voting unit of measurement which is deemed solely for bookkeeping purposes to be equivalent to one outstanding Share.  The RSUs are used solely as a device to determine the number of Shares to eventually be issued to Grantee if such RSUs vest. The RSUs shall not be treated as property or as a trust fund of any kind. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Agreement.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">On or as soon as administratively practical (and within thirty (30) days) following the applicable date of Service Condition (as defined in the Notice) vesting under the Service Vesting Schedule set forth in the Notice (a &#8220;Vesting Date&#8221;), the Company will deliver to Grantee a number of Shares (either by delivering one or more certificates for such Shares or by entering such Shares in book entry form, as determined by the Company in its discretion) equal to the number of RSUs that fully vest on the applicable Vesting Date, subject to the satisfaction of any applicable tax withholding obligations. No fractional RSUs or rights for fractional Shares shall be created pursuant to this Agreement.  For the avoidance of doubt, any RSUs that do not satisfy the Performance Condition (as defined in the Notice) shall be forfeited and shall not be settled in accordance with this Section 2(a).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The Company reserves the right to issue to the Grantee the cash equivalent of Shares, in part or in full satisfaction of the delivery of Shares, upon vesting of the RSUs, and to the extent applicable, references in the Agreement to Shares issuable in connection with the RSUs will include the potential issuance of its cash equivalent pursuant to such right.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividend and Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless and until such time as Shares are issued in settlement of vested RSUs, the Grantee will have no ownership of the Shares allocated to the RSUs, and will have no rights to vote such Shares and no rights to dividends.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Transfer Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The RSUs and any interest therein may not be sold, transferred by gift, pledged, hypothecated, or otherwise transferred or disposed of in any manner other than by will or the laws of descent or distribution or court order. The terms of the RSUs shall be binding upon the executors, administrators, heirs, successors and assigns of the Grantee.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Termination of Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If the Grantee&#8217;s Continuous Service terminates for any reason, including death or Disability, all unvested RSUs will be forfeited to the Company, and all rights of the Grantee to such RSUs will immediately terminate without payment of any consideration to the Grantee. The Administrator shall have the exclusive discretion to determine when the Grantee is no longer actively providing services for purposes of his or her RSU grant (including whether the Grantee may still be considered to be providing services while on a leave of absence).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt;text-decoration:underline">Tax Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Grantee is ultimately liable and responsible for all taxes owed by the Grantee in connection with the RSUs, regardless of any action the Company or any Related Entity takes with respect to any tax withholding obligations that arise in connection with the RSUs.  Neither the Company nor any Related Entity makes any representation or undertaking regarding the treatment of any tax withholding in connection with the grant or vesting of the RSUs or the subsequent sale of Shares issued in settlement of the RSUs.  The Company and its Related Entities do not commit and are under no obligation to structure the RSUs to reduce or eliminate the Grantee&#8217;s tax liability.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Payment of Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Prior to any event in connection with the RSUs that the Company determines may result in any tax withholding obligation, whether United States federal, state, local or non-U.S., </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">including any social insurance, employment tax, payment on account or other tax-related obligation (the &#8220;Tax Withholding Obligation&#8221;), the Grantee must arrange for the satisfaction of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:26.57pt">By Share Withholding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding Section 7(c) of the Plan, if permissible under Applicable Law, the Administrator may permit the Grantee to elect to authorize the Company to withhold from those Shares otherwise issuable upon settlement of the RSUs to the Grantee the whole number of Shares sufficient to satisfy up to the maximum applicable Tax Withholding Obligation.  The maximum applicable Tax Withholding Obligation is based on the applicable rates of the relevant tax authorities (for example, federal, state and local), including the Grantee&#8217;s share of payroll or similar taxes, as provided in the tax law, regulations or the authority&#8217;s administrative practices, not to exceed the highest statutory rate in that jurisdiction.  Any elections to have Shares withheld or sold for this purpose will be made in accordance with the requirements established by the Administrator for such elections and be in writing in a form acceptable to the Administrator.  Further, if permissible under Applicable Law, the Grantee hereby authorizes the Company to, upon the exercise of its sole discretion, withhold from those Shares otherwise issuable to the Grantee the whole number of Shares sufficient to satisfy the minimum applicable Tax Withholding Obligation.  The Grantee acknowledges that the withheld Shares may still not be sufficient to satisfy the Grantee&#8217;s minimum Tax Withholding Obligation.  Accordingly, the Grantee agrees to pay to the Company or any Related Entity as soon as practicable, including through additional payroll withholding, any amount of the Tax Withholding Obligation that is not satisfied by the withholding of Shares described above.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:23.8pt">By Check, Wire Transfer or Other Means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  At any time not less than five (5) business days (or such fewer number of business days as determined by the Administrator) before any Tax Withholding Obligation arises (e.g., a vesting date), the Grantee may elect to satisfy the Grantee&#8217;s Tax Withholding Obligation by delivering to the Company an amount that the Company determines is sufficient to satisfy the Tax Withholding Obligation by (x) wire transfer to such account as the Company may direct, (y) delivery of a certified check payable to the Company, or (z) such other means as specified from time to time by the Administrator.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, the Company or a Related Entity also may satisfy any Tax Withholding Obligation by offsetting any amounts (including, but not limited to, salary, bonus and severance payments) payable to the Grantee by the Company and&#47;or a Related Entity.  Furthermore, in the event of any determination that the Company and&#47;or a Related Entity has failed to withhold a sum sufficient to pay all withholding taxes due in connection with the RSUs, the Grantee agrees to pay the Company and&#47;or the Related Entity the amount of such deficiency in cash within five (5) days after receiving a written demand from the Company and&#47;or the Related Entity to do so, whether or not the Grantee is an employee of the Company and&#47;or the Related Entity at that time.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Stop-Transfer Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In order to ensure compliance with the restrictions on transfer set forth in this Agreement, the Notice or the Plan, the Company may issue appropriate &#8220;stop transfer&#8221; instructions to its transfer agent, if any, and, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records.  The Company may issue a &#8220;stop transfer&#8221; instruction if the Grantee fails to satisfy any Tax Withholding Obligations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Entire Agreement&#58; Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Notice, the Plan and this Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Grantee with respect to the subject matter hereof, and may not be modified adversely to the Grantee&#8217;s interest except by means of a writing signed by the Company and the Grantee.  These agreements are to be construed in accordance with and governed by the internal laws of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of Delaware to the rights and duties of the parties.  Should any provision of the Notice or this Agreement be determined to be illegal or unenforceable, the other provisions shall nevertheless remain effective and shall remain enforceable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The captions used in the Notice and this Agreement are inserted for convenience and shall not be deemed a part of the RSU award for construction or interpretation.  Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.  Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Administration and Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any question or dispute regarding the administration or interpretation of the Notice, the Plan or this Agreement shall be submitted by the Grantee or by the Company to the Administrator.  The resolution of such question or dispute by the Administrator shall be final and binding on all persons.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Venue and Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The parties agree that any suit, action, or proceeding arising out of or relating to the Notice, the Plan or this Agreement shall be brought in the United States District Court for Delaware (or should such court lack jurisdiction to hear such action, suit or proceeding, in a Delaware state court) and that the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">parties shall submit to the jurisdiction of such court.  The parties irrevocably waive, to the fullest extent permitted by law, any objection the party may have to the laying of venue for any such suit, action or proceeding brought in such court.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">THE PARTIES ALSO EXPRESSLY WAIVE ANY RIGHT THEY HAVE OR MAY HAVE TO A JURY TRIAL OF ANY SUCH SUIT, ACTION OR PROCEEDING.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If any one or more provisions of this Section 11 shall for any reason be held invalid or unenforceable, it is the specific intent of the parties that such provisions shall be modified to the minimum extent necessary to make it or its application valid and enforceable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery, upon deposit for delivery by an internationally recognized express mail courier service or upon deposit in the United States mail by certified mail (if the parties are within the United States), with postage and fees prepaid, addressed to the other party at its address as shown in these instruments, or to such other address as such party may designate in writing from time to time to the other party.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If the Grantee has received this Agreement or any other document related to the Plan translated into a language other than English and if the translated version is different than the English version, the English version will control, unless otherwise prescribed by Applicable Law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Nature of RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In accepting the RSUs, the Grantee acknowledges and agrees that&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, unless otherwise provided in the Plan and this Agreement&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the RSU award is voluntary and occasional and does not create any contractual or other right to receive future awards, or benefits in lieu of awards, even if awards have been awarded repeatedly in the past&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Grantee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">the Grantee&#8217;s participation in the Plan shall not create a right to any employment with the Grantee&#8217;s employer and shall not interfere with the ability of the Company or the employer to terminate the Grantee&#8217;s employment relationship, if any, at any time&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.01pt">the RSU is not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company or any Related Entity&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">in the event that the Grantee is not an Employee of the Company or any Related Entity, the RSU award and the Grantee&#8217;s participation in the Plan will not be interpreted to form an employment or service contract or relationship with the Company or any Related Entity&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the future value of the underlying Shares is unknown and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">in consideration of the RSUs, no claim or entitlement to compensation or damages shall arise from termination of the RSUs or diminution in value of the RSUs or Shares acquired upon vesting of the RSUs, resulting from termination of the Grantee&#8217;s Continuous Service by the Company or any Related Entity (for any reason whatsoever and whether or not in breach of local labor laws) and in consideration of the grant of the RSUs, the Grantee irrevocably releases the Company and any Related Entity from any such claim that may arise&#59; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing the Notice, the Grantee shall be deemed irrevocably to have waived his or her right to pursue or seek remedy for any such claim or entitlement&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">in the event of (i) a failure to satisfy the Performance Goals (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and&#47;or (ii) termination of the Grantee&#8217;s Continuous Service (whether or not in breach of local labor laws), the Grantee&#8217;s right to receive RSUs (or a portion of the RSUs corresponding to Performance Goals that were not achieved) under the Plan and to vest in such RSUs, if any, will (except as otherwise provided in the Notice or herein) terminate effective upon the earlier of (i) the date the Administrator, in its sole discretion, determines the Performance Goals have not been achieved or (ii) the date that the Grantee is no longer providing services and will not be extended by any notice period mandated under local law (e.g., providing services would not include a period of &#8220;garden leave&#8221; or similar period pursuant to local law)&#59; furthermore, in the event of termination of the Grantee&#8217;s Continuous Service (whether </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or not in breach of local labor laws), the Administrator shall have the exclusive discretion to determine when the Grantee is no longer providing services for purposes of the RSUs&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Grantee&#8217;s participation in the Plan or the Grantee&#8217;s acquisition or sale of Shares&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">the Grantee is hereby advised to consult with the Grantee&#8217;s own personal tax, legal and financial advisers regarding the Grantee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.91pt">The Grantee hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Grantee&#8217;s personal data as described in the Notice and this Agreement by and among, as applicable, the Grantee&#8217;s employer, the Company and any Related Entity for the exclusive purpose of implementing, administering and managing the Grantee&#8217;s participation in the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.34pt">The Grantee understands that the Company and the Grantee&#8217;s employer may hold certain personal information about the Grantee, including, but not limited to, the Grantee&#8217;s name, home address and telephone number, date of birth, social insurance or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, vested, unvested or outstanding in the Grantee&#8217;s favor, for the exclusive purpose of implementing, administering and managing the Plan (&#8220;Data&#8221;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">The Grantee understands that Data will be transferred to any third party assisting the Company with the implementation, administration and management of the Plan.  The Grantee understands that the recipients of the Data may be located in the Grantee&#8217;s country, or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections than the Grantee&#8217;s country.  The Grantee understands that the Grantee may request a list with the names and addresses of any potential recipients of the Data by contacting the Grantee&#8217;s local human resources representative.  The Grantee authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Grantee&#8217;s participation in the Plan.  The Grantee understands that Data will be held only as long as is necessary to implement, administer and manage the Grantee&#8217;s participation in the Plan.  The Grantee understands that the Grantee may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Grantee&#8217;s local human resources representative.  The Grantee understands, however, that refusal or withdrawal of consent may affect the Grantee&#8217;s ability to participate in the Plan.  For more information on the consequences of the Grantee&#8217;s refusal to consent or withdrawal of consent, the Grantee understands that the Grantee may contact the Grantee&#8217;s local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">END OF AGREEMENT</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>krys-20230331ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i466b336db2984244b4e941b80a8d1805_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Krish S. Krishnan, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q&#160;of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;8, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>krys-20230331ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie7d146b2f2e14d9ab2727e15277b89fc_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kathryn A. Romano, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q&#160;of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;8, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>krys-20230331ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5c73cfefe74e4354aad54c2a2b2b967d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Krish S. Krishnan, Chief Executive Officer, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Quarterly Report on Form&#160;10-Q&#160;for the three months ended March&#160;31, 2023, (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;8, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kathryn A. Romano, Chief Accounting Officer, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Quarterly Report on Form&#160;10-Q&#160;for the three months ended March&#160;31, 2023, (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;8, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>krys-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:451658bd-d88f-4282-9c6a-c1dd52cf3f31,g:9c0f2f52-9e92-4a03-8bd1-6f7b5787d327-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:krys="http://www.krystalbio.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.krystalbio.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.krystalbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.krystalbio.com/role/Organization">
        <link:definition>0000007 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholders" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders">
        <link:definition>0000009 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstruments" roleURI="http://www.krystalbio.com/role/FairValueInstruments">
        <link:definition>0000010 - Disclosure - Fair Value Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.krystalbio.com/role/BalanceSheetComponents">
        <link:definition>0000011 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies">
        <link:definition>0000012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.krystalbio.com/role/Leases">
        <link:definition>0000013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalization" roleURI="http://www.krystalbio.com/role/Capitalization">
        <link:definition>0000014 - Disclosure - Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.krystalbio.com/role/StockBasedCompensation">
        <link:definition>0000015 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.krystalbio.com/role/SubsequentEvents">
        <link:definition>0000016 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersTables" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables">
        <link:definition>0000019 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsTables" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables">
        <link:definition>0000020 - Disclosure - Fair Value Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables">
        <link:definition>0000021 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.krystalbio.com/role/LeasesTables">
        <link:definition>0000022 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables">
        <link:definition>0000023 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail">
        <link:definition>0000024 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail">
        <link:definition>0000027 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail">
        <link:definition>0000028 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>0000029 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1">
        <link:definition>0000029 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
        <link:definition>0000030 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>0000031 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>0000032 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>0000033 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumcommitmentsDetails" roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails">
        <link:definition>0000034 - Disclosure - Leases - Minimum commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumcommitmentsDetails_1" roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1">
        <link:definition>0000034 - Disclosure - Leases - Minimum commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails" roleURI="http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails">
        <link:definition>0000035 - Disclosure - Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseexpenseDetails" roleURI="http://www.krystalbio.com/role/LeasesLeaseexpenseDetails">
        <link:definition>0000036 - Disclosure - Leases - Lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail">
        <link:definition>0000037 - Disclosure - Capitalization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>0000038 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail">
        <link:definition>0000039 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail">
        <link:definition>0000040 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
        <link:definition>0000041 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysStockActivityDetails" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails">
        <link:definition>0000042 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="krys_MilestonesDomain" abstract="true" name="MilestonesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_EstimatedUsefulLivesOfAssetsTableTextBlock" abstract="false" name="EstimatedUsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="krys_ASTRAFacilityMember" abstract="true" name="ASTRAFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_StockIncentivePlanMember" abstract="true" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedPayrollAndBenefits" abstract="false" name="AccruedPayrollAndBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_SaleOfStockRemainingAvailableIssuanceAmount" abstract="false" name="SaleOfStockRemainingAvailableIssuanceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_PeriphaGenMember" abstract="true" name="PeriphaGenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_RemainingCommitmentAmount" abstract="false" name="RemainingCommitmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_InterestIncomeExpenseAndOtherNonoperatingNet" abstract="false" name="InterestIncomeExpenseAndOtherNonoperatingNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_AccruedPreclinicalAndClinicalExpenses" abstract="false" name="AccruedPreclinicalAndClinicalExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ClinicalSupplyAgreementMember" abstract="true" name="ClinicalSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LongTermMarketableSecuritiesMember" abstract="true" name="LongTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" abstract="false" name="IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_SaleOfStockAggregateOfferingPrice" abstract="false" name="SaleOfStockAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_IncreaseDecreaseInLeaseLiability" abstract="false" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_NumberOfMilestones" abstract="false" name="NumberOfMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="krys_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LitigationSettlementMilestonePaymentsSalesThreshold" abstract="false" name="LitigationSettlementMilestonePaymentsSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LitigationSettlementTotalConsideration" abstract="false" name="LitigationSettlementTotalConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_MilestonesAxis" abstract="true" name="MilestonesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="krys_NonEmployeeStockOptionMember" abstract="true" name="NonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_A2017IPOStockPlanMember" abstract="true" name="A2017IPOStockPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PlacementSharesMember" abstract="true" name="PlacementSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_ATMProgramMember" abstract="true" name="ATMProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="krys_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedConstructionInProgressCurrent" abstract="false" name="AccruedConstructionInProgressCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>krys-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:451658bd-d88f-4282-9c6a-c1dd52cf3f31,g:9c0f2f52-9e92-4a03-8bd1-6f7b5787d327-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="krys-20230331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_980227da-efb7-4976-b182-ef98b97c6f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ad5b4687-fdfb-4afc-9612-cb0227842df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_980227da-efb7-4976-b182-ef98b97c6f7a" xlink:to="loc_us-gaap_AccountsPayableCurrent_ad5b4687-fdfb-4afc-9612-cb0227842df0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_be8d0a0f-b186-4d6c-8ebe-05cbd95881cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_980227da-efb7-4976-b182-ef98b97c6f7a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_be8d0a0f-b186-4d6c-8ebe-05cbd95881cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ea660919-66bd-4956-8fa1-c0297b09089e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_980227da-efb7-4976-b182-ef98b97c6f7a" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ea660919-66bd-4956-8fa1-c0297b09089e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8ef9f41e-3441-4a4d-80a3-ba9997a71679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f77ac474-d989-464e-aaae-3c192649f1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ef9f41e-3441-4a4d-80a3-ba9997a71679" xlink:to="loc_us-gaap_LiabilitiesCurrent_f77ac474-d989-464e-aaae-3c192649f1e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_64f3acd7-0b28-488c-8771-a2459fb26577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ef9f41e-3441-4a4d-80a3-ba9997a71679" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_64f3acd7-0b28-488c-8771-a2459fb26577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_083d26c1-78a9-4280-8c0f-6a7b77cd5999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f3a8dfa-55b3-4ffb-9954-c5716d18108b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_083d26c1-78a9-4280-8c0f-6a7b77cd5999" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f3a8dfa-55b3-4ffb-9954-c5716d18108b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_18682920-5677-4f2b-9aa6-d286d70d9449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_083d26c1-78a9-4280-8c0f-6a7b77cd5999" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_18682920-5677-4f2b-9aa6-d286d70d9449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_26bf53a1-336c-4126-8126-d8ca5f94563d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_083d26c1-78a9-4280-8c0f-6a7b77cd5999" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_26bf53a1-336c-4126-8126-d8ca5f94563d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_28f952a0-0352-4dda-829c-6342c31738d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4cd8354f-93ce-46e9-aa72-97f0ffcef24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_28f952a0-0352-4dda-829c-6342c31738d9" xlink:to="loc_us-gaap_Liabilities_4cd8354f-93ce-46e9-aa72-97f0ffcef24a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_955abfea-a4d0-40b2-995c-a6d701db9d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_28f952a0-0352-4dda-829c-6342c31738d9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_955abfea-a4d0-40b2-995c-a6d701db9d7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd0a7c88-2d97-43be-997f-4b59b8b31d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_28f952a0-0352-4dda-829c-6342c31738d9" xlink:to="loc_us-gaap_StockholdersEquity_dd0a7c88-2d97-43be-997f-4b59b8b31d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_eccda599-3d95-46d4-8cb6-82565a41349d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_620dee62-5c67-4afc-8957-64926d5f9853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eccda599-3d95-46d4-8cb6-82565a41349d" xlink:to="loc_us-gaap_AssetsCurrent_620dee62-5c67-4afc-8957-64926d5f9853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f0601f3b-0a18-4e0c-8c47-433adbf02941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eccda599-3d95-46d4-8cb6-82565a41349d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f0601f3b-0a18-4e0c-8c47-433adbf02941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_24d1dd6c-434e-4f75-9f96-5348ceaa357a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eccda599-3d95-46d4-8cb6-82565a41349d" xlink:to="loc_us-gaap_LongTermInvestments_24d1dd6c-434e-4f75-9f96-5348ceaa357a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6c6de505-753f-430e-aafc-586c8020835c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eccda599-3d95-46d4-8cb6-82565a41349d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6c6de505-753f-430e-aafc-586c8020835c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d807da1f-c483-4753-9070-541ae5dbab39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_eccda599-3d95-46d4-8cb6-82565a41349d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d807da1f-c483-4753-9070-541ae5dbab39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aee0d04b-7675-4e94-95f3-27095383cb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4b1301b2-aa29-432c-b420-a0c33ede91d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aee0d04b-7675-4e94-95f3-27095383cb98" xlink:to="loc_us-gaap_CommonStockValue_4b1301b2-aa29-432c-b420-a0c33ede91d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c98d9b60-f833-42c8-977b-86a098929ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aee0d04b-7675-4e94-95f3-27095383cb98" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c98d9b60-f833-42c8-977b-86a098929ad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6e89291f-d49b-4e5c-80f4-645468307023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aee0d04b-7675-4e94-95f3-27095383cb98" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6e89291f-d49b-4e5c-80f4-645468307023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4ef75c11-1691-488d-a258-6caa0dfe028b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_aee0d04b-7675-4e94-95f3-27095383cb98" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4ef75c11-1691-488d-a258-6caa0dfe028b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="krys-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cdd1d6fa-d631-45e6-ae45-e1c1dc8fbabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_def518c5-900e-4eda-95b4-041ef4849d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cdd1d6fa-d631-45e6-ae45-e1c1dc8fbabc" xlink:to="loc_us-gaap_OperatingExpenses_def518c5-900e-4eda-95b4-041ef4849d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_afeb4029-638b-451e-ba4d-b2d3fd19f2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a3460f05-7450-4d17-af33-90d692a24793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_afeb4029-638b-451e-ba4d-b2d3fd19f2c5" xlink:to="loc_us-gaap_NetIncomeLoss_a3460f05-7450-4d17-af33-90d692a24793" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0a911e64-a232-4998-aea0-dc893043ae7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_afeb4029-638b-451e-ba4d-b2d3fd19f2c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0a911e64-a232-4998-aea0-dc893043ae7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_86d80432-5f67-4f8d-b5a8-dcbac8874f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1887b19e-d625-40dc-b661-bbd926868e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_86d80432-5f67-4f8d-b5a8-dcbac8874f00" xlink:to="loc_us-gaap_OperatingIncomeLoss_1887b19e-d625-40dc-b661-bbd926868e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_3df37b22-4b0a-4a4c-b918-25019f97a10c" xlink:href="krys-20230331.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_86d80432-5f67-4f8d-b5a8-dcbac8874f00" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_3df37b22-4b0a-4a4c-b918-25019f97a10c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e600d62d-0888-4d83-b6ab-f6be2e6ad93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a154a5e7-5323-4d21-80f3-6ae06d18022e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e600d62d-0888-4d83-b6ab-f6be2e6ad93b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a154a5e7-5323-4d21-80f3-6ae06d18022e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9db45620-cdba-4a4a-9b4a-ed49b95b412a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e600d62d-0888-4d83-b6ab-f6be2e6ad93b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9db45620-cdba-4a4a-9b4a-ed49b95b412a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_260e57c9-ee46-44a1-acd3-673936a9a10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e600d62d-0888-4d83-b6ab-f6be2e6ad93b" xlink:to="loc_us-gaap_LitigationSettlementExpense_260e57c9-ee46-44a1-acd3-673936a9a10c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="krys-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_268e4050-a9b6-454e-9931-8341a928b288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7d81b0c7-672f-49f9-819d-c375eadca21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_268e4050-a9b6-454e-9931-8341a928b288" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7d81b0c7-672f-49f9-819d-c375eadca21a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_16e47368-e66c-4bbc-b200-7801c41cf852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_268e4050-a9b6-454e-9931-8341a928b288" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_16e47368-e66c-4bbc-b200-7801c41cf852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19816db1-f4b8-4e38-b862-8ad4d0d72108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_4ab179c7-4b29-4ca3-bac4-837bc10897e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19816db1-f4b8-4e38-b862-8ad4d0d72108" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_4ab179c7-4b29-4ca3-bac4-837bc10897e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_79beb28f-fa70-400a-821f-54bf26baf054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19816db1-f4b8-4e38-b862-8ad4d0d72108" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_79beb28f-fa70-400a-821f-54bf26baf054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_da53cf4c-7f72-4258-9da7-daefd57c4440" xlink:href="krys-20230331.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19816db1-f4b8-4e38-b862-8ad4d0d72108" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_da53cf4c-7f72-4258-9da7-daefd57c4440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aeb12529-7794-44ab-bcbe-202eb7071907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19816db1-f4b8-4e38-b862-8ad4d0d72108" xlink:to="loc_us-gaap_NetIncomeLoss_aeb12529-7794-44ab-bcbe-202eb7071907" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_9968aaea-56e6-44d1-ac3d-6ee4d21c55f7" xlink:href="krys-20230331.xsd#krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19816db1-f4b8-4e38-b862-8ad4d0d72108" xlink:to="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_9968aaea-56e6-44d1-ac3d-6ee4d21c55f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1d31c668-eea3-4a6a-9b65-18b50c607ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19816db1-f4b8-4e38-b862-8ad4d0d72108" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1d31c668-eea3-4a6a-9b65-18b50c607ae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_f6507eaa-00f3-4036-a0df-918580780d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19816db1-f4b8-4e38-b862-8ad4d0d72108" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_f6507eaa-00f3-4036-a0df-918580780d7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_204a0b14-acf8-4ea6-a317-8dfada770a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19816db1-f4b8-4e38-b862-8ad4d0d72108" xlink:to="loc_us-gaap_DepreciationAndAmortization_204a0b14-acf8-4ea6-a317-8dfada770a29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c898f894-27a1-4ff3-b298-8d7275648f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19816db1-f4b8-4e38-b862-8ad4d0d72108" xlink:to="loc_us-gaap_ShareBasedCompensation_c898f894-27a1-4ff3-b298-8d7275648f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4a1a16e0-e985-40f7-99dc-dfe87704613b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19816db1-f4b8-4e38-b862-8ad4d0d72108" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4a1a16e0-e985-40f7-99dc-dfe87704613b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfe641ac-19d1-42b1-b638-413e12c85009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e650268f-b4c1-478c-bd57-f5f195fa8147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfe641ac-19d1-42b1-b638-413e12c85009" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e650268f-b4c1-478c-bd57-f5f195fa8147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_07da221d-1e1b-4ad7-9a4e-32ca6fb1fb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfe641ac-19d1-42b1-b638-413e12c85009" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_07da221d-1e1b-4ad7-9a4e-32ca6fb1fb33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_dbd770f2-fa2f-4833-9477-46233e5a7de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfe641ac-19d1-42b1-b638-413e12c85009" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_dbd770f2-fa2f-4833-9477-46233e5a7de6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de87d44f-132c-4642-a807-9facde6f4468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ac976070-2b6a-4c31-8315-349b4a78ead0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de87d44f-132c-4642-a807-9facde6f4468" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ac976070-2b6a-4c31-8315-349b4a78ead0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40abfd95-cbbe-44bd-b42e-3f6bca0cb002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de87d44f-132c-4642-a807-9facde6f4468" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40abfd95-cbbe-44bd-b42e-3f6bca0cb002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b32372b0-b24b-43ae-9f56-87e15c5742bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de87d44f-132c-4642-a807-9facde6f4468" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b32372b0-b24b-43ae-9f56-87e15c5742bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6638c54a-a652-4947-975e-0c08a9833e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de87d44f-132c-4642-a807-9facde6f4468" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6638c54a-a652-4947-975e-0c08a9833e38" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_12be326b-f72c-4574-8325-38141584a531" xlink:href="krys-20230331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36c5b574-9f45-4b07-b90e-2cb150a022a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_12be326b-f72c-4574-8325-38141584a531" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36c5b574-9f45-4b07-b90e-2cb150a022a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3cde86c1-55d1-49dc-8b3f-c15505648bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_12be326b-f72c-4574-8325-38141584a531" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3cde86c1-55d1-49dc-8b3f-c15505648bc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94deabd6-6657-4607-94d4-a830dabb4da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e8e2acd7-7d3b-4be6-9649-5035919cd048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94deabd6-6657-4607-94d4-a830dabb4da8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e8e2acd7-7d3b-4be6-9649-5035919cd048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5f8012b1-46ef-4aab-a801-c6b032ae80cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94deabd6-6657-4607-94d4-a830dabb4da8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5f8012b1-46ef-4aab-a801-c6b032ae80cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_599e1d73-bf3a-4920-a74f-a4d00692c07d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94deabd6-6657-4607-94d4-a830dabb4da8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_599e1d73-bf3a-4920-a74f-a4d00692c07d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_ef3359d6-d508-4049-855c-26b562b38e49" xlink:href="krys-20230331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6d9047ae-7c79-4785-b6f8-c1ffb146e49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_ef3359d6-d508-4049-855c-26b562b38e49" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6d9047ae-7c79-4785-b6f8-c1ffb146e49b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d97eb9b-6871-48c0-8fee-20ab691c1a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_ef3359d6-d508-4049-855c-26b562b38e49" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d97eb9b-6871-48c0-8fee-20ab691c1a26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20230331.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_69af15bd-0ccd-4c3d-b84c-f2c4db3e35d3" xlink:href="krys-20230331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_75b3229f-10c5-44cf-9c6d-f2d1f0c7fa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_69af15bd-0ccd-4c3d-b84c-f2c4db3e35d3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_75b3229f-10c5-44cf-9c6d-f2d1f0c7fa6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_46444c96-1318-4500-9f93-856d4a1f1dd5" xlink:href="krys-20230331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_69af15bd-0ccd-4c3d-b84c-f2c4db3e35d3" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_46444c96-1318-4500-9f93-856d4a1f1dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e8702a14-aae1-4f76-8c21-ae93db000b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_69af15bd-0ccd-4c3d-b84c-f2c4db3e35d3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e8702a14-aae1-4f76-8c21-ae93db000b63" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ca8dc9f8-b373-4119-aae1-ad5def9da406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e3e325a4-7fc4-42d3-89ba-b43aa5c73dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ca8dc9f8-b373-4119-aae1-ad5def9da406" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e3e325a4-7fc4-42d3-89ba-b43aa5c73dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7e7c0f05-a6f0-48fe-9a2b-a8e062c4aaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ca8dc9f8-b373-4119-aae1-ad5def9da406" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7e7c0f05-a6f0-48fe-9a2b-a8e062c4aaa9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_361ede66-7d1a-49ce-8138-556270836394" xlink:href="krys-20230331.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_14447e63-b31f-49be-96f3-bdbd52d58144" xlink:href="krys-20230331.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_361ede66-7d1a-49ce-8138-556270836394" xlink:to="loc_krys_AccruedPayrollAndBenefits_14447e63-b31f-49be-96f3-bdbd52d58144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_5c129cbf-ec74-4ca0-b0ea-10880cb435df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_361ede66-7d1a-49ce-8138-556270836394" xlink:to="loc_us-gaap_AccruedIncomeTaxes_5c129cbf-ec74-4ca0-b0ea-10880cb435df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_846bad0d-02e8-44fb-9bb6-5485f5ac8259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_361ede66-7d1a-49ce-8138-556270836394" xlink:to="loc_us-gaap_LitigationReserveCurrent_846bad0d-02e8-44fb-9bb6-5485f5ac8259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent_64472109-47d4-46dd-a1b1-d8edabcca03f" xlink:href="krys-20230331.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_361ede66-7d1a-49ce-8138-556270836394" xlink:to="loc_krys_AccruedConstructionInProgressCurrent_64472109-47d4-46dd-a1b1-d8edabcca03f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e49e85b8-cd35-4b85-a7e0-98a6d53d67a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_361ede66-7d1a-49ce-8138-556270836394" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e49e85b8-cd35-4b85-a7e0-98a6d53d67a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9d11bee3-1dc3-47f0-9a82-f3b5c4a4bab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_361ede66-7d1a-49ce-8138-556270836394" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9d11bee3-1dc3-47f0-9a82-f3b5c4a4bab1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_847c7a66-8307-4b95-a7aa-e08ef91a9183" xlink:href="krys-20230331.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_361ede66-7d1a-49ce-8138-556270836394" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_847c7a66-8307-4b95-a7aa-e08ef91a9183" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails" xlink:type="simple" xlink:href="krys-20230331.xsd#LeasesMinimumcommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d2af942f-e417-4904-81bb-87b614105c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d13d94e1-3a2f-4a3b-8ad3-68be517f7aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d2af942f-e417-4904-81bb-87b614105c92" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d13d94e1-3a2f-4a3b-8ad3-68be517f7aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c030eee7-51df-4981-b7ca-8af4563de370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d2af942f-e417-4904-81bb-87b614105c92" xlink:to="loc_us-gaap_OperatingLeaseLiability_c030eee7-51df-4981-b7ca-8af4563de370" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1" xlink:type="simple" xlink:href="krys-20230331.xsd#LeasesMinimumcommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b38c5d3-9e2c-4015-a6a8-0370f9455386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a2b4921b-c5cc-4943-ad63-90eeae1d7e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b38c5d3-9e2c-4015-a6a8-0370f9455386" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a2b4921b-c5cc-4943-ad63-90eeae1d7e78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_41c7500a-a88f-4062-98ef-e438d3b1da17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b38c5d3-9e2c-4015-a6a8-0370f9455386" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_41c7500a-a88f-4062-98ef-e438d3b1da17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7040a8d7-386b-472e-ada8-5cd3e6714bb5" xlink:href="krys-20230331.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b38c5d3-9e2c-4015-a6a8-0370f9455386" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7040a8d7-386b-472e-ada8-5cd3e6714bb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a067b65b-3a5b-4ab3-a76c-e616b175d449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b38c5d3-9e2c-4015-a6a8-0370f9455386" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a067b65b-3a5b-4ab3-a76c-e616b175d449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f59a4c86-c970-4f80-b13e-fefaddf54837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b38c5d3-9e2c-4015-a6a8-0370f9455386" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f59a4c86-c970-4f80-b13e-fefaddf54837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5a3d9e31-e1a6-46df-9a6a-c6ccd1a22e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b38c5d3-9e2c-4015-a6a8-0370f9455386" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5a3d9e31-e1a6-46df-9a6a-c6ccd1a22e98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesLeaseexpenseDetails" xlink:type="simple" xlink:href="krys-20230331.xsd#LeasesLeaseexpenseDetails"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/LeasesLeaseexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f9183f54-49a0-4d43-817a-61ad7c864b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_07f9ce54-dc02-4da1-a2bf-6c4f29c8f41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f9183f54-49a0-4d43-817a-61ad7c864b15" xlink:to="loc_us-gaap_OperatingLeaseCost_07f9ce54-dc02-4da1-a2bf-6c4f29c8f41e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e80c5b8f-8714-43ad-812e-b104b68f8eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f9183f54-49a0-4d43-817a-61ad7c864b15" xlink:to="loc_us-gaap_VariableLeaseCost_e80c5b8f-8714-43ad-812e-b104b68f8eb0" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>krys-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:451658bd-d88f-4282-9c6a-c1dd52cf3f31,g:9c0f2f52-9e92-4a03-8bd1-6f7b5787d327-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="krys-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="extended" id="i47264b9eefd34cb88afe88f83b4f68d8_CondensedConsolidatedStatementsofStockholdersEquityunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d7206f12-9d10-4954-8390-3060e5b45436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d7206f12-9d10-4954-8390-3060e5b45436" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_98fedcce-8142-4c92-8726-283913618955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_SharesOutstanding_98fedcce-8142-4c92-8726-283913618955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e3578dfe-09b6-424c-ae03-308ac7a9e233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_StockholdersEquity_e3578dfe-09b6-424c-ae03-308ac7a9e233" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_647b938b-abf0-439c-802d-f7f702faee5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_647b938b-abf0-439c-802d-f7f702faee5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b13eb7d3-2e82-4bf0-8e4e-57a2368c9f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b13eb7d3-2e82-4bf0-8e4e-57a2368c9f0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d3ff4393-b42c-440a-8977-a2102fbad02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d3ff4393-b42c-440a-8977-a2102fbad02f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_045de58a-c379-453d-bff0-0d63bde5dad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_045de58a-c379-453d-bff0-0d63bde5dad0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_56a4a456-8cbb-455c-8d64-d7850a0c5b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_56a4a456-8cbb-455c-8d64-d7850a0c5b77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09e599b2-9958-40a8-b088-1948b573c9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09e599b2-9958-40a8-b088-1948b573c9d2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9770ff67-eca4-4a21-8057-e4801ba61b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_NetIncomeLoss_9770ff67-eca4-4a21-8057-e4801ba61b1c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_99f8efa2-477a-429e-9736-5c375cdaa450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4fb5a896-e2bd-4ab2-8666-eda55087531e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3ca0d8af-38a0-4feb-9b85-15654307895d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d7206f12-9d10-4954-8390-3060e5b45436" xlink:to="loc_us-gaap_StatementTable_3ca0d8af-38a0-4feb-9b85-15654307895d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9e6a592d-3a33-4968-9127-e3227a5b5908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3ca0d8af-38a0-4feb-9b85-15654307895d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9e6a592d-3a33-4968-9127-e3227a5b5908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9e6a592d-3a33-4968-9127-e3227a5b5908_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9e6a592d-3a33-4968-9127-e3227a5b5908" xlink:to="loc_us-gaap_EquityComponentDomain_9e6a592d-3a33-4968-9127-e3227a5b5908_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9e6a592d-3a33-4968-9127-e3227a5b5908" xlink:to="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f4c63e18-ea05-4544-8059-45178f63102d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:to="loc_us-gaap_CommonStockMember_f4c63e18-ea05-4544-8059-45178f63102d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2dd67653-e974-4eaf-b012-cc08ee7b7863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2dd67653-e974-4eaf-b012-cc08ee7b7863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed5fb663-223d-4e93-8b1d-5e89f01cb332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed5fb663-223d-4e93-8b1d-5e89f01cb332" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4c9f4dcf-18e0-4c2f-8553-c806a2a694d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:to="loc_us-gaap_RetainedEarningsMember_4c9f4dcf-18e0-4c2f-8553-c806a2a694d5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="ia560c3d3c81648e68545cb5ef52e0ceb_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems_b101a67f-99e2-4cad-9ca6-6936bb5bb4e5" xlink:href="krys-20230331.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d78e18b9-addd-4d09-8ecd-3621e275c064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_b101a67f-99e2-4cad-9ca6-6936bb5bb4e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d78e18b9-addd-4d09-8ecd-3621e275c064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_02aa6ccc-5ed6-49ba-8be2-272aa3f4aede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_b101a67f-99e2-4cad-9ca6-6936bb5bb4e5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_02aa6ccc-5ed6-49ba-8be2-272aa3f4aede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_363c8c46-2035-49a1-99de-d5f14395cf41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_b101a67f-99e2-4cad-9ca6-6936bb5bb4e5" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_363c8c46-2035-49a1-99de-d5f14395cf41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable_913ef3f3-142f-408a-a5bb-2ae354361d03" xlink:href="krys-20230331.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_b101a67f-99e2-4cad-9ca6-6936bb5bb4e5" xlink:to="loc_krys_SignificantAccountingPoliciesTable_913ef3f3-142f-408a-a5bb-2ae354361d03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12c55172-85ab-467e-9a9e-57e637e30729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_krys_SignificantAccountingPoliciesTable_913ef3f3-142f-408a-a5bb-2ae354361d03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12c55172-85ab-467e-9a9e-57e637e30729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12c55172-85ab-467e-9a9e-57e637e30729_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12c55172-85ab-467e-9a9e-57e637e30729" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_12c55172-85ab-467e-9a9e-57e637e30729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c056205d-30d7-4d40-b8af-95cf7f8843eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12c55172-85ab-467e-9a9e-57e637e30729" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c056205d-30d7-4d40-b8af-95cf7f8843eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f21ef319-0633-41b3-b37f-3215ef59b3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c056205d-30d7-4d40-b8af-95cf7f8843eb" xlink:to="loc_us-gaap_EquipmentMember_f21ef319-0633-41b3-b37f-3215ef59b3d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended" id="iedb26be6d5224087af2e877d09332daf_SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_17e64fc6-64af-459f-82bb-6de765b726ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_09400673-0e0e-4d6a-9cb0-095b7de5e5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_17e64fc6-64af-459f-82bb-6de765b726ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_09400673-0e0e-4d6a-9cb0-095b7de5e5ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43e34e42-669b-4cf6-a38b-4499fe638bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_17e64fc6-64af-459f-82bb-6de765b726ef" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43e34e42-669b-4cf6-a38b-4499fe638bc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e17f48ef-d17c-485e-8ad2-fa4bbb8499db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43e34e42-669b-4cf6-a38b-4499fe638bc6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e17f48ef-d17c-485e-8ad2-fa4bbb8499db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e17f48ef-d17c-485e-8ad2-fa4bbb8499db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e17f48ef-d17c-485e-8ad2-fa4bbb8499db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e17f48ef-d17c-485e-8ad2-fa4bbb8499db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e17f48ef-d17c-485e-8ad2-fa4bbb8499db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_e4aa4ce8-821b-4df8-b67c-e52f4ee36545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_e4aa4ce8-821b-4df8-b67c-e52f4ee36545" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e279eea3-7472-4ef4-bde4-a79c8b171352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:to="loc_us-gaap_ComputerEquipmentMember_e279eea3-7472-4ef4-bde4-a79c8b171352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ManufacturingEquipmentMember_c7caae88-28a4-4334-869c-da8672e53ed8" xlink:href="krys-20230331.xsd#krys_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:to="loc_krys_ManufacturingEquipmentMember_c7caae88-28a4-4334-869c-da8672e53ed8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c3ac1a67-ff2f-44c8-86f4-c1c1d0ebef59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:to="loc_us-gaap_EquipmentMember_c3ac1a67-ff2f-44c8-86f4-c1c1d0ebef59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8be79c27-9d91-4738-85db-586e26ca0772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8be79c27-9d91-4738-85db-586e26ca0772" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4f97d187-30b0-4034-9ea1-1b3cc829f5a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43e34e42-669b-4cf6-a38b-4499fe638bc6" xlink:to="loc_srt_RangeAxis_4f97d187-30b0-4034-9ea1-1b3cc829f5a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4f97d187-30b0-4034-9ea1-1b3cc829f5a6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4f97d187-30b0-4034-9ea1-1b3cc829f5a6" xlink:to="loc_srt_RangeMember_4f97d187-30b0-4034-9ea1-1b3cc829f5a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e63e45be-2d18-4bd6-ae03-336309752f82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4f97d187-30b0-4034-9ea1-1b3cc829f5a6" xlink:to="loc_srt_RangeMember_e63e45be-2d18-4bd6-ae03-336309752f82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1743e4c9-90a8-4f77-a5b5-92b395359d2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e63e45be-2d18-4bd6-ae03-336309752f82" xlink:to="loc_srt_MinimumMember_1743e4c9-90a8-4f77-a5b5-92b395359d2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8d9712df-dfdb-4457-9999-1d711829e754" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e63e45be-2d18-4bd6-ae03-336309752f82" xlink:to="loc_srt_MaximumMember_8d9712df-dfdb-4457-9999-1d711829e754" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="i75a62efa098f4d5ba62f0c2d15fed0a7_FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49552127-5c1b-4bc4-8ecb-f0114eb7cf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49552127-5c1b-4bc4-8ecb-f0114eb7cf5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_870a4e65-e8ca-48a9-81ee-a46586d2aa75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_870a4e65-e8ca-48a9-81ee-a46586d2aa75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c608c184-40c8-42c0-9360-bc98be2689f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c608c184-40c8-42c0-9360-bc98be2689f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e93b0014-4752-4238-b00c-26cd86083491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e93b0014-4752-4238-b00c-26cd86083491" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_939e8d0e-c640-4c3c-a1c2-4b483aa08e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_939e8d0e-c640-4c3c-a1c2-4b483aa08e8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c53a8dda-74e3-4334-9a9c-b7bf68408d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c53a8dda-74e3-4334-9a9c-b7bf68408d6b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_68b5fb0b-05cf-42f2-9089-77aa4cd6bb55" xlink:href="krys-20230331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_68b5fb0b-05cf-42f2-9089-77aa4cd6bb55" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_c39f9b29-0ca5-40bf-9d41-22675a063e79" xlink:href="krys-20230331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_c39f9b29-0ca5-40bf-9d41-22675a063e79" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_d63be9c8-3ca4-4485-95be-4a7fbf82fecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_d63be9c8-3ca4-4485-95be-4a7fbf82fecc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_8dfc315f-af18-42f4-8db3-b3ed9a799d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_8dfc315f-af18-42f4-8db3-b3ed9a799d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8dfc315f-af18-42f4-8db3-b3ed9a799d27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8dfc315f-af18-42f4-8db3-b3ed9a799d27" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8dfc315f-af18-42f4-8db3-b3ed9a799d27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_44a77f8e-f474-473f-9344-fcb21bc66f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8dfc315f-af18-42f4-8db3-b3ed9a799d27" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_44a77f8e-f474-473f-9344-fcb21bc66f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_d3b95f15-5c6f-4802-b9c9-81e6d87d8079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_44a77f8e-f474-473f-9344-fcb21bc66f5a" xlink:to="loc_us-gaap_CashMember_d3b95f15-5c6f-4802-b9c9-81e6d87d8079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0b71d177-b287-44a6-bf89-4cb406898174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0b71d177-b287-44a6-bf89-4cb406898174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b71d177-b287-44a6-bf89-4cb406898174_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0b71d177-b287-44a6-bf89-4cb406898174" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b71d177-b287-44a6-bf89-4cb406898174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e72e62eb-7737-4a5e-b89f-091cfea2e251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0b71d177-b287-44a6-bf89-4cb406898174" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e72e62eb-7737-4a5e-b89f-091cfea2e251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_05f50c2a-6f82-4d66-8c16-ea2a7002130b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e72e62eb-7737-4a5e-b89f-091cfea2e251" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_05f50c2a-6f82-4d66-8c16-ea2a7002130b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1b40b791-9efd-4df3-8895-19f72b5ed333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e72e62eb-7737-4a5e-b89f-091cfea2e251" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1b40b791-9efd-4df3-8895-19f72b5ed333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3913cbca-0eef-4fbe-a233-108628cf46fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3913cbca-0eef-4fbe-a233-108628cf46fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3913cbca-0eef-4fbe-a233-108628cf46fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3913cbca-0eef-4fbe-a233-108628cf46fb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3913cbca-0eef-4fbe-a233-108628cf46fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8f61003a-ed39-4eae-ab03-2147852a2957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3913cbca-0eef-4fbe-a233-108628cf46fb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8f61003a-ed39-4eae-ab03-2147852a2957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_1f9caf9d-b4a6-4aef-b77b-906ad3f0ce2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8f61003a-ed39-4eae-ab03-2147852a2957" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_1f9caf9d-b4a6-4aef-b77b-906ad3f0ce2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_dfe699d0-7ae6-4f6a-b34c-65aa9b64f7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8f61003a-ed39-4eae-ab03-2147852a2957" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_dfe699d0-7ae6-4f6a-b34c-65aa9b64f7d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_358d3377-665a-4c01-a7bc-579adb48f570" xlink:href="krys-20230331.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8f61003a-ed39-4eae-ab03-2147852a2957" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_358d3377-665a-4c01-a7bc-579adb48f570" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c61d3088-a514-4f4d-a878-cd9f5500d106" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:to="loc_srt_RangeAxis_c61d3088-a514-4f4d-a878-cd9f5500d106" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c61d3088-a514-4f4d-a878-cd9f5500d106_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c61d3088-a514-4f4d-a878-cd9f5500d106" xlink:to="loc_srt_RangeMember_c61d3088-a514-4f4d-a878-cd9f5500d106_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c2e46fc-fa9b-42b6-8dd2-fe89d7dc5568" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c61d3088-a514-4f4d-a878-cd9f5500d106" xlink:to="loc_srt_RangeMember_3c2e46fc-fa9b-42b6-8dd2-fe89d7dc5568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_515b9969-c470-4a95-baeb-21c7b7c6981c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3c2e46fc-fa9b-42b6-8dd2-fe89d7dc5568" xlink:to="loc_srt_MinimumMember_515b9969-c470-4a95-baeb-21c7b7c6981c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bc18aa8b-988e-45b8-8422-79a386c5b6eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3c2e46fc-fa9b-42b6-8dd2-fe89d7dc5568" xlink:to="loc_srt_MaximumMember_bc18aa8b-988e-45b8-8422-79a386c5b6eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78e4d224-3654-4e7f-97d5-5a7cfbdf4857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78e4d224-3654-4e7f-97d5-5a7cfbdf4857" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78e4d224-3654-4e7f-97d5-5a7cfbdf4857_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78e4d224-3654-4e7f-97d5-5a7cfbdf4857" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78e4d224-3654-4e7f-97d5-5a7cfbdf4857_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dceab839-aede-435f-bc98-f05131d7363c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78e4d224-3654-4e7f-97d5-5a7cfbdf4857" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dceab839-aede-435f-bc98-f05131d7363c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_19782b6a-f750-4c39-a631-50e28d292278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dceab839-aede-435f-bc98-f05131d7363c" xlink:to="loc_us-gaap_CommercialPaperMember_19782b6a-f750-4c39-a631-50e28d292278" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ed1d8edc-de9a-477d-9e58-2afa41043561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dceab839-aede-435f-bc98-f05131d7363c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ed1d8edc-de9a-477d-9e58-2afa41043561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a9559002-b01b-4eca-8b73-738cb9a931ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dceab839-aede-435f-bc98-f05131d7363c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a9559002-b01b-4eca-8b73-738cb9a931ee" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended" id="i47408f12837040989734db5c73b81391_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99505798-1737-4461-9397-6a7bc193de96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0bd46536-1386-439e-b19b-5a2f1908f6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99505798-1737-4461-9397-6a7bc193de96" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0bd46536-1386-439e-b19b-5a2f1908f6c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_416204f1-3300-46db-96cc-bd9eeb78d708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99505798-1737-4461-9397-6a7bc193de96" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_416204f1-3300-46db-96cc-bd9eeb78d708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9b9e368f-9288-41e4-a0b3-22cd284b79f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99505798-1737-4461-9397-6a7bc193de96" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9b9e368f-9288-41e4-a0b3-22cd284b79f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_48579164-69dd-490a-8058-f1faab688e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99505798-1737-4461-9397-6a7bc193de96" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_48579164-69dd-490a-8058-f1faab688e01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b243654f-924a-4ddc-bec5-6c93d13bb455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_48579164-69dd-490a-8058-f1faab688e01" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b243654f-924a-4ddc-bec5-6c93d13bb455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b243654f-924a-4ddc-bec5-6c93d13bb455_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b243654f-924a-4ddc-bec5-6c93d13bb455" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b243654f-924a-4ddc-bec5-6c93d13bb455_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b243654f-924a-4ddc-bec5-6c93d13bb455" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_070f747d-56fb-4f27-b49b-a4ac34143ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_ConstructionInProgressMember_070f747d-56fb-4f27-b49b-a4ac34143ec3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_dd37522b-3d7c-4d20-b4e7-ab4a5e1ccdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_dd37522b-3d7c-4d20-b4e7-ab4a5e1ccdc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_f9bb1b62-bf3f-4e4e-be23-b4bf2b93288d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_f9bb1b62-bf3f-4e4e-be23-b4bf2b93288d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_86613fca-cf97-4521-b7a6-dd25518eb71b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_86613fca-cf97-4521-b7a6-dd25518eb71b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_25f842f4-213f-44ee-b0a2-b0d5919bd101" xlink:href="krys-20230331.xsd#krys_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_krys_LabEquipmentMember_25f842f4-213f-44ee-b0a2-b0d5919bd101" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a82c5797-8a78-499f-acc1-f478c72387a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a82c5797-8a78-499f-acc1-f478c72387a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d32b8c6a-6f94-4a4b-8a30-c6b24465b387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_ComputerEquipmentMember_d32b8c6a-6f94-4a4b-8a30-c6b24465b387" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="ia86dfedb1d454a168112ed35f27d2529_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_021b0cea-f9f6-4bc8-9fe1-ab0dd7f4fd3b" xlink:href="krys-20230331.xsd#krys_RemainingCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_krys_RemainingCommitmentAmount_021b0cea-f9f6-4bc8-9fe1-ab0dd7f4fd3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_805dc449-06f1-4087-ab18-9705bbf50b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_us-gaap_ProfessionalFees_805dc449-06f1-4087-ab18-9705bbf50b44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_f3516858-f5c7-4020-ac3b-b8b886d615b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_us-gaap_ContractualObligation_f3516858-f5c7-4020-ac3b-b8b886d615b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_2cb6a828-6a3d-4c3c-99d4-83a5f191eba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_us-gaap_LitigationSettlementExpense_2cb6a828-6a3d-4c3c-99d4-83a5f191eba9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_6fdace0a-8622-458e-af88-5ab378115e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_6fdace0a-8622-458e-af88-5ab378115e55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones_3776ff0d-a254-4cd7-8b8a-1b8203d7dc46" xlink:href="krys-20230331.xsd#krys_NumberOfMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_krys_NumberOfMilestones_3776ff0d-a254-4cd7-8b8a-1b8203d7dc46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_1bfe8f33-5826-4476-ab75-5ccc3fac62b1" xlink:href="krys-20230331.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_1bfe8f33-5826-4476-ab75-5ccc3fac62b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration_e0a7f236-69e0-4b3b-8aa4-c844d8823c31" xlink:href="krys-20230331.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_krys_LitigationSettlementTotalConsideration_e0a7f236-69e0-4b3b-8aa4-c844d8823c31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_78dce93b-4ac0-4cb2-85fb-e1e114f3f948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_78dce93b-4ac0-4cb2-85fb-e1e114f3f948" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b44e93c3-43ca-478a-9279-fff905768495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b44e93c3-43ca-478a-9279-fff905768495" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_cc4ab513-39e9-4cfc-953c-6b93df2106ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b44e93c3-43ca-478a-9279-fff905768495" xlink:to="loc_us-gaap_SupplyCommitmentAxis_cc4ab513-39e9-4cfc-953c-6b93df2106ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_cc4ab513-39e9-4cfc-953c-6b93df2106ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_cc4ab513-39e9-4cfc-953c-6b93df2106ee" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_cc4ab513-39e9-4cfc-953c-6b93df2106ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_482f3522-7c97-4af4-99c1-1393665d093d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_cc4ab513-39e9-4cfc-953c-6b93df2106ee" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_482f3522-7c97-4af4-99c1-1393665d093d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_fe0594e7-db05-41b4-80e4-f1151a2ff097" xlink:href="krys-20230331.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_482f3522-7c97-4af4-99c1-1393665d093d" xlink:to="loc_krys_ClinicalSupplyAgreementMember_fe0594e7-db05-41b4-80e4-f1151a2ff097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_0558e0fb-ee63-4417-b5f2-1d70327b5f3e" xlink:href="krys-20230331.xsd#krys_ASTRAFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_482f3522-7c97-4af4-99c1-1393665d093d" xlink:to="loc_krys_ASTRAFacilityMember_0558e0fb-ee63-4417-b5f2-1d70327b5f3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4a19f1d2-575d-4c85-87dc-2178915f2a9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b44e93c3-43ca-478a-9279-fff905768495" xlink:to="loc_srt_LitigationCaseAxis_4a19f1d2-575d-4c85-87dc-2178915f2a9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4a19f1d2-575d-4c85-87dc-2178915f2a9f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_4a19f1d2-575d-4c85-87dc-2178915f2a9f" xlink:to="loc_srt_LitigationCaseTypeDomain_4a19f1d2-575d-4c85-87dc-2178915f2a9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b7777b19-5d58-454c-9875-05a5a78b7d75" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_4a19f1d2-575d-4c85-87dc-2178915f2a9f" xlink:to="loc_srt_LitigationCaseTypeDomain_b7777b19-5d58-454c-9875-05a5a78b7d75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_b378696d-79f4-466e-85b6-38aa734fe042" xlink:href="krys-20230331.xsd#krys_PeriphaGenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b7777b19-5d58-454c-9875-05a5a78b7d75" xlink:to="loc_krys_PeriphaGenMember_b378696d-79f4-466e-85b6-38aa734fe042" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis_fbdcca0c-ab1e-435f-aab8-e97c659811e8" xlink:href="krys-20230331.xsd#krys_MilestonesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b44e93c3-43ca-478a-9279-fff905768495" xlink:to="loc_krys_MilestonesAxis_fbdcca0c-ab1e-435f-aab8-e97c659811e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_fbdcca0c-ab1e-435f-aab8-e97c659811e8_default" xlink:href="krys-20230331.xsd#krys_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_krys_MilestonesAxis_fbdcca0c-ab1e-435f-aab8-e97c659811e8" xlink:to="loc_krys_MilestonesDomain_fbdcca0c-ab1e-435f-aab8-e97c659811e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_0181ff2b-8b3c-408c-9c33-31dfd6e96da0" xlink:href="krys-20230331.xsd#krys_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_krys_MilestonesAxis_fbdcca0c-ab1e-435f-aab8-e97c659811e8" xlink:to="loc_krys_MilestonesDomain_0181ff2b-8b3c-408c-9c33-31dfd6e96da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember_982ebaf9-5ca6-480e-a0fb-4e22544d31ea" xlink:href="krys-20230331.xsd#krys_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_0181ff2b-8b3c-408c-9c33-31dfd6e96da0" xlink:to="loc_krys_MilestoneThreeMember_982ebaf9-5ca6-480e-a0fb-4e22544d31ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember_c366bb31-3aa6-4bee-8a5b-2c2bf25e7f57" xlink:href="krys-20230331.xsd#krys_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_0181ff2b-8b3c-408c-9c33-31dfd6e96da0" xlink:to="loc_krys_MilestoneOneMember_c366bb31-3aa6-4bee-8a5b-2c2bf25e7f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember_74fa3ed9-ba06-4af8-9e3a-22b4c987ce3b" xlink:href="krys-20230331.xsd#krys_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_0181ff2b-8b3c-408c-9c33-31dfd6e96da0" xlink:to="loc_krys_MilestoneTwoMember_74fa3ed9-ba06-4af8-9e3a-22b4c987ce3b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended" id="id2960882def9414cbee70e637b4ea309_CapitalizationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_037a84ae-060d-4e22-b69c-507b7219d5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_fd34f535-60ca-4cc3-b150-a3fb8a314ac6" xlink:href="krys-20230331.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_037a84ae-060d-4e22-b69c-507b7219d5d6" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_fd34f535-60ca-4cc3-b150-a3fb8a314ac6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_83c9f17f-7b1c-4f0a-85e1-6ed9dc95a43f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_037a84ae-060d-4e22-b69c-507b7219d5d6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_83c9f17f-7b1c-4f0a-85e1-6ed9dc95a43f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_49a44c95-f2fb-4fa1-861d-fe3464c1b204" xlink:href="krys-20230331.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_037a84ae-060d-4e22-b69c-507b7219d5d6" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_49a44c95-f2fb-4fa1-861d-fe3464c1b204" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_c4940b03-a340-42ec-86c3-e41c08c33a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_037a84ae-060d-4e22-b69c-507b7219d5d6" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_c4940b03-a340-42ec-86c3-e41c08c33a27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c29fff77-7960-48e0-ac6a-0a10d62ad163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_c4940b03-a340-42ec-86c3-e41c08c33a27" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c29fff77-7960-48e0-ac6a-0a10d62ad163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c29fff77-7960-48e0-ac6a-0a10d62ad163_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c29fff77-7960-48e0-ac6a-0a10d62ad163" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c29fff77-7960-48e0-ac6a-0a10d62ad163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dba43bce-cd44-41e1-aad4-682e15d3225d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c29fff77-7960-48e0-ac6a-0a10d62ad163" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dba43bce-cd44-41e1-aad4-682e15d3225d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_90dffa0f-73b7-4cf3-ac2e-853df88be0d1" xlink:href="krys-20230331.xsd#krys_PlacementSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dba43bce-cd44-41e1-aad4-682e15d3225d" xlink:to="loc_krys_PlacementSharesMember_90dffa0f-73b7-4cf3-ac2e-853df88be0d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_f5bc040c-c5d7-4f6e-87e0-b01ab1a61e9e" xlink:href="krys-20230331.xsd#krys_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dba43bce-cd44-41e1-aad4-682e15d3225d" xlink:to="loc_krys_PublicOfferingMember_f5bc040c-c5d7-4f6e-87e0-b01ab1a61e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_93eb7d3e-7bc7-4f3a-9660-1af9f2bdbec4" xlink:href="krys-20230331.xsd#krys_ATMProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dba43bce-cd44-41e1-aad4-682e15d3225d" xlink:to="loc_krys_ATMProgramMember_93eb7d3e-7bc7-4f3a-9660-1af9f2bdbec4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="i79e4daa399914d708fecd79b3e002b6a_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ff8b5cf9-2df8-447b-98ea-f32fb66a475b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ff8b5cf9-2df8-447b-98ea-f32fb66a475b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent_0a29c337-32f9-40a1-87f1-ac84d57b4cbf" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent_0a29c337-32f9-40a1-87f1-ac84d57b4cbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b06cc146-2be7-4d78-8c2d-20d52a128fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b06cc146-2be7-4d78-8c2d-20d52a128fa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_229cec3e-c784-4908-8ea1-987767e1f932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_229cec3e-c784-4908-8ea1-987767e1f932" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6d2e88b-c8d3-4162-b1d8-84f030eab0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6d2e88b-c8d3-4162-b1d8-84f030eab0e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6ab36673-ac76-443e-b211-33bd95ffee52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6ab36673-ac76-443e-b211-33bd95ffee52" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0b98494e-57a6-4a8c-8b8e-377e9054ac2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0b98494e-57a6-4a8c-8b8e-377e9054ac2d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eef50328-c4c9-4555-93b6-5d48b2195ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eef50328-c4c9-4555-93b6-5d48b2195ab5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825e0de0-40a3-431c-9b01-cfeeed439b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825e0de0-40a3-431c-9b01-cfeeed439b50" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f7bc0f9c-d6e5-41aa-b40b-6ce013b3098b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f7bc0f9c-d6e5-41aa-b40b-6ce013b3098b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4162f116-f7f0-41d3-8e2c-797c481727e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4162f116-f7f0-41d3-8e2c-797c481727e0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07372599-fb4a-424d-a73a-d6dab9ae0dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07372599-fb4a-424d-a73a-d6dab9ae0dec" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_916e113f-1bd6-4837-8e98-3462ae450343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_916e113f-1bd6-4837-8e98-3462ae450343" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8c380da4-5a41-4893-bee1-4cd3c1ae2286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3604dac2-65ec-4f3a-8f3e-9c1a109c3f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3604dac2-65ec-4f3a-8f3e-9c1a109c3f9b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest_5c905fbe-0a8b-48cb-bd15-5e8cb3fa4ba2" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest_5c905fbe-0a8b-48cb-bd15-5e8cb3fa4ba2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c7c912de-6090-445f-b5a2-817eaa622f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:to="loc_us-gaap_AwardTypeAxis_c7c912de-6090-445f-b5a2-817eaa622f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7c912de-6090-445f-b5a2-817eaa622f32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c7c912de-6090-445f-b5a2-817eaa622f32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7c912de-6090-445f-b5a2-817eaa622f32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c7c912de-6090-445f-b5a2-817eaa622f32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c5a85082-859f-4607-b3b6-5ba2bb03f198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c5a85082-859f-4607-b3b6-5ba2bb03f198" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_0a1ae492-8a19-4ab0-bb04-73efb1430ac5" xlink:href="krys-20230331.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_krys_NonEmployeeStockOptionMember_0a1ae492-8a19-4ab0-bb04-73efb1430ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_dbe5a8d1-ac88-4ba8-91a4-7cde7ea02b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_us-gaap_RestrictedStockMember_dbe5a8d1-ac88-4ba8-91a4-7cde7ea02b99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_e82bf50f-ef98-4c42-93a5-c3b4f2b2aa2b" xlink:href="krys-20230331.xsd#krys_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_krys_IncentiveStockOptionsMember_e82bf50f-ef98-4c42-93a5-c3b4f2b2aa2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0ac24323-e706-48d6-ac8b-c7d9ef35d239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0ac24323-e706-48d6-ac8b-c7d9ef35d239" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_73efed7e-6e87-417c-871c-6283d703a99e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_us-gaap_PerformanceSharesMember_73efed7e-6e87-417c-871c-6283d703a99e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5ac067fb-b36c-46be-91ab-a874a1053f19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:to="loc_srt_RangeAxis_5ac067fb-b36c-46be-91ab-a874a1053f19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5ac067fb-b36c-46be-91ab-a874a1053f19_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5ac067fb-b36c-46be-91ab-a874a1053f19" xlink:to="loc_srt_RangeMember_5ac067fb-b36c-46be-91ab-a874a1053f19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9157e36-207c-4238-b1a8-f60317375115" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5ac067fb-b36c-46be-91ab-a874a1053f19" xlink:to="loc_srt_RangeMember_f9157e36-207c-4238-b1a8-f60317375115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2a10be79-156c-49b4-ad96-1fcde818a3ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f9157e36-207c-4238-b1a8-f60317375115" xlink:to="loc_srt_MinimumMember_2a10be79-156c-49b4-ad96-1fcde818a3ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_29ea29e4-d142-42d3-8018-803be5671992" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f9157e36-207c-4238-b1a8-f60317375115" xlink:to="loc_srt_MaximumMember_29ea29e4-d142-42d3-8018-803be5671992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a72d6f42-66d3-434b-8902-5851a378fc95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:to="loc_us-gaap_PlanNameAxis_a72d6f42-66d3-434b-8902-5851a378fc95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a72d6f42-66d3-434b-8902-5851a378fc95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a72d6f42-66d3-434b-8902-5851a378fc95" xlink:to="loc_us-gaap_PlanNameDomain_a72d6f42-66d3-434b-8902-5851a378fc95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d9481483-ba9f-4a7d-88a9-af4988e0b71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a72d6f42-66d3-434b-8902-5851a378fc95" xlink:to="loc_us-gaap_PlanNameDomain_d9481483-ba9f-4a7d-88a9-af4988e0b71c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_316fb058-a117-4c77-afdc-35e26b7ba214" xlink:href="krys-20230331.xsd#krys_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d9481483-ba9f-4a7d-88a9-af4988e0b71c" xlink:to="loc_krys_StockIncentivePlanMember_316fb058-a117-4c77-afdc-35e26b7ba214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_A2017IPOStockPlanMember_beeb6ac9-4650-4c98-8743-88ba68d1d2d0" xlink:href="krys-20230331.xsd#krys_A2017IPOStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d9481483-ba9f-4a7d-88a9-af4988e0b71c" xlink:to="loc_krys_A2017IPOStockPlanMember_beeb6ac9-4650-4c98-8743-88ba68d1d2d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_96d8696f-d221-4ecb-8d92-fcaf0ce00e5e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:to="loc_srt_TitleOfIndividualAxis_96d8696f-d221-4ecb-8d92-fcaf0ce00e5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96d8696f-d221-4ecb-8d92-fcaf0ce00e5e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_96d8696f-d221-4ecb-8d92-fcaf0ce00e5e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_96d8696f-d221-4ecb-8d92-fcaf0ce00e5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9ff894bf-543f-4050-b247-1673d6598bcd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_96d8696f-d221-4ecb-8d92-fcaf0ce00e5e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9ff894bf-543f-4050-b247-1673d6598bcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c9a911c1-bf34-4733-86a0-e895515894aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9ff894bf-543f-4050-b247-1673d6598bcd" xlink:to="loc_srt_DirectorMember_c9a911c1-bf34-4733-86a0-e895515894aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_2bdabcea-aa92-4f86-94e3-8dac2098aff5" xlink:href="krys-20230331.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9ff894bf-543f-4050-b247-1673d6598bcd" xlink:to="loc_krys_NonEmployeeStockOptionMember_2bdabcea-aa92-4f86-94e3-8dac2098aff5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="extended" id="iebf649065bf14accbfde2900c24663aa_StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d7ec60f-2b7b-4275-8261-ac1d7a3ca918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_127902af-0035-4a40-8904-d5ab7ebc9df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d7ec60f-2b7b-4275-8261-ac1d7a3ca918" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_127902af-0035-4a40-8904-d5ab7ebc9df1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d924762b-1cb8-4058-bfa5-76405455aa33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d7ec60f-2b7b-4275-8261-ac1d7a3ca918" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d924762b-1cb8-4058-bfa5-76405455aa33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_35d6abd7-4162-4553-b3b9-915370c035ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d924762b-1cb8-4058-bfa5-76405455aa33" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_35d6abd7-4162-4553-b3b9-915370c035ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_35d6abd7-4162-4553-b3b9-915370c035ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_35d6abd7-4162-4553-b3b9-915370c035ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_35d6abd7-4162-4553-b3b9-915370c035ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9bd8b8b7-3a02-4d2e-8025-d2c0471b3c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_35d6abd7-4162-4553-b3b9-915370c035ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9bd8b8b7-3a02-4d2e-8025-d2c0471b3c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_805f7908-dc8c-4196-83ca-d15eef1d21fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9bd8b8b7-3a02-4d2e-8025-d2c0471b3c61" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_805f7908-dc8c-4196-83ca-d15eef1d21fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0f1980f0-6771-4a0c-aa0c-d23d6a2b8365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9bd8b8b7-3a02-4d2e-8025-d2c0471b3c61" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0f1980f0-6771-4a0c-aa0c-d23d6a2b8365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1aa0607b-0929-46da-ab0b-9c32fec169db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d924762b-1cb8-4058-bfa5-76405455aa33" xlink:to="loc_us-gaap_AwardTypeAxis_1aa0607b-0929-46da-ab0b-9c32fec169db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa0607b-0929-46da-ab0b-9c32fec169db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1aa0607b-0929-46da-ab0b-9c32fec169db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa0607b-0929-46da-ab0b-9c32fec169db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1aa0607b-0929-46da-ab0b-9c32fec169db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_015c797f-418f-47c7-bc75-4f1b83afe8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_015c797f-418f-47c7-bc75-4f1b83afe8a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7acac4c2-c6d7-4700-ae78-d7fcee0dab00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:to="loc_us-gaap_RestrictedStockMember_7acac4c2-c6d7-4700-ae78-d7fcee0dab00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_046d63e2-dde4-4d4f-8a99-8483b08c5bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_046d63e2-dde4-4d4f-8a99-8483b08c5bd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_184f8ed4-ff62-4f5d-afdc-86255e694d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:to="loc_us-gaap_PerformanceSharesMember_184f8ed4-ff62-4f5d-afdc-86255e694d18" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended" id="i841a26b4543147a18882da3d9d15d1e9_StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a9524fea-8173-4613-9656-5ffef77c7b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a9524fea-8173-4613-9656-5ffef77c7b5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_69812fae-8270-45eb-a47b-bf60ab2869a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_69812fae-8270-45eb-a47b-bf60ab2869a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf27c214-fcab-4a86-91f4-bf0641b5be9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf27c214-fcab-4a86-91f4-bf0641b5be9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_0dbe4538-12b5-428c-827b-fd0d37844e15" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_0dbe4538-12b5-428c-827b-fd0d37844e15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_09464b43-3e8c-42dc-9476-cb574aa217bb" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_09464b43-3e8c-42dc-9476-cb574aa217bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3d4407c8-d291-45d0-8be3-1ff354730818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3d4407c8-d291-45d0-8be3-1ff354730818" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa604b73-5230-497c-8f39-29186d939a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa604b73-5230-497c-8f39-29186d939a3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2814ae66-883c-49c1-ab21-b825af15dc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa604b73-5230-497c-8f39-29186d939a3c" xlink:to="loc_us-gaap_AwardTypeAxis_2814ae66-883c-49c1-ab21-b825af15dc7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2814ae66-883c-49c1-ab21-b825af15dc7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2814ae66-883c-49c1-ab21-b825af15dc7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2814ae66-883c-49c1-ab21-b825af15dc7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8eb282ef-89cb-4d44-ac1f-7b8e96829fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2814ae66-883c-49c1-ab21-b825af15dc7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8eb282ef-89cb-4d44-ac1f-7b8e96829fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2651cc43-4c07-40ea-a9a4-6f3fdb7754d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8eb282ef-89cb-4d44-ac1f-7b8e96829fd8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2651cc43-4c07-40ea-a9a4-6f3fdb7754d1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails" xlink:type="simple" xlink:href="krys-20230331.xsd#StockBasedCompensationScheduleofCompanysStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails" xlink:type="extended" id="ic0bdde45aa9e4adbb29777ff5d96131b_StockBasedCompensationScheduleofCompanysStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d3c6cb8-05d4-494e-a770-499de59ca277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d3c6cb8-05d4-494e-a770-499de59ca277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1639e932-eec5-4fd7-909a-21a28396d557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1639e932-eec5-4fd7-909a-21a28396d557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c371310a-61b0-49ab-9c6f-e6a7dbc4a1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c371310a-61b0-49ab-9c6f-e6a7dbc4a1c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_472fa27a-b260-4210-883b-9a5438bc8dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_472fa27a-b260-4210-883b-9a5438bc8dde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f6c21f23-8344-4306-977b-9fbc57b215ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f6c21f23-8344-4306-977b-9fbc57b215ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_236c7920-cf21-4d84-9239-d4e0a4b00535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d3c6cb8-05d4-494e-a770-499de59ca277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_735ad2dc-1194-4841-98e4-e83cdce9c9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_735ad2dc-1194-4841-98e4-e83cdce9c9a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c5f176fb-32ad-4273-b72a-41c8ac5034e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c5f176fb-32ad-4273-b72a-41c8ac5034e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a0026778-f0ab-4fc9-9ec5-3ae1f01216a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a0026778-f0ab-4fc9-9ec5-3ae1f01216a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4b876964-d490-44f5-8be9-ab0ab7c422a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4b876964-d490-44f5-8be9-ab0ab7c422a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c7260c7d-21ae-4435-a938-64f6833808c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9caed4b-8ee8-4b64-a2fa-3b34352cdaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d3c6cb8-05d4-494e-a770-499de59ca277" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9caed4b-8ee8-4b64-a2fa-3b34352cdaa4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05b51c4a-f5aa-49c6-8334-91ab4d07d206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9caed4b-8ee8-4b64-a2fa-3b34352cdaa4" xlink:to="loc_us-gaap_AwardTypeAxis_05b51c4a-f5aa-49c6-8334-91ab4d07d206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05b51c4a-f5aa-49c6-8334-91ab4d07d206_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_05b51c4a-f5aa-49c6-8334-91ab4d07d206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05b51c4a-f5aa-49c6-8334-91ab4d07d206_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a27fdcf2-058b-4be1-a4ac-954c58ea7d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_05b51c4a-f5aa-49c6-8334-91ab4d07d206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a27fdcf2-058b-4be1-a4ac-954c58ea7d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8f188879-1d90-43fc-9fa5-8e4aab66b693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a27fdcf2-058b-4be1-a4ac-954c58ea7d4b" xlink:to="loc_us-gaap_RestrictedStockMember_8f188879-1d90-43fc-9fa5-8e4aab66b693" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e3a8ec64-24e9-4903-9df4-6ab40567a046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a27fdcf2-058b-4be1-a4ac-954c58ea7d4b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e3a8ec64-24e9-4903-9df4-6ab40567a046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ed64c6f9-3ea7-401b-85c1-62b0757eccc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a27fdcf2-058b-4be1-a4ac-954c58ea7d4b" xlink:to="loc_us-gaap_PerformanceSharesMember_ed64c6f9-3ea7-401b-85c1-62b0757eccc2" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>krys-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:451658bd-d88f-4282-9c6a-c1dd52cf3f31,g:9c0f2f52-9e92-4a03-8bd1-6f7b5787d327-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_342984e6-c95b-44b5-9013-ecb4518df02a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a29a79ed-5f85-4e74-90a9-6e9206bdf740_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ATMProgramMember_b2045008-6ab0-4326-a5f7-d6d7cc954e9e_terseLabel_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:label id="lab_krys_ATMProgramMember_label_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program [Member]</link:label>
    <link:label id="lab_krys_ATMProgramMember_documentation_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember" xlink:href="krys-20230331.xsd#krys_ATMProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ATMProgramMember" xlink:to="lab_krys_ATMProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_21445f70-2323-4137-ad98-459d40367815_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_33a271c7-c0fb-4f1d-8fe6-4aa4ef7399fc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_155252b2-56af-4d41-8ea7-9047e1c8bb62_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_2b202c59-d2ba-4082-b3bd-b50464b76c40_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_138dc837-9455-49b1-ab74-0d555795bab5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43491c7d-69d4-4bce-a31d-7dc6ccde4486_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3d04df5e-f5c3-407d-aae4-1f5daadba20b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_014f0cdc-5de2-416c-870e-7b11049f1b9e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized impairment losses for long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7569d83b-a17d-4d0b-be59-5ed705980db0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_e0610f1a-cea1-4b22-88d5-8d3d07adda15_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f63db7c8-21b1-4190-af92-84f5cf3d6063_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_22fa1001-b1b7-4dca-b278-544012f2ca90_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3f388c88-bbf4-4af1-a879-ecc398bcdac6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent_06379b6b-1d56-4e0c-8cac-055062240b13_terseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period increase in shares authorized</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Period Increase, Percent</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Period Increase, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0a0b2228-8fb1-4d3f-a1c7-51509cb9a400_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_586c8dd3-a5a8-4f7a-94d6-fb8fe39292d8_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_a8284c16-24ef-49e1-a4ae-4b2e1e9dc973_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d70f5050-655e-4df9-9902-d08404334ef4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of the award (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e8f028b1-4147-46e5-b222-4283106c9422_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_0a35e342-4c5b-4bfd-a179-62c85c10aa8e_terseLabel_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreements</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_label_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreement [Member]</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_documentation_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical supply agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember" xlink:href="krys-20230331.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ClinicalSupplyAgreementMember" xlink:to="lab_krys_ClinicalSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_85eac817-3858-455a-834c-e0c9adba4e66_terseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_c61ee26d-1ab2-45f9-aefa-ba0b78213750_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and building improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_762518df-30de-43b9-995f-de2369f2e70f_terseLabel_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems" xlink:href="krys-20230331.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems" xlink:to="lab_krys_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9bad85dc-6570-483e-879b-bf291a71b474_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d62e8475-20f9-4206-8d6b-a2238d1b2ed8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.00001 par value; 80,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 25,796,213 shares issued and outstanding at March&#160;31, 2023; and 25,763,743 shares issued and outstanding at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ee71bb4e-fa7b-4633-9faf-7c861d15fc46_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_bd993a0a-9614-429b-9287-2a84c1c9e00e_terseLabel_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental condensed consolidated balance sheet information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:href="krys-20230331.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1e04598d-cb57-46e7-aeca-6c4b7b206ea0_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3f12efa0-d489-4307-a6dd-9b2e3e367620_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4dd596b7-b0bb-4294-9544-b2eef280d971_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_0d3ae931-1eb1-4225-ae78-66ad28c3c8a2_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d426ef0d-2a4c-45e4-b1cb-099f32d4b2f8_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestonesDomain_4a72a522-caeb-4990-85dd-c5215b8062d0_terseLabel_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_krys_MilestonesDomain_label_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_krys_MilestonesDomain_documentation_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain" xlink:href="krys-20230331.xsd#krys_MilestonesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestonesDomain" xlink:to="lab_krys_MilestonesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0170117f-78e1-4660-8574-8897292d7ba8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_22c268ad-af93-4702-bc7b-72582852bc71_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at March 31, 2023</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_ebb9c766-c0ee-4cbb-8fda-3e4ba732a8c5_terseLabel_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_label_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payroll And Benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_documentation_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits" xlink:href="krys-20230331.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPayrollAndBenefits" xlink:to="lab_krys_AccruedPayrollAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b2176e4-4dbc-44d1-9d34-a6258f208ee5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45d232bb-bec1-404d-968f-7349049b0d1f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f584a829-66ed-4fe5-9295-7ebf7503fc98_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b73b225a-de4f-4020-a8ae-b1e05a6faf78_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_7115a2d4-e4a7-4668-8871-f9e0bb7c69c8_terseLabel_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_label_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Lease Liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_documentation_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:href="krys-20230331.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:to="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4cdce1aa-e260-4934-8227-bb11f0079992_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ea79c582-d6bb-4449-9195-ddce6e1c2279_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_167b9d61-91d6-488e-b474-39b2cc5d2f7f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_69651782-21d9-4337-8a59-23692a07c695_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a8703580-f1c0-4b6b-b9b8-914b3ee57a0a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1ab78a85-c0c3-42f6-b0be-7869e3621d78_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4b46d41f-e099-4279-b3cf-9b0199bb6b68_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_bb5d8c91-1717-4ff2-975f-20f96537ac03_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_566a97bd-1d99-4244-a413-d7e13c160d4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_37728e37-975d-4c95-b0d9-c625a285cb5b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0efffca5-7e6f-4eb0-b08d-9127fb5f567c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_930dac48-496c-475f-afb2-b6a502986ae8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_ece4e4a1-e4fe-4989-873e-952a28e41aec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_524cfde6-90c6-4d26-b740-72d255ac40f3_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project management service fee</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1d1e4c8a-92df-43dd-9410-0e679c3ba3c6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_fcff671a-4f29-4c48-9544-b372350243ae_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_b673f6c4-acad-4644-bb19-f7a2944422bd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneThreeMember_84906989-6d2b-436f-baf6-7f417658f165_terseLabel_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_krys_MilestoneThreeMember_label_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_krys_MilestoneThreeMember_documentation_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember" xlink:href="krys-20230331.xsd#krys_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneThreeMember" xlink:to="lab_krys_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_fdaff56f-2637-410b-8741-c1797beeffcb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_5ec7a8d7-530f-4187-b807-e229546137ed_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ca4e6940-ca20-4f4a-bc26-14425065f91f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c4902317-a578-4e5b-9cc7-d6ecafa3ca7a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_8070efbd-2279-42dc-94f3-c98b591e85fa_terseLabel_en-US" xlink:label="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Accrued Legal Settlement And In-Process Research And Development</link:label>
    <link:label id="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Accrued Legal Settlement And In-Process Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:href="krys-20230331.xsd#krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:to="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_60d2ef5a-6998-4418-8b9e-c58a568dbb99_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f2c8633c-f39b-4fa0-b822-6da30525e336_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4357914b-e9a3-4bce-8411-086edf324dce_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_NumberOfMilestones_248dddce-f67e-40d7-bc74-d5f412356d14_terseLabel_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones</link:label>
    <link:label id="lab_krys_NumberOfMilestones_label_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Milestones</link:label>
    <link:label id="lab_krys_NumberOfMilestones_documentation_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones" xlink:href="krys-20230331.xsd#krys_NumberOfMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_NumberOfMilestones" xlink:to="lab_krys_NumberOfMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_610cb4a1-63cf-488f-8e63-387b6d302001_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0a76c426-3338-4890-971d-b4daa4de5bbe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Remaining Contractual Life (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7b0a0d8f-75fb-4df6-bbaf-719d2118943e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f6be3014-8d69-46b1-9d63-6a46109f683b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_5997d4b8-eac7-45b3-a66b-1bdf00dc98ed_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_96501271-db9d-40fb-81f4-2067f9cbfd1f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_776296d5-30f4-4c3a-8a36-8643e2e51a7c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5d3c9419-d4b9-408b-8a3b-53a27d80ce09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_49f25dc6-a45e-47c1-87c5-e14459f714b4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_842d9b13-cea3-464a-9460-ebe8a7fb50a7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd4fe290-c63b-4e8b-a35b-33031657cc96_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ASTRAFacilityMember_ea1f9da7-566d-4724-8432-870bf06b6422_terseLabel_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASTRA Facility</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_label_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A S T R A Facility [Member]</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_documentation_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASTRA facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember" xlink:href="krys-20230331.xsd#krys_ASTRAFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ASTRAFacilityMember" xlink:to="lab_krys_ASTRAFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_70f8e14d-cab1-41c8-af2b-0faaa08b1d8c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_87174ed7-b92d-4b49-bd5e-ea1c3f351468_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_5bce9237-08ec-490a-bb30-6101a6ff9ea2_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8582e108-85b7-4b08-91db-e35e180b1791_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7f72ef95-d348-46cd-a742-52ab8c3c8ed3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_9338354a-26c3-4e74-b91a-e452589306bf_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, aggregate offering price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_label_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_documentation_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:href="krys-20230331.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:to="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5536666b-8a39-4ef6-b313-46314e0be036_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6887f7f8-e196-44dc-a2d7-32c7fbfc12e7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5d33bbd8-040f-4cda-8c66-6e592da60ebb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e7ea42b2-3010-4ff3-9da3-5924c1da96cd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_94a50d0c-4334-454d-8cb4-6aa7749c46d3_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_68931047-cac3-4c99-b693-ca5a32a975de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_779541af-b932-414a-8a37-6b66874dddf1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_7eaaae9b-a1db-4cb4-8646-fcc46621b330_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock And Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0d1703d6-1bee-421f-b056-e2a009afcb64_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ManufacturingEquipmentMember_403375d5-590f-4316-b5c4-63892edb1d14_terseLabel_en-US" xlink:label="lab_krys_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_krys_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_krys_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_krys_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_krys_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ManufacturingEquipmentMember" xlink:href="krys-20230331.xsd#krys_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ManufacturingEquipmentMember" xlink:to="lab_krys_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_StockIncentivePlanMember_045ffc9e-b6ef-4c1c-add8-f50bb5f41f8e_terseLabel_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_label_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_documentation_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember" xlink:href="krys-20230331.xsd#krys_StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_StockIncentivePlanMember" xlink:to="lab_krys_StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1866a62c-c9e6-4fe6-9a4a-dfce229cc6a0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5caf4b0c-b1cf-408f-8f23-6557ebc08f02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_8c38a59b-8245-477f-9fcd-072de419032f_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bd549a07-e4fb-4f7a-95fc-87308f61d0ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_c16cbad9-a3e3-4021-a6fb-d66d8d8a1f4a_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, remaining available issuance amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_label_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_documentation_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:href="krys-20230331.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:to="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24bdd0e6-ac3d-425d-a8b6-0c1e20a86098_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_208ac09d-282f-4abc-adec-be6ec712f8b7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_43b176b3-1656-4a54-bf50-ddeb75209057_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_70f68bc0-bc05-447e-be3c-926fc46178c8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4102975c-b4d1-4e64-8b12-c50906719a13_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term, in years</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d84322-7cbc-492c-a91c-7becb602bc3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_fbdee3f5-bb7c-45f8-8c49-a689911fa3b8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_949c2dcb-5945-4ade-ad77-93ff1afd3bbb_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07404acd-007f-48a1-b2e9-ea5b24ea2999_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ca34de64-f885-4146-8275-c9edb2711315_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f60414bf-616f-40d4-8eb1-49abb1b9ce85_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0ae06e54-cd4c-4575-9d54-f20f6a30e634_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_ff3a8c96-3eae-4fee-b16a-a40f42cb5e1d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4f77a046-1f20-4f81-a974-745b4d23b3b9_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f1cc6349-aaa3-4d41-85b3-fbd1ed70f16c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2613cfe9-09bd-4d08-9131-b962141f2460_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5d6554e-a72d-4417-ad18-f4cfe1125306_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b52e14ef-97e0-46f9-adf8-24ba65c8a273_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d4bf596a-71c3-4130-ba68-5da7e35a14a3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3b1d2131-d311-48e7-acd3-4ca436e0c582_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6743c1e5-386c-4ba1-838c-a9271fba302f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9fde7ca1-f4d6-4cc4-a53f-1daec7a5a6fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7ea2f1a7-c6ea-4589-9e95-9bd39a03adb3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4666611c-f0da-43bd-b7da-c9ec9a1298e6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b864abdc-c8a3-4401-8355-7cfb0a490bff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_fcc3bb10-c9b4-4dfb-b039-6fe2cb1c5bfd_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_c80a0826-f50e-464a-988c-72ff53d99123_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d9261a37-f851-4389-8476-82e246dba4de_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_cebe17ca-b4ad-4a7a-b9e2-6e6a65d44fcc_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_5366f248-b5c9-4e8d-9130-bc2a02d9a544_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_619c5de4-f9a3-4f45-8054-8e3ecee2586b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8b57796d-c55d-442f-840b-d304a5b012d3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_bfbef5d8-8af6-4aec-8a3a-875397c0cc24_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_d46c9e88-d651-441d-b23b-412550f01871_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PeriphaGenMember_89ad39a9-e29d-4a02-96ee-dd69abc46c61_terseLabel_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen</link:label>
    <link:label id="lab_krys_PeriphaGenMember_label_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen [Member]</link:label>
    <link:label id="lab_krys_PeriphaGenMember_documentation_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember" xlink:href="krys-20230331.xsd#krys_PeriphaGenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PeriphaGenMember" xlink:to="lab_krys_PeriphaGenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cbfae2bf-d04e-4c4b-8979-9a8f0602a3c5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_e5d37313-ab1d-4f2a-a03c-d7c6b7c5d3c9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c6973f37-9bcd-4d06-a5aa-e1eae1ca2007_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_810b0964-5c76-4f62-a676-bb550e982c6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9e8eb146-4832-44dc-976c-436bd889571f_terseLabel_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="krys-20230331.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_68198c25-0654-4e2b-87cb-60f30ccbed02_terseLabel_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, total consideration</link:label>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_label_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Total Consideration</link:label>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_documentation_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Total Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration" xlink:href="krys-20230331.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LitigationSettlementTotalConsideration" xlink:to="lab_krys_LitigationSettlementTotalConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PublicOfferingMember_d3109b48-0f92-4a3a-8108-04d004a6e20f_terseLabel_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_krys_PublicOfferingMember_label_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_krys_PublicOfferingMember_documentation_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember" xlink:href="krys-20230331.xsd#krys_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PublicOfferingMember" xlink:to="lab_krys_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ad108732-d46b-4cc1-aa2e-5ed3533066c2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e1e305cf-b8dd-4e8b-b3e9-4fa5070e7baf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_540140d7-d8d1-429f-bb4d-5f41255baed8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_e31132cf-a48c-4ddd-81b6-9742f164ba5a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1a70863c-cbe0-4ce4-9ea7-41465c7bbfbc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8009a4e8-23fb-4029-8997-3d94974e404d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f31f5a72-60a8-44e0-9844-2fab29cf56fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5bb9c8ee-2d53-4754-ba62-56f5ee121951_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_d5b786ca-9958-40b1-9457-9865d7317992_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value, total</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:href="krys-20230331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b592dfbb-59a1-41fe-a05f-a680645e9982_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a0039635-ebbd-4585-ac65-f4905d09e288_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_0e33cc06-712c-460d-b055-089da012b358_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_367af393-c6bc-49aa-b964-eab9958b5fce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_c6427340-6ad3-4c3b-aa29-b899b0539502_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4deaf1a6-e1f1-48bf-8cc9-c7222f4f549d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_c5613e82-dc7d-4219-ad75-e67d7ed91475_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_1b96e540-8f00-468a-8523-929829f7fc96_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_39755fbf-2f4a-45bf-9581-49f38476e47a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fcbb4dd9-fe0a-42fd-9745-db4b0d75795c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_90542445-4ea2-44ad-b719-2da02d08eeb2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_118786ff-60dd-423b-b743-e194288eec3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_78385308-24ce-4e2d-8da8-e5612494ece8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ebc32f32-9b8e-4ed1-b936-f5242a1392ec_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_486a8b86-9130-415b-a94b-ba8488eb5555_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2369ede8-94e6-4029-b366-db6fc13769e5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_40977c6b-588c-4556-834c-916503e987fa_terseLabel_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Stock Option</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_label_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee stock option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember" xlink:href="krys-20230331.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_NonEmployeeStockOptionMember" xlink:to="lab_krys_NonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ac240f19-8c7d-4a1a-aee1-ea390e2b0769_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_d8c72044-41d2-4bc1-9439-f4c298af43c2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_503dbe87-f75d-4a6e-bbf6-3ab841b9cdce_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e1d93921-d2f2-4493-8fbb-251baa1b4384_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9609685f-c9b2-492f-8f57-26e7fe93f466_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7d87652-0237-4785-9762-e2f9f33ba438_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_170cb072-fb2c-4556-8b47-e88264d58026_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_cc784b6c-3485-4eea-bdb2-52d760f51857_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from insurance settlement, operating activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b284afd4-f194-4500-bf42-46315502f51e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6d131718-c902-40e7-9dc9-4eb0133a3aa2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_03668354-fb76-4db4-8258-d929e9a68dc2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_9f9675a3-ee80-4f75-b96f-5f520bacbc59_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_67ac0037-f0c1-4cc0-96aa-9434d6f159da_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_935108d8-74ce-4ae2-8e41-1d97f5739611_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a6919e6-fedc-44b3-8ff5-5f0521900c61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70187b17-3aa6-42a7-be4b-91fd477a4ca7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dd36bc15-ed1b-40ef-bae7-257456cd1e08_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (Years), exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_8d586fc9-930d-4e4f-a7ec-f5900a55ee09_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d50dfc58-dadc-466e-b3a3-94a8473f05ca_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b7d2f61b-32fe-4f74-8c4d-c2661c8d4be0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_aaa75f91-1a6c-4e8d-b3fd-0aa1895fabea_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ac7dc1e5-fa92-4486-8702-e513be6f9a5a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_02e5607e-9280-42cd-a0e3-c276d9642a93_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b2cea9a8-03ad-40d4-b939-47433afab178_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c9fc2bdd-d92a-44a5-a8c3-3724f08accb2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d00d852d-d959-4e46-96a8-eedfe21c84aa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0c5f6c98-12e0-417e-8b96-cd94f8361092_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net, (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_94a6053d-41bd-4135-8360-1aa8963101ab_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6816414d-11fc-4eda-beac-69ca69ea99ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_9abbe8f2-ef4f-4c51-b38d-c4917696db10_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_RemainingCommitmentAmount_64f0ccfc-cb86-4c65-8829-bdaf6c618082_terseLabel_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated remaining commitment</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_label_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Commitment Amount</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_documentation_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining commitment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount" xlink:href="krys-20230331.xsd#krys_RemainingCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_RemainingCommitmentAmount" xlink:to="lab_krys_RemainingCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_25ce2ce6-aaac-4a61-8792-5d5f13864739_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6b8befe5-8231-45f5-ab85-ffb029e45f13_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_8bacd679-3068-4860-be29-29a95689e834_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7873a018-aeb4-49fa-9556-c79917f16886_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f1760f38-c2a5-47a7-9164-7b99d7f78b6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_e33b40b4-e330-4d4e-b71d-e19a70a69437_terseLabel_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable" xlink:href="krys-20230331.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SignificantAccountingPoliciesTable" xlink:to="lab_krys_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_2d4ea3e3-7629-42b3-8562-bf6a6aa2ceea_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_780d441e-5b15-40fc-b4cf-89d36f3c64ec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ec20e09c-48c0-4d6f-97dd-8c2e67ef3172_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_9cb9fff0-8979-425d-a17f-f715086988a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_0a1c4be4-8d0e-43dc-9de9-ae8e5cacf6c8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8419cdf3-c9ee-4e8f-a40a-31309af30682_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8d5612c1-dc20-41ff-8cbe-7725364d5273_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_db5d68cb-6e58-4ee7-a266-07a9a1aeaef5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_525cef4e-1300-4762-8410-b35749cf8dfb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_cf8a58de-6790-4640-9a75-8758ea247f06_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_44c80cd4-edf8-4265-9071-0941ce8cced9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_08e22759-0a66-454f-85a3-b022ebe7ad13_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6534d3cf-ce7f-4ce6-8f03-59153ca531ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51eaa8a5-4cd5-463d-b88d-b7e774a81232_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest_ecd07629-89df-4aaf-9c8d-be7175f46480_terseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested And Expected to Vest</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested And Expected to Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f1a369d5-2d96-4c32-bf57-d8916cb0e785_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f33d27f9-db88-44c9-8914-2d765c3e2b95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to settlement of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_72d1c6b8-bacf-40e5-a689-e94eb8f4b1aa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9f6eb23d-4bfa-4265-8291-4d5571985d6c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_366a6aef-e7f4-430a-bf64-5c5c4de761f6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_1f908e81-3076-454c-8d6a-46a22105e914_totalLabel_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="krys-20230331.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_359f7f15-a98f-4b80-a2f8-32e3b37d0f4e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestonesAxis_589123c1-0e77-4c18-af8a-1a419186db47_terseLabel_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_krys_MilestonesAxis_label_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_krys_MilestonesAxis_documentation_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis" xlink:href="krys-20230331.xsd#krys_MilestonesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestonesAxis" xlink:to="lab_krys_MilestonesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_d9466064-acf4-4daf-b342-ae0a5e1b9c67_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_82675ef1-2234-475c-914c-7c5df0cd1517_verboseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f9f5e128-751b-4c3e-924f-826e8f2428c9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_5a7d4617-53e5-425b-826e-8f96f406ba8b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0b3b3757-7d26-4729-88ec-33bb9452242a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5d85af84-cd5f-4d73-bffb-7333b20a763e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f656a2a4-4d9b-4cd1-9312-55c57d0d994a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_bdf658c6-ea2d-4fbe-9589-2e4e1f11613d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_c9d900f3-b250-4430-b0ac-50f7b4ccd0ea_terseLabel_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Marketable Securities</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities [Member]</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember" xlink:href="krys-20230331.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LongTermMarketableSecuritiesMember" xlink:to="lab_krys_LongTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d70ba86b-9b6f-4758-ba12-9eba35fdbc27_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_01d66727-cc63-4121-889e-192f2aa7d2ba_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3659e7ab-3a98-454b-b593-a27a6aff73cf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e899f975-aad2-4b10-a71e-2f474c651c8d_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_debdce6a-9373-4ed5-bee7-225d61f49bb2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc2559c8-b404-4771-b13f-46c22c9b466f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_32856e3f-1e2b-43ca-b9ab-45d939877c1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a447e32e-8889-47f5-92b6-929690810a6c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cbe35b9a-473c-4d95-a72d-7de6bd9b94b5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dea806d1-485e-4347-b87c-9a4f40c85d43_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_a6452a74-3207-45dd-a43f-da3b852748fb_terseLabel_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, milestone payments, sales threshold</link:label>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_label_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Milestone Payments, Sales Threshold</link:label>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_documentation_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Milestone Payments, Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:href="krys-20230331.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:to="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneOneMember_df9ff38b-1c49-4f7e-863c-34d1484373b2_terseLabel_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_krys_MilestoneOneMember_label_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_krys_MilestoneOneMember_documentation_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember" xlink:href="krys-20230331.xsd#krys_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneOneMember" xlink:to="lab_krys_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_df93fd0f-3e8d-4fa8-b93b-b1b2d3a0df4d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_fd5d2faa-9e3c-4ce7-8565-59ff19742810_terseLabel_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_label_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense And Other Nonoperating Net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_documentation_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense) and other nonoperating, net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:href="krys-20230331.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:to="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_503f21d3-fe8d-4345-9c9d-04ee110e58b1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_d1149b4b-e971-4f89-8379-a781cef581b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_18fdf8b5-2e8c-4041-84e6-d82a3754e4b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_622b84ad-cbf1-4694-8f34-0602f72a31c8_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a3f6ee2e-fa76-4473-92bb-ce290ecaf760_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_266cc48e-0a36-4b0a-80e4-ff60d985516c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_dc978adb-0c08-4b3d-90ab-13a78301c8d6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1890375c-2af0-4066-a2a5-7d2686d9713d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_3fcef940-0336-4e7c-bf0b-264196cd3a19_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, amount capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b3856b2e-53fb-47c1-9048-78792602890c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4a308410-2609-4a87-b930-00ee2eab9c94_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c85a56f7-00d5-4e1e-b84c-b58e1237daef_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_2261eb64-a91f-40f0-8135-6354d87445aa_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a9584b47-01fa-408e-9de3-8da5624b0f96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered for taxes (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_2b4f4626-57b8-4e3a-abd3-f120ef061ccd_terseLabel_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_label_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preclinical And Clinical Expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_documentation_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:href="krys-20230331.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:to="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7179531f-a2d7-410b-bad2-f033d815b9cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_eb41c90f-58b6-4c09-810c-f128071a911e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0b17c453-cc19-4307-b6d7-79442bd1a10e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_844ffe04-c2a0-4432-aa1f-dd14aaedbcaa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities and currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9e77da59-8e01-4b50-9492-7d342c3acbc9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b86bbd23-afe6-4431-bbfd-8d1229bbaeb4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_081c4216-c3b5-4b32-bfed-03de4b2db13d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9b315f5a-34e4-4404-8093-641e4594a9b7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_9aaac5fd-e3b4-44fd-9fbb-4f9f7f8a9775_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PlacementSharesMember_d7c1d0a1-d156-4d6a-bf5d-0c50c531a26f_terseLabel_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:label id="lab_krys_PlacementSharesMember_label_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares [Member]</link:label>
    <link:label id="lab_krys_PlacementSharesMember_documentation_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember" xlink:href="krys-20230331.xsd#krys_PlacementSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PlacementSharesMember" xlink:to="lab_krys_PlacementSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_d9f0c6f1-5479-4379-b1b7-e889af1ba024_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3271bff6-fd75-4808-a717-44f2b66044ad_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_07d17490-583d-4067-8d25-eac34d059ef2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_4f3d0137-6c95-47dd-9ae0-f0e5cced9d73_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:href="krys-20230331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a895d71e-0736-4c0d-a2a3-ee20f3e2548f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0ee5043f-04b7-4a6a-8687-3ddf7dd90bad_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44a60a5e-52c9-4de2-8c55-7aa62985e063_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_0007fad1-657b-4593-9b1d-249e63cd2a91_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_2f7b1b63-e372-47ff-83ec-6972e59dbd83_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:to="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_bcff4fd1-a669-4466-858a-915f83b7203b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_315e2ca8-6135-48d8-9ccd-c4f4aab2f103_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_efaee503-6b68-477f-9ef1-f9d5529a93d8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e3937560-6a1a-4adf-beec-cddba41e211e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares remaining available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d47e00fe-5a64-4d63-ac1a-dd6ef31b410a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_38c5a5e4-8245-4bbb-9e07-53da1ba44c8c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_aeaeaccb-b416-4400-b694-87518c353126_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncentiveStockOptionsMember_dc8b49e3-18d2-43be-872c-1ff1b1c011ac_terseLabel_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember" xlink:href="krys-20230331.xsd#krys_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncentiveStockOptionsMember" xlink:to="lab_krys_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_44738a96-331e-40b8-a6e1-8c4a089de805_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_27d603e2-2fe7-4501-82e7-273b0af49a94_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_bdd12717-2c42-4e77-a6ed-9986a7edd3c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered for taxes and forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_4c5ad3b1-c48f-499b-9d0a-ba6235a1820b_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0db04b1b-f48a-4a80-8c2f-dfc3f8bc30f7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c2b7614f-6a54-4fbd-b2f3-626791eea3f6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_A2017IPOStockPlanMember_df6c240c-4e70-47eb-b771-37a991a08a3a_terseLabel_en-US" xlink:label="lab_krys_A2017IPOStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 IPO Stock Plan</link:label>
    <link:label id="lab_krys_A2017IPOStockPlanMember_label_en-US" xlink:label="lab_krys_A2017IPOStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 IPO Stock Plan [Member]</link:label>
    <link:label id="lab_krys_A2017IPOStockPlanMember_documentation_en-US" xlink:label="lab_krys_A2017IPOStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 IPO Stock Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_A2017IPOStockPlanMember" xlink:href="krys-20230331.xsd#krys_A2017IPOStockPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_A2017IPOStockPlanMember" xlink:to="lab_krys_A2017IPOStockPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_cb1919d3-092f-4a8b-81f0-c996d53a4f8e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_1b3eb6dd-0f27-4894-9051-bd67960cdfce_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f3784ef0-9dfd-4cf9-a250-0470a3ba4dda_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_e772283e-f472-4462-8995-f69994bc5f52_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ca324f82-5e60-4646-9861-16aaf01e1acc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_73d47e83-3011-40a9-845e-a462569066bd_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_ab8cb4cc-f6f8-427e-857b-b3e5340b4a8a_terseLabel_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_label_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction In Progress Current</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_documentation_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent" xlink:href="krys-20230331.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedConstructionInProgressCurrent" xlink:to="lab_krys_AccruedConstructionInProgressCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_6881a20b-0d8e-4b34-8479-c4dd4874fd62_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_e656dc17-b401-464f-8f6c-bfca1969a6a8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f4037f52-e80d-4776-a415-99b652650f6b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ec17afa1-5b28-4d52-a1e9-726ad326eb3a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43e30361-e1c5-4eb0-8112-3911fed36b05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a6d26d08-49b3-45e9-a575-c7a0f92d2de1_verboseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_f1224f1f-e33e-42c8-8ad1-584671257a2d_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1b37989f-8ea3-4374-a210-e8f6966475bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered for taxes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1ae90e63-7cfb-45ab-88cd-a9646ca285e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15277da3-d8ad-4f27-9f25-959618e6f583_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c2361d66-286e-45d6-a28b-8268fcd21e98_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_45163c6a-2663-4322-9493-264fb65c9e03_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Geographical Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_40f371a8-86f6-42ad-986c-486323968718_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_08eed18e-49b8-4288-8286-b8b92d052801_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1bc69f83-84ad-4581-b5e3-f752414aa393_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneTwoMember_144245b1-ca5f-4107-9ea4-9e1f33cad5db_terseLabel_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:label id="lab_krys_MilestoneTwoMember_label_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_krys_MilestoneTwoMember_documentation_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember" xlink:href="krys-20230331.xsd#krys_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneTwoMember" xlink:to="lab_krys_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_af614bee-fab1-45d4-b9bd-9ad37bb13a7b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_49b5e7ae-5cbe-4a6e-b691-8da5782166c2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_dc568ff3-cda4-4602-abe7-38538fcaa5bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f4c849c3-4675-4df2-800e-1d2dc94ed8cf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_846b1425-fd9b-417a-89ff-b37e15f8addd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_eb9a19d1-9a9f-45bc-8d1e-d8158abe88b9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_16502cf3-faa5-4b1b-b1d7-c8a4f0517aa0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30d78e48-c21b-48bf-9e04-6cdf55afc34e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock award outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1ecafeb4-8708-4853-b15b-4911a6f79b70_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b777bcac-3253-4adb-bf8e-5f003e1965cc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_b088b5a3-6ed3-4331-9989-866d4802909a_terseLabel_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Useful Lives of Assets</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_label_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of Assets [Table Text Block]</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the estimated useful lives of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:href="krys-20230331.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ac57ee80-9161-42b7-8405-4cbaede15e92_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_49177378-08c1-47d0-bcf4-cb22700331e1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_44fddf9d-3f0e-4947-b992-40cc9cc64246_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4130ea1f-0140-43ff-85bb-da0d5dc268ef_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1201aabd-b03b-4a09-82f7-d46df66edde9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a1e0244d-bb0c-459e-8d7e-54df1f1c138a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_33ca0019-1e27-4796-a80c-fb1759bd8c7e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_023361ff-89ea-4a90-b663-793af3b8a220_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ffce0cf1-2a5d-47ed-9203-4924e756c145_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LabEquipmentMember_82d7adc9-4d80-4bc4-8475-2d479a4ea359_terseLabel_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_krys_LabEquipmentMember_label_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_krys_LabEquipmentMember_documentation_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember" xlink:href="krys-20230331.xsd#krys_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LabEquipmentMember" xlink:to="lab_krys_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8117b292-ed77-4a58-b74d-45c2ffeab0c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value per share of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_3debc90a-e299-4f1c-98d1-8202f0a7585b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_995b5cea-6621-44bd-80d0-a3895106a45f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3f667ac4-594f-4280-b386-7014aad7ca3e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f17d5aad-5842-4d97-ac48-f0731dd0b300_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_22d6408e-7c46-4ab8-8da5-a06a38812b2f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4178b6bc-5c7e-44fb-bec4-a9b13d4ed6a8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9bca0fd0-3ed2-4814-bbba-44e622cf8cbb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_fe039090-19f2-497d-88c0-caf0cd6d92b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxes" xlink:to="lab_us-gaap_AccruedIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d04484f4-6d2c-40f4-b0fa-63e5033a45a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3d383611-e0a0-4ae0-874f-af34964559bf_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dce1d268-49bc-42da-a840-75f0ab0b960a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_911699d4-e06c-47fe-b800-ac884ae05663_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7ef92ec0-5e59-436b-85cb-9c83731f7dd7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_0ac32a15-2cd2-43ff-bf9e-b0659d4e747d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>krys-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:451658bd-d88f-4282-9c6a-c1dd52cf3f31,g:9c0f2f52-9e92-4a03-8bd1-6f7b5787d327-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/Cover" xlink:type="simple" xlink:href="krys-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_022fd104-5574-4986-beb8-e3f4fec5c04e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_DocumentType_022fd104-5574-4986-beb8-e3f4fec5c04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_072f5fca-dae9-4362-8975-0e887ab61dbb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_DocumentQuarterlyReport_072f5fca-dae9-4362-8975-0e887ab61dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4f54c2ed-a669-4eab-9706-6b3816ca9eb7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_DocumentPeriodEndDate_4f54c2ed-a669-4eab-9706-6b3816ca9eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5e70ec58-7f91-45ad-a68d-0e69308d29fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_DocumentTransitionReport_5e70ec58-7f91-45ad-a68d-0e69308d29fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a5dbcbbb-901b-4d3c-893a-6b7075182049" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityFileNumber_a5dbcbbb-901b-4d3c-893a-6b7075182049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0f8ffc9a-df0e-4e30-9a5c-e4d93ecccdf0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityRegistrantName_0f8ffc9a-df0e-4e30-9a5c-e4d93ecccdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5fcd425e-2caf-400e-b047-1ffa2c17c5e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5fcd425e-2caf-400e-b047-1ffa2c17c5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4fa00fa5-2a92-427f-9016-6afe81d5f1df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityTaxIdentificationNumber_4fa00fa5-2a92-427f-9016-6afe81d5f1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_73daaa9a-57b7-40df-aee8-e9193c9f591a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityAddressAddressLine1_73daaa9a-57b7-40df-aee8-e9193c9f591a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_08f2949d-32da-4e33-a066-5936782ea802" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityAddressAddressLine2_08f2949d-32da-4e33-a066-5936782ea802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4f2e006a-75ea-4494-90f2-391578bc1262" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityAddressCityOrTown_4f2e006a-75ea-4494-90f2-391578bc1262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d53d857f-ecd6-457c-8b43-903cfa243841" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityAddressStateOrProvince_d53d857f-ecd6-457c-8b43-903cfa243841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c62d022d-e398-4c99-a65a-868ffccc5efc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityAddressPostalZipCode_c62d022d-e398-4c99-a65a-868ffccc5efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_755a8e4e-d97e-4a79-927e-e2bdb2ff0b39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_CityAreaCode_755a8e4e-d97e-4a79-927e-e2bdb2ff0b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b8c32cf8-5251-4562-b9f2-a9a00cf3c044" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_LocalPhoneNumber_b8c32cf8-5251-4562-b9f2-a9a00cf3c044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_010badd2-5902-4f78-9d01-034493c2193c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_Security12bTitle_010badd2-5902-4f78-9d01-034493c2193c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4b9243a4-945e-460d-ace1-f6c0e0ae720c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_TradingSymbol_4b9243a4-945e-460d-ace1-f6c0e0ae720c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7592d541-6737-4556-bf68-686f06c76c3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_SecurityExchangeName_7592d541-6737-4556-bf68-686f06c76c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a54e5ae9-28ad-46a2-a1bd-232284041e65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityCurrentReportingStatus_a54e5ae9-28ad-46a2-a1bd-232284041e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_08f9eeb8-7461-43c1-86e0-6993d03423b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityInteractiveDataCurrent_08f9eeb8-7461-43c1-86e0-6993d03423b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a8f1990b-a19d-4cce-a2a4-90715ed1367f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityFilerCategory_a8f1990b-a19d-4cce-a2a4-90715ed1367f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_16806892-efd1-42d3-8746-371ba55f7e46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntitySmallBusiness_16806892-efd1-42d3-8746-371ba55f7e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_825fcde3-735a-41fd-b8df-ecbea914114f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityEmergingGrowthCompany_825fcde3-735a-41fd-b8df-ecbea914114f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0e34d38d-6565-4ede-943f-305eb207f01e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityShellCompany_0e34d38d-6565-4ede-943f-305eb207f01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_98979525-b15e-4bc4-9f3c-22de97b0e2fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_98979525-b15e-4bc4-9f3c-22de97b0e2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_28b4ddf0-bebd-4ec0-b7dc-70ea8660d66b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_AmendmentFlag_28b4ddf0-bebd-4ec0-b7dc-70ea8660d66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3b4505aa-2ad8-4ab4-8a19-d9811601fc1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_DocumentFiscalYearFocus_3b4505aa-2ad8-4ab4-8a19-d9811601fc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d770e4cc-b4fe-44a8-9d43-fc7016527f54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d770e4cc-b4fe-44a8-9d43-fc7016527f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_eeeab8a8-ca23-47a2-b81e-c9ddb8b6e6db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_EntityCentralIndexKey_eeeab8a8-ca23-47a2-b81e-c9ddb8b6e6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9c99d90b-a551-448f-8f11-5dfb7affb23b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3114da5f-bbcf-4410-a7da-41e01511bc8b" xlink:to="loc_dei_CurrentFiscalYearEndDate_9c99d90b-a551-448f-8f11-5dfb7affb23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="krys-20230331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cddbbe32-554f-4d7b-8adc-8b3c01badb45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5643a8ab-0d10-478f-b268-c49b46c02664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cddbbe32-554f-4d7b-8adc-8b3c01badb45" xlink:to="loc_us-gaap_AssetsAbstract_5643a8ab-0d10-478f-b268-c49b46c02664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3892bd72-2574-4042-9c2c-04e47f53b372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5643a8ab-0d10-478f-b268-c49b46c02664" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3892bd72-2574-4042-9c2c-04e47f53b372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_52f73be3-926c-4927-aa7d-4dbf5b3a0df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3892bd72-2574-4042-9c2c-04e47f53b372" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_52f73be3-926c-4927-aa7d-4dbf5b3a0df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bfce584c-3e97-4e37-a9a2-9305917f046e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3892bd72-2574-4042-9c2c-04e47f53b372" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bfce584c-3e97-4e37-a9a2-9305917f046e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2d0bfa27-ca51-48d0-b1e4-03cc2930813c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3892bd72-2574-4042-9c2c-04e47f53b372" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2d0bfa27-ca51-48d0-b1e4-03cc2930813c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fab32652-e412-41de-a57b-8637cd38d813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3892bd72-2574-4042-9c2c-04e47f53b372" xlink:to="loc_us-gaap_AssetsCurrent_fab32652-e412-41de-a57b-8637cd38d813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bc523b0e-cda8-453a-9f86-b396ad94fad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5643a8ab-0d10-478f-b268-c49b46c02664" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bc523b0e-cda8-453a-9f86-b396ad94fad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_4e847df2-7095-4c0a-a4a1-3697cffbd665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5643a8ab-0d10-478f-b268-c49b46c02664" xlink:to="loc_us-gaap_LongTermInvestments_4e847df2-7095-4c0a-a4a1-3697cffbd665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e97b2475-a6fe-4385-8b47-34d0273789b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5643a8ab-0d10-478f-b268-c49b46c02664" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e97b2475-a6fe-4385-8b47-34d0273789b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_64044ed0-df70-44e8-b99a-f03b5b7d6ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5643a8ab-0d10-478f-b268-c49b46c02664" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_64044ed0-df70-44e8-b99a-f03b5b7d6ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_28a12f9e-c8be-4888-94ed-e15f1775a180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5643a8ab-0d10-478f-b268-c49b46c02664" xlink:to="loc_us-gaap_Assets_28a12f9e-c8be-4888-94ed-e15f1775a180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c1ed74-dd15-4423-85aa-d93c64712e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cddbbe32-554f-4d7b-8adc-8b3c01badb45" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c1ed74-dd15-4423-85aa-d93c64712e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4c36cd11-2462-46d0-858d-2f5bd70a0fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c1ed74-dd15-4423-85aa-d93c64712e9e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4c36cd11-2462-46d0-858d-2f5bd70a0fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a90c33f7-23be-49d2-b8b1-1333fb98d9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c36cd11-2462-46d0-858d-2f5bd70a0fbe" xlink:to="loc_us-gaap_AccountsPayableCurrent_a90c33f7-23be-49d2-b8b1-1333fb98d9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d94cded4-e0fa-4375-b04e-4e89873cd0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c36cd11-2462-46d0-858d-2f5bd70a0fbe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d94cded4-e0fa-4375-b04e-4e89873cd0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_39016719-691f-4057-82d9-ba678c670779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c36cd11-2462-46d0-858d-2f5bd70a0fbe" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_39016719-691f-4057-82d9-ba678c670779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ad0f06e7-d802-4148-a035-91831473c804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4c36cd11-2462-46d0-858d-2f5bd70a0fbe" xlink:to="loc_us-gaap_LiabilitiesCurrent_ad0f06e7-d802-4148-a035-91831473c804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_16ecdbf2-d0b6-4403-b75f-fcca6ab81f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c1ed74-dd15-4423-85aa-d93c64712e9e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_16ecdbf2-d0b6-4403-b75f-fcca6ab81f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_22dd79d8-1f2e-4f1f-a19d-b0c1cc188528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c1ed74-dd15-4423-85aa-d93c64712e9e" xlink:to="loc_us-gaap_Liabilities_22dd79d8-1f2e-4f1f-a19d-b0c1cc188528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b645aa39-da11-43fa-ac92-aae88f12b0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c1ed74-dd15-4423-85aa-d93c64712e9e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b645aa39-da11-43fa-ac92-aae88f12b0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_677b4bf0-4b25-49e6-86b1-cdf0c041b5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c1ed74-dd15-4423-85aa-d93c64712e9e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_677b4bf0-4b25-49e6-86b1-cdf0c041b5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0e17f774-5987-4ff6-85aa-91a846360232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_677b4bf0-4b25-49e6-86b1-cdf0c041b5a8" xlink:to="loc_us-gaap_CommonStockValue_0e17f774-5987-4ff6-85aa-91a846360232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_788de381-d6ca-4f47-93b2-7aee4eea14b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_677b4bf0-4b25-49e6-86b1-cdf0c041b5a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_788de381-d6ca-4f47-93b2-7aee4eea14b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_37e9d0b0-fb3e-48a3-a690-adb978018d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_677b4bf0-4b25-49e6-86b1-cdf0c041b5a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_37e9d0b0-fb3e-48a3-a690-adb978018d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b22f0134-88a8-4875-b7a6-6c81daadb24f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_677b4bf0-4b25-49e6-86b1-cdf0c041b5a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b22f0134-88a8-4875-b7a6-6c81daadb24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a6abddf3-5c67-4bcc-bba3-afafd3409b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_677b4bf0-4b25-49e6-86b1-cdf0c041b5a8" xlink:to="loc_us-gaap_StockholdersEquity_a6abddf3-5c67-4bcc-bba3-afafd3409b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_40d66b97-fe65-4a4b-bbd3-f82f71bbf123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45c1ed74-dd15-4423-85aa-d93c64712e9e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_40d66b97-fe65-4a4b-bbd3-f82f71bbf123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="krys-20230331.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3b424d09-cda7-421e-9809-f5f70e32cb40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7c11f723-12f5-4bfb-b485-5ba3bc85b822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b424d09-cda7-421e-9809-f5f70e32cb40" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7c11f723-12f5-4bfb-b485-5ba3bc85b822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2472867d-0b8a-4d1f-ad75-08b51b7f1e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b424d09-cda7-421e-9809-f5f70e32cb40" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2472867d-0b8a-4d1f-ad75-08b51b7f1e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_be9aed9e-0c44-43e5-a23d-2880ed9a49cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b424d09-cda7-421e-9809-f5f70e32cb40" xlink:to="loc_us-gaap_CommonStockSharesIssued_be9aed9e-0c44-43e5-a23d-2880ed9a49cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7592371d-10ef-402c-9f64-6b4298512a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3b424d09-cda7-421e-9809-f5f70e32cb40" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7592371d-10ef-402c-9f64-6b4298512a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="krys-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_dca786fb-b96e-4d3e-a4c2-f5094501c7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_80fcc8c5-2a3d-46f8-85a4-8f673d97494c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dca786fb-b96e-4d3e-a4c2-f5094501c7ca" xlink:to="loc_us-gaap_OperatingExpensesAbstract_80fcc8c5-2a3d-46f8-85a4-8f673d97494c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fda40c38-272b-439a-9617-4a67ea6b5e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_80fcc8c5-2a3d-46f8-85a4-8f673d97494c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fda40c38-272b-439a-9617-4a67ea6b5e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7db65675-2847-4c6b-b51d-e58cdad2340e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_80fcc8c5-2a3d-46f8-85a4-8f673d97494c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7db65675-2847-4c6b-b51d-e58cdad2340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_e17001be-2cc7-485e-a2c9-1f32d3c2bad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_80fcc8c5-2a3d-46f8-85a4-8f673d97494c" xlink:to="loc_us-gaap_LitigationSettlementExpense_e17001be-2cc7-485e-a2c9-1f32d3c2bad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_87a67527-de47-41a4-9cc2-118fc0ae9ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_80fcc8c5-2a3d-46f8-85a4-8f673d97494c" xlink:to="loc_us-gaap_OperatingExpenses_87a67527-de47-41a4-9cc2-118fc0ae9ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0d83e9b6-2ffd-4151-b3d5-a81f8ab043b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dca786fb-b96e-4d3e-a4c2-f5094501c7ca" xlink:to="loc_us-gaap_OperatingIncomeLoss_0d83e9b6-2ffd-4151-b3d5-a81f8ab043b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_69309b32-5638-4f55-b2a9-8b067509f309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dca786fb-b96e-4d3e-a4c2-f5094501c7ca" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_69309b32-5638-4f55-b2a9-8b067509f309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_25c0f75b-4caa-4f63-a326-82428b50116b" xlink:href="krys-20230331.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_69309b32-5638-4f55-b2a9-8b067509f309" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_25c0f75b-4caa-4f63-a326-82428b50116b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b39d0f2c-0bc6-4376-a5f7-22481dc13564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dca786fb-b96e-4d3e-a4c2-f5094501c7ca" xlink:to="loc_us-gaap_NetIncomeLoss_b39d0f2c-0bc6-4376-a5f7-22481dc13564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f28454b1-b90a-49b4-8406-79aaf8b74d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dca786fb-b96e-4d3e-a4c2-f5094501c7ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f28454b1-b90a-49b4-8406-79aaf8b74d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_188e9423-38f9-4dcb-b1d4-9c414035a503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dca786fb-b96e-4d3e-a4c2-f5094501c7ca" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_188e9423-38f9-4dcb-b1d4-9c414035a503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e061e120-84ea-49b4-ad5d-c7dc35711776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dca786fb-b96e-4d3e-a4c2-f5094501c7ca" xlink:to="loc_us-gaap_EarningsPerShareBasic_e061e120-84ea-49b4-ad5d-c7dc35711776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7dc6312a-860b-4034-92e3-3b23f02ac298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dca786fb-b96e-4d3e-a4c2-f5094501c7ca" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7dc6312a-860b-4034-92e3-3b23f02ac298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e04cf15c-53ec-4bff-aee2-b409dee4fefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dca786fb-b96e-4d3e-a4c2-f5094501c7ca" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e04cf15c-53ec-4bff-aee2-b409dee4fefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9eb4bbbd-8b91-4ff1-960d-ae972dc6ecfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dca786fb-b96e-4d3e-a4c2-f5094501c7ca" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9eb4bbbd-8b91-4ff1-960d-ae972dc6ecfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="krys-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3941c3c2-9772-4a5c-a4f9-7060b73c0ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3ca0d8af-38a0-4feb-9b85-15654307895d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3941c3c2-9772-4a5c-a4f9-7060b73c0ff0" xlink:to="loc_us-gaap_StatementTable_3ca0d8af-38a0-4feb-9b85-15654307895d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9e6a592d-3a33-4968-9127-e3227a5b5908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3ca0d8af-38a0-4feb-9b85-15654307895d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9e6a592d-3a33-4968-9127-e3227a5b5908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9e6a592d-3a33-4968-9127-e3227a5b5908" xlink:to="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f4c63e18-ea05-4544-8059-45178f63102d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:to="loc_us-gaap_CommonStockMember_f4c63e18-ea05-4544-8059-45178f63102d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2dd67653-e974-4eaf-b012-cc08ee7b7863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2dd67653-e974-4eaf-b012-cc08ee7b7863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed5fb663-223d-4e93-8b1d-5e89f01cb332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed5fb663-223d-4e93-8b1d-5e89f01cb332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4c9f4dcf-18e0-4c2f-8553-c806a2a694d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_91ea0804-9142-467d-b642-16b22d3cd128" xlink:to="loc_us-gaap_RetainedEarningsMember_4c9f4dcf-18e0-4c2f-8553-c806a2a694d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d7206f12-9d10-4954-8390-3060e5b45436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3ca0d8af-38a0-4feb-9b85-15654307895d" xlink:to="loc_us-gaap_StatementLineItems_d7206f12-9d10-4954-8390-3060e5b45436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d7206f12-9d10-4954-8390-3060e5b45436" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_98fedcce-8142-4c92-8726-283913618955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_SharesOutstanding_98fedcce-8142-4c92-8726-283913618955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e3578dfe-09b6-424c-ae03-308ac7a9e233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_StockholdersEquity_e3578dfe-09b6-424c-ae03-308ac7a9e233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_647b938b-abf0-439c-802d-f7f702faee5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_647b938b-abf0-439c-802d-f7f702faee5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b13eb7d3-2e82-4bf0-8e4e-57a2368c9f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b13eb7d3-2e82-4bf0-8e4e-57a2368c9f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d3ff4393-b42c-440a-8977-a2102fbad02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d3ff4393-b42c-440a-8977-a2102fbad02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_045de58a-c379-453d-bff0-0d63bde5dad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_045de58a-c379-453d-bff0-0d63bde5dad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_56a4a456-8cbb-455c-8d64-d7850a0c5b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_56a4a456-8cbb-455c-8d64-d7850a0c5b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09e599b2-9958-40a8-b088-1948b573c9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_09e599b2-9958-40a8-b088-1948b573c9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9770ff67-eca4-4a21-8057-e4801ba61b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_NetIncomeLoss_9770ff67-eca4-4a21-8057-e4801ba61b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_99f8efa2-477a-429e-9736-5c375cdaa450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_SharesOutstanding_99f8efa2-477a-429e-9736-5c375cdaa450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4fb5a896-e2bd-4ab2-8666-eda55087531e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf15be89-f773-4243-9a23-6c666f399aaf" xlink:to="loc_us-gaap_StockholdersEquity_4fb5a896-e2bd-4ab2-8666-eda55087531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="krys-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_9766e94c-02b9-48a4-a918-e9ffd2f6c330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ed99013-cf25-4c6d-b48c-b06b16579172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_9766e94c-02b9-48a4-a918-e9ffd2f6c330" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ed99013-cf25-4c6d-b48c-b06b16579172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ad0f68e-febd-4b53-aa4b-62a01df96b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ed99013-cf25-4c6d-b48c-b06b16579172" xlink:to="loc_us-gaap_NetIncomeLoss_3ad0f68e-febd-4b53-aa4b-62a01df96b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1143c2d-9baa-4c18-94d7-35d51e03329c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ed99013-cf25-4c6d-b48c-b06b16579172" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1143c2d-9baa-4c18-94d7-35d51e03329c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_7344e94a-92f7-4894-afb7-38e18c0fc89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1143c2d-9baa-4c18-94d7-35d51e03329c" xlink:to="loc_us-gaap_DepreciationAndAmortization_7344e94a-92f7-4894-afb7-38e18c0fc89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ee89984a-f53e-4dbd-9672-7a4a18ce9d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1143c2d-9baa-4c18-94d7-35d51e03329c" xlink:to="loc_us-gaap_ShareBasedCompensation_ee89984a-f53e-4dbd-9672-7a4a18ce9d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_7f3560a2-b5e2-4b21-bd3d-42a619cf32b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d1143c2d-9baa-4c18-94d7-35d51e03329c" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_7f3560a2-b5e2-4b21-bd3d-42a619cf32b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1dd37ed5-6eeb-400a-8fbe-5c292d91b344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ed99013-cf25-4c6d-b48c-b06b16579172" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1dd37ed5-6eeb-400a-8fbe-5c292d91b344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9db9a90d-1d7e-4ae0-a4c4-d1fcb94373e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1dd37ed5-6eeb-400a-8fbe-5c292d91b344" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9db9a90d-1d7e-4ae0-a4c4-d1fcb94373e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_057928e7-e7aa-4d35-9ca9-107546aef3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1dd37ed5-6eeb-400a-8fbe-5c292d91b344" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_057928e7-e7aa-4d35-9ca9-107546aef3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_db79cacf-57d1-45d8-b94b-78bb8c1f73a3" xlink:href="krys-20230331.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1dd37ed5-6eeb-400a-8fbe-5c292d91b344" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_db79cacf-57d1-45d8-b94b-78bb8c1f73a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1b4f98d5-b141-43f6-ad9f-d46665c963ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1dd37ed5-6eeb-400a-8fbe-5c292d91b344" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1b4f98d5-b141-43f6-ad9f-d46665c963ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_44e8b832-4e8e-469f-aaad-6ed30f168e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1dd37ed5-6eeb-400a-8fbe-5c292d91b344" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_44e8b832-4e8e-469f-aaad-6ed30f168e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_35514533-971b-4723-b82f-75855c59730e" xlink:href="krys-20230331.xsd#krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1dd37ed5-6eeb-400a-8fbe-5c292d91b344" xlink:to="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_35514533-971b-4723-b82f-75855c59730e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f291cad5-38fb-4e6d-b60f-f09dd6e4cbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1ed99013-cf25-4c6d-b48c-b06b16579172" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f291cad5-38fb-4e6d-b60f-f09dd6e4cbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d78fa18-a104-4d0f-8e31-632365c474c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_9766e94c-02b9-48a4-a918-e9ffd2f6c330" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d78fa18-a104-4d0f-8e31-632365c474c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cf64b810-7508-4e2c-b849-a810506c7805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d78fa18-a104-4d0f-8e31-632365c474c8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cf64b810-7508-4e2c-b849-a810506c7805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6ed3a133-b8e2-4faf-a643-6aba0a8974b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d78fa18-a104-4d0f-8e31-632365c474c8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6ed3a133-b8e2-4faf-a643-6aba0a8974b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_a058aa0c-ebc6-43a5-b0f2-e99d7f230973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d78fa18-a104-4d0f-8e31-632365c474c8" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_a058aa0c-ebc6-43a5-b0f2-e99d7f230973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d02ef1bd-37a4-4142-ab09-7fa818b961f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3d78fa18-a104-4d0f-8e31-632365c474c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d02ef1bd-37a4-4142-ab09-7fa818b961f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d00b168-dd3c-424b-89a6-3413f8420c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_9766e94c-02b9-48a4-a918-e9ffd2f6c330" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d00b168-dd3c-424b-89a6-3413f8420c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2086025d-684e-4d88-86cf-3c6863d2d856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d00b168-dd3c-424b-89a6-3413f8420c33" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2086025d-684e-4d88-86cf-3c6863d2d856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5fa68605-137d-451f-8e32-59774ec1d003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d00b168-dd3c-424b-89a6-3413f8420c33" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5fa68605-137d-451f-8e32-59774ec1d003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a8f31c3-6af9-4ec5-a060-170ba2e53cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d00b168-dd3c-424b-89a6-3413f8420c33" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a8f31c3-6af9-4ec5-a060-170ba2e53cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e78e6289-fcee-427e-9d68-704f97ef832f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_9766e94c-02b9-48a4-a918-e9ffd2f6c330" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e78e6289-fcee-427e-9d68-704f97ef832f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0257f17e-6599-4509-bbf6-8a7befb3e30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_9766e94c-02b9-48a4-a918-e9ffd2f6c330" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0257f17e-6599-4509-bbf6-8a7befb3e30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_429a89cd-3000-44b3-b665-d907253d5a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_9766e94c-02b9-48a4-a918-e9ffd2f6c330" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_429a89cd-3000-44b3-b665-d907253d5a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d20307e3-7fdd-480c-96e4-1d6908050fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_9766e94c-02b9-48a4-a918-e9ffd2f6c330" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d20307e3-7fdd-480c-96e4-1d6908050fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_d57644f2-c9d4-4f14-88e4-a0a71def8f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_9766e94c-02b9-48a4-a918-e9ffd2f6c330" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_d57644f2-c9d4-4f14-88e4-a0a71def8f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d0c583da-8aaf-4c32-b3de-f4b89bba34c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_d57644f2-c9d4-4f14-88e4-a0a71def8f49" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d0c583da-8aaf-4c32-b3de-f4b89bba34c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8bdd3ac1-c70b-4158-b8b6-377501d6c859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_d57644f2-c9d4-4f14-88e4-a0a71def8f49" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8bdd3ac1-c70b-4158-b8b6-377501d6c859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Organization" xlink:type="simple" xlink:href="krys-20230331.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8391d6ca-8c66-4b20-8e29-15c07b071dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_868759ae-fe71-41ef-92df-e2e97f7e1489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8391d6ca-8c66-4b20-8e29-15c07b071dfa" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_868759ae-fe71-41ef-92df-e2e97f7e1489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="krys-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a3744973-38e7-4b81-9774-e7447edc7b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bcf2da38-bdfb-4231-b071-94ee451072f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3744973-38e7-4b81-9774-e7447edc7b6f" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_bcf2da38-bdfb-4231-b071-94ee451072f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="simple" xlink:href="krys-20230331.xsd#NetLossPerShareAttributabletoCommonStockholders"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f7e78fc5-259d-42da-b0b8-b64a234325ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9af7bb25-6021-4cb2-a609-94a33f2368a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f7e78fc5-259d-42da-b0b8-b64a234325ed" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9af7bb25-6021-4cb2-a609-94a33f2368a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="simple" xlink:href="krys-20230331.xsd#FairValueInstruments"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e0ba0cf9-7ac3-478c-a516-1b683574208e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_581949a3-bc51-4ea8-99f3-a1f832a42d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e0ba0cf9-7ac3-478c-a516-1b683574208e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_581949a3-bc51-4ea8-99f3-a1f832a42d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="krys-20230331.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_47b872bc-e73a-4d76-bb01-8a9b0abcac8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_858666be-77b5-4ae2-b1c6-062c93dc62b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_47b872bc-e73a-4d76-bb01-8a9b0abcac8c" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_858666be-77b5-4ae2-b1c6-062c93dc62b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="krys-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c5bfd0a9-92c8-4b34-a45b-f2a5b088f0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b2035123-dbf2-4ec6-b64c-d867d56c1348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c5bfd0a9-92c8-4b34-a45b-f2a5b088f0bc" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b2035123-dbf2-4ec6-b64c-d867d56c1348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Leases" xlink:type="simple" xlink:href="krys-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_be95ec61-6e10-4ebe-bcea-0cd80473b0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_a07e435e-64b5-4825-84f9-f2824c9ee125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_be95ec61-6e10-4ebe-bcea-0cd80473b0a4" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_a07e435e-64b5-4825-84f9-f2824c9ee125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Capitalization" xlink:type="simple" xlink:href="krys-20230331.xsd#Capitalization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Capitalization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b49e45be-74bb-4b0d-a284-c884bcb03e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bba39640-6336-4e27-89c4-c9186a258750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b49e45be-74bb-4b0d-a284-c884bcb03e99" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bba39640-6336-4e27-89c4-c9186a258750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="krys-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2e35bca-f3ba-4a3e-add5-356439387009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c0ca0528-43ab-43c5-b11b-477eecb20d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2e35bca-f3ba-4a3e-add5-356439387009" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c0ca0528-43ab-43c5-b11b-477eecb20d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="krys-20230331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_15610d67-4567-4cda-9f64-27d0ed5f2f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_a2c2d99a-405a-4247-a489-423a84db49d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_15610d67-4567-4cda-9f64-27d0ed5f2f77" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_a2c2d99a-405a-4247-a489-423a84db49d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="krys-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7ccf67df-58f9-4494-9f21-8f376d0760f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7ccf67df-58f9-4494-9f21-8f376d0760f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_8c451db0-88ca-4111-9d5c-331aa835f541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_UseOfEstimates_8c451db0-88ca-4111-9d5c-331aa835f541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e2b42155-e471-47f6-b8b9-861ee6965cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e2b42155-e471-47f6-b8b9-861ee6965cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_8c5ef1b9-4644-4b35-8579-1196aeff7cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_8c5ef1b9-4644-4b35-8579-1196aeff7cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a0d1da0c-73f9-4bdc-890a-151199426ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a0d1da0c-73f9-4bdc-890a-151199426ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_bfba69a1-cc9e-4ee8-a2d5-9f4ac5575e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_bfba69a1-cc9e-4ee8-a2d5-9f4ac5575e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5a3adac8-ffa6-4368-8fe1-0bc26f47d317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5a3adac8-ffa6-4368-8fe1-0bc26f47d317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_c763c8a7-8073-473b-bc3f-bdf83853325a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_c763c8a7-8073-473b-bc3f-bdf83853325a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_f38a5372-0687-4290-ae26-da30b424fe78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_f38a5372-0687-4290-ae26-da30b424fe78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_9a6f953e-59b4-40fa-9d9d-dd74dce9b73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_9a6f953e-59b4-40fa-9d9d-dd74dce9b73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3d658c67-daa4-40be-8c90-8eb8c6a741dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3d658c67-daa4-40be-8c90-8eb8c6a741dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_92c20b11-4e6b-407c-ba98-5a3cca1bceb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_92c20b11-4e6b-407c-ba98-5a3cca1bceb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20b68f60-38f1-4d85-bc1e-836620bfc758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e65fd8a-7cd3-463c-a740-a6fbd3e4d327" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20b68f60-38f1-4d85-bc1e-836620bfc758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="krys-20230331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_81a9f07a-8219-4a64-a4ce-727131b33b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_920aac6c-a377-4d06-b2f9-881fb6e5a27f" xlink:href="krys-20230331.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_81a9f07a-8219-4a64-a4ce-727131b33b14" xlink:to="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_920aac6c-a377-4d06-b2f9-881fb6e5a27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="simple" xlink:href="krys-20230331.xsd#NetLossPerShareAttributabletoCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7fb5655d-d29f-4295-a709-df75f0cebbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a644f927-0560-439d-b2c2-e6ce410b97a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7fb5655d-d29f-4295-a709-df75f0cebbbb" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a644f927-0560-439d-b2c2-e6ce410b97a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="simple" xlink:href="krys-20230331.xsd#FairValueInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7fc1a044-0ab7-478e-8dff-befc32f90d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ee1387b0-48aa-40ee-9af0-c6a7b8dfd883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7fc1a044-0ab7-478e-8dff-befc32f90d42" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ee1387b0-48aa-40ee-9af0-c6a7b8dfd883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="krys-20230331.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_798f2cb0-b51a-4231-bb16-bae389ec8f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c0c2d1b8-6b25-45d3-a314-90e60ae36930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_798f2cb0-b51a-4231-bb16-bae389ec8f1c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c0c2d1b8-6b25-45d3-a314-90e60ae36930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ca5f250d-a43f-469f-9ca9-723e77427f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_798f2cb0-b51a-4231-bb16-bae389ec8f1c" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ca5f250d-a43f-469f-9ca9-723e77427f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesTables" xlink:type="simple" xlink:href="krys-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_be6a576d-a6d3-48d5-8569-e3e49c32dd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0ecbc171-f1d6-4550-9068-6f5435ddf547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_be6a576d-a6d3-48d5-8569-e3e49c32dd1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0ecbc171-f1d6-4550-9068-6f5435ddf547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_1310a734-dc5c-404c-9e73-60ae19b938bf" xlink:href="krys-20230331.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_be6a576d-a6d3-48d5-8569-e3e49c32dd1d" xlink:to="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_1310a734-dc5c-404c-9e73-60ae19b938bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_25b501b2-e6be-49d6-89d5-7e384aafec43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_be6a576d-a6d3-48d5-8569-e3e49c32dd1d" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_25b501b2-e6be-49d6-89d5-7e384aafec43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="krys-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ed8076f-994a-4909-9970-a1c2ec4aeb53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2a13da32-f09f-40e5-85df-82b383aaeb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ed8076f-994a-4909-9970-a1c2ec4aeb53" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2a13da32-f09f-40e5-85df-82b383aaeb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_806bf1af-74f7-40bf-8528-06586b5734f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ed8076f-994a-4909-9970-a1c2ec4aeb53" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_806bf1af-74f7-40bf-8528-06586b5734f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f6a3dd99-0aa0-4fd4-b4dd-c0b25e0c044e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ed8076f-994a-4909-9970-a1c2ec4aeb53" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f6a3dd99-0aa0-4fd4-b4dd-c0b25e0c044e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_25b74705-332d-4e20-99a0-0eb627b53f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ed8076f-994a-4909-9970-a1c2ec4aeb53" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_25b74705-332d-4e20-99a0-0eb627b53f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_1262f1ba-dcf4-4e3f-9cc4-8a4e5598d3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ed8076f-994a-4909-9970-a1c2ec4aeb53" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_1262f1ba-dcf4-4e3f-9cc4-8a4e5598d3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#OrganizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_adb735fc-04fc-4ef1-93b0-7113b8e45dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4f20b0fc-d8b4-4c0d-b9cb-5f796e58235d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adb735fc-04fc-4ef1-93b0-7113b8e45dc0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4f20b0fc-d8b4-4c0d-b9cb-5f796e58235d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_7ab631b2-1fa9-4255-ab82-ae3bd8a98a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adb735fc-04fc-4ef1-93b0-7113b8e45dc0" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_7ab631b2-1fa9-4255-ab82-ae3bd8a98a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5e091ecb-c98a-4105-9109-829bbdc8f9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable_913ef3f3-142f-408a-a5bb-2ae354361d03" xlink:href="krys-20230331.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e091ecb-c98a-4105-9109-829bbdc8f9b5" xlink:to="loc_krys_SignificantAccountingPoliciesTable_913ef3f3-142f-408a-a5bb-2ae354361d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12c55172-85ab-467e-9a9e-57e637e30729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesTable_913ef3f3-142f-408a-a5bb-2ae354361d03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12c55172-85ab-467e-9a9e-57e637e30729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c056205d-30d7-4d40-b8af-95cf7f8843eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_12c55172-85ab-467e-9a9e-57e637e30729" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c056205d-30d7-4d40-b8af-95cf7f8843eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f21ef319-0633-41b3-b37f-3215ef59b3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c056205d-30d7-4d40-b8af-95cf7f8843eb" xlink:to="loc_us-gaap_EquipmentMember_f21ef319-0633-41b3-b37f-3215ef59b3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems_b101a67f-99e2-4cad-9ca6-6936bb5bb4e5" xlink:href="krys-20230331.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesTable_913ef3f3-142f-408a-a5bb-2ae354361d03" xlink:to="loc_krys_SignificantAccountingPoliciesLineItems_b101a67f-99e2-4cad-9ca6-6936bb5bb4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d78e18b9-addd-4d09-8ecd-3621e275c064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_b101a67f-99e2-4cad-9ca6-6936bb5bb4e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d78e18b9-addd-4d09-8ecd-3621e275c064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_02aa6ccc-5ed6-49ba-8be2-272aa3f4aede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_b101a67f-99e2-4cad-9ca6-6936bb5bb4e5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_02aa6ccc-5ed6-49ba-8be2-272aa3f4aede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_363c8c46-2035-49a1-99de-d5f14395cf41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_b101a67f-99e2-4cad-9ca6-6936bb5bb4e5" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_363c8c46-2035-49a1-99de-d5f14395cf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5e981cab-e7dc-4565-baf3-4876ac9b7e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43e34e42-669b-4cf6-a38b-4499fe638bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e981cab-e7dc-4565-baf3-4876ac9b7e3b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43e34e42-669b-4cf6-a38b-4499fe638bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e17f48ef-d17c-485e-8ad2-fa4bbb8499db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43e34e42-669b-4cf6-a38b-4499fe638bc6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e17f48ef-d17c-485e-8ad2-fa4bbb8499db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e17f48ef-d17c-485e-8ad2-fa4bbb8499db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_e4aa4ce8-821b-4df8-b67c-e52f4ee36545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_e4aa4ce8-821b-4df8-b67c-e52f4ee36545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e279eea3-7472-4ef4-bde4-a79c8b171352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:to="loc_us-gaap_ComputerEquipmentMember_e279eea3-7472-4ef4-bde4-a79c8b171352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ManufacturingEquipmentMember_c7caae88-28a4-4334-869c-da8672e53ed8" xlink:href="krys-20230331.xsd#krys_ManufacturingEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:to="loc_krys_ManufacturingEquipmentMember_c7caae88-28a4-4334-869c-da8672e53ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c3ac1a67-ff2f-44c8-86f4-c1c1d0ebef59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:to="loc_us-gaap_EquipmentMember_c3ac1a67-ff2f-44c8-86f4-c1c1d0ebef59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8be79c27-9d91-4738-85db-586e26ca0772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b15a050d-4615-4464-9d2a-074b418610eb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8be79c27-9d91-4738-85db-586e26ca0772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4f97d187-30b0-4034-9ea1-1b3cc829f5a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43e34e42-669b-4cf6-a38b-4499fe638bc6" xlink:to="loc_srt_RangeAxis_4f97d187-30b0-4034-9ea1-1b3cc829f5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e63e45be-2d18-4bd6-ae03-336309752f82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4f97d187-30b0-4034-9ea1-1b3cc829f5a6" xlink:to="loc_srt_RangeMember_e63e45be-2d18-4bd6-ae03-336309752f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1743e4c9-90a8-4f77-a5b5-92b395359d2e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e63e45be-2d18-4bd6-ae03-336309752f82" xlink:to="loc_srt_MinimumMember_1743e4c9-90a8-4f77-a5b5-92b395359d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8d9712df-dfdb-4457-9999-1d711829e754" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e63e45be-2d18-4bd6-ae03-336309752f82" xlink:to="loc_srt_MaximumMember_8d9712df-dfdb-4457-9999-1d711829e754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_17e64fc6-64af-459f-82bb-6de765b726ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43e34e42-669b-4cf6-a38b-4499fe638bc6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_17e64fc6-64af-459f-82bb-6de765b726ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_09400673-0e0e-4d6a-9cb0-095b7de5e5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_17e64fc6-64af-459f-82bb-6de765b726ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_09400673-0e0e-4d6a-9cb0-095b7de5e5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_066d03ee-60c1-48ed-9f92-0c03bec95eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1c77f848-9cdd-425c-8f76-bcf97756e723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_066d03ee-60c1-48ed-9f92-0c03bec95eaa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1c77f848-9cdd-425c-8f76-bcf97756e723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_65ead613-ded2-48e5-b5c3-9e1467f7a5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_e5b583e9-cbee-4c12-b159-252b87bbca95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_65ead613-ded2-48e5-b5c3-9e1467f7a5a8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_e5b583e9-cbee-4c12-b159-252b87bbca95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bc1d28b6-abb3-4874-b253-82c11c0635cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_e5b583e9-cbee-4c12-b159-252b87bbca95" xlink:to="loc_us-gaap_NetIncomeLoss_bc1d28b6-abb3-4874-b253-82c11c0635cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_de461320-22f3-4182-9ecf-5f1e0d935b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_65ead613-ded2-48e5-b5c3-9e1467f7a5a8" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_de461320-22f3-4182-9ecf-5f1e0d935b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5ca1138-1aca-4fc6-9e40-de5663ed6ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_de461320-22f3-4182-9ecf-5f1e0d935b74" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f5ca1138-1aca-4fc6-9e40-de5663ed6ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b4593df4-8b93-432b-a36e-38f3a2e7cc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_de461320-22f3-4182-9ecf-5f1e0d935b74" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b4593df4-8b93-432b-a36e-38f3a2e7cc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0ddda283-305e-40fa-bce6-8f6c49ef0bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_65ead613-ded2-48e5-b5c3-9e1467f7a5a8" xlink:to="loc_us-gaap_EarningsPerShareBasic_0ddda283-305e-40fa-bce6-8f6c49ef0bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5e39a330-8d4e-4d32-9ca5-afc200428587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_65ead613-ded2-48e5-b5c3-9e1467f7a5a8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5e39a330-8d4e-4d32-9ca5-afc200428587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_988064c3-5e79-4505-ad83-981631cb1b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_988064c3-5e79-4505-ad83-981631cb1b7b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_8dfc315f-af18-42f4-8db3-b3ed9a799d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_8dfc315f-af18-42f4-8db3-b3ed9a799d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_44a77f8e-f474-473f-9344-fcb21bc66f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_8dfc315f-af18-42f4-8db3-b3ed9a799d27" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_44a77f8e-f474-473f-9344-fcb21bc66f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_d3b95f15-5c6f-4802-b9c9-81e6d87d8079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_44a77f8e-f474-473f-9344-fcb21bc66f5a" xlink:to="loc_us-gaap_CashMember_d3b95f15-5c6f-4802-b9c9-81e6d87d8079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0b71d177-b287-44a6-bf89-4cb406898174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0b71d177-b287-44a6-bf89-4cb406898174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e72e62eb-7737-4a5e-b89f-091cfea2e251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0b71d177-b287-44a6-bf89-4cb406898174" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e72e62eb-7737-4a5e-b89f-091cfea2e251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_05f50c2a-6f82-4d66-8c16-ea2a7002130b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e72e62eb-7737-4a5e-b89f-091cfea2e251" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_05f50c2a-6f82-4d66-8c16-ea2a7002130b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1b40b791-9efd-4df3-8895-19f72b5ed333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e72e62eb-7737-4a5e-b89f-091cfea2e251" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1b40b791-9efd-4df3-8895-19f72b5ed333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3913cbca-0eef-4fbe-a233-108628cf46fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3913cbca-0eef-4fbe-a233-108628cf46fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8f61003a-ed39-4eae-ab03-2147852a2957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3913cbca-0eef-4fbe-a233-108628cf46fb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8f61003a-ed39-4eae-ab03-2147852a2957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_1f9caf9d-b4a6-4aef-b77b-906ad3f0ce2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8f61003a-ed39-4eae-ab03-2147852a2957" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_1f9caf9d-b4a6-4aef-b77b-906ad3f0ce2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_dfe699d0-7ae6-4f6a-b34c-65aa9b64f7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8f61003a-ed39-4eae-ab03-2147852a2957" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_dfe699d0-7ae6-4f6a-b34c-65aa9b64f7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_358d3377-665a-4c01-a7bc-579adb48f570" xlink:href="krys-20230331.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8f61003a-ed39-4eae-ab03-2147852a2957" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_358d3377-665a-4c01-a7bc-579adb48f570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c61d3088-a514-4f4d-a878-cd9f5500d106" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:to="loc_srt_RangeAxis_c61d3088-a514-4f4d-a878-cd9f5500d106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c2e46fc-fa9b-42b6-8dd2-fe89d7dc5568" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c61d3088-a514-4f4d-a878-cd9f5500d106" xlink:to="loc_srt_RangeMember_3c2e46fc-fa9b-42b6-8dd2-fe89d7dc5568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_515b9969-c470-4a95-baeb-21c7b7c6981c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3c2e46fc-fa9b-42b6-8dd2-fe89d7dc5568" xlink:to="loc_srt_MinimumMember_515b9969-c470-4a95-baeb-21c7b7c6981c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bc18aa8b-988e-45b8-8422-79a386c5b6eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3c2e46fc-fa9b-42b6-8dd2-fe89d7dc5568" xlink:to="loc_srt_MaximumMember_bc18aa8b-988e-45b8-8422-79a386c5b6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78e4d224-3654-4e7f-97d5-5a7cfbdf4857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78e4d224-3654-4e7f-97d5-5a7cfbdf4857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dceab839-aede-435f-bc98-f05131d7363c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78e4d224-3654-4e7f-97d5-5a7cfbdf4857" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dceab839-aede-435f-bc98-f05131d7363c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_19782b6a-f750-4c39-a631-50e28d292278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dceab839-aede-435f-bc98-f05131d7363c" xlink:to="loc_us-gaap_CommercialPaperMember_19782b6a-f750-4c39-a631-50e28d292278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ed1d8edc-de9a-477d-9e58-2afa41043561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dceab839-aede-435f-bc98-f05131d7363c" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ed1d8edc-de9a-477d-9e58-2afa41043561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a9559002-b01b-4eca-8b73-738cb9a931ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dceab839-aede-435f-bc98-f05131d7363c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a9559002-b01b-4eca-8b73-738cb9a931ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58e51e65-2ae7-4403-b47a-4799ba564beb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49552127-5c1b-4bc4-8ecb-f0114eb7cf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49552127-5c1b-4bc4-8ecb-f0114eb7cf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_870a4e65-e8ca-48a9-81ee-a46586d2aa75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_870a4e65-e8ca-48a9-81ee-a46586d2aa75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c608c184-40c8-42c0-9360-bc98be2689f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c608c184-40c8-42c0-9360-bc98be2689f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e93b0014-4752-4238-b00c-26cd86083491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e93b0014-4752-4238-b00c-26cd86083491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_939e8d0e-c640-4c3c-a1c2-4b483aa08e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_939e8d0e-c640-4c3c-a1c2-4b483aa08e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c53a8dda-74e3-4334-9a9c-b7bf68408d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c53a8dda-74e3-4334-9a9c-b7bf68408d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_68b5fb0b-05cf-42f2-9089-77aa4cd6bb55" xlink:href="krys-20230331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_68b5fb0b-05cf-42f2-9089-77aa4cd6bb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_c39f9b29-0ca5-40bf-9d41-22675a063e79" xlink:href="krys-20230331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_c39f9b29-0ca5-40bf-9d41-22675a063e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_d63be9c8-3ca4-4485-95be-4a7fbf82fecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bf979dff-818c-4987-a3e5-e3654593ea90" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_d63be9c8-3ca4-4485-95be-4a7fbf82fecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20230331.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4c974d1b-cd5e-404f-9f76-c6b0058a478a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_48579164-69dd-490a-8058-f1faab688e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4c974d1b-cd5e-404f-9f76-c6b0058a478a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_48579164-69dd-490a-8058-f1faab688e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b243654f-924a-4ddc-bec5-6c93d13bb455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_48579164-69dd-490a-8058-f1faab688e01" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b243654f-924a-4ddc-bec5-6c93d13bb455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b243654f-924a-4ddc-bec5-6c93d13bb455" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_070f747d-56fb-4f27-b49b-a4ac34143ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_ConstructionInProgressMember_070f747d-56fb-4f27-b49b-a4ac34143ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_dd37522b-3d7c-4d20-b4e7-ab4a5e1ccdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_dd37522b-3d7c-4d20-b4e7-ab4a5e1ccdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_f9bb1b62-bf3f-4e4e-be23-b4bf2b93288d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_f9bb1b62-bf3f-4e4e-be23-b4bf2b93288d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_86613fca-cf97-4521-b7a6-dd25518eb71b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_86613fca-cf97-4521-b7a6-dd25518eb71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_25f842f4-213f-44ee-b0a2-b0d5919bd101" xlink:href="krys-20230331.xsd#krys_LabEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_krys_LabEquipmentMember_25f842f4-213f-44ee-b0a2-b0d5919bd101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a82c5797-8a78-499f-acc1-f478c72387a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a82c5797-8a78-499f-acc1-f478c72387a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d32b8c6a-6f94-4a4b-8a30-c6b24465b387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b8299071-7aee-4094-883f-c4370f931832" xlink:to="loc_us-gaap_ComputerEquipmentMember_d32b8c6a-6f94-4a4b-8a30-c6b24465b387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99505798-1737-4461-9397-6a7bc193de96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_48579164-69dd-490a-8058-f1faab688e01" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99505798-1737-4461-9397-6a7bc193de96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0bd46536-1386-439e-b19b-5a2f1908f6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99505798-1737-4461-9397-6a7bc193de96" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0bd46536-1386-439e-b19b-5a2f1908f6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_416204f1-3300-46db-96cc-bd9eeb78d708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99505798-1737-4461-9397-6a7bc193de96" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_416204f1-3300-46db-96cc-bd9eeb78d708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9b9e368f-9288-41e4-a0b3-22cd284b79f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_99505798-1737-4461-9397-6a7bc193de96" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9b9e368f-9288-41e4-a0b3-22cd284b79f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#BalanceSheetComponentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1fb7f192-8d3f-45b6-a48d-3f0e4352ced7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2eb4dc47-9d62-4ce5-96e7-153c4d39f167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1fb7f192-8d3f-45b6-a48d-3f0e4352ced7" xlink:to="loc_us-gaap_Depreciation_2eb4dc47-9d62-4ce5-96e7-153c4d39f167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_81ffd87f-3eaf-4495-a3dc-9e1c2936bdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_21aa9d8f-034d-4f37-b4fe-b44dbad4219b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_81ffd87f-3eaf-4495-a3dc-9e1c2936bdaf" xlink:to="loc_us-gaap_LitigationReserveCurrent_21aa9d8f-034d-4f37-b4fe-b44dbad4219b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent_80a090cb-4fd8-4c96-ac94-8907867edaf1" xlink:href="krys-20230331.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_81ffd87f-3eaf-4495-a3dc-9e1c2936bdaf" xlink:to="loc_krys_AccruedConstructionInProgressCurrent_80a090cb-4fd8-4c96-ac94-8907867edaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2dc75006-246d-4479-bcaf-0e62a1c4ee55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_81ffd87f-3eaf-4495-a3dc-9e1c2936bdaf" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2dc75006-246d-4479-bcaf-0e62a1c4ee55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_6f57a54a-1a91-4d6c-ab09-e1af4631f06e" xlink:href="krys-20230331.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_81ffd87f-3eaf-4495-a3dc-9e1c2936bdaf" xlink:to="loc_krys_AccruedPayrollAndBenefits_6f57a54a-1a91-4d6c-ab09-e1af4631f06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_426d1804-6a19-4c91-bf83-900775e3f200" xlink:href="krys-20230331.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_81ffd87f-3eaf-4495-a3dc-9e1c2936bdaf" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_426d1804-6a19-4c91-bf83-900775e3f200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_578572df-3d09-44e3-a41e-1b00ef7d4243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_81ffd87f-3eaf-4495-a3dc-9e1c2936bdaf" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_578572df-3d09-44e3-a41e-1b00ef7d4243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_26feffb0-218f-40c9-ad5f-82abc2d0189d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_81ffd87f-3eaf-4495-a3dc-9e1c2936bdaf" xlink:to="loc_us-gaap_AccruedIncomeTaxes_26feffb0-218f-40c9-ad5f-82abc2d0189d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_ebc59698-f5b9-4032-a5d4-6124dce4ceb2" xlink:href="krys-20230331.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_81ffd87f-3eaf-4495-a3dc-9e1c2936bdaf" xlink:to="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_ebc59698-f5b9-4032-a5d4-6124dce4ceb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_055591ad-56e6-4de0-86fa-8685e7b1ec18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b44e93c3-43ca-478a-9279-fff905768495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_055591ad-56e6-4de0-86fa-8685e7b1ec18" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b44e93c3-43ca-478a-9279-fff905768495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_cc4ab513-39e9-4cfc-953c-6b93df2106ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b44e93c3-43ca-478a-9279-fff905768495" xlink:to="loc_us-gaap_SupplyCommitmentAxis_cc4ab513-39e9-4cfc-953c-6b93df2106ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_482f3522-7c97-4af4-99c1-1393665d093d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_cc4ab513-39e9-4cfc-953c-6b93df2106ee" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_482f3522-7c97-4af4-99c1-1393665d093d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_fe0594e7-db05-41b4-80e4-f1151a2ff097" xlink:href="krys-20230331.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_482f3522-7c97-4af4-99c1-1393665d093d" xlink:to="loc_krys_ClinicalSupplyAgreementMember_fe0594e7-db05-41b4-80e4-f1151a2ff097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_0558e0fb-ee63-4417-b5f2-1d70327b5f3e" xlink:href="krys-20230331.xsd#krys_ASTRAFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_482f3522-7c97-4af4-99c1-1393665d093d" xlink:to="loc_krys_ASTRAFacilityMember_0558e0fb-ee63-4417-b5f2-1d70327b5f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4a19f1d2-575d-4c85-87dc-2178915f2a9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b44e93c3-43ca-478a-9279-fff905768495" xlink:to="loc_srt_LitigationCaseAxis_4a19f1d2-575d-4c85-87dc-2178915f2a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b7777b19-5d58-454c-9875-05a5a78b7d75" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_4a19f1d2-575d-4c85-87dc-2178915f2a9f" xlink:to="loc_srt_LitigationCaseTypeDomain_b7777b19-5d58-454c-9875-05a5a78b7d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_b378696d-79f4-466e-85b6-38aa734fe042" xlink:href="krys-20230331.xsd#krys_PeriphaGenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b7777b19-5d58-454c-9875-05a5a78b7d75" xlink:to="loc_krys_PeriphaGenMember_b378696d-79f4-466e-85b6-38aa734fe042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis_fbdcca0c-ab1e-435f-aab8-e97c659811e8" xlink:href="krys-20230331.xsd#krys_MilestonesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b44e93c3-43ca-478a-9279-fff905768495" xlink:to="loc_krys_MilestonesAxis_fbdcca0c-ab1e-435f-aab8-e97c659811e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_0181ff2b-8b3c-408c-9c33-31dfd6e96da0" xlink:href="krys-20230331.xsd#krys_MilestonesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesAxis_fbdcca0c-ab1e-435f-aab8-e97c659811e8" xlink:to="loc_krys_MilestonesDomain_0181ff2b-8b3c-408c-9c33-31dfd6e96da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember_982ebaf9-5ca6-480e-a0fb-4e22544d31ea" xlink:href="krys-20230331.xsd#krys_MilestoneThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_0181ff2b-8b3c-408c-9c33-31dfd6e96da0" xlink:to="loc_krys_MilestoneThreeMember_982ebaf9-5ca6-480e-a0fb-4e22544d31ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember_c366bb31-3aa6-4bee-8a5b-2c2bf25e7f57" xlink:href="krys-20230331.xsd#krys_MilestoneOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_0181ff2b-8b3c-408c-9c33-31dfd6e96da0" xlink:to="loc_krys_MilestoneOneMember_c366bb31-3aa6-4bee-8a5b-2c2bf25e7f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember_74fa3ed9-ba06-4af8-9e3a-22b4c987ce3b" xlink:href="krys-20230331.xsd#krys_MilestoneTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_0181ff2b-8b3c-408c-9c33-31dfd6e96da0" xlink:to="loc_krys_MilestoneTwoMember_74fa3ed9-ba06-4af8-9e3a-22b4c987ce3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_b44e93c3-43ca-478a-9279-fff905768495" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_021b0cea-f9f6-4bc8-9fe1-ab0dd7f4fd3b" xlink:href="krys-20230331.xsd#krys_RemainingCommitmentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_krys_RemainingCommitmentAmount_021b0cea-f9f6-4bc8-9fe1-ab0dd7f4fd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_805dc449-06f1-4087-ab18-9705bbf50b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_us-gaap_ProfessionalFees_805dc449-06f1-4087-ab18-9705bbf50b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_f3516858-f5c7-4020-ac3b-b8b886d615b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_us-gaap_ContractualObligation_f3516858-f5c7-4020-ac3b-b8b886d615b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_2cb6a828-6a3d-4c3c-99d4-83a5f191eba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_us-gaap_LitigationSettlementExpense_2cb6a828-6a3d-4c3c-99d4-83a5f191eba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_6fdace0a-8622-458e-af88-5ab378115e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_6fdace0a-8622-458e-af88-5ab378115e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones_3776ff0d-a254-4cd7-8b8a-1b8203d7dc46" xlink:href="krys-20230331.xsd#krys_NumberOfMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_krys_NumberOfMilestones_3776ff0d-a254-4cd7-8b8a-1b8203d7dc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_1bfe8f33-5826-4476-ab75-5ccc3fac62b1" xlink:href="krys-20230331.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_1bfe8f33-5826-4476-ab75-5ccc3fac62b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration_e0a7f236-69e0-4b3b-8aa4-c844d8823c31" xlink:href="krys-20230331.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_krys_LitigationSettlementTotalConsideration_e0a7f236-69e0-4b3b-8aa4-c844d8823c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_78dce93b-4ac0-4cb2-85fb-e1e114f3f948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_a249c735-6006-4db5-a234-2d9ce8524a89" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_78dce93b-4ac0-4cb2-85fb-e1e114f3f948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails" xlink:type="simple" xlink:href="krys-20230331.xsd#LeasesMinimumcommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_40d87c71-3677-46fe-bb30-8e14346a425b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9ed732d4-2275-4237-8140-d63a4978efbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40d87c71-3677-46fe-bb30-8e14346a425b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9ed732d4-2275-4237-8140-d63a4978efbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_53581f1d-2497-439f-b3ed-74a424165c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40d87c71-3677-46fe-bb30-8e14346a425b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_53581f1d-2497-439f-b3ed-74a424165c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_167c9549-ab29-4878-a24d-0e30c66c5216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40d87c71-3677-46fe-bb30-8e14346a425b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_167c9549-ab29-4878-a24d-0e30c66c5216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_392649d3-07fd-41b1-8f15-2b7fda6bc28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40d87c71-3677-46fe-bb30-8e14346a425b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_392649d3-07fd-41b1-8f15-2b7fda6bc28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_301c43bc-e8f1-4860-ae52-f485846210e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40d87c71-3677-46fe-bb30-8e14346a425b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_301c43bc-e8f1-4860-ae52-f485846210e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b881c517-4ae6-4d38-861f-5bc6f7262863" xlink:href="krys-20230331.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40d87c71-3677-46fe-bb30-8e14346a425b" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b881c517-4ae6-4d38-861f-5bc6f7262863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d56a9b18-7011-4f8e-aa79-d9127864daaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40d87c71-3677-46fe-bb30-8e14346a425b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d56a9b18-7011-4f8e-aa79-d9127864daaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7a8a4ffa-f23e-4dd9-9f44-5ceb437de8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40d87c71-3677-46fe-bb30-8e14346a425b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7a8a4ffa-f23e-4dd9-9f44-5ceb437de8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5709fd6a-09c6-4074-b9b3-9a993d53269d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40d87c71-3677-46fe-bb30-8e14346a425b" xlink:to="loc_us-gaap_OperatingLeaseLiability_5709fd6a-09c6-4074-b9b3-9a993d53269d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1" xlink:type="simple" xlink:href="krys-20230331.xsd#LeasesMinimumcommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="krys-20230331.xsd#LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c6acb56b-8c84-44d3-b6dd-f34ff75ca111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bdaaf7f9-4746-4514-b505-4e7ad9870376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6acb56b-8c84-44d3-b6dd-f34ff75ca111" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bdaaf7f9-4746-4514-b505-4e7ad9870376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a9223c23-cf4e-493d-8fca-861092660c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6acb56b-8c84-44d3-b6dd-f34ff75ca111" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a9223c23-cf4e-493d-8fca-861092660c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cc192822-24f7-4a3d-9a4e-bcb6fadc3ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6acb56b-8c84-44d3-b6dd-f34ff75ca111" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cc192822-24f7-4a3d-9a4e-bcb6fadc3ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d24ea006-2169-490c-9b80-7de831afdd91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6acb56b-8c84-44d3-b6dd-f34ff75ca111" xlink:to="loc_us-gaap_OperatingLeaseLiability_d24ea006-2169-490c-9b80-7de831afdd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_03b39a32-900e-45f3-8700-3050e0e4a34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6acb56b-8c84-44d3-b6dd-f34ff75ca111" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_03b39a32-900e-45f3-8700-3050e0e4a34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6817bdf5-b3de-4475-bac5-2ea77ad92a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6acb56b-8c84-44d3-b6dd-f34ff75ca111" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6817bdf5-b3de-4475-bac5-2ea77ad92a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/LeasesLeaseexpenseDetails" xlink:type="simple" xlink:href="krys-20230331.xsd#LeasesLeaseexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/LeasesLeaseexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_30d53daf-06f4-489f-8c64-217f817967b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_12bf4562-4b4b-499b-915a-c9dce87a08b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_30d53daf-06f4-489f-8c64-217f817967b3" xlink:to="loc_us-gaap_OperatingLeaseCost_12bf4562-4b4b-499b-915a-c9dce87a08b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_de372266-8bc1-4af9-b142-4a161ea69713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_30d53daf-06f4-489f-8c64-217f817967b3" xlink:to="loc_us-gaap_VariableLeaseCost_de372266-8bc1-4af9-b142-4a161ea69713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_cf56e29e-1183-4a41-9295-2be06813d262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_30d53daf-06f4-489f-8c64-217f817967b3" xlink:to="loc_us-gaap_LeaseCost_cf56e29e-1183-4a41-9295-2be06813d262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e4b93d25-a652-4240-acce-afdfa778c4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_c4940b03-a340-42ec-86c3-e41c08c33a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e4b93d25-a652-4240-acce-afdfa778c4fd" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_c4940b03-a340-42ec-86c3-e41c08c33a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c29fff77-7960-48e0-ac6a-0a10d62ad163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_c4940b03-a340-42ec-86c3-e41c08c33a27" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c29fff77-7960-48e0-ac6a-0a10d62ad163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dba43bce-cd44-41e1-aad4-682e15d3225d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c29fff77-7960-48e0-ac6a-0a10d62ad163" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dba43bce-cd44-41e1-aad4-682e15d3225d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_90dffa0f-73b7-4cf3-ac2e-853df88be0d1" xlink:href="krys-20230331.xsd#krys_PlacementSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dba43bce-cd44-41e1-aad4-682e15d3225d" xlink:to="loc_krys_PlacementSharesMember_90dffa0f-73b7-4cf3-ac2e-853df88be0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_f5bc040c-c5d7-4f6e-87e0-b01ab1a61e9e" xlink:href="krys-20230331.xsd#krys_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dba43bce-cd44-41e1-aad4-682e15d3225d" xlink:to="loc_krys_PublicOfferingMember_f5bc040c-c5d7-4f6e-87e0-b01ab1a61e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_93eb7d3e-7bc7-4f3a-9660-1af9f2bdbec4" xlink:href="krys-20230331.xsd#krys_ATMProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dba43bce-cd44-41e1-aad4-682e15d3225d" xlink:to="loc_krys_ATMProgramMember_93eb7d3e-7bc7-4f3a-9660-1af9f2bdbec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_037a84ae-060d-4e22-b69c-507b7219d5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_c4940b03-a340-42ec-86c3-e41c08c33a27" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_037a84ae-060d-4e22-b69c-507b7219d5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_fd34f535-60ca-4cc3-b150-a3fb8a314ac6" xlink:href="krys-20230331.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_037a84ae-060d-4e22-b69c-507b7219d5d6" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_fd34f535-60ca-4cc3-b150-a3fb8a314ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_83c9f17f-7b1c-4f0a-85e1-6ed9dc95a43f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_037a84ae-060d-4e22-b69c-507b7219d5d6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_83c9f17f-7b1c-4f0a-85e1-6ed9dc95a43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_49a44c95-f2fb-4fa1-861d-fe3464c1b204" xlink:href="krys-20230331.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_037a84ae-060d-4e22-b69c-507b7219d5d6" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_49a44c95-f2fb-4fa1-861d-fe3464c1b204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0cab06d-d8f6-4156-bf25-a0e24977b1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0cab06d-d8f6-4156-bf25-a0e24977b1c3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c7c912de-6090-445f-b5a2-817eaa622f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:to="loc_us-gaap_AwardTypeAxis_c7c912de-6090-445f-b5a2-817eaa622f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c7c912de-6090-445f-b5a2-817eaa622f32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c5a85082-859f-4607-b3b6-5ba2bb03f198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c5a85082-859f-4607-b3b6-5ba2bb03f198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_0a1ae492-8a19-4ab0-bb04-73efb1430ac5" xlink:href="krys-20230331.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_krys_NonEmployeeStockOptionMember_0a1ae492-8a19-4ab0-bb04-73efb1430ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_dbe5a8d1-ac88-4ba8-91a4-7cde7ea02b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_us-gaap_RestrictedStockMember_dbe5a8d1-ac88-4ba8-91a4-7cde7ea02b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_e82bf50f-ef98-4c42-93a5-c3b4f2b2aa2b" xlink:href="krys-20230331.xsd#krys_IncentiveStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_krys_IncentiveStockOptionsMember_e82bf50f-ef98-4c42-93a5-c3b4f2b2aa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0ac24323-e706-48d6-ac8b-c7d9ef35d239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0ac24323-e706-48d6-ac8b-c7d9ef35d239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_73efed7e-6e87-417c-871c-6283d703a99e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c124d1f4-c4b9-448d-99c3-5c000f012f11" xlink:to="loc_us-gaap_PerformanceSharesMember_73efed7e-6e87-417c-871c-6283d703a99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5ac067fb-b36c-46be-91ab-a874a1053f19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:to="loc_srt_RangeAxis_5ac067fb-b36c-46be-91ab-a874a1053f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9157e36-207c-4238-b1a8-f60317375115" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5ac067fb-b36c-46be-91ab-a874a1053f19" xlink:to="loc_srt_RangeMember_f9157e36-207c-4238-b1a8-f60317375115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2a10be79-156c-49b4-ad96-1fcde818a3ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f9157e36-207c-4238-b1a8-f60317375115" xlink:to="loc_srt_MinimumMember_2a10be79-156c-49b4-ad96-1fcde818a3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_29ea29e4-d142-42d3-8018-803be5671992" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f9157e36-207c-4238-b1a8-f60317375115" xlink:to="loc_srt_MaximumMember_29ea29e4-d142-42d3-8018-803be5671992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a72d6f42-66d3-434b-8902-5851a378fc95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:to="loc_us-gaap_PlanNameAxis_a72d6f42-66d3-434b-8902-5851a378fc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d9481483-ba9f-4a7d-88a9-af4988e0b71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a72d6f42-66d3-434b-8902-5851a378fc95" xlink:to="loc_us-gaap_PlanNameDomain_d9481483-ba9f-4a7d-88a9-af4988e0b71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_316fb058-a117-4c77-afdc-35e26b7ba214" xlink:href="krys-20230331.xsd#krys_StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d9481483-ba9f-4a7d-88a9-af4988e0b71c" xlink:to="loc_krys_StockIncentivePlanMember_316fb058-a117-4c77-afdc-35e26b7ba214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_A2017IPOStockPlanMember_beeb6ac9-4650-4c98-8743-88ba68d1d2d0" xlink:href="krys-20230331.xsd#krys_A2017IPOStockPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d9481483-ba9f-4a7d-88a9-af4988e0b71c" xlink:to="loc_krys_A2017IPOStockPlanMember_beeb6ac9-4650-4c98-8743-88ba68d1d2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_96d8696f-d221-4ecb-8d92-fcaf0ce00e5e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:to="loc_srt_TitleOfIndividualAxis_96d8696f-d221-4ecb-8d92-fcaf0ce00e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9ff894bf-543f-4050-b247-1673d6598bcd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_96d8696f-d221-4ecb-8d92-fcaf0ce00e5e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9ff894bf-543f-4050-b247-1673d6598bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c9a911c1-bf34-4733-86a0-e895515894aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9ff894bf-543f-4050-b247-1673d6598bcd" xlink:to="loc_srt_DirectorMember_c9a911c1-bf34-4733-86a0-e895515894aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_2bdabcea-aa92-4f86-94e3-8dac2098aff5" xlink:href="krys-20230331.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9ff894bf-543f-4050-b247-1673d6598bcd" xlink:to="loc_krys_NonEmployeeStockOptionMember_2bdabcea-aa92-4f86-94e3-8dac2098aff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fcc87e6-377d-48c6-b841-86944594d8aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ff8b5cf9-2df8-447b-98ea-f32fb66a475b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ff8b5cf9-2df8-447b-98ea-f32fb66a475b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent_0a29c337-32f9-40a1-87f1-ac84d57b4cbf" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent_0a29c337-32f9-40a1-87f1-ac84d57b4cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b06cc146-2be7-4d78-8c2d-20d52a128fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b06cc146-2be7-4d78-8c2d-20d52a128fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_229cec3e-c784-4908-8ea1-987767e1f932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_229cec3e-c784-4908-8ea1-987767e1f932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6d2e88b-c8d3-4162-b1d8-84f030eab0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6d2e88b-c8d3-4162-b1d8-84f030eab0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6ab36673-ac76-443e-b211-33bd95ffee52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6ab36673-ac76-443e-b211-33bd95ffee52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0b98494e-57a6-4a8c-8b8e-377e9054ac2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0b98494e-57a6-4a8c-8b8e-377e9054ac2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eef50328-c4c9-4555-93b6-5d48b2195ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eef50328-c4c9-4555-93b6-5d48b2195ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825e0de0-40a3-431c-9b01-cfeeed439b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825e0de0-40a3-431c-9b01-cfeeed439b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f7bc0f9c-d6e5-41aa-b40b-6ce013b3098b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f7bc0f9c-d6e5-41aa-b40b-6ce013b3098b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4162f116-f7f0-41d3-8e2c-797c481727e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4162f116-f7f0-41d3-8e2c-797c481727e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07372599-fb4a-424d-a73a-d6dab9ae0dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_07372599-fb4a-424d-a73a-d6dab9ae0dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_916e113f-1bd6-4837-8e98-3462ae450343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_916e113f-1bd6-4837-8e98-3462ae450343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8c380da4-5a41-4893-bee1-4cd3c1ae2286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3604dac2-65ec-4f3a-8f3e-9c1a109c3f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3604dac2-65ec-4f3a-8f3e-9c1a109c3f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest_5c905fbe-0a8b-48cb-bd15-5e8cb3fa4ba2" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c138bd1-dd28-4bda-89e8-4c70fe94ef43" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest_5c905fbe-0a8b-48cb-bd15-5e8cb3fa4ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab3f1371-0a73-413e-9c0d-7185960d1b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b51f76ef-e80d-4908-b821-fe94faa5f889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab3f1371-0a73-413e-9c0d-7185960d1b55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b51f76ef-e80d-4908-b821-fe94faa5f889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f774f585-95d7-4cb0-b2ee-094f52e05f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b51f76ef-e80d-4908-b821-fe94faa5f889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f774f585-95d7-4cb0-b2ee-094f52e05f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2abb4fdd-bc53-49a8-992b-46301f7708e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b51f76ef-e80d-4908-b821-fe94faa5f889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2abb4fdd-bc53-49a8-992b-46301f7708e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_72b289ff-1789-4359-9db2-d95af0cc8b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b51f76ef-e80d-4908-b821-fe94faa5f889" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_72b289ff-1789-4359-9db2-d95af0cc8b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_150efa06-a83c-4422-a909-d91a0eef4459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b51f76ef-e80d-4908-b821-fe94faa5f889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_150efa06-a83c-4422-a909-d91a0eef4459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d1f3204b-f030-4804-b4bc-09779b5ef2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b51f76ef-e80d-4908-b821-fe94faa5f889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d1f3204b-f030-4804-b4bc-09779b5ef2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05bab018-749d-4996-ba5a-474cc97b23a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b51f76ef-e80d-4908-b821-fe94faa5f889" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05bab018-749d-4996-ba5a-474cc97b23a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_dc1f9a7a-ebb6-41cf-89ab-1d3b155a2396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab3f1371-0a73-413e-9c0d-7185960d1b55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_dc1f9a7a-ebb6-41cf-89ab-1d3b155a2396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1a73d0b-af5b-4839-ac9b-af9f474485a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab3f1371-0a73-413e-9c0d-7185960d1b55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1a73d0b-af5b-4839-ac9b-af9f474485a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8687e256-53e5-4302-8584-8467bbe802a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1a73d0b-af5b-4839-ac9b-af9f474485a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8687e256-53e5-4302-8584-8467bbe802a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49d20c1f-717a-4a64-a09f-e46df749dbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1a73d0b-af5b-4839-ac9b-af9f474485a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49d20c1f-717a-4a64-a09f-e46df749dbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_366b4785-ceb7-4e7b-b4f7-a3c788bd6527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1a73d0b-af5b-4839-ac9b-af9f474485a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_366b4785-ceb7-4e7b-b4f7-a3c788bd6527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c5c7d6c1-dd23-4cfb-902d-38f5059fe4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1a73d0b-af5b-4839-ac9b-af9f474485a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c5c7d6c1-dd23-4cfb-902d-38f5059fe4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f893a759-e90f-4915-abaa-81113440eec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1a73d0b-af5b-4839-ac9b-af9f474485a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f893a759-e90f-4915-abaa-81113440eec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d888b225-91e5-4ea1-8728-8c225a967fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1a73d0b-af5b-4839-ac9b-af9f474485a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d888b225-91e5-4ea1-8728-8c225a967fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_267f753b-a1f3-40e3-9b1c-fd175aeafd67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab3f1371-0a73-413e-9c0d-7185960d1b55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_267f753b-a1f3-40e3-9b1c-fd175aeafd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_450c4eaf-8daa-46d9-83d6-61796db21cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab3f1371-0a73-413e-9c0d-7185960d1b55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_450c4eaf-8daa-46d9-83d6-61796db21cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a4342719-be36-4dca-8e2c-26875c0178e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_450c4eaf-8daa-46d9-83d6-61796db21cbd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a4342719-be36-4dca-8e2c-26875c0178e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a4696274-69df-4fdd-bcd3-2f76b377a311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab3f1371-0a73-413e-9c0d-7185960d1b55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a4696274-69df-4fdd-bcd3-2f76b377a311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_0cd624f8-eaad-44d2-82c8-71b8bc9dd6bd" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab3f1371-0a73-413e-9c0d-7185960d1b55" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_0cd624f8-eaad-44d2-82c8-71b8bc9dd6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8e5541f4-faa5-4f1d-b449-4cd908a1e58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_0cd624f8-eaad-44d2-82c8-71b8bc9dd6bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8e5541f4-faa5-4f1d-b449-4cd908a1e58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1e548ac3-5c65-495d-ae4c-6119302afc65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_0cd624f8-eaad-44d2-82c8-71b8bc9dd6bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1e548ac3-5c65-495d-ae4c-6119302afc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1bc032f0-4bb8-4cb2-9a6c-aebd43afb90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab3f1371-0a73-413e-9c0d-7185960d1b55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1bc032f0-4bb8-4cb2-9a6c-aebd43afb90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_313fd201-f396-49a2-805a-0d102c488561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d924762b-1cb8-4058-bfa5-76405455aa33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_313fd201-f396-49a2-805a-0d102c488561" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d924762b-1cb8-4058-bfa5-76405455aa33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_35d6abd7-4162-4553-b3b9-915370c035ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d924762b-1cb8-4058-bfa5-76405455aa33" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_35d6abd7-4162-4553-b3b9-915370c035ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9bd8b8b7-3a02-4d2e-8025-d2c0471b3c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_35d6abd7-4162-4553-b3b9-915370c035ca" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9bd8b8b7-3a02-4d2e-8025-d2c0471b3c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_805f7908-dc8c-4196-83ca-d15eef1d21fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9bd8b8b7-3a02-4d2e-8025-d2c0471b3c61" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_805f7908-dc8c-4196-83ca-d15eef1d21fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0f1980f0-6771-4a0c-aa0c-d23d6a2b8365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9bd8b8b7-3a02-4d2e-8025-d2c0471b3c61" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_0f1980f0-6771-4a0c-aa0c-d23d6a2b8365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1aa0607b-0929-46da-ab0b-9c32fec169db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d924762b-1cb8-4058-bfa5-76405455aa33" xlink:to="loc_us-gaap_AwardTypeAxis_1aa0607b-0929-46da-ab0b-9c32fec169db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1aa0607b-0929-46da-ab0b-9c32fec169db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_015c797f-418f-47c7-bc75-4f1b83afe8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_015c797f-418f-47c7-bc75-4f1b83afe8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7acac4c2-c6d7-4700-ae78-d7fcee0dab00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:to="loc_us-gaap_RestrictedStockMember_7acac4c2-c6d7-4700-ae78-d7fcee0dab00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_046d63e2-dde4-4d4f-8a99-8483b08c5bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_046d63e2-dde4-4d4f-8a99-8483b08c5bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_184f8ed4-ff62-4f5d-afdc-86255e694d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5da3a313-daee-4358-977f-af75f9569e65" xlink:to="loc_us-gaap_PerformanceSharesMember_184f8ed4-ff62-4f5d-afdc-86255e694d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d7ec60f-2b7b-4275-8261-ac1d7a3ca918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d924762b-1cb8-4058-bfa5-76405455aa33" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d7ec60f-2b7b-4275-8261-ac1d7a3ca918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_127902af-0035-4a40-8904-d5ab7ebc9df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6d7ec60f-2b7b-4275-8261-ac1d7a3ca918" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_127902af-0035-4a40-8904-d5ab7ebc9df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20230331.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ede03c5e-f9b2-4b0c-937f-9055861f3a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa604b73-5230-497c-8f39-29186d939a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ede03c5e-f9b2-4b0c-937f-9055861f3a6d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa604b73-5230-497c-8f39-29186d939a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2814ae66-883c-49c1-ab21-b825af15dc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa604b73-5230-497c-8f39-29186d939a3c" xlink:to="loc_us-gaap_AwardTypeAxis_2814ae66-883c-49c1-ab21-b825af15dc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8eb282ef-89cb-4d44-ac1f-7b8e96829fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2814ae66-883c-49c1-ab21-b825af15dc7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8eb282ef-89cb-4d44-ac1f-7b8e96829fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2651cc43-4c07-40ea-a9a4-6f3fdb7754d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8eb282ef-89cb-4d44-ac1f-7b8e96829fd8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2651cc43-4c07-40ea-a9a4-6f3fdb7754d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa604b73-5230-497c-8f39-29186d939a3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a9524fea-8173-4613-9656-5ffef77c7b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a9524fea-8173-4613-9656-5ffef77c7b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_69812fae-8270-45eb-a47b-bf60ab2869a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_69812fae-8270-45eb-a47b-bf60ab2869a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf27c214-fcab-4a86-91f4-bf0641b5be9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf27c214-fcab-4a86-91f4-bf0641b5be9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_0dbe4538-12b5-428c-827b-fd0d37844e15" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_0dbe4538-12b5-428c-827b-fd0d37844e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_09464b43-3e8c-42dc-9476-cb574aa217bb" xlink:href="krys-20230331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_09464b43-3e8c-42dc-9476-cb574aa217bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3d4407c8-d291-45d0-8be3-1ff354730818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98bed44a-8f75-472f-af89-9365bdc1e11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3d4407c8-d291-45d0-8be3-1ff354730818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails" xlink:type="simple" xlink:href="krys-20230331.xsd#StockBasedCompensationScheduleofCompanysStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b5476e0-6cfb-41c3-9edd-bab3c86b82e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9caed4b-8ee8-4b64-a2fa-3b34352cdaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0b5476e0-6cfb-41c3-9edd-bab3c86b82e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9caed4b-8ee8-4b64-a2fa-3b34352cdaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05b51c4a-f5aa-49c6-8334-91ab4d07d206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9caed4b-8ee8-4b64-a2fa-3b34352cdaa4" xlink:to="loc_us-gaap_AwardTypeAxis_05b51c4a-f5aa-49c6-8334-91ab4d07d206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a27fdcf2-058b-4be1-a4ac-954c58ea7d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_05b51c4a-f5aa-49c6-8334-91ab4d07d206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a27fdcf2-058b-4be1-a4ac-954c58ea7d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8f188879-1d90-43fc-9fa5-8e4aab66b693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a27fdcf2-058b-4be1-a4ac-954c58ea7d4b" xlink:to="loc_us-gaap_RestrictedStockMember_8f188879-1d90-43fc-9fa5-8e4aab66b693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e3a8ec64-24e9-4903-9df4-6ab40567a046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a27fdcf2-058b-4be1-a4ac-954c58ea7d4b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e3a8ec64-24e9-4903-9df4-6ab40567a046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ed64c6f9-3ea7-401b-85c1-62b0757eccc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a27fdcf2-058b-4be1-a4ac-954c58ea7d4b" xlink:to="loc_us-gaap_PerformanceSharesMember_ed64c6f9-3ea7-401b-85c1-62b0757eccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d3c6cb8-05d4-494e-a770-499de59ca277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9caed4b-8ee8-4b64-a2fa-3b34352cdaa4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d3c6cb8-05d4-494e-a770-499de59ca277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d3c6cb8-05d4-494e-a770-499de59ca277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1639e932-eec5-4fd7-909a-21a28396d557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1639e932-eec5-4fd7-909a-21a28396d557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c371310a-61b0-49ab-9c6f-e6a7dbc4a1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c371310a-61b0-49ab-9c6f-e6a7dbc4a1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_472fa27a-b260-4210-883b-9a5438bc8dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_472fa27a-b260-4210-883b-9a5438bc8dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f6c21f23-8344-4306-977b-9fbc57b215ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f6c21f23-8344-4306-977b-9fbc57b215ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_236c7920-cf21-4d84-9239-d4e0a4b00535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_03c76aeb-430a-4017-bce3-4a833f864cf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_236c7920-cf21-4d84-9239-d4e0a4b00535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d3c6cb8-05d4-494e-a770-499de59ca277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_735ad2dc-1194-4841-98e4-e83cdce9c9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_735ad2dc-1194-4841-98e4-e83cdce9c9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c5f176fb-32ad-4273-b72a-41c8ac5034e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c5f176fb-32ad-4273-b72a-41c8ac5034e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a0026778-f0ab-4fc9-9ec5-3ae1f01216a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a0026778-f0ab-4fc9-9ec5-3ae1f01216a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4b876964-d490-44f5-8be9-ab0ab7c422a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4b876964-d490-44f5-8be9-ab0ab7c422a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c7260c7d-21ae-4435-a938-64f6833808c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0586ed49-711b-41c5-9c34-41b155180b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c7260c7d-21ae-4435-a938-64f6833808c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>krys-20230331_g1.jpg
<TEXT>
begin 644 krys-20230331_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" -# I4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH Y;QCX&L_&EUI)U.4&TL7G,UL8]WVA986B(W9&TC=G.#T[=:K^
M'/ <VDZA+=:QK!UEI=)BTJ3S;;89(XWD(9CN.25D"GU*D]\#L:* /'-#^#^H
M7'PW&F:G=I8ZI+>-.)[J$7,]JL86.W,<D<BE)4CBCPRL5^\"K UT&H_"Z>\3
M58$UJ![._P!2M]2^SWU@;@-)&B(R3?O%$L;>6#MPI!P<G%>AT4 <+X(^&O\
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MD,,5M;QP6\:10Q*$CCC4*J*!@  = !VH ?1110 4444 %%%% !1110 4444
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M ]#Z9J7^TV_Y\YO^^D_QJI<>;Y:_9_O>8F>GW=PW=?;-34 2_P!IM_SYS?\
M?2?XT?VFW_/G-_WTG^-144 2_P!IM_SYS?\ ?2?XT?VFW_/G-_WTG^-144 2
M_P!IM_SYS?\ ?2?XU%_:TWVO9]BE\K9G.5SG/KG%%0_O?MG_ $Q\OV^]G\^E
M %O^TV_Y\YO^^D_QH_M-O^?.;_OI/\:BHH E_M-O^?.;_OI/\:/[3;_GSF_[
MZ3_&HJ* )?[3;_GSF_[Z3_&C^TV_Y\YO^^D_QJ*B@ M]6F>',UE*&WL, J.
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M/_7'_=J"I[/_ %Q_W: +M%%% !1110 4444 %%%% !1110 4444 9^I?\?\
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M?] JR_\  =/\*@_X1W3?MYE_LVR\KRMNSR%^]GKC'I1S4^P6GW.8_P"%G?\
M4(_\F?\ ["C_ (6=_P!0C_R9_P#L*Z[^P=(_Z!5E_P" Z?X4?V#I'_0*LO\
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M%5?MO_3/_P >H^V_],__ !Z@"U157[;_ -,__'J/MO\ TS_\>H M455^V_\
M3/\ \>H^V_\ 3/\ \>H M455^V_],_\ QZC[;_TS_P#'J +5%5?MO_3/_P >
MH^V_],__ !Z@"U157[;_ -,__'J/MO\ TS_\>H M455^V_\ 3/\ \>H^V_\
M3/\ \>H M455^V_],_\ QZC[;_TS_P#'J +5%5?MO_3/_P >H^V_],__ !Z@
M"U157[;_ -,__'J/MO\ TS_\>H M455^V_\ 3/\ \>H^V_\ 3/\ \>H =>Q+
M-"BO((@)HV!/<AP0/Q(Q^-6*S;RZB>%!."JB6,@@_P 0<%1T]<58^V_],_\
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M('J<=..F*LT44 %%%117,$Y'DS1R9&X;'!R,XS^8Q0!+140N(FF$2R*SD,0
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M[ANZ^V:FJXS<=B914MSS_P#X0/4_^>]I_P!]M_\ $T?\('J?_/>T_P"^V_\
MB:] HJ_;3)]G$\__ .$#U/\ Y[VG_?;?_$T?\('J?_/>T_[[;_XFO0**/;3#
MV<3S_P#X0/4_^>]I_P!]M_\ $TS_ (0?4_.\OS;;[N[=N;;],[>M>AU#^]^V
M?],?+]OO9_/I1[:8>SB<+_P@>I_\][3_ +[;_P")H_X0/4_^>]I_WVW_ ,37
MH%%'MIA[.)Y__P ('J?_ #WM/^^V_P#B:Q]5TF?2+Q;:X:-Y&0./+)(P21W
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M_P"@59?^ Z?X59NI)8HE:!-[&5%(P3A2P#'CT!)J:G=H+%#^P=(_Z!5E_P"
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M^V2>B_E1]LD]%_*H** )_MDGHOY4?;)/1?RJ"B@"?[9)Z+^5'VR3T7\J@HH
M=:WEU]F3[2%,O.[CW]JE^V2>B_E5*VCDBMU29M[C.6SG/-34 3_;)/1?RH^V
M2>B_E4%% $_VR3T7\J/MDGHOY5!10!/]LD]%_*C[9)Z+^5044 3_ &R3T7\J
M/MDGHOY5!10!/]LD]%_*C[9)Z+^5044 3_;)/1?RJ6WN&ED*L !C/%4ZGL_]
M<?\ =H NT444 %%%% !1110 4444 %%%% !1110!GZE_Q_Z3_P!?;?\ HB6J
M^HW265O=74H8QP(\C!1R0H)./?BK&I?\?^D_]?;?^B):IZS:O>Z;?VL1423Q
M21J6/ + @9_.M-/=O_6IFK^];^M#&?QE8+:R7$<%U-'&(@S(JXWR8(3)8?,
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M** "BJEY<20W5A&F-L]P8WR.WE.W\U%6Z;5A)W"BBBD,***"0JDL< <DGM0
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MD8_&K%7&44M5<B2;V9YG_P +(U?_ )]K+_OV_P#\51_PLC5_^?:R_P"_;_\
MQ5>F45?/#^47++N>9_\ "R-7_P"?:R_[]O\ _%4?\+(U?_GVLO\ OV__ ,57
MIE%'/#^4.67<\S_X61J__/M9?]^W_P#BJ9_PL/5_/\WRK7[NW9M?;UZXW=:]
M/JOY2_VD9?,&_P G;Y??&<YHYX?RARR[GG?_  LC5_\ GVLO^_;_ /Q5'_"R
M-7_Y]K+_ +]O_P#%5Z911SP_E#EEW/,_^%D:O_S[67_?M_\ XJC_ (61J_\
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MPUXWO=:\97&D3+9@0?:!/ BE9+8QR;4RY8B3(SG:!CBCE871W-%%%2,****
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MW..@R<4 =+15"RM;N"[F>>?S(I-Q"EV;:=[$8!X VE1QZ5?H @NI%BB4O&)
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M*+L+(****0PHHHH *H:E<RV\MJ8D=UW.65.KXC8A?Q(_2K](5!QD X.1D=*
M.=^V:VMK'&\$YGA<O.ZQK\Z#!P.Q.&/3)RM2RR:G%"-LUT\I,X0>0I#%9 (P
MV%X!'.>/7-;U% %33I'DMW\S)VSRJI)SD!R!_A^%6Z0  8 P/:EH **** "B
MBB@ KG%U/5EDWBU=Q(5)#02 1\#*XZ]2?FZ<=*Z.B@#G=+N]4CFCBO(YBLF&
M>5X7;!R<J .G7J>!BEM=3UF011O9&,D1J6DA<D9"Y8] >I/;%=#10!A-K&H1
MVC3R6A5E"9A,+ G<J]&/'WV QUX-;:;O+7S,;\?-MZ9I64,,, 1D'!'<<BEH
M **** "BBB@"&Z61H0L0!)=0P..5W#=U]LU5_L+2O^@=;?\ ?H5:N(Y)(U$3
M;6$B,3G' 8$C\1D5-3NUL*R,_P#L+2O^@=;?]^A1_86E?] ZV_[]"M"BCF?<
M+(H?V'I?_0.M?^_2T?V)I?\ T#K7_OTM7Z*.9A9%#^Q-+_Z!UK_WZ6HO[$L/
MMG_(.M?)\O\ YY+][/Y]*U*A\N3[9YF[]WY>W;GOGKBCF8617_L72_\ H'6O
M_?E?\*/[%TO_ *!UK_WY7_"KU%',PLBC_8NE_P#0.M?^_*_X5S<7@@SZE<37
MDBPV[2L8XHNNW)Q[#BNRHJE.2V$XIE6QTVTTV'R[*!8AW('+?4]35JBBHW*(
M;;S?)_TC[^]O3IN.WI[8J:H;:.2.';,V]M['.<\%B0/R(J:@ HHHH **** (
M;GS?(/V?_697'3ID9Z^V:FJ&YCDD@*PML?*G.<< @G]*FH **** "BBB@ HH
MHH AMO.^SK]I_P!;SNZ>OM4U0VT<D5NJ3-O<9RV<YYJ:@ HHHH **** "BBB
M@ HHHH **** "I[/_7'_ ':@J>S_ -<?]V@"[1110 4444 %%%% !1110 44
M44 %4;[2+?4)4DG,@9  -C8Z'(_6KU%--IW0G%25F9U^NR\T=<EMMT1ECDG]
MQ+4SVCM(S K@DGK46I?\?^D_]?;?^B):T*J6R_KJR8[O^NA2^QR>J_G1]CD]
M5_.KM%064OL<GJOYT?8Y/5?SJ[10!2^QR>J_G1]CD]5_.KM% %+[')ZK^='V
M.3U7\ZNT4 4OL<GJOYT?8Y/5?SJ[10!2^QR>J_G1]CD]5_.KM% %+[')ZK^=
M'V.3U7\ZNT4 4OL<GJOYT?8Y/5?SJ[10!2^QR>J_G1]CD]5_.KM% %+[')ZK
M^='V.3U7\ZNT4 4OL<GJOYT?8Y/5?SJ[10!2^QR>J_G1]CD]5_.KM% %+[')
MZK^='V.3U7\ZNT4 4OL<GJOYT?8Y/5?SJ[10!F7=@9(5#RQQ@2QL"3U(<$#\
M3Q^-3?8Y/5?SJ6]6%H4%PQ1?.C((_O;QM'XG JQ0!2^QR>J_G1]CD]5_.KM%
M %+[')ZK^='V.3U7\ZNT4 4OL<GJOYU#]@/]H&3S8]_E;?+SSC/6M.J^V'^T
MBV\^?Y.-O;;GK^= $7V.3U7\Z/L<GJOYU=HH I?8Y/5?SH^QR>J_G5VB@"E]
MCD]5_.C[')ZK^=7:* ,RTL#';E8Y8Y!YCG<I[EB2/P/'X5-]CD]5_.I;%85M
MB+9RZ>9(<M_>WG</SR*L4 4OL<GJOYT?8Y/5?SJ[10!2^QR>J_G1]CD]5_.K
MM% &9>6!DMBLDL<:[E.YCQ]X'_ZU3?8Y/5?SJ6^6%K0BY<I'N7)7KG<,?KBK
M% %+[')ZK^='V.3U7\ZNT4 4OL<GJOYT?8Y/5?SJ[10!2^QR>J_G1]CD]5_.
MKM% &79Z>8K1$CFCE49PZG@\U/\ 8Y/5?SJ6P6%;*,6SL\7.UFZGDU8H I?8
MY/5?SH^QR>J_G5VB@"E]CD]5_.C[')ZK^=7:* *7V.3U7\Z/L<GJOYU=HH I
M?8Y/5?SH^QR>J_G5VB@"E]CD]5_.C[')ZK^=7:* *7V.3U7\ZEM[=HI"S$$8
MQQ5BB@ HHHH **** "BBB@ HHHH **** "BBB@#/U+_C_P!)_P"OMO\ T1+5
MV::*W@DFN)$BBC4N\CL%5% R22>@ [U2U+_C_P!)_P"OMO\ T1+47BJ&6X\'
M:S#;QO++)83HD:*69V,;   =23VJY;1_KJR([O\ KH2S^(-&MHR]SJUC"BQ+
M,6DN44"-CA7R3]TG@'H:<FMZ5)I;:G'J=F]@N=UVMPIB&#CE\XZ\=:\B.AZQ
M9>#+O3KK3+^6^DFT^]%]#;-([P@H/+("G#Q;2-F.G..3F_-X?U^_\.ZLEK9M
M<Z>;ZZO,7X>VN;UC$/+<QB/DA\D+M3)1/K1RH=V>G'7-)6.:0ZI9!((UEE8W
M"8C1AE68YX![$\&E36=,D1&CU&T=7G^S(5G4AIN?W8YY;@_+UXKR;5-%UB[?
M1;T:'<^5H^FV:ZG;(CDWZB1&$2C:-Y0+O(QP?EYK4L=+OE^*:^(CI-TND7%_
M+!'"87#13&)5^UE".%?:R[B!@<]Z.5!<]2HHHJ"@HHHH *AGN/)FMTVY\^0Q
MYSC'R,V??[M352U26PBM5;58T>'=P'A,@!"DDX ., -S0!2M_$MO-'$6MYED
MD1"%&TAG98SL!)'/[U>2 .OI4=MXGB-JTUY"\85V4E<87:BOSD]<-T&2<&KS
M_P!C2R>3)]A=]Q78VPG<  1CU 51^ ]*BW>'C&!G3"@)(&8\#@ _H /P% $;
M>(1#?7$%S:RIY48EVC:65<$LQ^;&!QT)/-2#Q#:FXB@\J?S))3$%VC*D$#+#
M.0/F'7G'.,4NW0-R1;=-W':53$>>>5P/?/'UJQ!::9* ]M!:.(Y"0T:*=K\9
M/'0\#\A0 FF:A_:44LHB:-%<! ^,E2BL"<$_WJNU%;VMO:1F.T@C@0G)6- H
M)QC.!]!4M !1110 4444 %%%% !1110 4444 %%%% %>]:%84-PA=?.C  _O
M;QM/X'!JQ65XE$S>'[A+12UPY18MK;2'+@ @]B#7$?V-XX_YZWO_ ('C_P"+
MJXQ4EN1*370],HKS/^QO''_/6]_\#Q_\71_8WCC_ )ZWO_@>/_BZOV:_F0N=
M]CL;[Q58:9K7]GZAOARBLLV,KSV..1_GI6Q%-'<0K+!(DL;#*NC @_0BO%]9
MM]2M;_R]::1KG8#F67S#M[<Y-;/A33?$9F$VE.]K QRSR_ZM_P#@)^]^7XBJ
ME27+>Y*J.]K'J55]T/\ :178?/\ )SN[;<]/SJ:(2")1,RM)CYBBX!/L,G'Y
MU#YJ_P!I&+RAO\G=YG?&<8KG-BQ1110 4444 %%%% %>Q:%K8FV0HGF2##?W
MMYW'\\FK%5[&59K8O'$(AYDB[5]0Y!/XD9_&K% !1110 4444 5[YH5M";E"
M\>Y<A>N=PQ^N*L57OI5AM"\D0E7<HVMTY8#].M6* "BBB@ HHHH **** *]@
MT+649MD9(N=JMU')JQ5>PE6>RCDCB$2MG"+T')JQ0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%+;QS2P2/G=!(9
M$P>^UE_DQJ6BB@ HHHH **** "BBB@ HHHH *KW=C!?>4+J-95B?>$905)VE
M>0?]XU8HH R+CP]!+'*(YY4,FXD?*58F1I!GC. S'H1Q5?3_  S]GM95N+J4
M2R*$WQ,,A0P;&XCDD@YSV..V:WZ* ,F+PY9PP^4KS$! @)(R %C7T](E_,_A
M=L+%+"!HHY))%+EAOQ\N>P   'L*LT4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% $-U)+%$K0)O8RHI&"<*6 8\>@)-35#=>?Y2_9?O^:F>GW=PW=?]
MG-34 %%%% &=-H.GW.J?VA<VXFGVA5\SE5QZ#I6CTZ444[MBL%0^9+]O,6S]
MUY6[?@_>STS]*FJ']_\ ;S_S[^5[?>S^?2D,FHHHH **** "BBB@"&TDEE@+
M3IL?>ZXP1P&(!Y]0 :FJ&T\_R#]J_P!9O?T^[N.WI_LXJ:@ HHHH **** (;
MN26*V+P)O?<H"X)X+ 'I[9J:H;OS_LQ^R_ZW<N.G3<,]?;-34 %%%% !1110
M 4444 0V<LLUJCW";)#G*X(QSZ&IJAL_/^RI]K_UW.[IZ\=/:IJ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H'L
M[>1R[PJ6/4XJ>B@"O_9]K_SP6C^S[7_G@M6** *_]GVO_/!:/[/M?^>"U8HH
M K_V?:_\\%H_L^U_YX+5BB@"O_9]K_SP6C^S[7_G@M6** *_]GVO_/!:/[/M
M?^>"U8HH K_V?:_\\%H_L^U_YX+5BB@"O_9]K_SP6C^S[7_G@M6** *_]GVO
M_/!:/[/M?^>"U8HH K_V?:_\\%H_L^U_YX+5BB@"O_9]K_SP6C^S[7_G@M6*
M* *_]GVO_/!:/[/M?^>"U8HH K_V?:_\\%H_L^U_YX+3-46ZDT^2.PXGD(0-
MNV[ 3R<]L#/8\XXK,B;688[VZN48,MJ6C3<&7S B]%!_O!O2@#6_L^U_YX+1
M_9]K_P \%K%\_7T=0L&97D<X?;@HIC )^;"\%B<9.1TI8AXAD6)YD6.4O&&P
MP*HN9-QP&P3@K^G<4 ;/]GVO_/!:/[/M?^>"UEVLWB%A<_:K:%2MN?)^8?/+
MM&,X/'.?;I0KZ\\S($"1G:%D=4R!E,M@,<G!DXZ<#Z4 :?\ 9]I_SP6E_L^U
M_P">"UB?:?$BRO&(8Y)%B5Q\JA264\$[NS#'&>G/O(LOB-I(X_(15,F&E8)D
M)DC) ;KC!P* -?\ L^U_YX+1_9]K_P \%K"+^)S<)(UN!MB*E%9-K',9S][K
MP_; 'UJ].^M-K!CMXT2R[2N5.?ESTSD9/'2@"_\ V?:_\\%H_L^U_P">"UF1
MG79=-MC-&D5W]H'F8((6,@@D@'!P3T^G?FH&F\4?9_DMH-XVYRRY.1SCG'!'
MY-QTH VO[/M?^>"TG]GVG_/!:QKJ7Q D,\PC_P!67*1J%P0&0J>#G[N\8[X]
MQ4<-WXANH;=XHBL;+F23"9/[P\ $C^'OT/6@#>_L^U_YX+1_9]K_ ,\%K'+>
M(EVQQ1*%\M<LQ5L':I/);).XN/3 %/M)==DU!9+^T*0+_!'(G)((/\70<'F@
M#5_L^U_YX+1_9]K_ ,\%K%U&'7I;JZ-J&$$G$068!DVC ]/O$D]^@Z5-?W&K
M_;+D6D6Z"%EP< = C'!W9/5N,8^O2@#4_L^U_P">"T?V?:_\\%K#6;Q)<1[?
M(5(G@;#Y57W%#C@,<?-C'ZT^5O$D42"UACD^0!@[#*G"9.2W/)D_[Y^E &Q_
M9]I_SP6E_L^U_P">"U0O)-:$V+:)2GEIR@4\Y^?[S#D#H.GOFJPF\0Q6K7%R
ML0*Q,S1*@.&VR8 .[GD1_P#?7L: -C^S[7_G@M']GVO_ #P6LB.?Q$LJF2U#
M1A_F'R LFXY/W^&QCCISUS4;OXG:#_4Q@NI#!=NY.$P0=W).7^F/ID V_P"S
M[7_G@M']GVO_ #P6L=)/$,6BR+]F\R\7:L>YT^88Y)Y]1SGKG\K4;:U_:T:R
M)$;(LY9N 5&6"CKD\!3GW.: +O\ 9]H?^6"TO]GVO_/!:Q9CXDEF9!%'&D;Y
M25&7Y\<<C=WP3C_:'I2K_P )#<M#]IB\D"XC9Q&ZC"9;<.IR,;3SW[&@#9_L
M^U_YX+1_9]K_ ,\%K*^TZY+I4<L,,9N#(P9, 8"@@?>(X+#.>H##BD:3Q(VY
M1##'M#8<%6WX4@<9XRRY^DB]U- &M_9]K_SP6C^S[7_G@M8-RWBB>&9!;I%N
M<[#$Z[@.<<[N.WOG].DC8O&&9&C)ZJV,C\B10!#_ &?:_P#/!:/[/M?^>"U8
MHH K?V?:?\\%I?[/M?\ G@M6** *_P#9]K_SP6C^S[7_ )X+5BB@"O\ V?:_
M\\%H_L^U_P">"U8HH K_ -GVO_/!:/[/M?\ G@M6** *_P#9]K_SP6C^S[7_
M )X+5BB@"O\ V?:_\\%H_L^U_P">"U8HH K_ -GVO_/!:DBMX8,^3&J9ZXJ2
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ"%'7IA3[''M4W_"+Z/Y>PVF5]#*Y]#Z^P_*K5MI5K9LALU:$( NU6.& W$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 445 UH&8MYTPR<X$A % $]%5_L8_Y[S_ /?TT?8Q_P ]
MY_\ OZ: +%%5_L8_Y[S_ /?TT?8Q_P ]Y_\ OZ: +%%5_L8_Y[S_ /?TT?8Q
M_P ]Y_\ OZ: +%%5_L8_Y[S_ /?TT?8Q_P ]Y_\ OZ: +%%5_L8_Y[S_ /?T
MT?8Q_P ]Y_\ OZ: +%%5_L8_Y[S_ /?TT?8Q_P ]Y_\ OZ: +%%5_L8_Y[S_
M /?TT?8Q_P ]Y_\ OZ: +%%5_L8_Y[S_ /?TT?8Q_P ]Y_\ OZ: +%%5_L8_
MY[S_ /?TT?8Q_P ]Y_\ OZ: +%%5_L8_Y[S_ /?TT?8Q_P ]Y_\ OZ: +%%5
M_L8_Y[S_ /?TT?8Q_P ]Y_\ OZ: +%%5_L8_Y[S_ /?TT?8Q_P ]Y_\ OZ:
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M+WL:_9G8D*LF3\A)! !QG!I3XK\.B\FM#K^EBYMU5YH?MD>^-6*A2RYR 2Z
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M97__ #QMO^^6_P :7]G8CLOO'[>!VM1"YA:X:W$J^<HR4SS^5<?_ ,)E?_\
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M\Z/L<?JWYU8HH K_ &./U;\Z/L<?JWYU8HH K_8X_5OSH^QQ^K?G5BB@"O\
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ML<?JWYT?8X_5OSJQ10!7^QQ^K?G1]CC]6_.K%% %?[''ZM^='V./U;\ZL44
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MU_.E5U8X5@3[&@!:*** "BBB@ HHHH **** "BBB@ IDDL<,9>:18T )+,V
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M@'(SP:N54HRCNA)I[!4#!OMT1"QE?+?+'[P.5P![=<_05/5=P/[2A/E,2(I
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MQ?\ 33_QV@"K15K[%_TT_P#':/L7_33_ ,=H JT5:^Q?]-/_ !VC[%_TT_\
M': *M%6OL7_33_QVC[%_TT_\=H JT5:^Q?\ 33_QVC[%_P!-/_': *M%6OL7
M_33_ ,=H^Q?]-/\ QV@"K15K[%_TT_\ ':/L7_33_P =H JT5:^Q?]-/_':/
ML7_33_QV@"K15K[%_P!-/_':/L7_ $T_\=H JT5:^Q?]-/\ QVC[%_TT_P#'
M: *M%6OL7_33_P =H^Q?]-/_ !V@#.M%*PL&B$1\V0[0>OSGYOQZ_C4]+862
M&W;RWD \Z7/F+SGS&S^&<X]L59^Q?]-/_':<MV);%6BK7V+_ *:?^.T?8O\
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M5K[%_P!-/_':/L7_ $T_\=H JU#"I$UP3$$#."&!^_\ *.?Z?A6A]B_Z:?\
MCM5K:R3[3=['<-YHW[EX)V+T]L8_'--;,0E%6OL7_33_ ,=H^Q?]-/\ QVD,
MJT5:^Q?]-/\ QVC[%_TT_P#': *M%6OL7_33_P =H^Q?]-/_ !V@"K15K[%_
MTT_\=H^Q?]-/_': *M%6OL7_ $T_\=H^Q?\ 33_QV@"K4]G_ *X_[M/^Q?\
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MO,VR ;<8\OY%X]_7\:GJ& -Y]SN6,#S!M*]6&U?O>^?TQ3741-1112&%%%%
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MN;L+(SD2@,K=$.Q>![=_J336S$RQ1112&%%%% !1110 4444 %%%% !1110
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MJ**YZ+Q0TTRQ)9 .Q10&G'!;;UP.GS<$9R*VK.Y%Y8P7*KM$T:R 9Z9&?ZT
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M\:2QL2&1U!!Y[@U+-I*3>);+6#*P>TM+BU6/'#"5X6)S[>0/^^C39?\ 7/\
M[QH3MJ@*4VE:?<,6GL;:4L027A4YP,#J/3BE&FV*SI,ME;B6, )((EW* ,
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M +]?_7J:VM9()"SS>8",8V8JU10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &;J=W>6]W:+:6[RQ%]
MUPRINPN0O_LQ;C)^7IS6?%K&I6]C;_:+9I;B5V&QHV#$!0<  =SD9/ KHJ0@
M$@D#(Z'TH YQM>U.-62/39;AT5-V$;*L51CG  _C(P.1MYIZZKJ\;R%M/DD
M8G:5(^7S, *0.3@]^RYKH0 ,X&,\GWHH QH-6OY=-@GETYX99)MC(R.=B[2=
MQ !/4;?QS[5676]8D7*:25/&=ZN,9 ..G8G![''%=%10!SI\0:BP8Q:6[J&8
M<)(<$;OE^[R25 R.!GFGG6]4,KA-)D*Q@%LJX+?,%(7C!/.?3 K?  Z#'?BB
M@#!TW5M2GO-M[8R)%(Q((A<; (U.WD#^+<,]S^%1C7=7:S,RZ/)E2 4*,&.2
M>0N.@ &?J*Z*B@#(O-0U&"[406321F%'?@G:2^" 0.3@Y^@JK_;NK;L?V-*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629609541200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Krystal Biotech, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1080209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2100 Wharton Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pittsburgh<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">15203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">586-5830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRYS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,799,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001711279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629607914048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 140,745<span></span>
</td>
<td class="nump">$ 161,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">209,642<span></span>
</td>
<td class="nump">217,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,042<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">355,429<span></span>
</td>
<td class="nump">383,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">163,073<span></span>
</td>
<td class="nump">161,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">5,129<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">7,814<span></span>
</td>
<td class="nump">8,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">531,847<span></span>
</td>
<td class="nump">558,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,109<span></span>
</td>
<td class="nump">3,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,553<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">29,414<span></span>
</td>
<td class="nump">23,305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">35,076<span></span>
</td>
<td class="nump">28,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,205<span></span>
</td>
<td class="nump">7,372<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">42,281<span></span>
</td>
<td class="nump">36,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.00001 par value; 80,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 25,796,213 shares issued and outstanding at March&#160;31, 2023; and 25,763,743 shares issued and outstanding at December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">815,776<span></span>
</td>
<td class="nump">803,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(728)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(326,056)<span></span>
</td>
<td class="num">(280,759)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">489,566<span></span>
</td>
<td class="nump">522,231<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 531,847<span></span>
</td>
<td class="nump">$ 558,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629609436080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">25,796,213<span></span>
</td>
<td class="nump">25,763,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">25,796,213<span></span>
</td>
<td class="nump">25,763,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629609455872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 12,288<span></span>
</td>
<td class="nump">$ 9,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">24,035<span></span>
</td>
<td class="nump">15,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">48,823<span></span>
</td>
<td class="nump">50,222<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(48,823)<span></span>
</td>
<td class="num">(50,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet', window );">Interest and other income, net</a></td>
<td class="nump">3,526<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,297)<span></span>
</td>
<td class="num">(49,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities and currency translation adjustment</a></td>
<td class="nump">574<span></span>
</td>
<td class="num">(1,034)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (44,723)<span></span>
</td>
<td class="num">$ (50,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share: basic (in dollars per share)</a></td>
<td class="num">$ (1.76)<span></span>
</td>
<td class="num">$ (1.99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share: diluted (in dollars per share)</a></td>
<td class="num">$ (1.76)<span></span>
</td>
<td class="num">$ (1.99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="nump">25,712,220<span></span>
</td>
<td class="nump">25,114,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="nump">25,712,220<span></span>
</td>
<td class="nump">25,114,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income (expense) and other nonoperating, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_InterestIncomeExpenseAndOtherNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629605149040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 593,576<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 734,523<span></span>
</td>
<td class="num">$ (163)<span></span>
</td>
<td class="num">$ (140,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes and forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes</a></td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments and other</a></td>
<td class="num">(1,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(49,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,965)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,199,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">548,554<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">740,500<span></span>
</td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(190,749)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,763,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">522,231<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">803,718<span></span>
</td>
<td class="num">(728)<span></span>
</td>
<td class="num">(280,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">2,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes and forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes</a></td>
<td class="num">(749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">10,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments and other</a></td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,297)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,297)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,796,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 489,566<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 815,776<span></span>
</td>
<td class="num">$ (154)<span></span>
</td>
<td class="num">$ (326,056)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629613594336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (45,297)<span></span>
</td>
<td class="num">$ (49,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">10,437<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="num">(605)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(327)<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(46)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">107<span></span>
</td>
<td class="num">(554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(3,465)<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment', window );">Accrued litigation settlement</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) operating activities</a></td>
<td class="num">(26,156)<span></span>
</td>
<td class="num">(15,493)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(5,381)<span></span>
</td>
<td class="num">(17,191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(145,576)<span></span>
</td>
<td class="num">(62,754)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">154,520<span></span>
</td>
<td class="nump">24,037<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">3,563<span></span>
</td>
<td class="num">(55,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net</a></td>
<td class="nump">2,223<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to settlement of restricted stock awards</a></td>
<td class="num">(749)<span></span>
</td>
<td class="num">(649)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">1,474<span></span>
</td>
<td class="num">(542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) in cash and cash equivalents</a></td>
<td class="num">(21,155)<span></span>
</td>
<td class="num">(71,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">161,900<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">140,745<span></span>
</td>
<td class="nump">269,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">11,865<span></span>
</td>
<td class="nump">14,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Initial recognition of right-of-use assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,394<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Accrued Legal Settlement And In-Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629603934432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations in April 2016. In March 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. In June 2018, the Company incorporated a wholly-owned subsidiary in Australia for the purpose of undertaking preclinical and clinical studies in Australia. In April 2019, the Company incorporated Jeune Aesthetics Inc ("Jeune Aesthetics"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. In January 2022, August 2022, and December 2022, the Company incorporated wholly-owned subsidiaries in Switzerland, Netherlands, and France, respectively, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's product pipeline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale Current Good Manufacturing Practices ("CGMP") manufacturing capabilities.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had an accumulated deficit of $326.1 million. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through its on hand cash and cash equivalents, the sale of equity, debt financings, and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.</span></div>The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to commercialize product candidates. The Company expects to incur significant costs to expand its commercialization capabilities in advance of the potential global regulatory approvals of its lead product, beremagene geperpavec (&#8220;B-VEC&#8221;). The Company believes that its cash, cash equivalents and short-term investments of approximately $350.4 million as of March&#160;31, 2023 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629613208464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022, as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on February 27, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of less than one year are classified as short-term investments on the condensed consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the condensed consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on investments is also classified as short-term investments on the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the condensed consolidated balance sheets. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest and other income, net, in the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s condensed consolidated financial statements, approximate fair value, primarily due to their short maturities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 financial instruments. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 47 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of useful life or remaining life of lease</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress is not depreciated until the asset is placed in service. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition.  In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to an amount by which the net book value exceeds the fair value of the asset.  Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company has not identified any triggering events or recognized any impairment losses for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease liabilities represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its condensed consolidated balance sheets and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain sale-leaseback criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with third-party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to equity awards granted are based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense for stock options, restricted stock awards, and restricted stock units is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense for performance-based restricted stock units is recognized for the awards that are probable of vesting over the service period of the award. On a quarterly basis, management estimates the probable number of performance-based restricted stock units that would vest until such time that the ultimate achievement of the performance criteria are known. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates stock price volatility by using its own historical data. The expected term of the Company&#8217;s stock options is estimated using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We record reclassifications from other comprehensive gains or losses to interest and other income, net on the condensed consolidated statements of operations related to realized gains on sales of available-for-sale securities.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its securities quarterly to determine whether an other-than-temporary impairment has occurred. The Company determined that there were no other-than-temporary impairments during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB that the Company adopts as of the specified effective date. There were no recently adopted accounting pronouncements that had a material impact on the Company&#8217;s condensed consolidated financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company&#8217;s condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629610158000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">Net Loss Per Share Attributable to Common Stockholders<div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,829,535 and 3,226,962 common share equivalents outstanding as of March&#160;31, 2023 and 2022, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.589%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,712,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,114,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.76)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.99)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629613086160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Instruments</a></td>
<td class="text">Fair Value Instruments<div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of March&#160;31, 2023 and December&#160;31, 2022, respectively (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:24.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.032%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,771&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,642&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,642&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:23.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.100%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,892&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,271&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company's long-term marketable securities mature between one year and two years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629610114032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,477&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,073&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $1.1 million and $462 thousand for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company placed a portion of its second commercial scale CGMP facility, ASTRA, into service during the three months ended March&#160;31, 2023 as it was determined that certain assets were ready for their intended use. On March 27, 2023, the Company received the permanent occupancy permit for ASTRA which allowed the Company to begin utilizing certain portions of the building.  As a result, assets relating to ASTRA were reclassified from construction in progress to leasehold improvements, manufacturing equipment, buildings and building improvements, furniture and fixtures, or computer equipment and software as of March&#160;31, 2023. As certain building improvements are not yet complete and certain qualification activities are still underway, the Company will continue to hold the remaining assets within construction in progress until validation has been completed and the assets are ready for their intended use. Validation of the facility is expected to be completed in 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629610080320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Research Organizations and Contract Manufacturing Organizations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs primarily relate to the manufacturing of our cell and virus banks and for the manufacturing of our sterile gel that is mixed with in-house produced vectors as part of the final drug product for B-VEC. Agreements with third parties may also include research and development consulting activities, clinical-</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial agreements, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage or pre-commercial products. The Company is obligated to make milestone payments under certain of these contracts. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The estimated remaining commitment as of March&#160;31, 2023 under these agreements is approximately $2.0 million. The Company has incurred research and development expenses under these agreements of $2.0 million and $1.8 million for the three months ended March&#160;31, 2023 and  2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to complete the interior build-out of our second CGMP facility, ASTRA. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of March&#160;31, 2023 is $11.9 million and primarily relates to the remaining building improvements and certain qualification activities of the facility. The Company has included costs incurred to-date associated with the ongoing build-out of ASTRA within construction in progress. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, Substantial Completion, as defined in the Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (the &#8220;Agreement&#8221;) with Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), the construction manager for ASTRA, had not been achieved. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement may not equate to the date of completion of ASTRA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, the Company entered into a binding term sheet to settle the dispute.  On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.  Upon approval of the Company's first product by the U.S. Food and Drug Administration, the Company will pay PeriphaGen an additional $12.5&#160;million, followed by three additional $12.5&#160;million contingent milestone payments upon reaching $100.0&#160;million in total cumulative sales, $200.0&#160;million in total cumulative sales and $300.0&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of the Company products by the Company and its affiliates and licensees, as reported by the Company in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the upfront settlement payment of $25.0&#160;million under litigation settlement expense on the condensed consolidated statements of operations for the three months ended March&#160;31, 2022. In accordance with ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has determined that FDA approval of B-VEC is now probable, and accordingly has accrued for an additional $12.5&#160;million litigation settlement liability as of March&#160;31, 2023. The remaining contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of March&#160;31, 2023, and therefore no additional accrual has been recorded.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received $0 and $768&#160;thousand of insurance proceeds during the three months ended March&#160;31, 2023 and 2022, respectively. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629614037968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future minimum commitments under the Company&#8217;s operating leases with lease terms in excess of 12 months were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:2pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's lease expense are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629609549440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capitalization</a></td>
<td class="text">Capitalization<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATM Program</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sold shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acted as the Company's agent and/or principal and could issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $150.0&#160;million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement were made pursuant to the Company's effective "shelf" registration statement on Form S-3. There were no shares issued under the ATM Program during the three months ended March&#160;31, 2023 and 2022. As of March&#160;31, 2023, there was a remaining $102.5&#160;million available for issuance under the ATM Program. The ATM Program expired on May 4, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629610150688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:9pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company adopted the 2017 IPO Stock Plan (the &#8220;Plan&#8221;), which governs the issuance of stock options and restricted stock to employees, certain non-employee consultants, and directors. Initially, the Company reserved 900&#160;thousand shares for issuance under the Plan with an initial sublimit for incentive stock options of 900&#160;thousand shares. On an annual basis, the amount of shares available for issuance under the Plan increases by an amount equal to four percent of the total outstanding shares as of the last day of the preceding calendar year. The sublimit of incentive stock options is not subject to the increase. The Company has historically granted stock options and restricted stock awards to its employees. In February 2023, the Company began issuing restricted stock units and performance-based restricted stock units to certain employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and non-employees vest ratably over a four-year period and stock options granted to directors of the Company vest ratably over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTExNQ_1ff19d5b-7ebe-44d5-815e-fa8e50130fbf">one</span>-year to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTE0Nw_06c5c353-58b3-42d1-85b7-6f88da10a8be">three</span>-year periods. Stock options have a life of ten years. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 287,600 and 1,179,500 stock options to employees, non-employees, and directors of the Company during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,582,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#CCECFF;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,021)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,625)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785,135&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.75&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,066&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,428&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.08&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March&#160;31, 2023 and the exercise price of outstanding in-the-money options.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three months ended March&#160;31, 2023 and 2022 was $1.1&#160;million and $36&#160;thousand, respectively </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three months ended March&#160;31, 2023 and 2022 was $56.86 and $43.09, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $109.2&#160;million of unrecognized stock-based compensation expense related to employees', non-employees', and directors&#8217; option awards that is expected to be recognized over a weighted-average period of 2.8 years as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three months ended March&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTc3_6f3f7115-1588-4f4d-bb1c-32086269f4cb">four</span>-year period. The Company granted zero RSAs to employees of the Company during each of the three months ended March&#160;31, 2023 and March&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,649)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $3.3 million of unrecognized stock-based compensation expense related to employees&#8217;&#160;RSAs that is expected to be recognized over a weighted-average period of&#160;1.9 years as of March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;) granted to employees vest ratably over a four-year period. The Company granted 186,900 and zero RSUs to employees of the Company during the three months ended March&#160;31, 2023, and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.91&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $15.0 million of unrecognized stock-based compensation expense related to employees&#8217;&#160;RSU awards that is expected to be recognized over a weighted-average period of&#160;3.9 years as of March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSUs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="text-align:justify;text-indent:31.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based restricted stock units (&#8220;PSUs&#8221;) granted to employees vest ratably over two years based upon continued service through the vesting date and the achievement of specific regulatory and commercial performance criteria as determined by the Compensation Committee of the Company&#8217;s Board of Directors. The performance criteria are to be completed by the end of the year in which the PSU awards were granted. Each PSU represents the right to receive one share of the Company's common stock upon vesting. The Company recognizes stock-based compensation expense for the fair value of the PSU awards relating to the portion of the awards that are probable of vesting over the service period. On a quarterly basis, management estimates the probable number of PSU&#8217;s that would vest until such time that the ultimate achievement of the performance criteria are known.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2023, the Company estimates that 100% of the PSUs granted will be eligible to vest.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 60,000 and zero PSUs to employees of the Company during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested PSUs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested PSUs as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.91&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $4.7 million of unrecognized stock-based compensation expense related to employees&#8217;&#160;PSU awards that is expected to be recognized over a weighted-average period of&#160;1.9 years as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to PSUs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares remaining available for grant under the Company&#8217;s stock incentive plan were 1,005,626, with a sublimit for incentive stock options of 2,629, at March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of manufacturing facilities. There was $162&#160;thousand and $141&#160;thousand of stock-based compensation that was capitalized in the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629610024160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require recognition or disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629609250784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022, as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on February 27, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text">Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of less than one year are classified as short-term investments on the condensed consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the condensed consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on investments is also classified as short-term investments on the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the condensed consolidated balance sheets. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest and other income, net, in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s condensed consolidated financial statements, approximate fair value, primarily due to their short maturities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 financial instruments. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 47 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of useful life or remaining life of lease</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.</span></div>Construction in progress is not depreciated until the asset is placed in service.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition.  In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to an amount by which the net book value exceeds the fair value of the asset.  Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company has not identified any triggering events or recognized any impairment losses for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease liabilities represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its condensed consolidated balance sheets and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain sale-leaseback criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with third-party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to equity awards granted are based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense for stock options, restricted stock awards, and restricted stock units is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense for performance-based restricted stock units is recognized for the awards that are probable of vesting over the service period of the award. On a quarterly basis, management estimates the probable number of performance-based restricted stock units that would vest until such time that the ultimate achievement of the performance criteria are known. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates stock price volatility by using its own historical data. The expected term of the Company&#8217;s stock options is estimated using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect </span></div>to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We record reclassifications from other comprehensive gains or losses to interest and other income, net on the condensed consolidated statements of operations related to realized gains on sales of available-for-sale securities.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its securities quarterly to determine whether an other-than-temporary impairment has occurred. The Company determined that there were no other-than-temporary impairments during the three months ended March&#160;31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB that the Company adopts as of the specified effective date. There were no recently adopted accounting pronouncements that had a material impact on the Company&#8217;s condensed consolidated financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company&#8217;s condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629610086432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock', window );">Summary of Estimated Useful Lives of Assets</a></td>
<td class="text">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 47 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 10 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of useful life or remaining life of lease</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated useful lives of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_EstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629610059904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.589%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,965)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,712,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,114,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.76)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.99)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629609549440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of March&#160;31, 2023 and December&#160;31, 2022, respectively (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:24.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.032%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,771&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,642&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,642&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:23.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.100%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(419)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,892&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,271&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company's long-term marketable securities mature between one year and two years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629609983232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,477&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,073&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses And Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629603838192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, future minimum commitments under the Company&#8217;s operating leases with lease terms in excess of 12 months were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-top:2pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's lease expense are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental condensed consolidated balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629607826272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company's Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,582,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#CCECFF;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,021)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,625)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,785,135&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.75&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,066&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,428&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.08&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March&#160;31, 2023 and the exercise price of outstanding in-the-money options.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSUs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to PSUs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Stock Options, Valuation Assumptions</a></td>
<td class="text">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three months ended March&#160;31, 2023 and 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock And Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTc3_6f3f7115-1588-4f4d-bb1c-32086269f4cb">four</span>-year period. The Company granted zero RSAs to employees of the Company during each of the three months ended March&#160;31, 2023 and March&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,649)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div>The Company granted 186,900 and zero RSUs to employees of the Company during the three months ended March&#160;31, 2023, and 2022, respectively.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSUs as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,900&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.91&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Share-Based Payment Arrangement, Performance Shares, Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 60,000 and zero PSUs to employees of the Company during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested PSUs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested PSUs as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.91&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629607829120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 326,056<span></span>
</td>
<td class="nump">$ 280,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 350,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629607786000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Recognized impairment losses for long lived assets | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629613819168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and building improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and building improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">47 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_ManufacturingEquipmentMember', window );">Manufacturing equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_ManufacturingEquipmentMember', window );">Manufacturing equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629610032384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share</a></td>
<td class="nump">3,829,535<span></span>
</td>
<td class="nump">3,226,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629609482864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (45,297)<span></span>
</td>
<td class="num">$ (49,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="nump">25,712,220<span></span>
</td>
<td class="nump">25,114,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="nump">25,712,220<span></span>
</td>
<td class="nump">25,114,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share: basic (in dollars per share)</a></td>
<td class="num">$ (1.76)<span></span>
</td>
<td class="num">$ (1.99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share: diluted (in dollars per share)</a></td>
<td class="num">$ (1.76)<span></span>
</td>
<td class="num">$ (1.99)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629603944384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 140,745<span></span>
</td>
<td class="nump">$ 161,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(314)<span></span>
</td>
<td class="num">(835)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">355,563<span></span>
</td>
<td class="nump">384,448<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">355,516<span></span>
</td>
<td class="nump">383,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">97,442<span></span>
</td>
<td class="nump">63,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">97,431<span></span>
</td>
<td class="nump">63,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">49,573<span></span>
</td>
<td class="nump">82,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">49,506<span></span>
</td>
<td class="nump">81,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">67,803<span></span>
</td>
<td class="nump">76,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(190)<span></span>
</td>
<td class="num">(393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">67,834<span></span>
</td>
<td class="nump">76,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">140,745<span></span>
</td>
<td class="nump">161,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">209,642<span></span>
</td>
<td class="nump">217,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">97,431<span></span>
</td>
<td class="nump">63,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">45,344<span></span>
</td>
<td class="nump">77,214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">66,867<span></span>
</td>
<td class="nump">76,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">5,129<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">4,162<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">967<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">140,745<span></span>
</td>
<td class="nump">161,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Aggregate Fair Value</a></td>
<td class="nump">140,745<span></span>
</td>
<td class="nump">161,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">140,745<span></span>
</td>
<td class="nump">161,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">214,818<span></span>
</td>
<td class="nump">222,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(314)<span></span>
</td>
<td class="num">(835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">214,771<span></span>
</td>
<td class="nump">221,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 209,642<span></span>
</td>
<td class="nump">217,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 5,129<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash and cash equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 140,745<span></span>
</td>
<td class="nump">161,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Aggregate Fair Value</a></td>
<td class="nump">140,745<span></span>
</td>
<td class="nump">161,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash and cash equivalents | Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 140,745<span></span>
</td>
<td class="nump">$ 161,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629613837072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 170,959<span></span>
</td>
<td class="nump">$ 168,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(7,886)<span></span>
</td>
<td class="num">(6,793)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">163,073<span></span>
</td>
<td class="nump">161,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">122,935<span></span>
</td>
<td class="nump">131,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">24,442<span></span>
</td>
<td class="nump">24,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">10,236<span></span>
</td>
<td class="nump">9,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and building improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">9,736<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,108<span></span>
</td>
<td class="nump">2,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,164<span></span>
</td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 338<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629610044784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629613618608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedConstructionInProgressCurrent', window );">Accrued construction in progress</a></td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">11,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">3,839<span></span>
</td>
<td class="nump">3,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedPayrollAndBenefits', window );">Accrued payroll and benefits</a></td>
<td class="nump">2,661<span></span>
</td>
<td class="nump">6,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedPreclinicalAndClinicalExpenses', window );">Accrued preclinical and clinical expenses</a></td>
<td class="nump">1,635<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxes', window );">Accrued taxes</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_AccruedExpensesAndOtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">$ 29,414<span></span>
</td>
<td class="nump">$ 23,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedConstructionInProgressCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued construction in progress current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedConstructionInProgressCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPayrollAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll and benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPayrollAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPreclinicalAndClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical and clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPreclinicalAndClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629608455456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Proceeds from insurance settlement, operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_NumberOfMilestones', window );">Number of milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementTotalConsideration', window );">Litigation settlement, total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember', window );">Clinical Supply Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_RemainingCommitmentAmount', window );">Estimated remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Project management service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember', window );">ASTRA Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Milestone Payments, Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LitigationSettlementMilestonePaymentsSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LitigationSettlementTotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Total Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LitigationSettlementTotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_NumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_NumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_RemainingCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining commitment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_RemainingCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080549-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=krys_PeriphaGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=krys_PeriphaGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629609358784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Minimum commitments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023 (remaining nine months)</a></td>
<td class="nump">$ 1,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">1,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">10,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum operating lease payments</a></td>
<td class="nump">17,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">8,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 8,758<span></span>
</td>
<td class="nump">$ 8,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629613727264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 7,814<span></span>
</td>
<td class="nump">$ 8,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,553<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,205<span></span>
</td>
<td class="nump">7,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 8,758<span></span>
</td>
<td class="nump">$ 8,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, in years</a></td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
<td class="text">12 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629607950032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 463<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629610465488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember', window );">Placement Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_SaleOfStockAggregateOfferingPrice', window );">Sale of stock, aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_SaleOfStockRemainingAvailableIssuanceAmount', window );">Sale of stock, remaining available issuance amount</a></td>
<td class="nump">$ 102.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockRemainingAvailableIssuanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Available Issuance Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockRemainingAvailableIssuanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629604385728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent', window );">Period increase in shares authorized</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">287,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised | $</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Share-based payment arrangement, amount capitalized | $</a></td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">287,600<span></span>
</td>
<td class="nump">1,179,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant</a></td>
<td class="nump">1,005,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krys_A2017IPOStockPlanMember', window );">2017 IPO Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 56.86<span></span>
</td>
<td class="nump">$ 43.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="nump">$ 9,461<span></span>
</td>
<td class="nump">$ 5,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="nump">$ 109,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Stock award outstanding (in shares)</a></td>
<td class="nump">44,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="nump">$ 432<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant</a></td>
<td class="nump">2,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">186,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Stock award outstanding (in shares)</a></td>
<td class="nump">186,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="nump">$ 329<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Stock award outstanding (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest', window );">Expected to vest</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Period Increase, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested And Expected to Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krys_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krys_A2017IPOStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krys_A2017IPOStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629613601248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">3,582,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">287,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(42,021)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled or forfeited (in shares)</a></td>
<td class="num">(42,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,785,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,582,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable end of period (in shares)</a></td>
<td class="nump">961,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 61.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">81.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">53.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">65.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">62.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable end of period (in dollars per share)</a></td>
<td class="nump">$ 55.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- average Remaining Contractual Life (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (Years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (Years), exercisable</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 66,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at March 31, 2023</a></td>
<td class="nump">$ 24,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629605146560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 9,461<span></span>
</td>
<td class="nump">$ 5,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">2,353<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">7,108<span></span>
</td>
<td class="nump">4,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629612118272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail) - Share-based Payment Arrangement, Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of the award (years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.06%<span></span>
</td>
<td class="nump">1.79%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 81.83<span></span>
</td>
<td class="nump">$ 62.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140629608428960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Stock Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(12,649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Surrendered for taxes (in shares)</a></td>
<td class="num">(9,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">44,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Surrendered for taxes (in dollars per share)</a></td>
<td class="nump">78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">186,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Surrendered for taxes (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">186,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">81.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Surrendered for taxes (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 81.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Surrendered for taxes (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">81.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Surrendered for taxes (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 81.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>krys-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krys="http://www.krystalbio.com/20230331"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krys-20230331.xsd" xlink:type="simple"/>
    <context id="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie832448b6e8a4a0395ec135879c734ce_I20230501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i65fbf7b333674008878005497a15d13f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9ac3e0fd9317440dac10b07c59703d04_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia96e3d34d40c48289e74f96e776c6ed1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3896475111104dd6abbb477aef133548_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d9b884d4558463fa0d98791f90f9606_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iabc9e0eb98364fb3ad07b8cf7150e319_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic94d5fe5213a4f26a3256b3f0bfc26d1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5450c8199b9e4fd5afb2a7b09a42d9f0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0494490052724969ad4dda9da8c25266_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i81b0f3dfb98b42caa153a99313d719d9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ida72ac9ff53040f28071df8ab44a4388_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib1c089ca6dbf4946b9175e1adec58907_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0f638a7b209c4dacaa94a230ca55e1ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id70922e6d9374781a321436c00157066_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id41bc98a3a7d4b52bf0e3a53731fb357_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6f630d3e1e44ce5aa3f5e2ff715bbfb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d637ac1bef94cb39b5dba2d17d51f98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia05e2f5705fb414dae7eddeea359d8c8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i344d0fb131be4470b723a325e38905bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff9d64d433fc4c8581724468d59dc4ca_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibcfa5a617a40436f9e9057caaa0a86ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i241ffd0cd8bc4e4f8afe5a3a324b02c1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i76bbae0d55ce463db494ea5540773374_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i56232f71838b463888f902e03c7adab8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib576e67237ad45acaa64f5f64e381e6f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id93c5ffaa22a4251b0b179d55468758a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3d5858b254a74055947c9db86b18c8a3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i98497d61c2dc4015859731c29c4a5191_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4d5a1d7d6d3b45cc86f55259988312d1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1ad7d5c593e74fa481f25d0584ed5bb3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iff57f58cd1564684a2781fa990333e72_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i96507c2336ed410dba27455fd3d47784_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iab72ff6d793d4c95b00695f6313daf97_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4634ec644b074dc2a73fb4d688425c09_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3a98446c7d2a422cb8484c551d8569e1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7c577603e2e64c98b5ecf7704120a266_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib56d0e98532345689136cfae336cfbd6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iacdb4dc62a9b4428bdc804b7838f7fdc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i254b57e74219457a9976070bb3f01cca_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia4bcbb3bbdfb443c9dc1d6277b193724_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i93a24294ea254807b3a01f15a488820e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia679ddbe0c9148b596ce5d22d0a1c72d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie55cf1b68f5343cd983d4229a5bf466c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia810a7f2836b4a4c8b9329aa2c255208_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8cd9dad418b8488cb10071f2be3a4912_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia0bea5cf40f844f38d74969a8559b2c5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i199b309fe28245b5b261791cfe807797_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i821aef589ece4731b6e9f4ebc1acba43_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia170328c9e7e4a0ca886658a03a5bf79_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6f5f311477c243739da11f1d6cf25133_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9e4f7f10a1f943dba2eb0d494342e180_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i25bc3c11b7b447f38c5ac9085cb16011_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib7dabfb39094405ea129e230c5fea918_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idc0dea8cd85c4b10a8ca0270bc96ca37_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9db97cf4a1ee43798607ccb440a0c691_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i19390a3c5c074f8cb033de62ea4926ba_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i955d93f6b8e8480aac09b577bc03fd18_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4a9e54233c0c409fbb144f9054234dc7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3253f0426d1b464d823eff67b81326d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iabfee1fcc75f4f5cb247fc8dcaa4469f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd001999a79b40e58c92b5976170c12c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i558055bb178d47cf8d6907260c65860d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i848d726cc7ea4e92bb8c216498e171d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i708d874019134729a370416147542b1e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if91c8903d66e47ed89c8a8a928e0ad19_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04d0048badcd4c6aa1082f735dda5fa5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4fd54f5b9a434b3b9b37bebfcedd8570_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54381d9b7697447d972984381f5addb6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfe9d0765d4040a88c16e531654af652_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4dad77b16170425f951687a001a58cf7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie09632b1d13f447d83cab24d09f19673_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36bffbb608004cf7bd1c29662284954f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1642cf0b875e42d18be7877570ce84d9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id90668d113b34bf0b03c32cdd534454d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26fb1563e4c745bcb1ecf87c332f3971_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b41653db9f6419aab13fd18aaffc538_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9e884919c2f4f82a2242d01a6e29dba_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i63f3f336a5e844e5b596e41d4095f2d6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3336d8df96f44c03b0edde5a7b3f3f1a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2e13fb41138141a8a45f22e1363c6694_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95624b73ce524801a03f62c6d6488c4d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i70f55b22e3c64c36aa9d32e22506ddb0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib70c320c8793401f8ad427840ed747f4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib7c0541a8fd74c0fab5d9a8c2a1fb295_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib1679847f2284f818043b46f19f6d0fe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibf9eb878f8f5476899e4bdc1684dbc88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc7771852e944942a97a47f105d3ddb4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie1402d218b7f411a89c2d0a991370111_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5c4f65d06694451b7c17b1d48fc362e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icc58ce8deb464b0999c8eba8a23d5170_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c8785f3fae3400a93aa066e59ff0830_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i788e335dd01542c6877956cecd45ef64_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa1cfbf80d374c378d2f9b338ebb5deb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i77d7d7ecd78845e5bd5596242784b33d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifc4c065296114490bb18d3287e10eee4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i59d538d178644369ac955f83b6d3c6cb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic7ccbd4c24004f7c9a76c78c77580c61_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="i38665521367949c5a5b7b6f4a45a6367_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3a63fc072ee84250a08db24153192cce_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iac262c9c6f0f403486081e497b2c7281_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4243169cc3fd4a5b9a86b7ea453f05f5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i34cbc871f0d741f2a78e2f78568df717_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="iaa962a4885f645e19feb14d38de37c30_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="i450e68ee6678498fa0a8d69ede89d91d_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="id69a8a353b3642439f10c5a61f8f2f64_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="i6d80521c426d495a9687ea96ad9ca399_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4eb18cd516042b7aab83e20049963ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i204fc13707f54377a36f6695aa4c916f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if019f17b70c645eab7cf5f73638d1837_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i514f2cde4cee40baaa8b763c557430ae_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:A2017IPOStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iab062c8a7a8c411fa82f2d7c0deec53b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i99bf40e31c9c43caaa925da542ea4133_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0b2264b9c9914e3abaee4de6745b7cf8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id23450f1c26144fca1df4aefaa3a147d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i228ec404a39040e2a3b2cf301e832687_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iedcfd366e93c4c2d8c5b5452e2b1caf3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id58086907cf445e3b68de6647460560d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib13481cdbf0441e49f4f32596d741801_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2350fa2df2594c7d83ae40618dfdbd3f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i65adaea3f9a54843afd31a5010fe66a3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4f30b015d0b54cef9f1f1fe7e1c87a6b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i91dfabdbc99a482ca88701984073bc51_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i29f8fe089ab942b2b54a2474e590165e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i645b28bb0a98487cb270051dfc6fdcfe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49ef87a5ae2a4962839a23c59b1310dc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icc7538673d38443ba7514e523de7d067_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if52d01079bea47b58f76c834f2bd69aa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idef73c4961e74f54a77c41e6d1e60853_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7af32a972cdb4a749407af929c2d1837_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ide792579d6fa48f0b86d34c66b1032f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibfcec0e0e32c41ff965b11623a8537b6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia4b071d986514acea476f82fe822eeb2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i67805b5822e040868da524c3ac650689_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib38669f3d3714bb9a64a611f418227d2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie8865efa296147f4b6d4959a17d55e59_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i89b2e6b1732847ebb483c440b3b816ea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7bce8d3bcf1140e8aceb74a97f62d71a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8817887d7f81412584905713f1293a84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0633520e282645f49e4915cae45e1e31_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9a5c357849b34fb4847ad068877525ca_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i447050dc5b89452bb373864b41c4e5ab_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib03c89f358de41aba14e7922b0f06df8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>krys:segment</measure>
    </unit>
    <unit id="milestone">
        <measure>krys:milestone</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80L2ZyYWc6OTZlZTRiODQxMmQyNDU3NGEwMWZmZTMwNzFhMmY5MDAvdGFibGU6YmE2YjIxODRhZjdhNGQ5Yzk1YWE5OTQ3MGYxZGFjODYvdGFibGVyYW5nZTpiYTZiMjE4NGFmN2E0ZDljOTVhYTk5NDcwZjFkYWM4Nl8zLTEtMS0xLTUxMzA3_0630ae97-758b-4309-8e54-99e01f9956fe">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80L2ZyYWc6OTZlZTRiODQxMmQyNDU3NGEwMWZmZTMwNzFhMmY5MDAvdGFibGU6YmE2YjIxODRhZjdhNGQ5Yzk1YWE5OTQ3MGYxZGFjODYvdGFibGVyYW5nZTpiYTZiMjE4NGFmN2E0ZDljOTVhYTk5NDcwZjFkYWM4Nl81LTEtMS0xLTUxMzA3_6f90c0a9-e50d-4301-a006-4f16706fb888">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80L2ZyYWc6OTZlZTRiODQxMmQyNDU3NGEwMWZmZTMwNzFhMmY5MDAvdGFibGU6YmE2YjIxODRhZjdhNGQ5Yzk1YWE5OTQ3MGYxZGFjODYvdGFibGVyYW5nZTpiYTZiMjE4NGFmN2E0ZDljOTVhYTk5NDcwZjFkYWM4Nl82LTEtMS0xLTUxMzA3_75d36a49-2797-483d-8a3d-8501437683df">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80L2ZyYWc6OTZlZTRiODQxMmQyNDU3NGEwMWZmZTMwNzFhMmY5MDAvdGFibGU6YmE2YjIxODRhZjdhNGQ5Yzk1YWE5OTQ3MGYxZGFjODYvdGFibGVyYW5nZTpiYTZiMjE4NGFmN2E0ZDljOTVhYTk5NDcwZjFkYWM4Nl85LTEtMS0xLTUxMzA3_23884cec-4620-4f75-97f2-0d70ff1e01fa">0001711279</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80L2ZyYWc6OTZlZTRiODQxMmQyNDU3NGEwMWZmZTMwNzFhMmY5MDAvdGFibGU6YmE2YjIxODRhZjdhNGQ5Yzk1YWE5OTQ3MGYxZGFjODYvdGFibGVyYW5nZTpiYTZiMjE4NGFmN2E0ZDljOTVhYTk5NDcwZjFkYWM4Nl8xMC0xLTEtMS01MTMwNw_f2800e32-95f4-40a0-a8f6-ae841cab1315">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iab062c8a7a8c411fa82f2d7c0deec53b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTExNQ_1ff19d5b-7ebe-44d5-815e-fa8e50130fbf">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i99bf40e31c9c43caaa925da542ea4133_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTE0Nw_06c5c353-58b3-42d1-85b7-6f88da10a8be">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i91dfabdbc99a482ca88701984073bc51_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTc3_6f3f7115-1588-4f4d-bb1c-32086269f4cb">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDcw_27cfe17b-2453-44e5-8139-4fb43befdd3b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6OTA1YmU5ZDJmOGQ0NDAwMmI2NjAyNjdiMGE2MDAxMWMvdGFibGVyYW5nZTo5MDViZTlkMmY4ZDQ0MDAyYjY2MDI2N2IwYTYwMDExY18wLTAtMS0xLTUxMzA3_bb465fa9-9b0c-4023-ba0e-2754ceb1c56c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDI_eb354631-0132-43f6-ae6a-22f156abaf2c">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6YWY3ZmRiMzIzNTdjNGM5MjliNGY1NjJkYTkzZjE4YmYvdGFibGVyYW5nZTphZjdmZGIzMjM1N2M0YzkyOWI0ZjU2MmRhOTNmMThiZl8wLTAtMS0xLTUxMzA3_12eb106f-464a-4cc7-9ac1-cd7b0cd79d25">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDcx_8bc12d30-ab75-4b7e-a780-5c840593a039">001-38210</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDYy_0a43febc-4f16-44d1-baa1-7f9612fe3797">Krystal Biotech, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6Yzg4MDlhYWNjOTgwNGI3NDg1ZTA0OGVmN2JjNTFlODUvdGFibGVyYW5nZTpjODgwOWFhY2M5ODA0Yjc0ODVlMDQ4ZWY3YmM1MWU4NV8wLTAtMS0xLTUxMzA3_c3da81b3-18a1-4d3c-bb32-f71dd65554ab">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6Yzg4MDlhYWNjOTgwNGI3NDg1ZTA0OGVmN2JjNTFlODUvdGFibGVyYW5nZTpjODgwOWFhY2M5ODA0Yjc0ODVlMDQ4ZWY3YmM1MWU4NV8wLTItMS0xLTUxMzA3_a02e247b-9593-4d31-882a-226420c6809e">82-1080209</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDYz_b383172f-e0b6-4ebe-8b31-b051d1c1e05e">2100 Wharton Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDU4_1bc9069a-1248-4c33-91e8-b73d30a2174c">Suite 701</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDcy_7a7d66db-13d5-4de8-9185-ad92cbcc55ce">Pittsburgh</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDcz_0f6100bb-fc72-453f-b251-aec29e74e6fb">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl81OTk_86439a48-4970-411f-af0e-2e22d31d766d">15203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDc0_30f5cc36-269e-47bd-aa7a-0774f099dc24">412</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDU5_06f933a5-dc34-42cf-87da-233af33ffc92">586-5830</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6N2FlYjBhYjM5ZWY5NDVjNWJjNGRkZGUwMmM3MjkyZGUvdGFibGVyYW5nZTo3YWViMGFiMzllZjk0NWM1YmM0ZGRkZTAyYzcyOTJkZV8xLTAtMS0xLTUxMzA3_a45bcd25-a58d-4597-9b12-4eaf8ae15fa2">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6N2FlYjBhYjM5ZWY5NDVjNWJjNGRkZGUwMmM3MjkyZGUvdGFibGVyYW5nZTo3YWViMGFiMzllZjk0NWM1YmM0ZGRkZTAyYzcyOTJkZV8xLTEtMS0xLTUxMzA3_2751ea7c-9180-472f-8101-032e56575948">KRYS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6N2FlYjBhYjM5ZWY5NDVjNWJjNGRkZGUwMmM3MjkyZGUvdGFibGVyYW5nZTo3YWViMGFiMzllZjk0NWM1YmM0ZGRkZTAyYzcyOTJkZV8xLTItMS0xLTUxMzA3L3RleHRyZWdpb246ZmQ1NWZhNmY4MjhiNGIyMGE0NjkyYzhkNDY5M2I3NDdfNA_00db8dd3-a29e-45f4-87b0-ec3828ac38fa">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDY1_a0da9f0b-7c25-4b39-9d0b-705066e128fd">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDY2_c76f9aa0-555a-44e2-8323-de5f4f9f3e47">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6MWRmMDI1NWM1ZGM1NGZkZTkxMDAwYThjM2EzNDM1NTAvdGFibGVyYW5nZToxZGYwMjU1YzVkYzU0ZmRlOTEwMDBhOGMzYTM0MzU1MF8wLTAtMS0xLTUxMzA3_21cf53b9-b808-4dc9-89a1-28b66182c8c0">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGFibGU6MWRmMDI1NWM1ZGM1NGZkZTkxMDAwYThjM2EzNDM1NTAvdGFibGVyYW5nZToxZGYwMjU1YzVkYzU0ZmRlOTEwMDBhOGMzYTM0MzU1MF8xLTYtMS0xLTUxMzA3_faefbae9-e215-4911-8a40-3af5579ab677">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDYw_35808663-5ebb-4af4-a0d5-062377101ac9">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yNDYx_d1314b17-62fc-4882-a6ff-6f2b099cc74d">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie832448b6e8a4a0395ec135879c734ce_I20230501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xL2ZyYWc6ZmZiZWU3MjMzZGQyNDhhZGJiOWJiMTg3YjQ5MThlZDIvdGV4dHJlZ2lvbjpmZmJlZTcyMzNkZDI0OGFkYmI5YmIxODdiNDkxOGVkMl8yMzkw_2ec91c25-1832-4610-8016-f0956b483135"
      unitRef="shares">25799738</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNC0xLTEtMS01MTMwNw_57dc8e87-ae08-47bd-be1c-bb7690fa9e81"
      unitRef="usd">140745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNC0zLTEtMS01MTMwNw_c51913db-e3a2-4ca3-9300-2a0c82600ef1"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNS0xLTEtMS01MTMwNw_a87e3408-abbb-493a-9b2f-6cb84380085d"
      unitRef="usd">209642000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNS0zLTEtMS01MTMwNw_d3b8313b-163a-4ee3-82d8-8e3a685b9961"
      unitRef="usd">217271000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNi0xLTEtMS01MTMwNw_29e01e24-1efd-465b-9b4e-3936e9e69aaa"
      unitRef="usd">5042000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNi0zLTEtMS01MTMwNw_745950ed-b600-4f06-ae56-0c21e3354a58"
      unitRef="usd">4608000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNy0xLTEtMS01MTMwNw_da0a1302-7131-47ec-8605-209900f6176a"
      unitRef="usd">355429000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfNy0zLTEtMS01MTMwNw_27db1d29-bd57-49b0-943c-4d6c8a91637a"
      unitRef="usd">383779000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfOC0xLTEtMS01MTMwNw_981cc80c-0fc5-4b8f-8ee1-ebee7e6833ef"
      unitRef="usd">163073000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfOC0zLTEtMS01MTMwNw_e257d66f-18be-4ecb-a9e5-38f328fd4358"
      unitRef="usd">161684000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfOS0xLTEtMS01MTMwNw_dcf7ea40-206f-4582-8399-afc51fffea15"
      unitRef="usd">5129000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfOS0zLTEtMS01MTMwNw_770bde68-7319-4858-bfaf-77bd6000d7c8"
      unitRef="usd">4621000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTAtMS0xLTEtNTEzMDc_aa471eef-4f4f-40a8-b832-bf5aef90d859"
      unitRef="usd">7814000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTAtMy0xLTEtNTEzMDc_bfbe311b-8a84-4b80-952e-d6ce2568f69f"
      unitRef="usd">8042000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTEtMS0xLTEtNTEzMDc_d6a6bf34-fe10-4a0f-9f77-3b8cd5fb7761"
      unitRef="usd">402000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTEtMy0xLTEtNTEzMDc_70344ef0-b5d0-44f8-841d-63cdce9be4d3"
      unitRef="usd">324000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTItMS0xLTEtNTEzMDc_7b895697-b3aa-4f0a-a2c1-c0235a34a6e3"
      unitRef="usd">531847000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTItMy0xLTEtNTEzMDc_ff0f1164-0445-47d5-adb0-60e6d2a99513"
      unitRef="usd">558450000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTUtMS0xLTEtNTEzMDc_69503879-bf8f-4310-b185-6d9af579bb11"
      unitRef="usd">4109000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTUtMy0xLTEtNTEzMDc_b2ea3b35-4464-408a-9999-5a262684ad43"
      unitRef="usd">3981000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTYtMS0xLTEtNTEzMDc_5b3e48e0-0d7b-4b96-b8ad-9ca89f489530"
      unitRef="usd">1553000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTYtMy0xLTEtNTEzMDc_a8a04e94-471d-409d-a720-9dd78beca57f"
      unitRef="usd">1561000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTctMS0xLTEtNTEzMDc_bbebbbc4-7930-41e1-a50c-417eaf55c674"
      unitRef="usd">29414000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTctMy0xLTEtNTEzMDc_d9ccbce6-64cd-426c-8bd3-f5addf12ff20"
      unitRef="usd">23305000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTktMS0xLTEtNTEzMDc_e0a3f95c-899e-400b-85b1-8dced13e7649"
      unitRef="usd">35076000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMTktMy0xLTEtNTEzMDc_3a513b01-5045-4289-b274-29d6e499b938"
      unitRef="usd">28847000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjAtMS0xLTEtNTEzMDc_8c4bd913-a9a2-4e45-bdda-ea9c0e20439c"
      unitRef="usd">7205000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjAtMy0xLTEtNTEzMDc_83635f99-42fa-478b-9c23-4000c297a4a5"
      unitRef="usd">7372000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjEtMS0xLTEtNTEzMDc_618cf14b-17c1-4ab1-8a7b-ac9c82c9ca56"
      unitRef="usd">42281000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjEtMy0xLTEtNTEzMDc_46bb6374-4bd3-4e2b-b8cd-294e4d2d1a4e"
      unitRef="usd">36219000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjItMS0xLTEtNTEzMDc_943bde5c-7a3c-4ae7-bd3a-e0195053b442"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjItMy0xLTEtNTEzMDc_4f199416-008f-4d56-9b80-d09738d43c17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8xOA_3855e2cf-c90f-4744-9d6f-9c4564769ba9"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8xOA_d1b21de7-0312-496d-808a-9d389c04df39"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8zMg_ca57cd85-654f-4a5b-a581-e5f8c0912ac9"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8zMg_eab650f5-ae4d-4b3b-88b8-e903e6fea51a"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV82Nw_2c5518b8-82de-4258-a2f3-e8e4647d2727"
      unitRef="shares">25796213</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV82Nw_b95f7f58-d99e-447e-8596-367f022b9956"
      unitRef="shares">25796213</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8xMTE_0493a3ab-2ec3-4a9c-8ac0-76560b24414d"
      unitRef="shares">25763743</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMC0xLTEtNTEzMDcvdGV4dHJlZ2lvbjpkZjlhNjc3NzNmNTQ0MTBlOGZmMWQzYzJiNWRlOTUxOV8xMTE_759d8ef2-31c4-4a74-9870-12aa18173ef0"
      unitRef="shares">25763743</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMS0xLTEtNTEzMDc_066922ee-2d61-4396-95fa-93a278660586"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjUtMy0xLTEtNTEzMDc_4795b4a7-ac39-47f5-855b-af514e61769a"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjYtMS0xLTEtNTEzMDc_34c5b21d-9e7a-400c-aadf-5f3d6fbfacc5"
      unitRef="usd">815776000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjYtMy0xLTEtNTEzMDc_8df3ce49-2498-4ed1-8abb-18cd1c7c4c9e"
      unitRef="usd">803718000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjctMS0xLTEtNTEzMDc_71831431-037f-469a-8e0c-09bbfad44975"
      unitRef="usd">-154000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjctMy0xLTEtNTEzMDc_5a5eb667-7d5b-456a-a745-78fddff40a53"
      unitRef="usd">-728000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjgtMS0xLTEtNTEzMDc_5a226711-6850-45cb-9244-5f1745142b88"
      unitRef="usd">-326056000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjgtMy0xLTEtNTEzMDc_aa4566ae-61ba-461b-afc7-22ad06538e06"
      unitRef="usd">-280759000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjktMS0xLTEtNTEzMDc_15e8d3a0-e699-4fff-99ad-ae1ce1de193e"
      unitRef="usd">489566000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMjktMy0xLTEtNTEzMDc_32448fbd-d682-4355-afff-9717619c1815"
      unitRef="usd">522231000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMzAtMS0xLTEtNTEzMDc_30d43000-8fab-428b-ba55-0bf82fd809a3"
      unitRef="usd">531847000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xNi9mcmFnOjA1ZmJhZDNhY2I1NzQ0MjI5ZGViODMyMzg2YmM2Nzg0L3RhYmxlOjQxZDMzMDllM2FhMzQ1ZDdhZTk0ZTZkMjViYzg1OTgyL3RhYmxlcmFuZ2U6NDFkMzMwOWUzYWEzNDVkN2FlOTRlNmQyNWJjODU5ODJfMzAtMy0xLTEtNTEzMDc_3b828344-3517-4b60-a0c9-e7e7ba440010"
      unitRef="usd">558450000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMy0xLTEtMS01MTMwNw_da25850e-a37e-4a49-9995-ad0c80ef67a7"
      unitRef="usd">12288000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMy0zLTEtMS01MTMwNw_78f295f4-325d-476d-a146-9c4ba5bdb134"
      unitRef="usd">9314000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNC0xLTEtMS01MTMwNw_52317d78-02ad-497e-b19c-58086ff715a2"
      unitRef="usd">24035000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNC0zLTEtMS01MTMwNw_1446b987-2c3b-47cc-8218-4c351624bed3"
      unitRef="usd">15908000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNS0xLTEtMS01MTMwNw_78eb8645-a9a2-45b2-aacf-f549f73f67fd"
      unitRef="usd">12500000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNS0zLTEtMS01MTMwNw_7907f6f3-9025-4f5b-acb0-87ad42c120ce"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:OperatingExpenses
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNi0xLTEtMS01MTMwNw_9177abcb-8a41-42a8-ab66-e5e24eaee44c"
      unitRef="usd">48823000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNi0zLTEtMS01MTMwNw_cdf69cc7-c42e-42d9-a574-8b64da4e9f97"
      unitRef="usd">50222000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNy0xLTEtMS01MTMwNw_68b4a24e-f6d3-42fe-a71f-b0f86f701fae"
      unitRef="usd">-48823000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfNy0zLTEtMS01MTMwNw_7f13bd2d-a538-42bc-9844-7b14ce817c3a"
      unitRef="usd">-50222000</us-gaap:OperatingIncomeLoss>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfOS0xLTEtMS01MTMwNw_a303a687-df91-45e8-b0d6-a029305275af"
      unitRef="usd">3526000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfOS0zLTEtMS01MTMwNw_b09a17c6-86c2-4c6e-8c13-c070028b0af2"
      unitRef="usd">257000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <us-gaap:NetIncomeLoss
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTEtMS0xLTEtNTEzMDc_d36b2a9a-3231-44fb-a502-c1cc3619127c"
      unitRef="usd">-45297000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTEtMy0xLTEtNTEzMDc_384e3bc4-5b89-428e-8b46-5707eae361e8"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTItMS0xLTEtNTEzMDc_ca871dcc-0bdd-47f8-9adc-841a8db30297"
      unitRef="usd">574000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTItMy0xLTEtNTEzMDc_0826f4b0-031b-4a14-9ace-1e39b17dc00b"
      unitRef="usd">-1034000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTMtMS0xLTEtNTEzMDc_83c7fa04-0742-486c-8cfe-bf9f82ee6594"
      unitRef="usd">-44723000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTMtMy0xLTEtNTEzMDc_a8eb94df-bf47-4ccb-af28-597431da0253"
      unitRef="usd">-50999000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTUtMS0xLTEtNTEzMDc_2263bcd1-914b-4bbe-9a3f-972377552aa2"
      unitRef="usdPerShare">-1.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTUtMS0xLTEtNTEzMDc_f9e646be-8de7-45b2-9cc7-00cfba285036"
      unitRef="usdPerShare">-1.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTUtMy0xLTEtNTEzMDc_6f69f59c-f452-4f98-8e89-c52ae8d7a4d6"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTUtMy0xLTEtNTEzMDc_9fc88a79-bc67-475b-86f3-a2a668972fd8"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTctMS0xLTEtNTEzMDc_36622f4f-7e72-42f8-bfe6-b4eae7d249d8"
      unitRef="shares">25712220</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTctMS0xLTEtNTEzMDc_7dbae351-fed3-4e71-9bd4-e7b6722b5752"
      unitRef="shares">25712220</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTctMy0xLTEtNTEzMDc_67cacb9a-ca46-4ae3-9c56-b357b5f9f6c1"
      unitRef="shares">25114453</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8xOS9mcmFnOjYxNDc0NTNjOWE2ODRkYjI4NDlmYjQ0YWZmNzMzZGQzL3RhYmxlOjVjZmZjYTE3MDA3ODQ3N2NiYTM5NmY1MmRiNmE0ZDQ4L3RhYmxlcmFuZ2U6NWNmZmNhMTcwMDc4NDc3Y2JhMzk2ZjUyZGI2YTRkNDhfMTctMy0xLTEtNTEzMDc_f95a6ee1-67d9-4c28-9367-ed872d3ea722"
      unitRef="shares">25114453</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i65fbf7b333674008878005497a15d13f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy0xLTEtMS01MTMwNw_40ee573d-8193-487f-8e28-6dca4fde676f"
      unitRef="shares">25763743</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i65fbf7b333674008878005497a15d13f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy0zLTEtMS01MTMwNw_d757c2cf-98a4-4011-a11e-db1a481900ec"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ac3e0fd9317440dac10b07c59703d04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy01LTEtMS01MTMwNw_fa178cd5-7132-4686-a1b4-9ff04cacc1ae"
      unitRef="usd">803718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia96e3d34d40c48289e74f96e776c6ed1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy03LTEtMS01MTMwNw_54376fdf-8c0b-436d-8c23-76adadc67e64"
      unitRef="usd">-728000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3896475111104dd6abbb477aef133548_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy05LTEtMS01MTMwNw_609332bc-92c8-417f-89df-7ab6315dfd45"
      unitRef="usd">-280759000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfMy0xMS0xLTEtNTEzMDc_4e10e79d-ce54-427d-909c-111b4f9ddb01"
      unitRef="usd">522231000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0d9b884d4558463fa0d98791f90f9606_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNC0xLTEtMS01MTMwNw_c4923ded-c6b2-4c1a-891d-760e77d0755a"
      unitRef="shares">42021</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iabc9e0eb98364fb3ad07b8cf7150e319_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNC01LTEtMS01MTMwNw_5787f89b-946b-4c31-8f37-14e63b04fba0"
      unitRef="usd">2208000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNC0xMS0xLTEtNTEzMDc_3d002a05-ff6c-4a5c-95ad-22a9c6918ea8"
      unitRef="usd">2208000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i0d9b884d4558463fa0d98791f90f9606_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNS0xLTEtMS01MTMwNw_c583a5a8-efc5-4d15-aba0-5703272e79b7"
      unitRef="shares">9551</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iabc9e0eb98364fb3ad07b8cf7150e319_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNS01LTEtMS01MTMwNw_e31a4688-4a45-431f-b67c-1abc5be8f507"
      unitRef="usd">749000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNS0xMS0xLTEtNTEzMDc_d6060089-dcc0-4bc8-88e6-c7291601b1ed"
      unitRef="usd">749000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iabc9e0eb98364fb3ad07b8cf7150e319_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNi01LTEtMS01MTMwNw_b2cac571-0708-4820-b679-ba455017e146"
      unitRef="usd">10599000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNi0xMS0xLTEtNTEzMDc_b135efcc-5b48-4975-88bc-da4051bb3d6c"
      unitRef="usd">10599000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic94d5fe5213a4f26a3256b3f0bfc26d1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNy03LTEtMS01MTMwNw_878b2486-e791-49a4-bbb6-a7391f2ba8e7"
      unitRef="usd">574000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfNy0xMS0xLTEtNTEzMDc_ac41ab49-d388-454a-abfb-6467b6647e29"
      unitRef="usd">574000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i5450c8199b9e4fd5afb2a7b09a42d9f0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOC05LTEtMS01MTMwNw_a1d45122-e4fb-45c8-b2d2-eabf1af1fb48"
      unitRef="usd">-45297000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOC0xMS0xLTEtNTEzMDc_0d3d6c96-0c54-4eb7-88bf-b5334804c960"
      unitRef="usd">-45297000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i0494490052724969ad4dda9da8c25266_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS0xLTEtMS01MTMwNw_5aadbd94-1a6a-4902-b43c-d27ef2b32135"
      unitRef="shares">25796213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0494490052724969ad4dda9da8c25266_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS0zLTEtMS01MTMwNw_60bbd574-04b0-40c9-8f98-e4cf32864468"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81b0f3dfb98b42caa153a99313d719d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS01LTEtMS01MTMwNw_724bbb81-6e85-4c41-993d-13d89b4f977b"
      unitRef="usd">815776000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida72ac9ff53040f28071df8ab44a4388_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS03LTEtMS01MTMwNw_86880be3-5d7e-45d0-91ff-78284bfdb5b0"
      unitRef="usd">-154000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1c089ca6dbf4946b9175e1adec58907_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS05LTEtMS01MTMwNw_9ad1f215-a044-4497-947c-06a017c77ab3"
      unitRef="usd">-326056000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmI1ODgyYzNhNTZiYjQzODc4NGZjYzI0YTQ0Y2U4MmY5L3RhYmxlcmFuZ2U6YjU4ODJjM2E1NmJiNDM4Nzg0ZmNjMjRhNDRjZTgyZjlfOS0xMS0xLTEtNTEzMDc_32be236f-43b4-4224-bfce-dba75d130e4f"
      unitRef="usd">489566000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i0f638a7b209c4dacaa94a230ca55e1ce_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy0xLTEtMS01MTMwNw_f6165fe0-8f56-4bff-819d-6460ac9ed3f7"
      unitRef="shares">25207985</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0f638a7b209c4dacaa94a230ca55e1ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy0zLTEtMS01MTMwNw_7d0825d7-42ef-47bc-a254-94a57667cd47"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id70922e6d9374781a321436c00157066_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy01LTEtMS01MTMwNw_5c365ba7-3fcb-4446-a5b9-00d466644a30"
      unitRef="usd">734523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id41bc98a3a7d4b52bf0e3a53731fb357_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy03LTEtMS01MTMwNw_e7c93519-45ec-494b-a478-9675c136583f"
      unitRef="usd">-163000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6f630d3e1e44ce5aa3f5e2ff715bbfb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy05LTEtMS01MTMwNw_a5a29472-18a7-40a0-8943-9beb39d1360f"
      unitRef="usd">-140784000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d637ac1bef94cb39b5dba2d17d51f98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfMy0xMS0xLTEtNTEzMDc_438a8703-d51d-4ff5-a802-a1e27973407f"
      unitRef="usd">593576000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia05e2f5705fb414dae7eddeea359d8c8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNC0xLTEtMS01MTMwNw_41480cbe-afa7-48c7-9153-1d607b1e488f"
      unitRef="shares">1475</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i344d0fb131be4470b723a325e38905bf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNC01LTEtMS01MTMwNw_de4f8fb1-b5cb-4f04-a489-23a02f1e34a3"
      unitRef="usd">55000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNC0xMS0xLTEtNTEzMDc_0060b719-c276-40fe-be84-b029b0d4e10f"
      unitRef="usd">55000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ia05e2f5705fb414dae7eddeea359d8c8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNS0xLTEtMS03NTQ3MQ_e88b9a61-ca99-4a27-8265-d57136d77ee4"
      unitRef="shares">10379</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i344d0fb131be4470b723a325e38905bf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNS01LTEtMS03NTQ2NQ_92d24094-c730-4e34-8529-16d8b240039c"
      unitRef="usd">649000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNS0xMS0xLTEtNzU0NzE_1d020ff1-f520-4b96-9793-728489428632"
      unitRef="usd">649000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i344d0fb131be4470b723a325e38905bf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNS01LTEtMS01MTMwNw_601d80b7-da62-46f3-92bd-1ad388662231"
      unitRef="usd">6571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNS0xMS0xLTEtNTEzMDc_1e6ce29d-fee8-4996-9bbf-a3d6be52d82e"
      unitRef="usd">6571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iff9d64d433fc4c8581724468d59dc4ca_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNi03LTEtMS01MTMwNw_b1d97e39-7aed-47c1-bfea-47adb94f8245"
      unitRef="usd">-1034000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNi0xMS0xLTEtNTEzMDc_0a5e9076-5d19-40df-b67c-a7062eb6b534"
      unitRef="usd">-1034000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ibcfa5a617a40436f9e9057caaa0a86ab_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNy05LTEtMS01MTMwNw_19338bbd-c1b3-4d59-ae3f-12c19d3d4e65"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfNy0xMS0xLTEtNTEzMDc_b304421f-95bc-4989-b056-c5b5d4aab986"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i241ffd0cd8bc4e4f8afe5a3a324b02c1_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC0xLTEtMS01MTMwNw_1a9ea3e9-a652-4a68-a5cd-398bb0649efc"
      unitRef="shares">25199081</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i241ffd0cd8bc4e4f8afe5a3a324b02c1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC0zLTEtMS01MTMwNw_059bf86f-8dbb-4c53-b4a8-ea343891fefd"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i76bbae0d55ce463db494ea5540773374_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC01LTEtMS01MTMwNw_805d8169-c0c0-4e67-813f-b63d2026021c"
      unitRef="usd">740500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i56232f71838b463888f902e03c7adab8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC03LTEtMS01MTMwNw_983e5ec0-5409-444f-b56c-ca1afbef2f14"
      unitRef="usd">-1197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib576e67237ad45acaa64f5f64e381e6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC05LTEtMS01MTMwNw_bbde1857-357b-47ca-887d-a9b84acd5709"
      unitRef="usd">-190749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id93c5ffaa22a4251b0b179d55468758a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yMi9mcmFnOjQ1ZDI0ODg3MWRlZjQ3NjQ4YjJkZTU2ZmE3ZWU1ZmFjL3RhYmxlOmM1OTdmZTEwNjYwMDQyNWNiMTdlMzBmMWI2MzU0N2Q0L3RhYmxlcmFuZ2U6YzU5N2ZlMTA2NjAwNDI1Y2IxN2UzMGYxYjYzNTQ3ZDRfOC0xMS0xLTEtNTEzMDc_c3c8461d-45a4-4313-8029-ee17d2ae64a7"
      unitRef="usd">548554000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMy0xLTEtMS01MTMwNw_f2bb617e-730d-4c22-9844-83133453ccdc"
      unitRef="usd">-45297000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMy0zLTEtMS01MTMwNw_3c3dc8ab-1b10-4e31-98d7-90312d99e847"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNS0xLTEtMS01MTMwNw_70da3dd4-0492-41ba-8b08-988079935d9d"
      unitRef="usd">705000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNS0zLTEtMS01MTMwNw_a64095e4-e944-422a-8b41-99ac1bcebce4"
      unitRef="usd">1015000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNi0xLTEtMS01MTMwNw_36408d0a-1fdc-44ad-bc2e-6a8e1f914e72"
      unitRef="usd">10437000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNi0zLTEtMS01MTMwNw_5f0c2550-03bc-4d5b-9158-d51228c4b8c7"
      unitRef="usd">6430000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTAtMS0xLTEtNTEzMDc_0a77ca16-dec1-4fab-a2e8-fa08b05c6eac"
      unitRef="usd">-605000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTAtMy0xLTEtNTEzMDc_efc6e60c-ffbe-4a8e-aed4-32ae03cbd5c8"
      unitRef="usd">-135000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTItMS0xLTEtNTEzMDc_604cd620-e13f-4f8e-9fb8-968150aecdfb"
      unitRef="usd">327000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTItMy0xLTEtNTEzMDc_868cf330-54ae-4d7b-8535-917308dd7967"
      unitRef="usd">-820000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTQtMS0xLTEtNTEzMDc_d4f08d96-e0a8-4ae3-a2e4-98a0f8a3ccae"
      unitRef="usd">46000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTQtMy0xLTEtNTEzMDc_8e465cce-84f7-4f70-be04-60f36f0cb90b"
      unitRef="usd">-9000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTUtMS0xLTEtNTEzMDc_7eae9a68-c0b1-4946-9774-be240492012d"
      unitRef="usd">-165000</krys:IncreaseDecreaseInLeaseLiability>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTUtMy0xLTEtNTEzMDc_21f1826a-09fe-443a-b60f-0f8e77ef462d"
      unitRef="usd">-126000</krys:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTYtMS0xLTEtNTEzMDc_dec49bc0-6d35-4ec5-a494-353774f5f005"
      unitRef="usd">107000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTYtMy0xLTEtNTEzMDc_d0fa41e7-3029-4ff9-b20f-955e62651923"
      unitRef="usd">-554000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTctMS0xLTEtNTEzMDc_2d822262-d0f8-4888-832f-2addcb339f57"
      unitRef="usd">-3465000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTctMy0xLTEtNTEzMDc_a66581e0-a786-4689-b065-70e09df55390"
      unitRef="usd">2013000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTgtMS0xLTEtNTEzMDc_411c1c98-0913-49f2-acfe-6b610f866f8e"
      unitRef="usd">12500000</krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment>
    <krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTgtMy0xLTEtNTEzMDc_4da5d988-1e45-45e6-85a3-55609e5d5e6f"
      unitRef="usd">25000000</krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTktMS0xLTEtNTEzMDc_5ea383ca-3189-42cd-89a2-f74e4c4c174a"
      unitRef="usd">-26156000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTktMy0xLTEtNTEzMDc_7181c2c1-9986-4f10-a452-3f7f3019c6f5"
      unitRef="usd">-15493000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMTktMy0xLTEtNTEzMDc_bb1f5e30-bac0-44e7-b9ba-370f8533aedf"
      unitRef="usd">-15493000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjItMS0xLTEtNTEzMDc_2cd3e256-dc2f-497e-b321-61fa0680e326"
      unitRef="usd">5381000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjItMy0xLTEtNTEzMDc_f44aa005-ea36-43df-9c36-6b8157e1c430"
      unitRef="usd">17191000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjMtMS0xLTEtNTEzMDc_7f0e3178-e2c7-4578-9423-b491e88e734f"
      unitRef="usd">145576000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjMtMy0xLTEtNTEzMDc_10d265c0-45db-4e30-8bbc-2e626044379e"
      unitRef="usd">62754000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjQtMS0xLTEtNTEzMDc_7e3b5d5c-69ac-402d-9908-269402eafadd"
      unitRef="usd">154520000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjQtMy0xLTEtNTEzMDc_9e288101-1bf4-4dcc-8579-8d81b3327b32"
      unitRef="usd">24037000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjYtMS0xLTEtNTEzMDc_65973937-5dbd-4579-8099-ad3f0b8a02f8"
      unitRef="usd">3563000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjYtMy0xLTEtNTEzMDc_786c15c7-242d-4c46-8d9d-1ad5b6cc9b67"
      unitRef="usd">-55908000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjktMS0xLTEtNTEzMDc_3eb83b1d-a2b8-42e3-9046-d25a6d3ab549"
      unitRef="usd">2223000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMjktMy0xLTEtNTEzMDc_6468b43d-16c9-4802-926e-20fc12efae8b"
      unitRef="usd">107000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzAtMS0xLTEtNTEzMDc_58f29c6f-25d2-42f3-9da6-f67a4ce5f0e9"
      unitRef="usd">749000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzAtMy0xLTEtNTEzMDc_7ca83459-009d-4366-a11e-68f72a441ab1"
      unitRef="usd">649000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzItMS0xLTEtNTEzMDc_2d57e89a-7553-4751-a695-22c291295d72"
      unitRef="usd">1474000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzItMy0xLTEtNTEzMDc_1e6c2c0b-3d36-4e85-9085-fe24a3d7a0a8"
      unitRef="usd">-542000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzQtMS0xLTEtODEwNzc_636c7f34-ed34-4c0d-a51b-86e7c2f5e1f3"
      unitRef="usd">-36000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzQtMy0xLTEtODE4NjM_25189e8f-b88c-4778-af83-b1adf95287e7"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzQtMS0xLTEtNTEzMDc_2079312a-fd70-4087-adb3-c138c080bcdf"
      unitRef="usd">-21155000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzQtMy0xLTEtNTEzMDc_11f089f8-8904-41c0-8094-97d5ed9f0e5b"
      unitRef="usd">-71943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzYtMS0xLTEtNTEzMDc_8e6f1a0f-2689-4139-89d5-7a2ce8fd5d18"
      unitRef="usd">161900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4d637ac1bef94cb39b5dba2d17d51f98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzYtMy0xLTEtNTEzMDc_7b6d3afa-bd7e-45f0-9abe-9fc1cdf71bf2"
      unitRef="usd">341246000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzctMS0xLTEtNTEzMDc_6cd1ea02-b178-4ad1-b5ef-03b84d74a817"
      unitRef="usd">140745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id93c5ffaa22a4251b0b179d55468758a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfMzctMy0xLTEtNTEzMDc_70d45dad-c789-4fd5-8786-0f027532c13e"
      unitRef="usd">269303000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNDAtMS0xLTEtNTEzMDc_ccd98aeb-e060-42e2-9447-e67c826171b9"
      unitRef="usd">11865000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNDAtMy0xLTEtNTEzMDc_1126a1a9-0f63-4f92-b804-b91790cda07e"
      unitRef="usd">14507000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNDMtMS0xLTEtNzc2Njc_7e03f979-0ac8-44e9-bbeb-0d1279156fbd"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8yNS9mcmFnOmJlYzAzMjk0OWRkNTRiNDRiNzNhZjg0Mjc3MWRiMDA5L3RhYmxlOmVhYjQ4N2EwYTk2NTQ2YTRhMTM0YTA4YTA0ODU5N2JjL3RhYmxlcmFuZ2U6ZWFiNDg3YTBhOTY1NDZhNGExMzRhMDhhMDQ4NTk3YmNfNDMtMy0xLTEtNzc2Njc_04055a3a-5e8b-4d19-a095-9ae730936978"
      unitRef="usd">1394000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zMS9mcmFnOjljZjc0MTdmZDdlMDQzOGNhZmRkYWM3NTcyNTY5YTE5L3RleHRyZWdpb246OWNmNzQxN2ZkN2UwNDM4Y2FmZGRhYzc1NzI1NjlhMTlfMjcxNQ_a31cbe2e-7943-4960-862d-19f10539fffe">Organization&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Krystal Biotech, Inc. (the&#160;&#x201c;Company,&#x201d;&#160;or&#160;&#x201c;we&#x201d;&#160;or other similar pronouns) commenced operations in April 2016. In March 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. In June 2018, the Company incorporated a wholly-owned subsidiary in Australia for the purpose of undertaking preclinical and clinical studies in Australia. In April 2019, the Company incorporated Jeune Aesthetics Inc ("Jeune Aesthetics"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. In January 2022, August 2022, and December 2022, the Company incorporated wholly-owned subsidiaries in Switzerland, Netherlands, and France, respectively, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's product pipeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#x2019;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#x2019;s office or potentially in the patient&#x2019;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale Current Good Manufacturing Practices ("CGMP") manufacturing capabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company had an accumulated deficit of $326.1 million. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#x2019;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through its on hand cash and cash equivalents, the sale of equity, debt financings, and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.&lt;/span&gt;&lt;/div&gt;The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to commercialize product candidates. The Company expects to incur significant costs to expand its commercialization capabilities in advance of the potential global regulatory approvals of its lead product, beremagene geperpavec (&#x201c;B-VEC&#x201d;). The Company believes that its cash, cash equivalents and short-term investments of approximately $350.4 million as of March&#160;31, 2023 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zMS9mcmFnOjljZjc0MTdmZDdlMDQzOGNhZmRkYWM3NTcyNTY5YTE5L3RleHRyZWdpb246OWNmNzQxN2ZkN2UwNDM4Y2FmZGRhYzc1NzI1NjlhMTlfMTIwMA_7d1c2db0-f216-4ec0-ae01-838d5cb1b95d"
      unitRef="usd">-326100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zMS9mcmFnOjljZjc0MTdmZDdlMDQzOGNhZmRkYWM3NTcyNTY5YTE5L3RleHRyZWdpb246OWNmNzQxN2ZkN2UwNDM4Y2FmZGRhYzc1NzI1NjlhMTlfNTQ5NzU1ODE4NDQ5_a4de5d2d-1b1b-4ddd-bc9c-e1f26464d3ef"
      unitRef="usd">350400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0Mzg_d2160ae5-967b-4df7-86c2-07f70df4e403">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022, as filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 27, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of less than one year are classified as short-term investments on the condensed consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the condensed consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on investments is also classified as short-term investments on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the condensed consolidated balance sheets. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest and other income, net, in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s condensed consolidated financial statements, approximate fair value, primarily due to their short maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 financial instruments. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 47 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of useful life or remaining life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress is not depreciated until the asset is placed in service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition.  In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to an amount by which the net book value exceeds the fair value of the asset.  Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company has not identified any triggering events or recognized any impairment losses for the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease liabilities represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its condensed consolidated balance sheets and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain sale-leaseback criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with third-party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ASC, Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 718"), to account for stock-based compensation. Compensation costs related to equity awards granted are based on the estimated fair value of the awards on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense for stock options, restricted stock awards, and restricted stock units is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense for performance-based restricted stock units is recognized for the awards that are probable of vesting over the service period of the award. On a quarterly basis, management estimates the probable number of performance-based restricted stock units that would vest until such time that the ultimate achievement of the performance criteria are known. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates stock price volatility by using its own historical data. The expected term of the Company&#x2019;s stock options is estimated using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We record reclassifications from other comprehensive gains or losses to interest and other income, net on the condensed consolidated statements of operations related to realized gains on sales of available-for-sale securities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its securities quarterly to determine whether an other-than-temporary impairment has occurred. The Company determined that there were no other-than-temporary impairments during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB that the Company adopts as of the specified effective date. There were no recently adopted accounting pronouncements that had a material impact on the Company&#x2019;s condensed consolidated financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDg_04bee15d-322f-49b6-9fe2-b783d218a70e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022, as filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 27, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NTA_4b734a10-9aa7-49b8-a750-bb07bc3b4854">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDQ_0a479ff4-2b6d-4864-9d1b-96f707d505ba">Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMzk1Nw_8ba93aad-0e58-4707-8b6a-59512165925c"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDY_92425d09-f5c1-462f-a370-a98ad89ad8f0">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NTE_20242550-f2fd-4d63-bbc1-1365375e93dc">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of less than one year are classified as short-term investments on the condensed consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the condensed consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on investments is also classified as short-term investments on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the condensed consolidated balance sheets. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest and other income, net, in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDU_24b73128-e110-4e96-95a9-23d1dab9324d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s condensed consolidated financial statements, approximate fair value, primarily due to their short maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of commercial paper, corporate bonds, and U.S. government agency securities are considered to be Level 2 financial instruments. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0Mzk_38ff6f4f-e87f-4c7f-842e-74f436144c85">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 47 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of useful life or remaining life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the estimated useful lives of its property and equipment on a continuing basis. In evaluating the useful lives, the Company considers how long assets will remain functionally effective, whether the technology continues to be relevant and considers other competitive and economic factors. If the assessment indicates that the assets will be used for a shorter or longer period than previously anticipated, the useful life of the assets is adjusted, resulting in a change in estimate. Changes in estimates are accounted for on a prospective basis by depreciating the current carrying values of the assets over their revised remaining useful lives.&lt;/span&gt;&lt;/div&gt;Construction in progress is not depreciated until the asset is placed in service.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <krys:EstimatedUsefulLivesOfAssetsTableTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDc_5deb2460-16dc-4672-830c-62b2ffa4b79f">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 47 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of useful life or remaining life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</krys:EstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3d5858b254a74055947c9db86b18c8a3_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMC0xLTEtMS04MjQwMS90ZXh0cmVnaW9uOjlmNjJiYmRjN2VkYzRiYWI4OTBjMGVmNjk4ODQxOGJhXzU0OTc1NTgxMzkyNw_7fe5cd98-852d-4d1f-ab60-c3ae7f161fd3">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i98497d61c2dc4015859731c29c4a5191_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMC0xLTEtMS04MjQwMS90ZXh0cmVnaW9uOjlmNjJiYmRjN2VkYzRiYWI4OTBjMGVmNjk4ODQxOGJhXzU0OTc1NTgxMzkxNg_4d19d2d1-a8bb-44d2-8408-176eec963d42">P47Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4d5a1d7d6d3b45cc86f55259988312d1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMC0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOmRhYjQ2OWYyNjJhMzQyMTg4OWNhMzk1MTBjYzQyYTcwXzQ_a72cd3a9-10ad-45c5-b5b9-093e0c680e3a">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1ad7d5c593e74fa481f25d0584ed5bb3_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMC0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOmRhYjQ2OWYyNjJhMzQyMTg4OWNhMzk1MTBjYzQyYTcwXzk_be98d1b8-e8f8-46de-9c9d-33266fdf83d0">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iff57f58cd1564684a2781fa990333e72_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMi0xLTEtMS04NTE4Ny90ZXh0cmVnaW9uOmZhZTYyZmUzMjhkNTQxNGJhYTNmN2MwMzU3Y2I5MmFkXzU0OTc1NTgxMzg5Mg_371c3721-765b-4217-98e9-f71cf0db6e4d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i96507c2336ed410dba27455fd3d47784_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMi0xLTEtMS04NTE4Ny90ZXh0cmVnaW9uOmZhZTYyZmUzMjhkNTQxNGJhYTNmN2MwMzU3Y2I5MmFkXzU0OTc1NTgxMzg5Ng_98570ac0-38f5-4720-9c63-d84604a0b5e4">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iab72ff6d793d4c95b00695f6313daf97_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMS0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOmMwNWE4ODFkNmIzMjQ2ZDRhNGRkOGY5N2M1M2M1OTA5XzQ_4cfaa986-f7f4-44fd-9a06-0324261e440d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4634ec644b074dc2a73fb4d688425c09_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMS0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOmMwNWE4ODFkNmIzMjQ2ZDRhNGRkOGY5N2M1M2M1OTA5Xzk_03c01a90-4016-4722-9428-8ca609038913">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3a98446c7d2a422cb8484c551d8569e1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMi0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOjdkNWYwOGZhZjlkNzQ3OWZiZGY3ODU2N2VhMzUyMTdmXzQ_a8747b76-f0fe-4001-a94f-03868739f3bb">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7c577603e2e64c98b5ecf7704120a266_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RhYmxlOmRiMmQxZTA0N2QzNTQxZjE4YWZhNWRjMTljZjVjZGQ2L3RhYmxlcmFuZ2U6ZGIyZDFlMDQ3ZDM1NDFmMThhZmE1ZGMxOWNmNWNkZDZfMi0xLTEtMS01MTMwNy90ZXh0cmVnaW9uOjdkNWYwOGZhZjlkNzQ3OWZiZGY3ODU2N2VhMzUyMTdmXzk_f8a472e5-98ff-4ada-ab4a-c6fb862b9443">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0MzY_859515ab-7a9d-42b5-95dc-93806c02167c">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. We review the recoverability of the net book value of long-lived assets whenever events and circumstances indicate ("triggering events") that the net book value of an asset may not be recoverable from the estimated undiscounted future cash flows expected to result from its use and eventual disposition.  In cases where a triggering event occurs and undiscounted expected future cash flows are less than the net book value, we recognize an impairment loss equal to an amount by which the net book value exceeds the fair value of the asset.  Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. The Company has not identified any triggering events or recognized any impairment losses for the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ib56d0e98532345689136cfae336cfbd6_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTA5ODY_6e5cb831-0317-4d59-bd5d-7ad873a4d301"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="iacdb4dc62a9b4428bdc804b7838f7fdc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTA5ODY_82f448a3-5f35-4b97-b3ae-e55c149d27ab"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0Mzc_3d3cea22-c2de-4849-b54a-25e25c889f51">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease liabilities represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s existing lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its condensed consolidated balance sheets and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain sale-leaseback criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDA_83f21c49-8f45-401a-a3ca-2026d8bb6ffa">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with third-party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDE_633aba07-2846-4ec6-9d5f-cf002456ab18">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification, or ASC, Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 718"), to account for stock-based compensation. Compensation costs related to equity awards granted are based on the estimated fair value of the awards on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense for stock options, restricted stock awards, and restricted stock units is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense for performance-based restricted stock units is recognized for the awards that are probable of vesting over the service period of the award. On a quarterly basis, management estimates the probable number of performance-based restricted stock units that would vest until such time that the ultimate achievement of the performance criteria are known. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates stock price volatility by using its own historical data. The expected term of the Company&#x2019;s stock options is estimated using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect &lt;/span&gt;&lt;/div&gt;to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDI_b1181981-648d-4ea6-ab54-19097804a449">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We record reclassifications from other comprehensive gains or losses to interest and other income, net on the condensed consolidated statements of operations related to realized gains on sales of available-for-sale securities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its securities quarterly to determine whether an other-than-temporary impairment has occurred. The Company determined that there were no other-than-temporary impairments during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNC9mcmFnOjlhZTlmYTViOWMyMjRiOWFhMzgwOTQwMTMwZTVjNDViL3RleHRyZWdpb246OWFlOWZhNWI5YzIyNGI5YWEzODA5NDAxMzBlNWM0NWJfMTc0NDM_a9eb8dc0-9957-41bc-b866-ff02d420a8e6">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB that the Company adopts as of the specified effective date. There were no recently adopted accounting pronouncements that had a material impact on the Company&#x2019;s condensed consolidated financial statements, and no recently issued accounting pronouncements that are expected to have a material impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RleHRyZWdpb246MDE4NzZjYjFmYmVkNGRjNmFiMzkxMDU3NWZhYTg2MzlfOTU4_3a77733b-c936-4309-8271-661b460b6539">Net Loss Per Share Attributable to Common Stockholders&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,829,535 and 3,226,962 common share equivalents outstanding as of March&#160;31, 2023 and 2022, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160; diluted common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,712,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,114,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per&lt;br/&gt;&#160;&#160; common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RleHRyZWdpb246MDE4NzZjYjFmYmVkNGRjNmFiMzkxMDU3NWZhYTg2MzlfNjYz_cf7f74c7-8b1d-4e64-911e-2190cde3dc58"
      unitRef="shares">3829535</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RleHRyZWdpb246MDE4NzZjYjFmYmVkNGRjNmFiMzkxMDU3NWZhYTg2MzlfNjcw_d73ac615-41f1-4105-a766-7067c7e6fc59"
      unitRef="shares">3226962</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RleHRyZWdpb246MDE4NzZjYjFmYmVkNGRjNmFiMzkxMDU3NWZhYTg2MzlfOTU5_7fbb6e88-09b9-4ecc-a795-bfa4853f9287">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160; diluted common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,712,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,114,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per&lt;br/&gt;&#160;&#160; common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNC0xLTEtMS01MTMwNw_e8179e0a-c0ca-410c-ae91-ddaecef135c0"
      unitRef="usd">-45297000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNC0zLTEtMS01MTMwNw_f0635654-2e79-4752-8814-0d5a43a02aaa"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNi0xLTEtMS01MTMwNw_692beee2-ba12-4681-b310-16afc01c5e46"
      unitRef="shares">25712220</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNi0xLTEtMS01MTMwNw_f2e413e0-70b2-4c21-9383-dd44b154d77a"
      unitRef="shares">25712220</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNi0zLTEtMS01MTMwNw_37f821fb-f040-4864-9566-4dcf4a8e58b5"
      unitRef="shares">25114453</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNi0zLTEtMS01MTMwNw_7017b58b-2e80-4783-af81-73d3f754e596"
      unitRef="shares">25114453</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNy0xLTEtMS01MTMwNw_30c32ccb-7e44-4cd5-9a62-a416b611495c"
      unitRef="usdPerShare">-1.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNy0xLTEtMS01MTMwNw_7420f32c-3557-4b00-b509-cf26d98bc851"
      unitRef="usdPerShare">-1.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNy0zLTEtMS01MTMwNw_220675fd-c4e5-496e-bf52-08bdf081b989"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF8zNy9mcmFnOjAxODc2Y2IxZmJlZDRkYzZhYjM5MTA1NzVmYWE4NjM5L3RhYmxlOjAwZDJiN2Y4YjlkNTRiZDhiNjJlNjI0YjFjYjVjNGNmL3RhYmxlcmFuZ2U6MDBkMmI3ZjhiOWQ1NGJkOGI2MmU2MjRiMWNiNWM0Y2ZfNy0zLTEtMS01MTMwNw_be8b50a4-7a31-4599-b7f9-853ac107decb"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RleHRyZWdpb246MWU0NDhlNTgwNjc0NDBlNjkzMjUxMDkxZDYzMmQ4NGNfNTA0_e356d8bb-626e-453e-bf34-248dfc1dbfac">Fair Value Instruments&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of March&#160;31, 2023 and December&#160;31, 2022, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;384,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company's long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#x2019;s fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RleHRyZWdpb246MWU0NDhlNTgwNjc0NDBlNjkzMjUxMDkxZDYzMmQ4NGNfNTA1_fa02d024-8790-48cb-b66f-d07d53794cdd">&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of March&#160;31, 2023 and December&#160;31, 2022, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;384,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The Company's long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i254b57e74219457a9976070bb3f01cca_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNC0xLTEtMS01MTMwNw_1f0446c3-f103-4b6b-ba42-918f4886361f"
      unitRef="usd">140745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i254b57e74219457a9976070bb3f01cca_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNC03LTEtMS01MTMwNw_d93d1687-f2eb-466e-869e-99d49e7f523b"
      unitRef="usd">140745000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia4bcbb3bbdfb443c9dc1d6277b193724_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNC05LTEtMS01MTMwNw_01f63e93-6b45-4f70-8b61-8771e53e6248"
      unitRef="usd">140745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i93a24294ea254807b3a01f15a488820e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNS0xLTEtMS01MTMwNw_183efadb-dcd1-4814-9cf2-162451da2c62"
      unitRef="usd">140745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i93a24294ea254807b3a01f15a488820e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNS03LTEtMS01MTMwNw_3556263a-a31e-49cd-9033-7e2cbc23ae69"
      unitRef="usd">140745000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia679ddbe0c9148b596ce5d22d0a1c72d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfNS05LTEtMS01MTMwNw_3c8726da-bb68-40f4-9dd7-264347f9730d"
      unitRef="usd">140745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie55cf1b68f5343cd983d4229a5bf466c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC0xLTEtMS01MTMwNw_5477e92b-7440-4889-bbd0-d6c48f96119a"
      unitRef="usd">97442000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie55cf1b68f5343cd983d4229a5bf466c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC0zLTEtMS01MTMwNw_5f82dc18-d253-4879-9484-496ebe5180a3"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie55cf1b68f5343cd983d4229a5bf466c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC01LTEtMS01MTMwNw_218cf31c-52e6-4135-9b18-a0b94804e230"
      unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie55cf1b68f5343cd983d4229a5bf466c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC03LTEtMS01MTMwNw_52561489-cd5c-43f0-af7b-3a43a3568752"
      unitRef="usd">97431000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia810a7f2836b4a4c8b9329aa2c255208_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC0xMS0xLTEtNTEzMDc_421d355c-4d16-42e6-a980-d5ffa589f8ce"
      unitRef="usd">97431000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8cd9dad418b8488cb10071f2be3a4912_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOC0xMy0xLTEtNTEzMDc_17bdaf8c-81ab-4317-9749-9abe86325124"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia0bea5cf40f844f38d74969a8559b2c5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS0xLTEtMS01MTMwNw_d3b0a28c-9bfe-4fed-a206-f9845b9d1326"
      unitRef="usd">49573000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia0bea5cf40f844f38d74969a8559b2c5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS0zLTEtMS01MTMwNw_97540618-74a2-427f-aaf5-6b2899ba8c66"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia0bea5cf40f844f38d74969a8559b2c5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS01LTEtMS01MTMwNw_ac41b602-fc9d-486a-9cd9-572344012a47"
      unitRef="usd">106000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia0bea5cf40f844f38d74969a8559b2c5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS03LTEtMS01MTMwNw_64ec3f1c-9c6c-4c2e-a235-d15e8280f432"
      unitRef="usd">49506000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i199b309fe28245b5b261791cfe807797_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS0xMS0xLTEtNTEzMDc_e22d542f-89d6-4f48-8308-cbe6fc939105"
      unitRef="usd">45344000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i821aef589ece4731b6e9f4ebc1acba43_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfOS0xMy0xLTEtNTEzMDc_7b8d4aab-d2a8-4c90-9d4f-df658ba025fc"
      unitRef="usd">4162000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia170328c9e7e4a0ca886658a03a5bf79_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtMS0xLTEtNTEzMDc_dd4f4943-8cf0-44ce-a3fc-0cb2bd958d62"
      unitRef="usd">67803000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia170328c9e7e4a0ca886658a03a5bf79_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtMy0xLTEtNTEzMDc_0b0b1ac8-a231-4fb7-8591-d9654fd8ce33"
      unitRef="usd">221000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia170328c9e7e4a0ca886658a03a5bf79_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtNS0xLTEtNTEzMDc_53356420-285c-4525-bf51-a5ae20996485"
      unitRef="usd">190000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia170328c9e7e4a0ca886658a03a5bf79_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtNy0xLTEtNTEzMDc_111eebb3-8d26-4612-b486-df431a7e5885"
      unitRef="usd">67834000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6f5f311477c243739da11f1d6cf25133_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtMTEtMS0xLTUxMzA3_0515fd53-96ae-4336-a9bf-e90b59759d8c"
      unitRef="usd">66867000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e4f7f10a1f943dba2eb0d494342e180_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTAtMTMtMS0xLTUxMzA3_a6b228e9-ca7f-45ca-a58e-476cdc8105a0"
      unitRef="usd">967000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i25bc3c11b7b447f38c5ac9085cb16011_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtMS0xLTEtNTEzMDc_fb53f1d6-7177-401b-8483-0909362929ee"
      unitRef="usd">214818000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i25bc3c11b7b447f38c5ac9085cb16011_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtMy0xLTEtNTEzMDc_eef0742a-49ca-48ca-85dc-ca145d125a4a"
      unitRef="usd">267000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i25bc3c11b7b447f38c5ac9085cb16011_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtNS0xLTEtNTEzMDc_7c2568c1-5e16-43d8-b70a-f29908ac6083"
      unitRef="usd">314000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25bc3c11b7b447f38c5ac9085cb16011_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtNy0xLTEtNTEzMDc_7766aefe-6d04-4e97-844a-64ac50274eab"
      unitRef="usd">214771000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7dabfb39094405ea129e230c5fea918_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtMTEtMS0xLTUxMzA3_57bbc433-a52d-4cca-a212-8d825192080e"
      unitRef="usd">209642000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idc0dea8cd85c4b10a8ca0270bc96ca37_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTEtMTMtMS0xLTUxMzA3_b3c762ca-3240-45cf-86d6-9835e188fc05"
      unitRef="usd">5129000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItMS0xLTEtNTEzMDc_217083aa-0fe7-46bb-971d-75735dda77ca"
      unitRef="usd">355563000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItMy0xLTEtNTEzMDc_b7cdda35-d50f-40ee-9d1a-8e89482b60ea"
      unitRef="usd">267000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItNS0xLTEtNTEzMDc_eaae2bec-3872-40d1-914a-9af7c5ecf2c3"
      unitRef="usd">314000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItNy0xLTEtNTEzMDc_baea3687-902d-42e6-b311-d52bc435fa50"
      unitRef="usd">355516000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i9db97cf4a1ee43798607ccb440a0c691_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItOS0xLTEtNTEzMDc_9b10f525-0300-4758-9cc5-a2e7634fa7bb"
      unitRef="usd">140745000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i19390a3c5c074f8cb033de62ea4926ba_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItMTEtMS0xLTUxMzA3_289912e3-8b37-4923-b6e2-855955b8c389"
      unitRef="usd">209642000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i955d93f6b8e8480aac09b577bc03fd18_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjZlNzdhNzJiNTg0YTQ4OTVhNjIzMDJkYzJiNDhiOWU5L3RhYmxlcmFuZ2U6NmU3N2E3MmI1ODRhNDg5NWE2MjMwMmRjMmI0OGI5ZTlfMTItMTMtMS0xLTUxMzA3_81573c19-452b-4f36-857e-2dd0d2d9a739"
      unitRef="usd">5129000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4a9e54233c0c409fbb144f9054234dc7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMy0xLTEtMS01MTMwNw_b57954cd-667c-4202-b092-0ecf86bc1a42"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4a9e54233c0c409fbb144f9054234dc7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMy03LTEtMS01MTMwNw_be00766c-e852-4364-ab1e-cccda38d8c97"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3253f0426d1b464d823eff67b81326d7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMy05LTEtMS01MTMwNw_b4b0b54e-1c91-45cd-bac7-95b9ad50fee2"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iabfee1fcc75f4f5cb247fc8dcaa4469f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNS0xLTEtMS01MTMwNw_3c03e55a-19ba-41b3-a45a-2be35ae4f5c4"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iabfee1fcc75f4f5cb247fc8dcaa4469f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNS03LTEtMS01MTMwNw_34399be3-8efb-4314-b1e0-79e63214ae08"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibd001999a79b40e58c92b5976170c12c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNS05LTEtMS01MTMwNw_51011ffb-bfd9-4374-a04b-c89d8e2cdfbf"
      unitRef="usd">161900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i558055bb178d47cf8d6907260c65860d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy0xLTEtMS01MTMwNw_8e98d7c6-4bc3-428f-8879-2223c37e3f1e"
      unitRef="usd">63624000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i558055bb178d47cf8d6907260c65860d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy0zLTEtMS01MTMwNw_31b15f3c-6b62-4db5-9591-2af768f51701"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i558055bb178d47cf8d6907260c65860d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy01LTEtMS01MTMwNw_0e28fb19-07c2-4d82-8e64-e2db2561405b"
      unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i558055bb178d47cf8d6907260c65860d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy03LTEtMS01MTMwNw_d433e627-32eb-4296-96df-7d0370b19cdd"
      unitRef="usd">63606000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i848d726cc7ea4e92bb8c216498e171d6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy0xMS0xLTEtNTEzMDc_e723e8fd-5d67-4449-a293-9ea09b7a6d98"
      unitRef="usd">63606000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i708d874019134729a370416147542b1e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfNy0xMy0xLTEtNTEzMDc_c7bee97f-c38f-4be3-b648-fa181460e127"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if91c8903d66e47ed89c8a8a928e0ad19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC0xLTEtMS01MTMwNw_f734869f-e106-4697-8a3c-243785f03758"
      unitRef="usd">82241000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if91c8903d66e47ed89c8a8a928e0ad19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC0zLTEtMS01MTMwNw_3455c190-3f5e-4a01-9bcf-25b986caf8b6"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if91c8903d66e47ed89c8a8a928e0ad19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC01LTEtMS01MTMwNw_fdfc340b-7d63-4c0e-b990-5469c9c5059c"
      unitRef="usd">419000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if91c8903d66e47ed89c8a8a928e0ad19_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC03LTEtMS01MTMwNw_b7c8ba08-090c-4633-947b-bb493164a368"
      unitRef="usd">81835000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i04d0048badcd4c6aa1082f735dda5fa5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC0xMS0xLTEtNTEzMDc_7fc3bb8e-20fc-432b-843d-444c90e8b424"
      unitRef="usd">77214000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4fd54f5b9a434b3b9b37bebfcedd8570_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOC0xMy0xLTEtNTEzMDc_d4660052-f0f5-4e57-be11-8c1c4dbb3bf6"
      unitRef="usd">4621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i54381d9b7697447d972984381f5addb6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS0xLTEtMS01MTMwNw_b8ada7a6-137e-4683-85a2-aaab5c14462c"
      unitRef="usd">76683000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i54381d9b7697447d972984381f5addb6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS0zLTEtMS01MTMwNw_9c4a037d-1648-4d9f-b351-8fdd3a90e2e6"
      unitRef="usd">161000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i54381d9b7697447d972984381f5addb6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS01LTEtMS01MTMwNw_10aead66-8f8f-49e8-9d1b-a32cb6207663"
      unitRef="usd">393000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i54381d9b7697447d972984381f5addb6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS03LTEtMS01MTMwNw_c7884a85-1bcb-483d-981e-f1262f7ecdc9"
      unitRef="usd">76451000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfe9d0765d4040a88c16e531654af652_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS0xMS0xLTEtNTEzMDc_4ae680f0-1549-4eb6-bfe8-bd5430cfaf10"
      unitRef="usd">76451000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4dad77b16170425f951687a001a58cf7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfOS0xMy0xLTEtNTEzMDc_3c34d47f-e2a0-4003-b61e-18aa250f946f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie09632b1d13f447d83cab24d09f19673_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtMS0xLTEtNTEzMDc_99d0c699-97e7-4219-a489-d3ed49ea5d15"
      unitRef="usd">222548000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie09632b1d13f447d83cab24d09f19673_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtMy0xLTEtNTEzMDc_b49f94f0-ccb5-499e-bf3b-e6b6ee9f3bde"
      unitRef="usd">179000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie09632b1d13f447d83cab24d09f19673_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtNS0xLTEtNTEzMDc_430eec76-6958-4601-b4aa-7dd31b647144"
      unitRef="usd">835000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie09632b1d13f447d83cab24d09f19673_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtNy0xLTEtNTEzMDc_2c6e489d-cd62-4c6b-9681-45d48843863f"
      unitRef="usd">221892000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i36bffbb608004cf7bd1c29662284954f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtMTEtMS0xLTUxMzA3_a9908fc8-b037-473f-8ed6-ee544b027e3b"
      unitRef="usd">217271000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1642cf0b875e42d18be7877570ce84d9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTMtMTMtMS0xLTUxMzA3_c5f3cf68-d2ae-4e83-bb90-3af48bd16a70"
      unitRef="usd">4621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtMS0xLTEtNTEzMDc_ce3e4ad1-97d8-4bac-a879-dea798f64234"
      unitRef="usd">384448000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtMy0xLTEtNTEzMDc_956859cf-4f22-4f8f-98eb-e89777c1ae7a"
      unitRef="usd">179000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtNS0xLTEtNTEzMDc_d72d532a-9d87-4784-a748-acdd7b243231"
      unitRef="usd">835000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtNy0xLTEtNTEzMDc_d90424e5-f8e2-486a-94c5-7b568cd83615"
      unitRef="usd">383792000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="id90668d113b34bf0b03c32cdd534454d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtOS0xLTEtNTEzMDc_330f3e15-7950-4416-b3bc-6fa4412c2504"
      unitRef="usd">161900000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i26fb1563e4c745bcb1ecf87c332f3971_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtMTEtMS0xLTUxMzA3_7d05d51c-ba93-45ff-89c5-c5b206b71be2"
      unitRef="usd">217271000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i4b41653db9f6419aab13fd18aaffc538_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RhYmxlOjdlM2U3ZDJlYTg5NDQ2ZTY5ODM5MTA2YmRlMjc2NzA4L3RhYmxlcmFuZ2U6N2UzZTdkMmVhODk0NDZlNjk4MzkxMDZiZGUyNzY3MDhfMTQtMTMtMS0xLTUxMzA3_7a2d3cc8-4fe0-4537-9d4c-597ac697e8ac"
      unitRef="usd">4621000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ib7dabfb39094405ea129e230c5fea918_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RleHRyZWdpb246MWU0NDhlNTgwNjc0NDBlNjkzMjUxMDkxZDYzMmQ4NGNfMjcz_060d0e53-60fb-4a4e-a3ae-99e749e8a490">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="id9e884919c2f4f82a2242d01a6e29dba_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RleHRyZWdpb246MWU0NDhlNTgwNjc0NDBlNjkzMjUxMDkxZDYzMmQ4NGNfMzQ2_3ca4f886-2f1f-4009-8329-3f74c2264ee6">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i63f3f336a5e844e5b596e41d4095f2d6_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80MC9mcmFnOjFlNDQ4ZTU4MDY3NDQwZTY5MzI1MTA5MWQ2MzJkODRjL3RleHRyZWdpb246MWU0NDhlNTgwNjc0NDBlNjkzMjUxMDkxZDYzMmQ4NGNfMzUz_35d59bc9-ee11-4ff3-8930-174de46cf13f">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RleHRyZWdpb246MmE2YmI4M2I1ZGZiNDQ5NTgxMzkyNDNlYjUzYTQ1ZTdfMzg4_877e001e-6184-4cfb-8e85-4841cd288eab">Balance Sheet Components&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $1.1 million and $462 thousand for the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company placed a portion of its second commercial scale CGMP facility, ASTRA, into service during the three months ended March&#160;31, 2023 as it was determined that certain assets were ready for their intended use. On March 27, 2023, the Company received the permanent occupancy permit for ASTRA which allowed the Company to begin utilizing certain portions of the building.  As a result, assets relating to ASTRA were reclassified from construction in progress to leasehold improvements, manufacturing equipment, buildings and building improvements, furniture and fixtures, or computer equipment and software as of March&#160;31, 2023. As certain building improvements are not yet complete and certain qualification activities are still underway, the Company will continue to hold the remaining assets within construction in progress until validation has been completed and the assets are ready for their intended use. Validation of the facility is expected to be completed in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RleHRyZWdpb246MmE2YmI4M2I1ZGZiNDQ5NTgxMzkyNDNlYjUzYTQ1ZTdfMzg5_e79b1149-e13d-4174-b37c-b05fc299987c">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3336d8df96f44c03b0edde5a7b3f3f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfMi0xLTEtMS01MTMwNw_243afc9e-333c-4485-97de-bb0c21a45147"
      unitRef="usd">122935000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2e13fb41138141a8a45f22e1363c6694_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfMi0zLTEtMS01MTMwNw_51893789-dcaa-446d-a5ab-6fb4704e3181"
      unitRef="usd">131331000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i95624b73ce524801a03f62c6d6488c4d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfMy0xLTEtMS01MTMwNw_e6169e47-92c6-4daa-bc6c-3e06cbf80d35"
      unitRef="usd">24442000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i70f55b22e3c64c36aa9d32e22506ddb0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfMy0zLTEtMS01MTMwNw_18c329ee-6195-420a-8106-6170081e80b4"
      unitRef="usd">24217000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib70c320c8793401f8ad427840ed747f4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNS0xLTEtMS04Njk4OA_523946e7-3dd0-4e2b-8eef-08cd970cf461"
      unitRef="usd">10236000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib7c0541a8fd74c0fab5d9a8c2a1fb295_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNS0zLTEtMS04Njk4OA_91c1ccf2-33ba-4350-b671-f11c0233124a"
      unitRef="usd">9783000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib1679847f2284f818043b46f19f6d0fe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNi0xLTEtMS04NzUxOA_da84b89d-9391-4052-8f7a-05a75c157d08"
      unitRef="usd">9736000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibf9eb878f8f5476899e4bdc1684dbc88_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNi0zLTEtMS04NzUxOA_cd99d24e-e637-4b34-88ae-63a15d923c80"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifc7771852e944942a97a47f105d3ddb4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNi0xLTEtMS04MzY1Mg_8a1a7806-41c1-4017-8965-94b9225a375e"
      unitRef="usd">2108000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie1402d218b7f411a89c2d0a991370111_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNi0zLTEtMS04MzY1Mg_7f1673b3-746f-4a9d-ac5d-5ae9d3a95b3d"
      unitRef="usd">2089000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib5c4f65d06694451b7c17b1d48fc362e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNC0xLTEtMS01MTMwNw_7c8fb942-84f3-43c8-b1d5-3149f4860dff"
      unitRef="usd">1164000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icc58ce8deb464b0999c8eba8a23d5170_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNC0zLTEtMS01MTMwNw_d9c74e94-7f8e-42ce-aeaa-e87309a4056e"
      unitRef="usd">957000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6c8785f3fae3400a93aa066e59ff0830_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNS0xLTEtMS01MTMwNw_8eb4bb43-a175-4a27-9dbc-ee5d75d23d26"
      unitRef="usd">338000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i788e335dd01542c6877956cecd45ef64_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNS0zLTEtMS01MTMwNw_31bf68b4-2e2a-4dc0-8a33-09082c217693"
      unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNy0xLTEtMS01MTMwNw_0a1afe49-e32e-483f-9511-dbbcda2f35ce"
      unitRef="usd">170959000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfNy0zLTEtMS01MTMwNw_61a01b18-7e98-42e2-aed9-b16550739a43"
      unitRef="usd">168477000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfOC0xLTEtMS01MTMwNw_917f1619-5eb1-410e-b8f0-c5870ef0ac82"
      unitRef="usd">7886000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfOC0zLTEtMS01MTMwNw_03adbfc2-9592-4aaa-b3d4-9e9c2695ac24"
      unitRef="usd">6793000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfOS0xLTEtMS01MTMwNw_27bef250-fd5e-4473-84af-cdb0046d441b"
      unitRef="usd">163073000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOmIyYWY0YWZhYjYyYzQxYTU4NjJmNTM2ZWY3YTQyYjBkL3RhYmxlcmFuZ2U6YjJhZjRhZmFiNjJjNDFhNTg2MmY1MzZlZjdhNDJiMGRfOS0zLTEtMS01MTMwNw_fa1d34ed-21c0-4cfc-ab12-a00f29080e34"
      unitRef="usd">161684000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RleHRyZWdpb246MmE2YmI4M2I1ZGZiNDQ5NTgxMzkyNDNlYjUzYTQ1ZTdfMTU3_c86af8ed-c7e3-4369-883a-5fa34250a0af"
      unitRef="usd">1100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RleHRyZWdpb246MmE2YmI4M2I1ZGZiNDQ5NTgxMzkyNDNlYjUzYTQ1ZTdfNTQ5NzU1ODE0MzA1_f16bc821-f913-4b02-8506-abdb422abf96"
      unitRef="usd">462000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RleHRyZWdpb246MmE2YmI4M2I1ZGZiNDQ5NTgxMzkyNDNlYjUzYTQ1ZTdfMzg3_5243e101-d9a4-4a3d-90f4-be4006e49c97">&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:LitigationReserveCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMy0xLTEtMS04Mjc5OA_b969d587-1da4-4099-921c-0f4538bbdf85"
      unitRef="usd">12500000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMy0zLTEtMS04Mjc5OA_bd6a186f-a086-441d-bafe-2a54c911eafc"
      unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <krys:AccruedConstructionInProgressCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMi0xLTEtMS01MTMwNw_88aa61f0-da27-48a8-9a0d-13b98253416c"
      unitRef="usd">8407000</krys:AccruedConstructionInProgressCurrent>
    <krys:AccruedConstructionInProgressCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMi0zLTEtMS01MTMwNw_2be75908-8a05-4a17-93ac-bbf603fb3e1f"
      unitRef="usd">11452000</krys:AccruedConstructionInProgressCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMy0xLTEtMS01MTMwNw_8c5ab509-ceb8-4cde-842f-64114ba79c2f"
      unitRef="usd">3839000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMy0zLTEtMS01MTMwNw_5c56b3c8-65ad-4605-bbc6-95267b70b0f9"
      unitRef="usd">3397000</us-gaap:AccruedProfessionalFeesCurrent>
    <krys:AccruedPayrollAndBenefits
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNC0xLTEtMS01MTMwNw_77443f8d-0cbe-4fd2-a760-5e50c06587ce"
      unitRef="usd">2661000</krys:AccruedPayrollAndBenefits>
    <krys:AccruedPayrollAndBenefits
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNC0zLTEtMS01MTMwNw_ed38fb8e-32a0-41d7-b8f9-16f54cb0f61e"
      unitRef="usd">6781000</krys:AccruedPayrollAndBenefits>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNS0xLTEtMS01MTMwNw_a39f1aa7-2732-445d-bb2e-f1160d1fe5be"
      unitRef="usd">1635000</krys:AccruedPreclinicalAndClinicalExpenses>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNS0zLTEtMS01MTMwNw_2fbb1963-862e-4b68-a424-2bbc788c71c8"
      unitRef="usd">1365000</krys:AccruedPreclinicalAndClinicalExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNy0xLTEtMS01MTMwNw_56525cb5-09b2-4e2e-9d68-077be725adf6"
      unitRef="usd">321000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfNy0zLTEtMS01MTMwNw_603cf2f8-c3f6-496d-8fdf-41d094f89cf6"
      unitRef="usd">267000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxes
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfOC0xLTEtMS01MTMwNw_8749498e-8922-443a-a461-08baf651ff45"
      unitRef="usd">51000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:AccruedIncomeTaxes
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfOC0zLTEtMS01MTMwNw_19574c77-14a7-4218-8110-fd59ea4d34d6"
      unitRef="usd">43000</us-gaap:AccruedIncomeTaxes>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMTAtMS0xLTEtNTEzMDc_1a6f517e-2580-417c-afe2-8f073e07447a"
      unitRef="usd">29414000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80My9mcmFnOjJhNmJiODNiNWRmYjQ0OTU4MTM5MjQzZWI1M2E0NWU3L3RhYmxlOjAyZjgzMzgyOWZiNTQzNjk5N2JlOTFkZWI0ZDk4N2JiL3RhYmxlcmFuZ2U6MDJmODMzODI5ZmI1NDM2OTk3YmU5MWRlYjRkOTg3YmJfMTAtMy0xLTEtNTEzMDc_59421324-ba83-407f-b6cf-0adf4ea6ae86"
      unitRef="usd">23305000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzcxNDY4MjU1OTY2NjY_ee617311-0de2-4004-8745-0c2e7218579c">Commitments and Contingencies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Agreements with Contract Research Organizations and Contract Manufacturing Organizations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs primarily relate to the manufacturing of our cell and virus banks and for the manufacturing of our sterile gel that is mixed with in-house produced vectors as part of the final drug product for B-VEC. Agreements with third parties may also include research and development consulting activities, clinical-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;trial agreements, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage or pre-commercial products. The Company is obligated to make milestone payments under certain of these contracts. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The estimated remaining commitment as of March&#160;31, 2023 under these agreements is approximately $2.0 million. The Company has incurred research and development expenses under these agreements of $2.0 million and $1.8 million for the three months ended March&#160;31, 2023 and  2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASTRA Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracted with various third parties to complete the interior build-out of our second CGMP facility, ASTRA. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of March&#160;31, 2023 is $11.9 million and primarily relates to the remaining building improvements and certain qualification activities of the facility. The Company has included costs incurred to-date associated with the ongoing build-out of ASTRA within construction in progress. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023, Substantial Completion, as defined in the Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (the &#x201c;Agreement&#x201d;) with Whiting-Turner Contracting Company (&#x201c;Whiting-Turner&#x201d;), the construction manager for ASTRA, had not been achieved. Whiting-Turner&#x2019;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#x2019;s work under the Agreement may not equate to the date of completion of ASTRA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen&#x2019;s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, the Company entered into a binding term sheet to settle the dispute.  On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.  Upon approval of the Company's first product by the U.S. Food and Drug Administration, the Company will pay PeriphaGen an additional $12.5&#160;million, followed by three additional $12.5&#160;million contingent milestone payments upon reaching $100.0&#160;million in total cumulative sales, $200.0&#160;million in total cumulative sales and $300.0&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of the Company products by the Company and its affiliates and licensees, as reported by the Company in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the upfront settlement payment of $25.0&#160;million under litigation settlement expense on the condensed consolidated statements of operations for the three months ended March&#160;31, 2022. In accordance with ASC Topic 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has determined that FDA approval of B-VEC is now probable, and accordingly has accrued for an additional $12.5&#160;million litigation settlement liability as of March&#160;31, 2023. The remaining contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of March&#160;31, 2023, and therefore no additional accrual has been recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received $0 and $768&#160;thousand of insurance proceeds during the three months ended March&#160;31, 2023 and 2022, respectively. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <krys:RemainingCommitmentAmount
      contextRef="iaa1cfbf80d374c378d2f9b338ebb5deb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzkwMw_009b3332-9e79-4b17-9fc4-546877249fdd"
      unitRef="usd">2000000</krys:RemainingCommitmentAmount>
    <us-gaap:ProfessionalFees
      contextRef="i77d7d7ecd78845e5bd5596242784b33d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzExMTM_c5cbb135-24fc-4877-944d-42dde3e6fc8f"
      unitRef="usd">2000000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="ifc4c065296114490bb18d3287e10eee4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU0OTc1NTgyMjI2MA_f1b322f7-5520-4106-9403-1a686996afa1"
      unitRef="usd">1800000</us-gaap:ProfessionalFees>
    <us-gaap:ContractualObligation
      contextRef="i59d538d178644369ac955f83b6d3c6cb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzIyMzM_1ab1d652-8721-406e-a5e0-8c3fbedb6286"
      unitRef="usd">11900000</us-gaap:ContractualObligation>
    <us-gaap:LitigationSettlementExpense
      contextRef="ic7ccbd4c24004f7c9a76c78c77580c61_D20220428-20220428"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU0NTY_df51a786-b483-4002-beea-7bfd4432fbd5"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i38665521367949c5a5b7b6f4a45a6367_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU4MjU_6ff2f47e-dc7f-407f-bfaf-39021497db41"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <krys:NumberOfMilestones
      contextRef="i38665521367949c5a5b7b6f4a45a6367_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU4NDE_377fb2ee-eaa8-451f-893f-c683700e977c"
      unitRef="milestone">3</krys:NumberOfMilestones>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i3a63fc072ee84250a08db24153192cce_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU4NTU_34a37769-6de7-4a00-a4ed-faebbca5bf3b"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="iac262c9c6f0f403486081e497b2c7281_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU4NTU_3c573956-1f7d-494e-ab40-737ac53500aa"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i4243169cc3fd4a5b9a86b7ea453f05f5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU4NTU_9c098b6a-3ca8-4489-b966-5c3d9052ac0a"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="i34cbc871f0d741f2a78e2f78568df717_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU5MDI_55457818-260a-4790-b7b6-b56567f2f791"
      unitRef="usd">100000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="iaa962a4885f645e19feb14d38de37c30_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU5MzI_17d455d5-a050-4c1c-a85b-da36db39ebca"
      unitRef="usd">200000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="i450e68ee6678498fa0a8d69ede89d91d_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU5NjU_293c9aec-e720-4b87-9a4a-6b32e4418431"
      unitRef="usd">300000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementTotalConsideration
      contextRef="id69a8a353b3642439f10c5a61f8f2f64_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzYzODA_d9c5f5a2-1920-4ef1-8eb9-a7de4fe221d7"
      unitRef="usd">75000000</krys:LitigationSettlementTotalConsideration>
    <us-gaap:LitigationSettlementExpense
      contextRef="i38665521367949c5a5b7b6f4a45a6367_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzY0MDk_e6d16fbe-9505-4785-9bb1-e5e18eeb46e6"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i38665521367949c5a5b7b6f4a45a6367_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzU0OTc1NTgyMTg5NQ_6ff2f47e-dc7f-407f-bfaf-39021497db41"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzY3NDk_427ac81f-797c-4398-9cb1-92cc0c36f1bf"
      unitRef="usd">0</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF84OTAvZnJhZzo1MzJhMTczYTYxYWY0NDZiYjRlZDNjNjQzMTg5ZGJlNS90ZXh0cmVnaW9uOjUzMmExNzNhNjFhZjQ0NmJiNGVkM2M2NDMxODlkYmU1XzY3NTY_cd6c4435-2023-418d-a370-c53177080ca1"
      unitRef="usd">768000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RleHRyZWdpb246ZTllNzMwYzY0MzRhNDg3ZGEwMDExZWE4MTE0ODJmMzdfMTI3NzE_a84eebb3-9806-4d5f-9f77-757451ea492b">Leases&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, future minimum commitments under the Company&#x2019;s operating leases with lease terms in excess of 12 months were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental condensed consolidated balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RleHRyZWdpb246ZTllNzMwYzY0MzRhNDg3ZGEwMDExZWE4MTE0ODJmMzdfMTI3NzA_76c18255-8e9d-4a14-8b13-54b152fb633c">&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, future minimum commitments under the Company&#x2019;s operating leases with lease terms in excess of 12 months were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfMS0xLTEtMS01MTMwNw_9bfab988-9dae-4a59-bfe0-ba4f74e5b366"
      unitRef="usd">1240000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfMi0xLTEtMS01MTMwNw_e6700e1f-7cab-4a25-9dcd-df40055bb8a0"
      unitRef="usd">1539000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfMy0xLTEtMS01MTMwNw_b43862ea-5815-487e-ab1f-63bf980c1b13"
      unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfNC0xLTEtMS01MTMwNw_255aa9ec-7f9f-465c-b1b6-26090a0dbca9"
      unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfNS0xLTEtMS01MTMwNw_d73ab51d-9b5c-4b1a-8362-c5f0d8b85e12"
      unitRef="usd">1300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfNi0xLTEtMS01MTMwNw_f391b363-e2cc-46ca-8295-5e04c31a04cc"
      unitRef="usd">10762000</krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfNy0xLTEtMS01MTMwNw_6c201861-3617-4c95-b41b-06b2a2c8275f"
      unitRef="usd">17395000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfOC0xLTEtMS01MTMwNw_55af7e4b-fb7d-4bcd-b9f6-a57a7ef228a4"
      unitRef="usd">8637000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjg4ODZjMjNhMDU0YTQxMmM5YWJlMmIwNDVlMDY2OTMzL3RhYmxlcmFuZ2U6ODg4NmMyM2EwNTRhNDEyYzlhYmUyYjA0NWUwNjY5MzNfOS0xLTEtMS01MTMwNw_939cba47-69d5-4078-bd5d-716ec2e8f06a"
      unitRef="usd">8758000</us-gaap:OperatingLeaseLiability>
    <krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RleHRyZWdpb246ZTllNzMwYzY0MzRhNDg3ZGEwMDExZWE4MTE0ODJmMzdfMTI3NzI_160daf24-9986-4192-8639-45e0a38ed215">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental condensed consolidated balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfMy0xLTEtMS01MTMwNw_10e85699-7672-446d-83e0-7ab5ae43c0fc"
      unitRef="usd">7814000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfMy0zLTEtMS01MTMwNw_3c4aead0-b814-4602-9577-0c35d34979df"
      unitRef="usd">8042000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNC0xLTEtMS01MTMwNw_24bd9991-0aa6-48c0-9b1f-41fea92716bb"
      unitRef="usd">1553000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNC0zLTEtMS01MTMwNw_fd23dea4-312c-4ee3-854e-d2dcde7748c6"
      unitRef="usd">1561000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNS0xLTEtMS01MTMwNw_a276b849-bb7b-412c-b31a-67def0739aed"
      unitRef="usd">7205000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNS0zLTEtMS01MTMwNw_1cdb9bd9-78f2-47c2-b6ee-e7ba48ae98ad"
      unitRef="usd">7372000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNi0xLTEtMS01MTMwNw_70469166-5667-4f61-b54f-7e86308c0e41"
      unitRef="usd">8758000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNi0zLTEtMS01MTMwNw_7f39f9e3-e69d-412f-8580-1ddfa190e026"
      unitRef="usd">8933000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNy0xLTEtMS01MTMwNw_ad6fd445-e602-4388-b5bc-103c3115e111">P12Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfNy0zLTEtMS01MTMwNw_aea51ab0-b918-472c-b549-990e4d6db81b">P12Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfOC0xLTEtMS01MTMwNw_ae3694dd-dacc-4b2f-ba97-46f2e3ab7527"
      unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOmE5MjgzZjEzODk2MDRiYjdiYjAwODU5ODUzOGM3YzkyL3RhYmxlcmFuZ2U6YTkyODNmMTM4OTYwNGJiN2JiMDA4NTk4NTM4YzdjOTJfOC0zLTEtMS01MTMwNw_d76e155e-bf9a-47ad-8031-cf494b5b689d"
      unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RleHRyZWdpb246ZTllNzMwYzY0MzRhNDg3ZGEwMDExZWE4MTE0ODJmMzdfMTI3NzM_faa78c5d-6866-4466-8dc6-e96ab4613f27">&lt;div style="margin-top:2pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:-36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNC0xLTEtMS01MTMwNw_02a8cae1-4e45-45f5-850f-f791922a4904"
      unitRef="usd">463000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNC0zLTEtMS01MTMwNw_418183df-1201-4217-bae0-0c7200811846"
      unitRef="usd">409000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNS0xLTEtMS01MTMwNw_e57abad2-ff8b-4707-80a3-56ac739844f7"
      unitRef="usd">59000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNS0zLTEtMS01MTMwNw_10c7ee5c-910c-426b-9982-b308967cc9f3"
      unitRef="usd">49000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNi0xLTEtMS01MTMwNw_8bb48221-dfd1-4d72-91e5-8f2eac4e4aee"
      unitRef="usd">522000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80Ni9mcmFnOmU5ZTczMGM2NDM0YTQ4N2RhMDAxMWVhODExNDgyZjM3L3RhYmxlOjM0YTRlYWEyNzc2YjRkMmNhNTM3NmFiN2ViZDUwM2M1L3RhYmxlcmFuZ2U6MzRhNGVhYTI3NzZiNGQyY2E1Mzc2YWI3ZWJkNTAzYzVfNi0zLTEtMS01MTMwNw_a18fc096-00ae-46c5-b4b3-d39b21f299a9"
      unitRef="usd">458000</us-gaap:LeaseCost>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80OS9mcmFnOmU5MDJkOGU4NDU3ODQ2YmVhMWFhYTk4MzViNTRlZWIyL3RleHRyZWdpb246ZTkwMmQ4ZTg0NTc4NDZiZWExYWFhOTgzNWI1NGVlYjJfMjA0Nw_d65cada0-c970-4f33-8d92-b4078fd5cf67">Capitalization&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ATM Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sold shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acted as the Company's agent and/or principal and could issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $150.0&#160;million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement were made pursuant to the Company's effective "shelf" registration statement on Form S-3. There were no shares issued under the ATM Program during the three months ended March&#160;31, 2023 and 2022. As of March&#160;31, 2023, there was a remaining $102.5&#160;million available for issuance under the ATM Program. The ATM Program expired on May 4, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <krys:SaleOfStockAggregateOfferingPrice
      contextRef="i6d80521c426d495a9687ea96ad9ca399_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80OS9mcmFnOmU5MDJkOGU4NDU3ODQ2YmVhMWFhYTk4MzViNTRlZWIyL3RleHRyZWdpb246ZTkwMmQ4ZTg0NTc4NDZiZWExYWFhOTgzNWI1NGVlYjJfNTMx_04b00116-b80a-4b27-94f9-b025d06e4e24"
      unitRef="usd">150000000</krys:SaleOfStockAggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia4eb18cd516042b7aab83e20049963ed_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80OS9mcmFnOmU5MDJkOGU4NDU3ODQ2YmVhMWFhYTk4MzViNTRlZWIyL3RleHRyZWdpb246ZTkwMmQ4ZTg0NTc4NDZiZWExYWFhOTgzNWI1NGVlYjJfNzE0NjgyNTU4NTU0Nw_86d38bd0-8877-4b36-a61e-1fe44c7858e9"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i204fc13707f54377a36f6695aa4c916f_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80OS9mcmFnOmU5MDJkOGU4NDU3ODQ2YmVhMWFhYTk4MzViNTRlZWIyL3RleHRyZWdpb246ZTkwMmQ4ZTg0NTc4NDZiZWExYWFhOTgzNWI1NGVlYjJfNzE0NjgyNTU4NTU0Nw_fd3a9219-441e-40bd-aaae-185ff756713b"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <krys:SaleOfStockRemainingAvailableIssuanceAmount
      contextRef="if019f17b70c645eab7cf5f73638d1837_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF80OS9mcmFnOmU5MDJkOGU4NDU3ODQ2YmVhMWFhYTk4MzViNTRlZWIyL3RleHRyZWdpb246ZTkwMmQ4ZTg0NTc4NDZiZWExYWFhOTgzNWI1NGVlYjJfNTAwMA_aa90b0b4-e6e1-436e-853d-7063b466fe09"
      unitRef="usd">102500000</krys:SaleOfStockRemainingAvailableIssuanceAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIwMw_84440eb3-5d1d-4981-8bfe-bae6fec48c45">Stock-Based Compensation&lt;div style="margin-top:9pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company adopted the 2017 IPO Stock Plan (the &#x201c;Plan&#x201d;), which governs the issuance of stock options and restricted stock to employees, certain non-employee consultants, and directors. Initially, the Company reserved 900&#160;thousand shares for issuance under the Plan with an initial sublimit for incentive stock options of 900&#160;thousand shares. On an annual basis, the amount of shares available for issuance under the Plan increases by an amount equal to four percent of the total outstanding shares as of the last day of the preceding calendar year. The sublimit of incentive stock options is not subject to the increase. The Company has historically granted stock options and restricted stock awards to its employees. In February 2023, the Company began issuing restricted stock units and performance-based restricted stock units to certain employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted to employees and non-employees vest ratably over a four-year period and stock options granted to directors of the Company vest ratably over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTExNQ_1ff19d5b-7ebe-44d5-815e-fa8e50130fbf"&gt;one&lt;/span&gt;-year to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTE0Nw_06c5c353-58b3-42d1-85b7-6f88da10a8be"&gt;three&lt;/span&gt;-year periods. Stock options have a life of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 287,600 and 1,179,500 stock options to employees, non-employees, and directors of the Company during the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,582,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CCECFF;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March&#160;31, 2023 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three months ended March&#160;31, 2023 and 2022 was $1.1&#160;million and $36&#160;thousand, respectively &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three months ended March&#160;31, 2023 and 2022 was $56.86 and $43.09, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $109.2&#160;million of unrecognized stock-based compensation expense related to employees', non-employees', and directors&#x2019; option awards that is expected to be recognized over a weighted-average period of 2.8 years as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three months ended March&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards ("RSAs") granted to employees vest ratably over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTc3_6f3f7115-1588-4f4d-bb1c-32086269f4cb"&gt;four&lt;/span&gt;-year period. The Company granted zero RSAs to employees of the Company during each of the three months ended March&#160;31, 2023 and March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $3.3 million of unrecognized stock-based compensation expense related to employees&#x2019;&#160;RSAs that is expected to be recognized over a weighted-average period of&#160;1.9 years as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units (&#x201c;RSUs&#x201d;) granted to employees vest ratably over a four-year period. The Company granted 186,900 and zero RSUs to employees of the Company during the three months ended March&#160;31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $15.0 million of unrecognized stock-based compensation expense related to employees&#x2019;&#160;RSU awards that is expected to be recognized over a weighted-average period of&#160;3.9 years as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSUs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-Based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance-based restricted stock units (&#x201c;PSUs&#x201d;) granted to employees vest ratably over two years based upon continued service through the vesting date and the achievement of specific regulatory and commercial performance criteria as determined by the Compensation Committee of the Company&#x2019;s Board of Directors. The performance criteria are to be completed by the end of the year in which the PSU awards were granted. Each PSU represents the right to receive one share of the Company's common stock upon vesting. The Company recognizes stock-based compensation expense for the fair value of the PSU awards relating to the portion of the awards that are probable of vesting over the service period. On a quarterly basis, management estimates the probable number of PSU&#x2019;s that would vest until such time that the ultimate achievement of the performance criteria are known.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March 31, 2023, the Company estimates that 100% of the PSUs granted will be eligible to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 60,000 and zero PSUs to employees of the Company during the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested PSUs as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested PSUs as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $4.7 million of unrecognized stock-based compensation expense related to employees&#x2019;&#160;PSU awards that is expected to be recognized over a weighted-average period of&#160;1.9 years as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to PSUs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares remaining available for grant under the Company&#x2019;s stock incentive plan were 1,005,626, with a sublimit for incentive stock options of 2,629, at March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the portion of stock-based compensation that relates to work performed on the construction of manufacturing facilities. There was $162&#160;thousand and $141&#160;thousand of stock-based compensation that was capitalized in the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i514f2cde4cee40baaa8b763c557430ae_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTA5OTUxMTYzMTk1MjY_3d57bc9a-2ca9-45c0-b920-404b9b6e1a7a"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i514f2cde4cee40baaa8b763c557430ae_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNzE0NjgyNTYyMjI4Mw_9607b19c-7602-486b-9d14-0567bf32c3e0"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNzE0NjgyNTYyMjQxMw_747e6891-b2e0-402d-a28a-4a34d17bc4ed"
      unitRef="number">0.04</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIwNA_8062a912-6ecb-49fd-810a-3c353bc05fa4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMjU3_1d634cb3-d48b-49e2-98d5-3e7ca8d77bb2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0b2264b9c9914e3abaee4de6745b7cf8_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMjgy_5585bbed-5791-40f6-87e7-c2a55eb04d81"
      unitRef="shares">287600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id23450f1c26144fca1df4aefaa3a147d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MTc3OA_7a437c4b-63b2-4e1c-9dc0-58c240c7b726"
      unitRef="shares">1179500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIxMA_ed377766-3c1a-4dd5-b29d-e1f2ae89441f">&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,582,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CCECFF;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,785,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CCEEFF;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March&#160;31, 2023 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMS0xLTEtMS01MTMwNw_74d629c9-93bc-4fc5-ab24-5209502fb40c"
      unitRef="shares">3582181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMS0zLTEtMS01MTMwNw_722b08a2-a5f2-4bc9-ba0a-e289a4b4d3c6"
      unitRef="usdPerShare">61.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i228ec404a39040e2a3b2cf301e832687_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMS01LTEtMS01MTMwNw_08c2edd0-d599-409d-9596-a04f52609910">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5f60354e5b814800b6f7eb4d9ce867a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMS03LTEtMS01MTMwNw_0230f9b9-389d-4a34-98a1-b2fdb84e8f11"
      unitRef="usd">64880000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMi0xLTEtMS01MTMwNw_94086e2b-483b-418f-89c5-7adead538266"
      unitRef="shares">287600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMi0zLTEtMS01MTMwNw_e40facbb-b65b-4876-a0c3-a3cfece7459e"
      unitRef="usdPerShare">81.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMy0xLTEtMS01MTMwNw_d375aca1-551a-4ec1-a1f8-f812867d08a1"
      unitRef="shares">42021</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfMy0zLTEtMS01MTMwNw_ec6574f3-e588-4b93-b8a3-ea2845e81076"
      unitRef="usdPerShare">53.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNC0xLTEtMS01MTMwNw_6dbf77f9-b6fe-4a0a-b983-1a9193c3e529"
      unitRef="shares">42625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNC0zLTEtMS01MTMwNw_b7fb86b8-6422-432e-bc83-c22a6a0d3675"
      unitRef="usdPerShare">65.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNS0xLTEtMS01MTMwNw_9c86c055-69bf-4570-b86e-2446e0435b87"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNS0zLTEtMS01MTMwNw_730cc662-61cc-4f47-9ef3-dcd02ea0a08b"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNi0xLTEtMS01MTMwNw_c394b7c6-c09a-460f-ab9c-c0b74a331157"
      unitRef="shares">3785135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNi0zLTEtMS01MTMwNw_8bf5a720-4817-40dd-a4d3-d6fe22116771"
      unitRef="usdPerShare">62.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNi01LTEtMS01MTMwNw_13a1a7fb-a558-4481-a0bf-d90dd1412414">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNi03LTEtMS01MTMwNw_8edfdcba-69ce-429c-aceb-8620c7869a17"
      unitRef="usd">66066000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNy0xLTEtMS01MTMwNw_f40c4747-25e9-4927-a022-8642ba03ab68"
      unitRef="shares">961428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNy0zLTEtMS01MTMwNw_73abdd3b-ae1d-4485-8e70-8bf76a196194"
      unitRef="usdPerShare">55.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNy01LTEtMS01MTMwNw_063f71f3-7aa8-430a-818a-e7317014b91e">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmQ3NDY5ZWVjNjYzYjQwNzliMGM2ZjYzN2RiNGEzM2RkL3RhYmxlcmFuZ2U6ZDc0NjllZWM2NjNiNDA3OWIwYzZmNjM3ZGI0YTMzZGRfNy03LTEtMS01MTMwNw_56145de0-a085-45ed-a3fc-01222c954666"
      unitRef="usd">24033000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTA5OA_6fb2a0a3-d744-4f71-8f86-595d618e61dd"
      unitRef="usd">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1MjEwMA_a6b8e8b4-7def-48b4-a26c-d47d33284e8f"
      unitRef="usd">36000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTMzNQ_99b58857-6261-4aea-891b-6ea34290a115"
      unitRef="usdPerShare">56.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTM5OA_3ae080b3-a808-41ac-a403-57c05d1bfe52"
      unitRef="usdPerShare">43.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="iedcfd366e93c4c2d8c5b5452e2b1caf3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTM0_5d1af1a8-36c0-47f9-a6ad-b9286bc4d298"
      unitRef="usd">109200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id58086907cf445e3b68de6647460560d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTQ1_80133a9f-8583-4103-8852-4d9b36a44d58">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIwOA_df46618b-940f-4f04-8f10-6bc5369be330">&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSUs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and Development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to PSUs in the condensed consolidated statement of operations for the three months ended March&#160;31, 2023 and 2022 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib13481cdbf0441e49f4f32596d741801_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfMy0xLTEtMS01MTMwNw_53342617-6ec9-47d1-bfe7-34037b46cdc4"
      unitRef="usd">2353000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2350fa2df2594c7d83ae40618dfdbd3f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfMy0zLTEtMS01MTMwNw_dc7a1ec9-5963-483f-9332-12136e37a2a0"
      unitRef="usd">1368000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i65adaea3f9a54843afd31a5010fe66a3_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfNC0xLTEtMS01MTMwNw_3c637d6f-3b11-4c1f-9181-e3816d2b1a71"
      unitRef="usd">7108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4f30b015d0b54cef9f1f1fe7e1c87a6b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfNC0zLTEtMS01MTMwNw_dec3f8a2-46aa-4656-a14b-0c15e45d9e1a"
      unitRef="usd">4582000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfNS0xLTEtMS01MTMwNw_e51c73df-6ee0-40ef-a889-f4f5a011ae59"
      unitRef="usd">9461000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmYyMTcxOWNkMzBlZjRlZThiOTcxMjk5MDRlMWNkYWNlL3RhYmxlcmFuZ2U6ZjIxNzE5Y2QzMGVmNGVlOGI5NzEyOTkwNGUxY2RhY2VfNS0zLTEtMS01MTMwNw_c1659f70-9912-426c-9d97-d507dd1fd8de"
      unitRef="usd">5950000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIwOQ_4f24c38e-46e9-4f85-88fe-2b903023fe72">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three months ended March&#160;31, 2023 and 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfMi0xLTEtMS01MTMwNw_bf5aec04-9106-45e9-8754-a0b552a88b48"
      unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfMi0zLTEtMS01MTMwNw_31d8cab2-b8d1-469d-8f9f-d5e97f78aa32"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfMy0xLTEtMS01MTMwNw_750777b9-8a93-4746-b7e8-fa014c10574e">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfMy0zLTEtMS01MTMwNw_b622e41c-93ab-442e-aa4d-50055b5da0a2">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNC0xLTEtMS01MTMwNw_c1133274-2c96-445b-a31c-5120884f79eb"
      unitRef="number">0.0406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNC0zLTEtMS01MTMwNw_4cdaec58-3bb4-4a81-969a-e590f1fe67eb"
      unitRef="number">0.0179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNS0xLTEtMS01MTMwNw_9675c642-0b20-419d-a86e-b4bc16add690"
      unitRef="usdPerShare">81.83</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNS0zLTEtMS01MTMwNw_4486a1d9-79b7-4d3f-a493-ca58d78e9762"
      unitRef="usdPerShare">62.53</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNi0xLTEtMS01MTMwNw_336ac167-f910-41c5-96b6-7f5d8bb0105e"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNi0zLTEtMS01MTMwNw_f5658619-b6d3-4bad-890d-c41216e8a8f4"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNy0xLTEtMS04NzA1MA_36cfed79-5fff-4b77-8757-a127082a64d1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i865107105dfa411197c509ac7cebdd9f_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmMwMzcxZDRjMWJhYzQyYjRiZWMxNDgzYjUzNjI2MmFlL3RhYmxlcmFuZ2U6YzAzNzFkNGMxYmFjNDJiNGJlYzE0ODNiNTM2MjYyYWVfNy0zLTEtMS04NzA1MA_97177a32-a0ac-4050-ad8c-dbb9c441fbf1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMzIxMQ_6f1db7ed-7b11-47b8-a107-44623c6125ff">&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards ("RSAs") granted to employees vest ratably over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTc3_6f3f7115-1588-4f4d-bb1c-32086269f4cb"&gt;four&lt;/span&gt;-year period. The Company granted zero RSAs to employees of the Company during each of the three months ended March&#160;31, 2023 and March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company granted 186,900 and zero RSUs to employees of the Company during the three months ended March&#160;31, 2023, and 2022, respectively.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSUs as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTgy_873a3897-51c5-4d24-bfd1-52334380a759"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i29f8fe089ab942b2b54a2474e590165e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTgy_d35bc165-d391-4fad-acf3-bb38c5e89437"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i645b28bb0a98487cb270051dfc6fdcfe_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMS0xLTEtMS01MTMwNw_2fa9a972-4cd3-4359-a2bf-3f2a892f1e95"
      unitRef="shares">66600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i645b28bb0a98487cb270051dfc6fdcfe_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMS0zLTEtMS01MTMwNw_893061cf-851a-415b-8e67-02ca111d9847"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMi0xLTEtMS01MTMwNw_4df37eef-ba39-4507-9f55-0bae170ade35"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMi0zLTEtMS01MTMwNw_10dfc2d0-5eaf-4f67-a1ea-6ca1022db496"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMy0xLTEtMS01MTMwNw_3fa69c4f-ef7d-4e78-88e9-334ea4ef0590"
      unitRef="shares">12649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfMy0zLTEtMS01MTMwNw_a0cce921-112f-47aa-aa95-6939726e95d7"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfNC0xLTEtMS01MTMwNw_820cccdf-d089-4b7d-981e-47fb0557af79"
      unitRef="shares">9551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfNC0zLTEtMS01MTMwNw_df0afb8d-0c7a-4b84-b3b8-01ff72062b05"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i49ef87a5ae2a4962839a23c59b1310dc_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfNS0xLTEtMS01MTMwNw_6f874aeb-2854-4a1f-a9e4-631c86c26a01"
      unitRef="shares">44400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i49ef87a5ae2a4962839a23c59b1310dc_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQyMmMwZTRlMTUzNzQ4Zjg5NDA5N2I3ZjM1OWEwYjhjL3RhYmxlcmFuZ2U6NDIyYzBlNGUxNTM3NDhmODk0MDk3YjdmMzU5YTBiOGNfNS0zLTEtMS01MTMwNw_4e349a2e-f965-4fc0-9592-6c6f3b822b79"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i49ef87a5ae2a4962839a23c59b1310dc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDA2_6b375db8-06e2-4f03-8d99-dc33af38a9cc"
      unitRef="usd">3300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDc2_044c8535-4b8d-4a70-8773-f32fd2ebf255">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc7538673d38443ba7514e523de7d067_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmVkMzEyNGMxYTU5ZTQzNWI4YjZhMDMzZjljYWNjYmI5L3RhYmxlcmFuZ2U6ZWQzMTI0YzFhNTllNDM1YjhiNmEwMzNmOWNhY2NiYjlfMy0xLTEtMS01MTMwNw_30f7c728-5cc1-44f5-84c6-cb4046e7ffb8"
      unitRef="usd">432000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if52d01079bea47b58f76c834f2bd69aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmVkMzEyNGMxYTU5ZTQzNWI4YjZhMDMzZjljYWNjYmI5L3RhYmxlcmFuZ2U6ZWQzMTI0YzFhNTllNDM1YjhiNmEwMzNmOWNhY2NiYjlfMy0zLTEtMS01MTMwNw_55786195-6ce1-45d3-a3ee-9dfdb5bf27f3"
      unitRef="usd">480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmVkMzEyNGMxYTU5ZTQzNWI4YjZhMDMzZjljYWNjYmI5L3RhYmxlcmFuZ2U6ZWQzMTI0YzFhNTllNDM1YjhiNmEwMzNmOWNhY2NiYjlfNC0xLTEtMS01MTMwNw_b7aef16c-375d-463f-95c4-55d0d26ccae7"
      unitRef="usd">432000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29f8fe089ab942b2b54a2474e590165e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmVkMzEyNGMxYTU5ZTQzNWI4YjZhMDMzZjljYWNjYmI5L3RhYmxlcmFuZ2U6ZWQzMTI0YzFhNTllNDM1YjhiNmEwMzNmOWNhY2NiYjlfNC0zLTEtMS01MTMwNw_75e4937b-5463-4a9a-a3c1-618e67541e3a"
      unitRef="usd">480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="idef73c4961e74f54a77c41e6d1e60853_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNzE0NjgyNTYyMjM4Mw_6a1ab800-c77f-4c21-898e-50a1dac11b30">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MjA4_0f9e9232-2669-4d94-988c-6bf46a86938a"
      unitRef="shares">186900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7af32a972cdb4a749407af929c2d1837_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MjE3_dd9fa0e4-382e-422b-a166-b19494d93393"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ide792579d6fa48f0b86d34c66b1032f8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMS0xLTEtMS04MTM2OA_9008707e-5e0a-4fa8-81cb-454493c92a65"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ide792579d6fa48f0b86d34c66b1032f8_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMS0zLTEtMS04NDg5Mw_3bf84df5-5449-4faa-b7d4-c8ff989c9fa9"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMi0xLTEtMS04MTM2OA_bc19db5e-938a-4ff0-a2e8-74dd02415a59"
      unitRef="shares">186900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMi0zLTEtMS04MTM3OA_5eb38850-1a3e-4b5d-8004-4263b4b5827b"
      unitRef="usdPerShare">81.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMy0xLTEtMS04MTM2OA_46dedfeb-5c18-48fb-ab17-8b5dd6ef3fd7"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfMy0zLTEtMS04NDg5Mw_608b5a8a-f22d-44d9-add7-3f7c78b9f570"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfNC0xLTEtMS04MTM2OA_57a80fb9-1ea2-4f9e-a6e3-f716abc12ff2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfNC0zLTEtMS04NDg5Mw_3d94953e-ad09-46d2-9db0-daa2064b4445"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibfcec0e0e32c41ff965b11623a8537b6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfNS0xLTEtMS04MTM2OA_5f8440fa-5f6e-43b3-87b8-5500c00bc811"
      unitRef="shares">186900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ibfcec0e0e32c41ff965b11623a8537b6_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc4Yzg4MDIyODYzZDQyM2RhMTJiMWE2NmQ1MzEwMTVlL3RhYmxlcmFuZ2U6NzhjODgwMjI4NjNkNDIzZGExMmIxYTY2ZDUzMTAxNWVfNS0zLTEtMS04MTM3OA_b6b26302-eab6-44b5-a9e7-253c8bef4807"
      unitRef="usdPerShare">81.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ibfcec0e0e32c41ff965b11623a8537b6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDY0_80ec366c-876d-4068-9d73-c37d99db7db9"
      unitRef="usd">15000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDgz_808c97bc-0580-4223-9fca-aa2ddff1078d">P3Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4b071d986514acea476f82fe822eeb2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfMi0xLTEtMS04MTUzMA_3f9283d2-1d4f-48a4-a11d-42e3453ae891"
      unitRef="usd">143000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67805b5822e040868da524c3ac650689_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfMi0zLTEtMS04NDkxMA_1a995d12-ca00-4bdf-9a1a-5dac09886c8c"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib38669f3d3714bb9a64a611f418227d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfMi0xLTEtMS03ODYxMg_545b5b31-f399-4008-ab8f-975f57660fbb"
      unitRef="usd">186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie8865efa296147f4b6d4959a17d55e59_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfMi0zLTEtMS03ODYxMg_56d99efa-37f4-4fac-9c9f-e56485b82a13"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i036750d5c15d48f8bb6e619a41820b25_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfNC0xLTEtMS04NDkxMA_723d3184-1233-4121-b82e-6d3067d2da6f"
      unitRef="usd">329000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7af32a972cdb4a749407af929c2d1837_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOmZkMjEwZGFhNDM2YTRhNjM4NzJmNjNlYzc1N2UxOWE0L3RhYmxlcmFuZ2U6ZmQyMTBkYWE0MzZhNGE2Mzg3MmY2M2VjNzU3ZTE5YTRfNC0zLTEtMS04NDkxMA_c07ec363-5297-4d0f-86c3-5aae743169a1"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest
      contextRef="i89b2e6b1732847ebb483c440b3b816ea_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTA5OTUxMTYzMTk1MTc_d613485e-629d-41eb-8da6-5b4c8c10fc3a"
      unitRef="number">1</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTA5OTUxMTYzMTk1MjI_7b0014a6-0da5-453d-961d-67d7de1f148b">&lt;div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 60,000 and zero PSUs to employees of the Company during the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested PSUs as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested PSUs as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MzAz_6547b7d9-2530-4721-85b3-3002c05652ca"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7bce8d3bcf1140e8aceb74a97f62d71a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MzEz_b74d8e06-3c18-41e8-894d-d5219d42bafa"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8817887d7f81412584905713f1293a84_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMS0xLTEtMS04MTQzNw_3a4ceaa1-a28f-4772-898a-dadd7ca1e926"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8817887d7f81412584905713f1293a84_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMS0zLTEtMS04NDk1Ng_a906b509-03a2-4445-a8e1-a49284a9638c"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMi0xLTEtMS04MTQzNw_9189815c-8714-4a72-bd14-1c6421eb2569"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMi0zLTEtMS04MTQzNw_a5ac915b-5926-41b8-b0b0-f3f824ded86d"
      unitRef="usdPerShare">81.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMy0xLTEtMS04MTQzNw_93ef014e-578c-4fc3-a5f6-d112fe35fa37"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfMy0zLTEtMS04NDk1Ng_7c13e2b6-515e-4a2d-8855-df81757f526d"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfNC0xLTEtMS04MTQzNw_acb95d06-86ad-4fae-b72e-c91ad9d6d10d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfNC0zLTEtMS04NDk1Ng_b4fad009-99c9-4915-8d2d-60f84e97a32c"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i89b2e6b1732847ebb483c440b3b816ea_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfNS0xLTEtMS04NDk1Ng_060ae162-4a91-471d-beef-88777309f030"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i89b2e6b1732847ebb483c440b3b816ea_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjQwMGZhOTRjODhmODQ1NGViYTg1YzFmZGZkMmUwMThhL3RhYmxlcmFuZ2U6NDAwZmE5NGM4OGY4NDU0ZWJhODVjMWZkZmQyZTAxOGFfNS0zLTEtMS04MTQ0NQ_64d670ad-0af7-4efb-8c2f-301c73a7c11b"
      unitRef="usdPerShare">81.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i89b2e6b1732847ebb483c440b3b816ea_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDI0_c3317e54-ed20-4f2b-9075-e3292670f084"
      unitRef="usd">4700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1NDkw_b884fe01-b0e1-4d8f-9dfa-5aaabca7ec35">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0633520e282645f49e4915cae45e1e31_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc5MTdhYmJlNGJjMDRjZjg5MDJjZTI4YTkzMWRlMjA2L3RhYmxlcmFuZ2U6NzkxN2FiYmU0YmMwNGNmODkwMmNlMjhhOTMxZGUyMDZfMi0xLTEtMS04NDk2MA_c7daea82-2933-4082-a30f-e5c9e39cb4bd"
      unitRef="usd">215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9a5c357849b34fb4847ad068877525ca_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc5MTdhYmJlNGJjMDRjZjg5MDJjZTI4YTkzMWRlMjA2L3RhYmxlcmFuZ2U6NzkxN2FiYmU0YmMwNGNmODkwMmNlMjhhOTMxZGUyMDZfMi0zLTEtMS04NDk2MA_bbb85b81-f3b0-401a-8ab4-4b936358bf43"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie626e4a820c549f5a715d9cecf2901a5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc5MTdhYmJlNGJjMDRjZjg5MDJjZTI4YTkzMWRlMjA2L3RhYmxlcmFuZ2U6NzkxN2FiYmU0YmMwNGNmODkwMmNlMjhhOTMxZGUyMDZfMy0xLTEtMS04NDk2MA_3b546d82-edfc-48a9-892a-5aeeb6113208"
      unitRef="usd">215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7bce8d3bcf1140e8aceb74a97f62d71a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RhYmxlOjc5MTdhYmJlNGJjMDRjZjg5MDJjZTI4YTkzMWRlMjA2L3RhYmxlcmFuZ2U6NzkxN2FiYmU0YmMwNGNmODkwMmNlMjhhOTMxZGUyMDZfMy0zLTEtMS04NDk2MA_f1b86f5c-9d85-4a5e-913c-ad0fe0d5b413"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i447050dc5b89452bb373864b41c4e5ab_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTYw_8ab18a81-5f2d-4845-9108-4444fc4a20f0"
      unitRef="shares">1005626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib03c89f358de41aba14e7922b0f06df8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfNTQ5NzU1ODI1MTY4_7d449634-0338-4935-8a9e-3431da8be903"
      unitRef="shares">2629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1Mjc0MA_23549d6e-4221-4089-92e4-883a80cccb42"
      unitRef="usd">162000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="idc7bb9e3d8bc4e51a23af611896afcd7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81Mi9mcmFnOmRiOGRhYTlhYWE4NzQ0MjJhZDlkZDdkNGI1NGRhMDVjL3RleHRyZWdpb246ZGI4ZGFhOWFhYTg3NDQyMmFkOWRkN2Q0YjU0ZGEwNWNfMTY0OTI2NzQ1Mjc0OQ_b66d261c-0cff-483d-86d2-f3a93f55fea4"
      unitRef="usd">141000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjJiZGNmM2ViZTAyZDQwNGQ5ZjkzMzBjMGQ0ZWVjYjBkL3NlYzoyYmRjZjNlYmUwMmQ0MDRkOWY5MzMwYzBkNGVlY2IwZF81NS9mcmFnOmJkOTk3YWE1MGNkNjRhNjhiNDY4OWQ4YzZkMzJmMmQxL3RleHRyZWdpb246YmQ5OTdhYTUwY2Q2NGE2OGI0Njg5ZDhjNmQzMmYyZDFfMzcw_9e1f24b7-cd1c-4058-88d0-5692e4ca4dbf">Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require recognition or disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MX&R*'*KKXUU@9.-:X4H:;*QN6.'5!\HFX/I:2O,0V.XZ7*;Y'U!+ P04
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MXBQ__<6?>K_9:+V2L1.244<R&K.^? "+6&2%"9V<;"%S;'1DV4@WEJ;&DDY
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MTVU#\%5[4_(C%X*7[>.247G&4@;R]P7GXFM#7;[<W_^=_@M02P,$%     @
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MD&G]LZQ%<=F@0",H0O"957(KP$>%)C]</U,6=6:A)[,ND5?A9\S?@Q"^ RA
MH0//ZN7+D0=.V'DY-/K"$7U?=X1C2:L-N-!I2R4E3B\U6B*W%EW1IV*',W(^
M424K"+\CD^7OO\$D^,-EXI&4'1@<=09'/NW++ZH!%4PXC6Q6)F:E[C)WRVD4
MHW1^-KO;A^\22],D[L0.@,4=L-@;B8O\7U54369+IAI1QJJ,%@14+6+]5%]G
M.N=K71@JM5D7/^R-7WS,^!U)V8&;DLY-B3=^'XA2FE'<M-HJ![AD7-+_S .7
MY8VZ>"]:\R >1-26@0$<B>>\ SKW KV1+/LYU8T\!QDK%;N)!C1YT-?$A77N
MP!&%P_RSI9(H#-QH%QW:A1?M5[DE_)W.+Q>NA?6/T\1RHD,(AB-.3#M8J;<H
M5EM<;8@89+H01!6)#GY!\2TM1K,^/6;6'TG9@1]@T+-AX W0-2<[3/.G[&G,
M9SIJBHPY5VVC]8N3XP([-B$:YI5#:H%&\@KNT3A\/K- Q:KI"W!"&V>4#&':
M0ND(2-2#1%Z0?Q%5IUTV/3JQ(4=^)\,B<$JA9 1?S]+0RXG+BRQCM6:&'7[$
MMX6S>;0J#KN'%6-;:!K'T0B^GE2AGU45/EX3;W8^4ZKM'QRF:&3[UQ9# 0Q'
M\/?<"[V<U>'7^#9-FU8Y*@LS:3KAQK:S41P$0[BVF)8:*ZJ>!*&?!;\\S0$G
M[2#P]L63 +3);HH2&%MEYI"#<92.^;KG13CW]O2KZHZ(%XR<T,NOK^W>Q])V
M:'1/K]#/K]<US[985X;:M>RX#I9\-%5"?M5T-YIF#E*-PP4<QLK%O7.8PI%8
M]?0+O:QV")N:P)D)U8DU=8"(XGAN999#,$'SL2Z$>HY$SW$DRPC)!5AS5JJ]
MJ*RYR:X7@$<V]ZEDC]&PH!UR* KV1K1#Z#U+(C]+=@6M<N..JJTFN'W<*V[:
MU8R_N)'-C6&<A$,C'#0;QVFP&+&BIU&$O*7]B598;5J>+6WD9>/7EO:QM!T:
MW7,S\G/SE1"ULIKH+%.#?JFY0\_^H],TLCD8(60%R4_GAV![HD9^HOZ.'XB>
M(M0DR4EAWJBH;67/==H(Y23)::9_,X8 ?(^Y^^4)<K#V/$J'ICBDDFAD:$,]
M:2,_:3]3,^LN&9^I&0>51_-H:(,M-8TC-&)#3^3(3^0?UVN2&:^3A\QL=H!B
M<0*R=N.CDLF8J)G"7&BZN,/%:!]SL'8X;, .H9&)!/6LCOS;71V,DYQD7$_2
MNF&]$K>]J9TB"./A_.>24T07C4PEJ"=HY"?HU1A:@"6X)1M:53J5-'L33EGN
M-,*F89C U)H*'7)A!%$TLDU /5TC/UU[C2!Z)/?"MWD91L$\LF)@RZ$D#8.1
M&(0]?X>!ESYNZMVN:4.X !^HR HF:M[P]Q>U@33F]>.C-O2EC!-Z)X=7O\ \
MDK9#/_7#0N@?%GY4IH'OGI\I51UF19TW[PKQ8!/9O#X;[-R<SK/G!0@7UM[,
M)1;%8YP5]E-%Z-^<7U4JK"HC]"O1C;Y635'3E#X'F;+U5'5\SSN%5GGB;'8M
M<%L$ANEP')WMG664A&_,$8\ QJ?-^__N:7>,=&$.3P;/+^'IJCD,ZM4T9U.?
M,5>-1H""K)7*X/U<^9(WQSW-C60[<V)RRZ1DI;G<$IP3K@74[VO&Y-.-_H/N
MT&WY/U!+ P04    "  D0ZA6)2=R.]4&  !F#P  &    'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;*57VW+;-A#]%8S229L969)EQW'CRXSMW)LTGKA)'CI]
M@,"5B#$(,  HQ?GZG@5(FG9MMS-]D0@0>SM[=A<\W#A_&4JB*+Y7QH:C41EC
M_7PZ#:JD2H:)J\GBS=+Y2D8L_6H::D^R2$*5F<YGL[UI);4='1^FO7-_?.B:
M:+2E<R]"4U727YV2<9NCT?:HV_BD5V7DC>GQ82U7=$'Q<WWNL9KV6@I=D0W:
M6>%I>30ZV7Y^NLOGTX$OFC9A\"PXDH5SE[QX6QR-9NP0&5*1-4C\K>F,C&%%
M<.-;JW/4FV3!X7.G_56*';$L9* S9[[J(I9'H_V1*&@I&Q,_N<T;:N-YROJ4
M,R']BDT^NP.+J@G15:TPUI6V^5]^;W$8".S/[A&8MP+SY'<VE+Q\(:,\/O1N
M(SR?AC9^2*$F:3BG+2?E(GJ\U9"+QQ_]2EK]0S)$A],(C;P_5:WT:9:>WR.]
M(SXX&\L@7MJ"BIOR4WC2NS/OW#F=/ZCP@_03L;,]%O/9?.<!?3M]>#M)W\X]
M^DZ4<HV-VJ[$N3-::0KBSY-%B!YT^.NN@+.^W;OU<8D\#[54=#1"#03R:QH=
M/WZTO3<[>,#;W=[;W8>T_VLR_KNT^,U?A2B-.-4NDBK'XJU5$_%++$D\?K0_
MG\\.SEQ52WLU3LOM ^%\]V9#@ST'$12QKK217M3>60 :G@CE*M2FHD*@0?AD
M- AMQ4GMM4'ZMO<FL"F04%7R\ME8L/'6*L3MFGR$^-*[2DAQ)HU&C[%:"@-C
M_,9HN=!&1SZ=I:+#R1=DY$9ZZ-I2SM<N&Q\+:0NA2FE7$-4Q""LKRMIO@2'>
MOS]C57=C!*??-9;8Y_V;/FO;V8,%*3:E,^9JRVTLEJ%9!%UH]+4$0L,,@_\"
M(24==0/)0,(M18-:\5%>,BE!(H4\:@4WDO_=(L2F8+(.E27?>GQ_?<"Y=\01
MG%# B:A5X,C$+Z/;VZ,G8S;0 3J^/ZCQ_PZ$Y65G600(,0<*G8B349>V8?Q0
M^O,QHEXA[G;!&E^0HFH!+N:M>V._.X(6RXN-CC_(&R@<B]^)N<W/(9MXY248
M/<:P"36E<6'NCAQQR(71H>30$6C4B/1F';QL/#9ZX8*@S-4HF9CQX?+Q"G)=
MQ4)M2\B? ]=9T:@H:ET3U_E$?"7!G)=BD=EJG7&KZ\I8.@P++D;;F6+7;EOB
MO179E(**"O1#VZ:FAA/P+6#\Q%)X-E7H0)AW2,[GP(*N2<=P"G9J(R-?"1"<
MC$*'-!J3>;(K:"6/U9N++UOHY1L2"A>&2&(-5)T/68B62V[(-IHK^&R =H+*
MRYH:=A"DMX&]#5RL"H,[,$@:]I&@R"!7F+VZ-L@)]SX1 !]5</@/(,X"W,>V
MGQU ;H/#4B%?!(;!BLWJE=<+Z&><TAI1L3F(H[<YS#3V,CG-/D2.@ILBV+[F
M3+80I>PP&@W+)Z"Z2!E;Z^R6MFL9$")+8XSK2H*DHM_UN"]1"D\6_)HK/M]:
M0!=1DC2Q5)P4$&-)@:]$<A =(YE4UX[SHUOEF;8YL_WATJ$M+J[N5SL1'Q'
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M+W-H965T,3$N>&ULG5=;;]LV%/XK!VY0M( 06Q??TB1 DK;;@'0-DJY[&/9
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MLKGPC6Y&:+Y,&G*/QN6SM$"C2M^>'J?\"BXE1V^%H.$'J-V;SD:'C>N',)I
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MFCQ'*W5!E-H@KZ)!R 242\UJ$$&*[P.F6.W1=AF5C*"A1+5P+&7:LTHY'.'
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M[^8C"=_.&BD9+UBIN"B)9).+SE7XYKJ+X\V KYPM5.N:H"5C(;[AE\_912=
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MWE35C*_(,6_S[QNP%J6T-RF;4HR$&V 5<]L$B0%"Q-SL#X"8O+@7PV?HQ<F
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M/SU]MBBP]G,Q=*CR. ^.L#@ +QP]7(P3A+NN42U+$.RM@AU 7\@#A_*&$-U
M-D"ABQVEF"G\F*A'\;M^91@G)E!+X3%.LRXX;I@C&PQI?L6/WG5Q1A*"P.0-
M<#S0ZHHG_^#A(MG:4=IXKRG!XIAP,MKZN"XG"]R(BB& B(0/&"X.T//464SB
M#AF2YL; ??+H@B&3>*94.[O>&.V;-\09T[(AU?3; #0BH[@<PKGZG6?/S)/G
MYKU.&!)V+SAQ] #T;L7#9>N(03S1S#$PZ0*:_3E([-DT>Z;7(@^%2L<4-^H&
MNI"- ZKW/4HV=DG7=%#9&QYG('\7\^1X[U+BS3!N_DW9]2(MN^H@][TK%CLL
M!R-"I8JD3NT;"/&OCB^KK<&?=.#G<=R")A$"^Z-N]F$2DU2/;S_Y;FVX&)NI
MZ7/Q0#]DZQ!JYXP+SZ>FR[8O8.%X92R8!";2(K\*;XD<K[$6' >"L>KU@I3H
M@;Y^F.#4&IWVP=V41+1IE+#\[ATV6H2;+K_&R_.*O]Z%[C@L*!F@RUPM<,-?
MUW=4/<1RN;^U[UOH"RZ^^/FS<EMJ'C!SP+_W6W@#_$:K9/R]BUQ=8_02;X&$
M2'O(ZU2X8)?];L0TQ4>A% TP_6II]*Z86^)R6)P&9R? =4=8BA_B)>MI"4CF
MRFOT0:^!NE<TKE;<:F)P8BY>23]S<#K_*P47Q13_!^.FD]5O!2+*K\),QFBH
M.^L LTOV%2\9+!Y'=?GO@M W6 _D>IF_RKH47\;W&/PD"-4#YJ]0\.!V<4UA
MZH;#&*POZ\7Y16IH(6_E+2+T>YCRQ__\;900C_/@V#WVH)N1<]<#OE*GNS,"
MR**A,=VXQL;Q_OS-DUQ>PXP&6>=$VN2?)JM\J,[XQS%V&8\!51P@M$6[#!6!
M^I=6C51DHE +BGNCZ =>O@;7Y=75^_?@9I.$=+G]=/X>^F<:\"M^ LN:#O[F
MAL6T"GX?2/&.5(F\M:'_47YNRA]#*EZ@RYK@!-.(,/7J#FKBL@:C2F5W;]BP
M1\G=T3@!4]R3"!R*8XX$0=4SN-"F6UFSO:5B!_&RB@KP?;.UU&-("/EC?P6?
M\4]><.OK/X#@I- ]RGZ1K55V0[\[Y_A*,O\X6_PV_K;=.?^B6UK./XP'LKY!
MU6_4&EX]63X%:V_YM^;X0V]V]/MN*]/WIJ4_L8BG+"Z YVMC^O !-XB_^/?Z
M_P%02P,$%     @ )$.H5L]->?_H @  8 8  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL?57;;MLP#/T5P@.&#5CKQ$DOR)( 22_8@!8(FG5[&/:@
MV'0L5)9<4:[;OQ\E)VX"I'E)=#D\/*1(>MP8^T0%HH/74FF:1(5SU2B.*2VP
M%'1J*M1\DQM;"L=;NXZILBBR8%2J..GUSN-22!U-Q^%L8:=C4SLE-2XL4%V6
MPK[-49EF$O6C[<&#7!?.'\33<276N$3W6"TL[^*.)9,E:I)&@\5\$LWZH_G0
MXP/@M\2&=M;@(UD9\^0W/[-)U/."4&'J/(/@OQ>\0J4\$<MXWG!&G4MON+O>
MLM^&V#F6E2"\,NJ/S%PQB2XCR# 7M7(/IOF!FWC./%]J%(5?:%KL61)!6I,S
MY<:8%912M__B=9.''8/+W@<&R<8@";I;1T'EM7!B.K:F >O1S.87(=1@S>*D
M]H^R=)9O)=NYZ;)]## Y+.5:RURF0CN8I:FIM9-Z#0NC9"J1X,LOL5)(7\>Q
M8\?>/$XW3N:MD^0#)P.X-]H5!#<ZPVS?/F;!G>IDJWJ>'"6\%_84!OUOD/22
MP1&^09>%0> ;?,!W*-R_LQ4YRU7S[U# +=_P,)_OI!%5(L5)Q*U":%\PFG[^
MU#_O?3^B=MBI'1YCWWVS&W*22Q,S>"3,:P5W7./D;V9$Z.B0]./DU\B*4RE"
MSTCBQDN-Y5>#FGQZ7('@T^*+_<3;0HFN,!F8%[3A%CM)=2M);27Y6\Y&A:$3
M002%WZ I9%J L/X$<J-X3M (YK54&7LD$#J#U68'LJPLN^*QX @NX 2&%_"&
MPA)<F;*J'8O YUI6'A LR>2N\>0#!F^Q]T+7.3]M;3WGNX'')+T-Z$ZLC!7.
M<*;W$?TMXK:V6C()!D^Y?/5KVO-TASPR"J.R?>7<1UP5/BE=DG($8SD_?I)Z
M5>U)SE!F.%0U\4[7EVC78;81A$IN!T!WVHW/63LUWN'M[.5^6DOM9>5LVCN]
M.(O MO.LW3A3A1FR,HXG4E@6_ E ZP%\GQOCMAOOH/NH3/\#4$L#!!0    (
M "1#J%:CNTA?L (  .<%   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM
M;)U4;6_:,!#^*Z=LFHK$R MOA4$D:#NMTEJATJT?IGTPR4&L)G9F.]#]^YT=
MR*A&^; OR=F^Y[GG?+Z;[*1ZUAFB@9<B%WKJ9<:48]_7288%TQU9HJ"3M50%
M,[14&U^7"EGJ0$7N1T$P\ O&A1=/W-Y"Q1-9F9P+7"C055$P]7N.N=Q-O= [
M;#SP36;LAA]/2K;!)9IOY4+1RF]84EZ@T%P*4+B>>K-P/.]9?^?PG>-.']E@
M,UE)^6P7M^G4"ZP@S#$QEH'1;XM7F.>6B&3\VG-Z34@+/+8/[)]=[I3+BFF\
MDOD33TTV]2X]2''-JMP\R-T7W.?3MWR)S+7[PJ[V'0P]2"IM9+$'DX*"B_K/
M7O;W< 2X#-X 1'M Y'37@9S*:V98/%%R!\IZ$YLU7*H.3>*XL$59&D6GG' F
MOJ>Z?Y5:PP(5+#.F$&;&*+ZJ#%OE"$;"E2P*NK^ED<ES)O,4E8:+1WNJ6Q/?
MD A+Y2?[@/,Z8/1&P"[<26$R#3<BQ?0UWB?Q30;1(8-Y=);PCJD.=,,V1$'4
M/</7;6ZDZ_BZ;_#=,"6XV!S?R(_92AM%#^CGJ7QKNMYI.MM48UVR!*<>=8U&
MM44O_O N' 2?SHCM-6)[Y]CC)35I6E&=Y!K^KY2G,CH?\S%3B*^J"!>W DPF
M*\U$JMN +PF6!K330%M0DJ)ZE=(C;;E2V4\$]U6!BAFIQDY_;O6_AXM>OQV-
MABUGCMJC0;\%UR@D-4#M^^2Z#=./;$OP#=K.Y(F+E?*\HA-(ZEQ=6 U1OST,
MHW84!=8,PUZ[U^_"_!^4.(BPDBEZV!D.6K4Q&K5.5<P_:C[*9>-&C*;PE3!U
M'S:[S12;U<W[U[T>@?24-UQHR'%-T* S['N@ZK%2+XPL72NOI*'!X,R,)C$J
MZT#G:RG-86$#-+,]_@-02P,$%     @ )$.H5AZGN=J"!   9 L  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C N>&ULU5;?C]HX$/Y71G356Z0L)$Y(PNZ"
MQ&[;NTI7:56VO8?3/9@P!&N3F-H&ROWU-W9"8'] G^^!X!G/?/[&_IS,[5:J
M)[U$-/"S+"H]ZBR-65WW^SI;8LEU3ZZPHIF%5"4W9*J\KU<*^=PEE46?^7[<
M+[FH.N-;YWM0XUNY-H6H\$&!7I<E5[L[+.1VU DZ>\=7D2^-=?3'MRN>XQ3-
MM]6#(JO?HLQ%B946L@*%BU%G$ES?13;>!7P7N-5'8["5S*1\LL;G^:CC6T)8
M8&8L J>_#=YC45@@HO&CP>RT2]K$X_$>_9.KG6J9<8WWLOA+S,URU$D[,,<%
M7Q?FJ]S^@4T] XN7R4*[)VSKV)B"L[4VLFR2B4$IJOJ?_VSVX2@A]4\DL":!
M.=[U0H[E!V[X^%;)+2@;36AVX$IUV41.5/90ID;1K* \,_[$A8+OO%@C?*ZT
M46O:<*/A\I'/"M3=V[ZA16QH/VL [VI =@(PA"^R,DL-'ZLYSI_G]XE<RY#M
M&=ZQLX!?N.I!&'C ?!:>P0O;BD.'%_ZZX@]"9X74:X4:_I[,J'P2R3]OU5Q#
M1F]#VHMSK5<\PU&';H9&M<'.^/V[(/9OSA".6L+1.?3QM+XO(!=PS_72<T_X
M^&,M-KQPI\6K.4PV7!3VT*[HIEY-:0:FF*V5, +U6R6=7_1QB;"0!=U94>5@
MG!I +XFYH9E[6:YXM7O_+F5!<J,A<[SL$_ %+_Z,E[:\=,L+9CO0(J_$0F2\
M,B"J#6IC)4A@!G-)97-M*R<59,M6!@[Y V98SE#MO<RCMX1>H;OGQ0XN145D
MY5I3L.Y>OX28E%(9\2_.J1IMX'<EM6Z>DSQ7F!,!<&)Q^VU7=(/IDO*N#*K2
M(CZAVYNCO8;+H M_RBH_&\,H!HDF!-<'_%<;> %!Y'M)-*"1VVQV\VQTF#T7
M-UW/C#2\:(/V$_O_O?_4?,V47=MS+U%E@K!6?$5;/TR\*&*04-%IUUEAT*:]
M,.^E6DEE=W4FZ40@&GJ#)(1P2,E^W'6V'[?AT< +HP@B+X@9?.M->Y#+#:K*
MJ8.^%U6V.U92G'BI'P)C <$-_:YSA%$+%\=>&B<PI%^['RR(O#1(@9'S,@RB
MKO,DR8$S\X=>3 4.O( -X=%E74 X&'B#.*21S;QH<AM_$#\[CCW"18/Q2K7_
M%R'&@3?T_5-";&?/Q1V$V 2]$F+C/S5_6HAQZ,4L@@$5%':==22E%^9+(:;,
M8U$ 00B743#L0AJ0<@ZW($D\D@4),29M_5J(2>S%:6A+(%T,B0PYHL%!4B_,
M@QCI!3:(4@@2NA"T?M=JV4N'["#&@)B0.&LFK1C3B.Y@:K>>,B^:7.L/O63(
MGAW)'N&BP; *>7SC?:X/TBH/LCDJDMHA^FK2^QIDA;!#KD JH&^$[CE)'8'^
MIJ%H17@6;89FBW@$::5HMM(9NO?6I[1_U/F0('+7W]'W2*XK4S=!K;=M(2=U
MYW0(K_M/NA^YJ(@L+BC5[R6##JBZIZL-(U>NCYI)0UV9&RZI#49E VA^(:79
M&W:!MK$>_P=02P,$%     @ )$.H5KJW92_Z P  ,@D  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&ULG5;;;MLX$/V5@1H4"2#$NDM.;0-QDJ(+I+M!
MTNX^+/:!ED8V44IT22I._GZ'E"T[@&,4?9%XF3ESAG,&Y&0CU0^]0C3PTHA6
M3[V5,>NKT4B7*VR8OI1K;&FGEJIAAJ9J.=)KA:QR3HT814&0C1K&6V\V<6L/
M:C:1G1&\Q0<%NFL:IE[G*.1FZH7>;N&1+U?&+HQFDS5;XA.:[^L'1;/1@%+Q
M!EO-90L*ZZEW'5[-4VOO#/[FN-$'8["9+*3\82=_5%,OL(108&DL J/?,]Z@
M$!:(:/S<8GI#2.MX.-ZA?W:Y4RX+IO%&BG]X9593K_"@PIIUPCS*S1?<YN,(
MEE)H]X5-;YN./2@[;62S=28&#6_[/WO9GL.!0Q&\XQ!M'2+'NP_D6-XRPV83
M)3>@K#6AV8%+U7D3.=[:HCP91;N<_,QLS@1K2X0GIX ;V:QEBZW1</Z-+03J
MB\G(4!AK/"JWD/,>,GH',H:OLC4K#7=MA=5;_Q'1&SA&.X[SZ"3@5Z8N(0Y]
MB((H/H$7#SG'#B_^I9P?43"#%=QR70JI.X4:_KU>:*-(,?\=2[]'3XZCVRZZ
MTFM6XM2C-M&HGM&;??P09L&G$]R3@7MR"GWV1%U9=0)!UO"@J#>5>0765G#W
ML^-KZA;CPY]HCM$^"7R<]IL(N(_0TKF5DCI3&TO$K!!J*:C!>;N$<][2BNPT
M.>F+*Z#RE2M7OULLL5F@<I,;\C>JZYN37-9*+BFPAC,(H\@?QZD=D64<AW"/
MU'DK*2K@#1D^8^-$&B5^DD3V%X4Y!6J[FHK6*4MCH MAX$=Q!F,_+V*8=UQ4
M=M^FM-A-WJ"2(9E__%!$8?0)[ME"*F:D>CV C/PP*.@;%&/XW*F64U!TD#5_
M,4Y#H1]F"8S3W'559RCMO;^UU+(V&T9N<5P0QP"^2<.$/8<C9PYA'OCC= QA
M5OA)GL-U679-UTNW0BI9R9D[RO/<+XKL LXS/Q_'%W"JAG3 6>P'>>Q&H9\5
M"9P0:3J(-/UED1)/U1''NQ>Z1S2=RS71^(L4H^"F4\JF=L_9@@MN..ICNCT9
MZ[AN=T%Q%]3F+EW0<AM4[(/NI$P.OROF74 +N.SKH-$8X13E%.VG5.&S054[
MA_*]+J J!SF$H9^DT6!-NS5MDBT)I4:B'OM%/*9O/,[W5NQ540*]PK'%FMM6
M\;,L!-)$$1[ 84GGR4O6&P^3X=Q($M2'U(-9NBW:L?.+HQ"B;$_ L!=:34-(
MXJVHSR :^TF8V &1#=*C,AL=W&,-JJ6[K6UYNM;T5]JP.CP(KOM[<&_>OR:H
M3DO>:A!8DVMPF9.*5']#]Q,CU^Y67$A#=ZP;KNA1@\H:T'XMI=E-;(#AF33[
M'U!+ P04    "  D0ZA6!$#M%10$  #N"0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6R-5FUOVS80_BL'M>L:0(UER;)LUS:0I"L68,&"I&L_#/M
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M0]5AR%55<>O#0D,UUF!+A"M5U4P^O7LSB8?91_+3(Q7M?F^Y+5L9+.K* )>
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MO%C2@PRU4Z#_:Z7L;N("]$^\Y;]02P,$%     @ )$.H5LP>RG2I!@  4Q4
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MYD=J):US.'&@;0+''%I2YWKA=$P]C&%ZH7.]$+6F87K (=_0)YRUA;@3(7I
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M971S+W-H965T,C<N>&ULK55=;],P%/TK5I 02&-)D[9L(XW4=D.;Q%"U"GA
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MVC,G:TX-G8R4W!%EK9'-#EQL'!K5,&&SN# *=QGBS.0;'I2O4FMR#8HL"JJ
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M2 ;-'?"F&7(S*X#3!,YI=\ERWA/R<<6^S>1*S:P_<)\8UE$4X1007:F9P0-
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MTDW0?'@ RX4& (B!&T ,FNAG=]1BASD*D!@<^?M!,"[[[E_@5^S=[4X!C $
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M8Z<K/SS\QLC:]=]:&NQFMRQQWH*R 7B_D=(<-_8#W03/_@!02P,$%     @
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M>+1WCP>\?8&R =A?26F>&O9\'^]S^7]02P,$%     @ )$.H5NO%T:8#!@
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M;1KWCHKCQ[84T%1>TPP%.UL*9-40BF;^BZM-YMB>S/?EE WK$MP.ZRLX*"T
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M/6>'*_P2 6D"\/U""/T\,9==^VV3_ 502P,$%     @ )$.H5C%/@&R$ @
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MP<V-7'V&UD]B^7+)M7N251.;8'"^T$96+1@55$PT;_K4UJ$'0)[=@+ %A-N
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M3L=ZJQ)U<E@7%"]MNK3B2B=?]G&C$VH0IH-N7W.N[@IF@#9%G_T&4$L#!!0
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M1>3[F?5%P2]YYK*^7-KKS[)GDT88MYWS27OQW5/,,L^U:2M;H#[.P5XY1K;
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MV0WJ]Q5C\G"2):AV\V?_ 5!+ P04    "  D0ZA6<^%:OPH%   Y(@  &0
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M.((Y  \8$D75>W#G?10V[ZEP_3^^T6]02P,$%     @ )$.H5I>*NQS
M$P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B
M#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z1
M0J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ
M0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?V
MD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  D0ZA6
MX36K4:8#  !='   #P   'AL+W=O<FMB;V]K+GAM;,6976^;,!2&_XK%57>1
M)4"2?JBIU(]UJ]2UU:AZ.SEPDE@U-K--^O'K9T/3F:8YVHW%5< 0\W 2WL<V
MQT]2/<ZE?"3/)1=Z%JV,J8Z&0YVOH*3ZJZQ V",+J4IJ[*Y:#G6E@!9Z!6!*
M/DQ&H^FPI$Q$)\>;ON[4T-^1!G+#I+"-KN&!P9/^=]SMDC73;,XX,R^SJ-GF
M$)&2"5:R5RAFT2@B>B6??DC%7J4PE&>YDIS/HK@]\ #*L'RK.7.0]W2NFQ9#
MY[^H!9E%TY'M<,&4-LT93?_4,J[!GMSNU49>,FY 75 #WY6L*R:6KAM[%T/O
M-IHZ;#[;(AZI_RFC7"Q8#A<RKTL0IJVC NX A5ZQ2D=$T!)FT;E<@W+W8R]P
M5;3W9BR45REUQ.P!=54T>"%11 %"0T'LEI:<%9:C(&>44Y$#\2 3!#+I$?)W
MXD&F"&3:"V3F<.Q7/<@Q CGN$;)3R0D".>D3,O4@IPCD-"SDK5I2P5Z; Q[1
M/D*T'Y8HJ\N2JA<B%R1C2\'LUZ@PY#3/92T,\R /$,B#L) WMM]KJ36Y T6R
M%55 3HU1;%[;+'<@[Y"'".1A6,A+RA1YH+P&<B6T4<WYV@_L$9;8H[!TFVQN
M1&<?D;*2XB,?:I3@2BE+9IJ2$2J:A]A8TX+(&70@,:/$@95R#51W:3!UQ*'=
M02MFAT#;<1)CKH@#RR(S,G\<G-$VB4O;D][BPS01!_9$5L\U_*GM2>3;^N,3
M@*DA#NP&-(D[EHTQ7\1]"J/CV1@S1MRG,KK5Q)P1]R(-LG?OO*:_^"-IS!Y)
M3_9X _4Q,8DD@272YO.GU4,G(H&UL2L2/ZD>YI,DL$_\P2D9D-.B8&Z3<OO7
MM!WZF)A@DM""00-H[&-BGDF">P;#G/B8F'62P-;!<]*/\P2S3A+8.CAFYT?'
MK),$MLZ..!^0]M_@8V+620);9V><6U#;O;\T@EDG[<LZ;3CYF)AUTL#60:O9
M76C"+)0&7P]#9EADX&.B"V*!+?3F\ 'YZ99]ZY+D'O?>A8^)62@-;*%W3/?
M%#6')NCKJN)NW<[XF)B%TL 6>L=L-@@\N\$'V#J"H8S[<Y\4LU :V$+=J>S6
MX,/'Q"R4AI[[[!K(;0<29J$TL(40S(_QCEDH#6PA#-/JTE_[QBPT#FPA!-/I
MWL?$+#0.;"'T1^]8:(Q9:-Q8:+AYG57 @@DH;NPEM&W/*<_O%'$?[6+<>.*F
MSXN:\W/;=BNN)2TV;\<V;_9._@)02P,$%     @ )$.H5K[+,T&9 0  =1D
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W938Z"0!"&X:L8#F!;
M5?@W45>S<3OQ D1;,8(0NB>CMQ^C"_W(+&9C^EN1;D+Q)B1/""R^?%7$8W,.
MY;$-@TM=G<,R*V-L/YP+V]+711@VK3_?SNR;KB[B;=D=7%ML3\7!.QV-)JY[
MG9&M%J\S!YMKZ_\SL=GOCUO_V6R_:W^.?PQV/TUW"J7W,1MLBN[@XS)SE^JY
M'=S](,/;Y&RPWBVS;KV3S*4.4@C2]$$&098^*(>@/'W0&(+&Z8,F$#1)'S2%
MH&GZH!D$S=('S2%HGCY(1BCCB""IAS6!UH)<"X'7@F +@=B"9 N!V8)H"X':
M@FP+@=N"< N!W()T"X'=@G@+@=Z*>BN!WHIZ*X'>VGO9)M!;46\ET%M1;R70
M6U%O)=!;46\ET%M1;R706U%O)=!;46\ET-M0;R/0VU!O(]#;4&\CT-MZ'TL(
M]#;4VPCT-M3;"/0VU-L(]#;4VPCT-M3;"/0VU-L(],Y1[YQ [QSUS@GTSE'O
M_)UZAWBM?'CV/-9X_W=2'6_7^N?M[\O'9N^YW'%V\)=E]0M02P,$%     @
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M:->X5F5S]&?=#YOY)U!+ 0(4 Q0    ( "1#J%8'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    "  D0ZA6T> M)VP$  !4#P  &
M    @(&E%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M)$.H5GYZFV)F!@  "RP  !@              ("!1QL  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "1#J%8]( ].A@8  ( ;   8
M          " @>,A  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    "  D0ZA6)2=R.]4&  !F#P  &               @(&?*   >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ )$.H5LEK$@4E&   =TH
M !@              ("!JB\  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( "1#J%:)3'@\W@,  *()   8              " @05(  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  D0ZA69KKTL;L$
M  #@"P  &0              @($93   >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( "1#J%;>YD$YAP4   <-   9              "
M@0M1  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ )$.H
M5O?CZ((&"P  #AT  !D              ("!R58  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    "  D0ZA6-9&Y0;H#  !;"   &0
M        @($&8@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( "1#J%8$?%E4JP,  $X(   9              " @?=E  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ )$.H5B\$*%IL"@  ]R(
M !D              ("!V6D  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    "  D0ZA6'[6+ I8"   $!@  &0              @(%\=
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "1#J%8G@J1*
MIA@  /U/   9              " @4EW  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ )$.H5L]->?_H @  8 8  !D
M ("!)I   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  D
M0ZA6H[M(7[ "  #G!0  &0              @(%%DP  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "1#J%8>I[G:@@0  &0+   9
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M970R-"YX;6Q02P$"% ,4    "  D0ZA6.D^M7]4"  #,"   &0
M    @('IK   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M "1#J%:](-X>!@0  %D8   9              " @?6O  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ )$.H5@+.4LJB @  )P8  !D
M             ("!,K0  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    "  D0ZA6&2G;(#0#   #"@  &0              @($+MP  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( "1#J%;V+L^P4@D
M "Y0   9              " @7:Z  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ )$.H5LQ+$4U_!   :AD  !D              ("!
M_\,  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  D0ZA6
M?,T31&L"  #-!0  &0              @(&UR   >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "1#J%:9WJF/00,  -L)   9
M      " @5?+  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ )$.H5NO%T:8#!@  MR\  !D              ("!S\X  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  D0ZA6N@UPK!$#   E"P
M&0              @($)U0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( "1#J%9F02-/' ,  .<(   9              " @5'8  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ )$.H5C%/@&R$
M @  UP8  !D              ("!I-L  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    "  D0ZA6SY8Q\G(#  "N#P  &0
M@(%?W@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( "1#
MJ%9!+IB+]@D  ,%C   9              " @0CB  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ )$.H5FU'21J$!0  V1\  !D
M         ("!->P  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    "  D0ZA6<^%:OPH%   Y(@  &0              @('P\0  >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "1#J%97-47[7 ,  ,P)
M   9              " @3'W  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ )$.H5BD>;S59!0  CR4  !D              ("!Q/H
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  D0ZA6AQUG
MYCD#  #P$P  #0              @ %4  $ >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( "1#J%:7BKL<P    !,"   +              "  ;@# 0!?<F5L
M<R\N<F5L<U!+ 0(4 Q0    ( "1#J%;A-:M1I@,  %T<   /
M  "  :$$ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  D0ZA6OLLS09D!
M  !U&0  &@              @ %T" $ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  D0ZA6(]5N#:@!  "X&0  $P
M@ %%"@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ,@ R )4-   ># $
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>152</ContextCount>
  <ElementCount>224</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Fair Value Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstruments</Role>
      <ShortName>Fair Value Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Capitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Capitalization</Role>
      <ShortName>Capitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Fair Value Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsTables</Role>
      <ShortName>Fair Value Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/FairValueInstruments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/BalanceSheetComponents</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/StockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Leases - Minimum commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails</Role>
      <ShortName>Leases - Minimum commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Leases - Lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/LeasesLeaseexpenseDetails</Role>
      <ShortName>Leases - Lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Capitalization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail</Role>
      <ShortName>Capitalization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="krys-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  krys-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="krys-20230331.htm">krys-20230331.htm</File>
    <File>krys-20230331.xsd</File>
    <File>krys-20230331_cal.xml</File>
    <File>krys-20230331_def.xml</File>
    <File>krys-20230331_lab.xml</File>
    <File>krys-20230331_pre.xml</File>
    <File>krys-20230331ex101rsu.htm</File>
    <File>krys-20230331ex102psu.htm</File>
    <File>krys-20230331ex311.htm</File>
    <File>krys-20230331ex312.htm</File>
    <File>krys-20230331ex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>krys-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="477">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "krys-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 14,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 477,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 152,
   "dts": {
    "calculationLink": {
     "local": [
      "krys-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "krys-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "krys-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "krys-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "krys-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "krys-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 350,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 8
   },
   "keyCustom": 22,
   "keyStandard": 202,
   "memberCustom": 16,
   "memberStandard": 28,
   "nsprefix": "krys",
   "nsuri": "http://www.krystalbio.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.krystalbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Fair Value Instruments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.krystalbio.com/role/FairValueInstruments",
     "shortName": "Fair Value Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.krystalbio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Capitalization",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.krystalbio.com/role/Capitalization",
     "shortName": "Capitalization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.krystalbio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.krystalbio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Fair Value Instruments (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsTables",
     "shortName": "Fair Value Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.krystalbio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Organization - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail",
     "shortName": "Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i3d5858b254a74055947c9db86b18c8a3_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i3d5858b254a74055947c9db86b18c8a3_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromInsuranceSettlementOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Leases - Minimum commitments (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails",
     "shortName": "Leases - Minimum commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ie16c7372e2984e8989f4e6a4c2d3b0b3_I20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Leases - Lease expense (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.krystalbio.com/role/LeasesLeaseexpenseDetails",
     "shortName": "Leases - Lease expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i6d80521c426d495a9687ea96ad9ca399_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "krys:SaleOfStockAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Capitalization - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
     "shortName": "Capitalization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i6d80521c426d495a9687ea96ad9ca399_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "krys:SaleOfStockAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i5f60354e5b814800b6f7eb4d9ce867a5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ib13481cdbf0441e49f4f32596d741801_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
     "shortName": "Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i2ed28fd2a6cf4e4484b47f20db1b3f5b_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i645b28bb0a98487cb270051dfc6fdcfe_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Activity (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Company's Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "ia872d0940c3d4fa48ee53b62b03dedd1_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i0f638a7b209c4dacaa94a230ca55e1ce_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i0f638a7b209c4dacaa94a230ca55e1ce_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.krystalbio.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20230331.htm",
      "contextRef": "i4498b1103c1c4931abe6717f6bd58590_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 44,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "krys_A2017IPOStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 IPO Stock Plan",
        "label": "2017 IPO Stock Plan [Member]",
        "terseLabel": "2017 IPO Stock Plan"
       }
      }
     },
     "localname": "A2017IPOStockPlanMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_ASTRAFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASTRA facility.",
        "label": "A S T R A Facility [Member]",
        "terseLabel": "ASTRA Facility"
       }
      }
     },
     "localname": "ASTRAFacilityMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_ATMProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Program",
        "label": "ATM Program [Member]",
        "terseLabel": "ATM Program"
       }
      }
     },
     "localname": "ATMProgramMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_AccruedConstructionInProgressCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued construction in progress current.",
        "label": "Accrued Construction In Progress Current",
        "terseLabel": "Accrued construction in progress"
       }
      }
     },
     "localname": "AccruedConstructionInProgressCurrent",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current Liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPayrollAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payroll and benefits.",
        "label": "Accrued Payroll And Benefits",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "AccruedPayrollAndBenefits",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPreclinicalAndClinicalExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical and clinical expenses.",
        "label": "Accrued Preclinical And Clinical Expenses",
        "terseLabel": "Accrued preclinical and clinical expenses"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalExpenses",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale",
        "totalLabel": "Aggregate fair value, total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale amortized cost.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ClinicalSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical supply agreement.",
        "label": "Clinical Supply Agreement [Member]",
        "terseLabel": "Clinical Supply Agreements"
       }
      }
     },
     "localname": "ClinicalSupplyAgreementMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_EstimatedUsefulLivesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the estimated useful lives of assets.",
        "label": "Estimated Useful Lives Of Assets [Table Text Block]",
        "terseLabel": "Summary of Estimated Useful Lives of Assets"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Accrued Legal Settlement And In-Process Research And Development",
        "label": "Increase (Decrease) Accrued Legal Settlement And In-Process Research And Development",
        "terseLabel": "Accrued litigation settlement"
       }
      }
     },
     "localname": "IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liability.",
        "label": "Increase Decrease In Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_InterestIncomeExpenseAndOtherNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income (expense) and other nonoperating, net.",
        "label": "Interest Income Expense And Other Nonoperating Net",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseAndOtherNonoperatingNet",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LitigationSettlementMilestonePaymentsSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Milestone Payments, Sales Threshold",
        "label": "Litigation Settlement, Milestone Payments, Sales Threshold",
        "terseLabel": "Litigation settlement, milestone payments, sales threshold"
       }
      }
     },
     "localname": "LitigationSettlementMilestonePaymentsSalesThreshold",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LitigationSettlementTotalConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Total Consideration",
        "label": "Litigation Settlement, Total Consideration",
        "terseLabel": "Litigation settlement, total consideration"
       }
      }
     },
     "localname": "LitigationSettlementTotalConsideration",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term Marketable Securities"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Equipment",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone Two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestonesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones",
        "label": "Milestones [Axis]",
        "terseLabel": "Milestones [Axis]"
       }
      }
     },
     "localname": "MilestonesAxis",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_MilestonesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones [Domain]",
        "label": "Milestones [Domain]",
        "terseLabel": "Milestones [Domain]"
       }
      }
     },
     "localname": "MilestonesDomain",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_NonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee stock option.",
        "label": "Non Employee Stock Option [Member]",
        "terseLabel": "Non-Employee Stock Option"
       }
      }
     },
     "localname": "NonEmployeeStockOptionMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_NumberOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Milestones",
        "label": "Number of Milestones",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "localname": "NumberOfMilestones",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "krys_PeriphaGenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PeriphaGen",
        "label": "PeriphaGen [Member]",
        "terseLabel": "PeriphaGen"
       }
      }
     },
     "localname": "PeriphaGenMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PlacementSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Shares",
        "label": "Placement Shares [Member]",
        "terseLabel": "Placement Shares"
       }
      }
     },
     "localname": "PlacementSharesMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_RemainingCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining commitment amount.",
        "label": "Remaining Commitment Amount",
        "terseLabel": "Estimated remaining commitment"
       }
      }
     },
     "localname": "RemainingCommitmentAmount",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_SaleOfStockAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Aggregate Offering Price",
        "label": "Sale Of Stock, Aggregate Offering Price",
        "terseLabel": "Sale of stock, aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingPrice",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_SaleOfStockRemainingAvailableIssuanceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Available Issuance Amount",
        "label": "Sale Of Stock, Remaining Available Issuance Amount",
        "terseLabel": "Sale of stock, remaining available issuance amount"
       }
      }
     },
     "localname": "SaleOfStockRemainingAvailableIssuanceAmount",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental condensed consolidated balance sheet information related to leases.",
        "label": "Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Period Increase, Percent",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Period Increase, Percent",
        "terseLabel": "Period increase in shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPeriodIncreasePercent",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested And Expected to Vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested And Expected to Vest",
        "terseLabel": "Expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVest",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock incentive plan.",
        "label": "Stock Incentive Plan [Member]",
        "terseLabel": "Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://www.krystalbio.com/20230331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r239",
      "r351",
      "r360",
      "r373",
      "r374",
      "r384",
      "r388",
      "r394",
      "r424",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r239",
      "r351",
      "r360",
      "r373",
      "r374",
      "r384",
      "r388",
      "r394",
      "r424",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r232",
      "r239",
      "r269",
      "r270",
      "r271",
      "r327",
      "r351",
      "r360",
      "r373",
      "r374",
      "r384",
      "r388",
      "r394",
      "r419",
      "r424",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r232",
      "r239",
      "r269",
      "r270",
      "r271",
      "r327",
      "r351",
      "r360",
      "r373",
      "r374",
      "r384",
      "r388",
      "r394",
      "r419",
      "r424",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r414",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r393"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxes": {
     "auth_ref": [
      "r1",
      "r2",
      "r79",
      "r93",
      "r100"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.",
        "label": "Accrued Income Taxes",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r58",
      "r117"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r120",
      "r357",
      "r365",
      "r366"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r17",
      "r20",
      "r80",
      "r318",
      "r361",
      "r362",
      "r404",
      "r405",
      "r406",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r393"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r409",
      "r410",
      "r411",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares surrendered for taxes"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r76",
      "r77",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r92",
      "r99",
      "r119",
      "r139",
      "r171",
      "r179",
      "r181",
      "r188",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r286",
      "r288",
      "r299",
      "r393",
      "r422",
      "r423",
      "r458"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r112",
      "r121",
      "r139",
      "r188",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r286",
      "r288",
      "r299",
      "r393",
      "r422",
      "r423",
      "r458"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 3.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r185",
      "r195"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r49",
      "r184",
      "r195",
      "r353"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r48",
      "r195"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and building improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r40",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r114",
      "r375"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r35",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r29",
      "r34",
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r29",
      "r90"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r15",
      "r96",
      "r105"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r201",
      "r202",
      "r370",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r409",
      "r410",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r393"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.00001 par value; 80,000,000 shares authorized at March\u00a031, 2023 and December\u00a031, 2022; 25,796,213 shares issued and outstanding at March\u00a031, 2023; and 25,763,743 shares issued and outstanding at December\u00a031, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r21",
      "r125",
      "r127",
      "r131",
      "r354",
      "r358"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r98",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Debt securities, available-for-sale, term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r32",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r32",
      "r56"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r243",
      "r275",
      "r276",
      "r278",
      "r283",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r132",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r153",
      "r155",
      "r157",
      "r158",
      "r159",
      "r163",
      "r293",
      "r294",
      "r355",
      "r359",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share: basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r132",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r155",
      "r157",
      "r158",
      "r159",
      "r163",
      "r293",
      "r294",
      "r355",
      "r359",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share: diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Share-based payment arrangement, amount capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Estimated weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r64",
      "r110",
      "r128",
      "r129",
      "r130",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r165",
      "r189",
      "r231",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r292",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r318",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r295",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Cash, Cash Equivalents and Available-for-Sale Securities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r216",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r296",
      "r324",
      "r325",
      "r326",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r216",
      "r233",
      "r238",
      "r296",
      "r324",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r216",
      "r233",
      "r238",
      "r296",
      "r325",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r216",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r324",
      "r325",
      "r326",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r186",
      "r187",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r217",
      "r229",
      "r290",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r381",
      "r415",
      "r416",
      "r417",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r32",
      "r55",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Recognized impairment losses for long lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company, Capital Share Transactions [Abstract]",
        "terseLabel": "Investment Company, Capital Share Transactions [Abstract]"
       }
      }
     },
     "localname": "InvestmentCompanyCapitalShareTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r315",
      "r392"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesLeaseexpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesLeaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Future minimum operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023 (remaining nine months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r316"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r139",
      "r188",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r287",
      "r288",
      "r289",
      "r299",
      "r379",
      "r422",
      "r458",
      "r459"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r95",
      "r103",
      "r393",
      "r408",
      "r418",
      "r454"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r113",
      "r139",
      "r188",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r287",
      "r288",
      "r289",
      "r299",
      "r393",
      "r422",
      "r458",
      "r459"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r15",
      "r420"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Accrued litigation settlement"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement, amount awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r29",
      "r30",
      "r33"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r33",
      "r97",
      "r106",
      "r111",
      "r124",
      "r126",
      "r130",
      "r139",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r156",
      "r171",
      "r178",
      "r180",
      "r182",
      "r188",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r294",
      "r299",
      "r380",
      "r422"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r171",
      "r178",
      "r180",
      "r182",
      "r380"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r310",
      "r392"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesLeaseexpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesLeaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesMinimumcommitmentsDetails",
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r314",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r313",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term, in years"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities and currency translation adjustment",
        "verboseLabel": "Unrealized gain (loss) on investments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r393"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to settlement of restricted stock awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r26",
      "r47",
      "r133"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "auth_ref": [
      "r135",
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.",
        "label": "Proceeds from Insurance Settlement, Operating Activities",
        "terseLabel": "Proceeds from insurance settlement, operating activities"
       }
      }
     },
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Project management service fee"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r57",
      "r116"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r59",
      "r104",
      "r356",
      "r393"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r78",
      "r109",
      "r466"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r53",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r65",
      "r102",
      "r364",
      "r366",
      "r393"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r110",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r189",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r292",
      "r361",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r312",
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Initial recognition of right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses And Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Capitalization, Equity [Line Items]",
        "terseLabel": "Schedule of Capitalization, Equity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.",
        "label": "Schedule of Capitalization, Equity [Table]",
        "terseLabel": "Schedule of Capitalization, Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r73",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r240",
      "r242",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Company's Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Fair Value of Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock And Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographical Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Surrendered for taxes (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Surrendered for taxes (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Stock award outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares reserved (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r247",
      "r266",
      "r267",
      "r268",
      "r269",
      "r272",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "terseLabel": "Share-Based Payment Arrangement, Performance Shares, Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of the award (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at March 31, 2023"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (Years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares surrendered for taxes and forfeitures (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term Marketable Securities"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r40",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r16",
      "r64",
      "r110",
      "r128",
      "r129",
      "r130",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r165",
      "r189",
      "r231",
      "r279",
      "r280",
      "r281",
      "r284",
      "r285",
      "r292",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r318",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r165",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net, (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r65",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r64",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r46",
      "r393",
      "r408",
      "r418",
      "r454"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r138",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Capitalization"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Capitalization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r3",
      "r94",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r3",
      "r94",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r186",
      "r187",
      "r217",
      "r229",
      "r290",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r415",
      "r416",
      "r417",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r377",
      "r385",
      "r387",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. government agency securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r166",
      "r167",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r311",
      "r392"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/LeasesLeaseexpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/LeasesLeaseexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r154",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding: diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r153",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding: basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080549-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r397": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r398": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r399": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r401": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001711279-23-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001711279-23-000029-xbrl.zip
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MP=F=2O442%8IU1PI5;1."IP$LI$'Q!US2&NG432819FB%<0NK6J\#/"6_W\
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M7PQ^LY3%5,G$3AQ8N*.P87L=&+?^%7&L#Z5114"3@Z;#VSL!6$JE(@1)+3!
MDW?(4,Z12 00BG#JM,Y[GLME+&[G,1X.3U4*8X:M>N($H[+J9[;JFYL"6" 9
MTD8DB;,0,I \7>(5HM0&+ 6#^"$75FF\K,3ME=)3L>I)IC3FI&E+_S'KYQX0
M!OW&K1PF-9=R=4GC<(_?"J@F!U2WF]@2$75@%J,H<Y<IT&)DC W(1N(C"9$8
M%I=6N3;+@&<3FMR=F2XN$\R _,:F/ZD)F,KTG]CT;_:RA3!#)Q=0D)HBSH0
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M<1N'<7<IW*=D[C*;,<L2PP05TA7,PV=%D9O<V?1JD+LBQWP9VC6 =A= R^8
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MMHO^YCK+9P[S '6H')S@U,O*13%[#EZ., YF?+-U\+!>#(4)ZX/'IX]B286
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M#=+GXV1(]VTV=@$THH+1F.FFS'1O/B>*%=)[1JC.+6$B9T3:5!.9^R(I+$]
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M_19N/QZC2(^'WI/?HQ\B?O#NQ+EXT29(!J^6:1=1$9K6PL;Q?K-A+2:N&(8
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M?CWX\/'\\ \0/+]TOAY<OLD./WR"=?N8'>Z]IP?T'YC'^POLUQBL8Z)@A2Z
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M:QM*O\SFVG,8$A$;R:@C@;"4_;*:>>LH#]@D8J1B)2-BV:V*QE;C9-)+8$S
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ME_N>V<0U(+VT"B^V]O?%3NI\>57!6[."8+<]W_!\!NM^Q^ <0J</?'J!UP\
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MA%7U6 W;]7LU1NJ5MIEER1R/>&V;B9>Z&QO1QT,7N^,;0N^P(6^L'?H3M1@
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MXE$PI9/CA#!-.+$:&"31_$?)O)2&W[7<M"#>DR'>Y QZ0;1A*D]-\-8"XLF
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MGCX@EDK#PA)IJ$8/6I#(A!Z)5!H&D@(&Q^!!"['M54#\4+;!O2';X)+>>BU
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M):?J,X9#M"/< 2P>_^0;:)G>#F#!9=:_?NULD[\:GW\&*=4J!.44VO93H8K
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MN!@(?I;T:G^#Q]B&>^U<7,!$C_-;_/GWD-\BCTU]V-T9*9^?^9XP?+1^_AK
M1.!YL'/#\8<N#]RX=&&X.5ZV,SB&G>0.CFW+'GR-O#@?S,RLT\5LGR\&XS>
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MWMEV$A]E1ATID<2D4IO\T8,MO'7H8G_FUDD>TGG,'$P^AF'OMW+OCWR4GUO
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MDX](#[X?*L!<2P)1),81X6XL&ZB!S'H( ^ KT ]MJ%80?R=!HD*,V+?Z!+2
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MW@CRABH"NPAXT>*^+JHE/$S0=2N6"781FN+U?EUP2KD8X:E<.]A%@,(%9%U
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MC'$Z?D7"OZ/Q-2 3")5$RK ]]._&O^?,)D(\$$$PMZ>ZST_$97H)63+A;DK
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M#2$P;,Z3&PZ:M%)*'_>57CZW3_^?X T'^&\_ NC0I>7]2V +9]H79 %D745
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M#(AM)@%5O;P0F:OMS]"=7--TK?<N1'HH%SE+S\,?OW^BKYB%)H5,Q@@GR2^
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M"M1>3#):YG-MV8H^9)>3,7:E<LE]*W"ESC<M]+>.P#KM?&.$B2'8P))VG S
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M23 K(W?&84K-HPB/NU/Y-@AJH:2E]T]+JE;/WJX_(K'Y][_\+U!+ P04
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M.A;.2)^%:(\S<X5\%1)A98LPPH7;\-SH>FEMSB=?'\.<:I)O,:4Q(F[A&#<
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M^"D5&ETA7UI:8\!L0"QW(GO#,;*OH@<I_S#2%D.JK*"VS&/X91'1^ T+0K%
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MGN9E%8>4$2.K$ZJKQ$B5 #_W51RE[,O_@B#D&JWKDJ>(X/VW_F0_J*?((RO
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M1#?S]/"N)25I0_HMZZ+YQ6T)N/JA'N(]JZM[JT4V2I?7PP@G, !#QCI_R($
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M<9XL:XI*BEK"LZ 3O<_1M3+?VQ)%)0"%7\ B#V\K%21N\J^-T\(O57$5$6&
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M/_UK]=A\VVE!<EN+W;8XX8V)?FVEKA32^$@/)49?4>21_IM^@V- TNN!=J*
M"F(0SW)%LU<H,ZCV"(A@;V1>[V>I(]A#+98\,/V('W+ULKJVS'H78YE7RT]+
M@\SP=NRHEETX45L/0[?TO8?M))'QHD7B AV9^-K,FCV7[\[QW#<FEWJ#W2QH
M6]F%$[-EBQSQ(N[,YM0#.P\[)Y)M7,=L'=7JIFGF\4[]<EJ4JRB+$??<SR]%
MK1&YX0_FJI'ABQKLF\+3'*H(-A9SC!26[LOK5<J>?4]>>1%$76G*%&3?WB2,
M$H$!<*AG'.QED8=JO/0H@8Z!=N*?$21<\RKB(M3M8YAEH#QMH'/<+]L>N[I\
MD%QRQI=,EUDO[_?;/E5\J\W0&T@NS[1>0*\J-"S^A/#D4N;^!;GV</&ND6)2
MQ_S]2H]X?A*:'KL$> 6$S8@3Q#"@X-YD5DQVJY%8Y2X2ADDM,$U1L7'!D0;.
MIFNE"!NF](BF[Q)A?VJ,WWDJ"&Z(GDRG#9EN]GW&=NGX0LG8 Q,M2(TVC]S#
M83*K]I#J>"/;KEY2X]S?U58Z^@M;QUK__)4BTO8T2]=D[OQJ@F1T2^4CIJ-=
M$++2]O0M?2.IBQLJ@A E-8&'=W^%N]V9N"V)D^*<>^)-N7[44WII?6,,G35:
M"J/$KZR+.9JUAT1S@T0>Z$3]=!'X"<9F>9^1G7:'/8<1G4KK*"LSI<4JJW6^
MB(-8A9L_G4')>Y) DR;F23O2BM(1#FN84:CSK[_S]*[HC/^>1MF?/F6EB /5
MZ[PSC/]B0:NA!>H%X'N!V.^L]S9?XNGGA:#I2#&6V3#T!4) -D&,F(JK*6WZ
MK!RO1= 69P<(&1JR*1+)&R&8Z]_.KYND>QV=Y)Z4,D&2< 1$;,S$R6ZPLK^1
M<311Q0XK"8?,6^>X!/&D6QS-K*UDOZ.-:@@Y7*3\P!)"$[ 9NR).U.0S=ES^
M@#[EP;6IL+ O )K8=2'<(]^182@JQ!#PH\1RBD'P]2 7?V95PF 'Z5S'^/P"
MS-LE3M9Y:_?"F3PL&AMZ;#>S8O*R*946R<,8 85 H/ZKP_!D6KHK2[%1 \!\
ML\I@#(]Y[RM*#J#U'X9L*TOG-6, IQ;V +DI"GD4FRH,6*(:;=O8A@&/VR[4
MFKXO)4\-U)NJFHDF;J=VDI<R,$"QB1]<[CK! !\6&/!01T4UO6<&9^.:NNQ"
M^J3L\@H&]-G=.0 =4CG@H2FH./B@L.T@9!H\9)5^O0F^2!9>PBZ' 6E3PN>C
M,."0LXR9N(GRU(MRZ@;DJ7%S"U[E_NUT^6<.]"Z>60MOU S=GK3]EI'Y"16O
M_?STJS)C;1CP)OHY#$@ONPFZ8UX);+NI9WT,O8L&&<]LCM*G>#>5P!U4!C!
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M</?7<O:/LDCY;_*L*DNM@Z^I;X2U>?HCD#S:28MHO/Z2GG^%Y)_SJN)&&CI
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M:E)1MM@ K6*$@13HQR)7+V)JN\985-<>]]/T4L95T-DW]Q4<0A"Y?3ZYWYG
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M9L-^:?'01R2X4G;@&"6M?/^K;!QRBRD9ZC>?2 0C.@U@7T]KPQ!MAFM.GN'
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MF_KG9CCFT99N*V4.8(1+F!/UOBJ(#ZY[1>$7F&T-7#_+P"J[K0U1NQ_9?+'
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M8I(R*P6T)TK6%\P\(;>DP?&)3!8E@(1+VP?9OPK@.1ED:>NG@R @*@.00E4
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M'B'^E"8+KFQQ0!#I:<G=4;4^K-IG;QUK$*/_LDI;TU'2TB.3XEXM\I)"&8#
ME%20X4_!?)KQICB\DY<TQMPY;>K#%&C[B:U5L N!:1K!*R&"JR^65B)$I.)V
MSN%"">^BU*HFZ!D^3+>^VIZ5HR$BTL49DG9NZ:4,JVQM/W15&A-.H0Q4LX24
MUI;7FSN_%&.(44Z*=3&=47V>&%DK ?&X9<(=N?1JG?(D/6S*S)XSPQOT\J(5
MGPK'Z,A33<O:4+,BGM[C9X_ 1"*R@QDQ=4W**L^8W7:U:')(@M"^?6Q)VXAO
M0/0(>?GT18IA@WKQU])\PS+RFV;G2>./IUSAZ)<BTB,,!_I-EKP(U6*KU:_]
MA? U<QTWX:*29?1&*RQPZ./]_%()$R! $"_P'K"3/:PE+<=+=RFHP5[T;5QG
M]U@,-8[29R_ZL=;<JU>Z<>$0ZT0#6XVCR_SV,>VYF?:B+9"6UKO-5MA%86V3
M\YC%_,2R/7B(K;>471UIFP>7X,A;<U&&18U!7C=3X\:OW/[+ C5Y-/4IU'80
M/P5OL=6<V5N*QNJZ4<ED2O,$J==&7&)[ZTQ/YVCN6MDEL1DYY)<8X+QM18W-
MGP;?LKQUM,8*_)#[^%H!(_WEKH&F*#+"H_VK!#I$1!GRR22/5<LW4I.%'^HW
M:_U7C]KX-X:L7\[["KJTNI=TFUY)&,]%:KYQ)XU7/5UQ*$Y(*4MOI9 /;J9.
M9:8M,,/[SHY6#3?@@B2-""C*5SE<S,Z];)>:4%$LOT'P)WA[$_PTZK'!?K26
MD2RIZ6QF=-4Q/P0"Y^FQZ% U0D!BNM"<0TBX?[-)ZF]F5FP'4U/QZLFK5Q2O
M^;:APE?AQ_< 'Z4@Z]0PSH/5%#_+Q[L)O4D%ZTP]6;.B/B\<?/H:?.3:N$([
M59>51YWKV^U8 L,[GBD0\Z\.T.\:[U$Z+BW<+O$-=A-L!JU'K; FQCM<$U:#
MH,=W^TU39$ZJZ>:=M4P40GTY7$IBFE8M^ECBQ6Z'6>?;>ZB7R2:[S944XP85
MQP;( U,IIG!HS+EDM[4.MF&*U!L10XT-P)4OU>8!1R2@DL+N&?5W'H_D6-^L
M;SJRK24UFEZ#/Y\V8PU:Q9?/MU5C1F;T&[Z-I.7Z)'M,@R-9#F##GJS1*/YX
MP1:# E]W;<3U>9;+(6C+$H22_MY9D'XX@IHZ$<71?0 6?4IL50>AM[@[4P!C
M(CJ1TTU8V5Y_5*NS\DO*"Z^W+D*^EA3^/3O)7V F%5\CGNP[T>FZ?#35+F M
M7KP ;P7%Y\]Y,S#T^*6_DHNA@)Y M$6.;ZD+OP;C*BA-T%5(T:S)3U!JN$D8
M,-*%H+2<PX%D^ $4( !\?+4JE.;P\H@M(&O,<]3R);,0]Y-/2^L21,$OF#1#
MV^U"?OS"*OQ%GH;<<A_-O;TNP&-THGT'_\R'-4J,C P'6QSWY(01_WN?*W:T
M]3-G-8;9B0:)],*V 3(3J5N-CCAR(S9C1\40AQ[>:+"Y%Y8#WR.Q33/UN]*8
M[9$"!XQX4Q0*1-EE0?2,COE':B%QE.SXL'D+MR^?LD[)%961NP6R(+_W'7LI
M-3&K:75S#V@MMVZR[Q8';$..LOW2&MS$W"72,P?LKAC1=#J(#>95]+1F,"*$
M.2'ZV0D=UQB-G9 G.ZX6"JHYYC6+^Z\GER-@;*05B4*,B85LXV/;Y'(TEKKJ
M>OSV5R>>.%?TOG.Q*3<^"-F=J[XKV%S?DJR[Y".>S,W3Y,TIQC@]EGG<CW/,
M4QOCO!')_^9*0[4[!/G+W7Q4=01FE<XS9W=F$>-\51WIKB<0C26!!HJ"()!>
MHGOV@#Q3OX$ENBA"=M<U?-E,=[89ZW5<79,&T;0,41N!.%?HI?47?=:+\X+\
M9IA%3:D<P?@&E&QMLQ*S?.RR5P8Q''J17WHW 'WN:8!IY'D.+AO[MS)^3O%6
M-?%9Z:NFE1R3V[/+#<,]0ZLX-9IX+BGP=]E\5$J$['+) !Z2?Y;=/9WM->VC
M,6%D=K*:U=S!? I>BO*1 4F#^HJ:.K4W;8')N.3;[D=7S\),A@<@:5$UYQ<_
MXL7-JA\<_".O)?WP2HU[ -BY^:!4[8^7=?,_T_D_D/^_@^!96.TU#4W7/_:\
MUC;0B[SI6OO.B:5+ YY]L$$W&W0NI@O<5-L%.V]SL>+(^F"\V1*Q<HA(;<RL
M?[V.7>.SA:E'WA+4K?,>X!'$.V%]#^!9O0<T=1K]?.GU\_A_@1+KH@=*:NNQ
MH=<,0+VHF\ZU[ZZD^F9_I"2GK2V+C^;-AC#SLF[H&OFV"-Q\4,*O]VQ_9\B*
M_1TR?4_Y'G"RR'BSJ_S'R[CE"3+/\[VN#I[>G5/=*#7?7@1#;W 3_G@E.<SO
M #3E"W->IJW0&)AC@S9$0IF!Q!3;N6VSZE_0Y:@SG7_W/O;%G__:0_AUW4:D
M9)-/3LKJE<5_%R_^,''YJEH:'J&."Y\1-ZXR=+$6631^&8LB:V"A1>9M+B']
M"1D^=[P'POCTWX:$\W<J!G\=UF]7LK][V_1WJDA_[Z'\I\O1O>DU%^8\TL;8
M!&02;7"[""%6A'/-XZBE?V,,+8F!'$N-#CU,A#]Z.@-K-=P2.Q__;_(@=8K]
MSSCL_R_)"^ /4,76#I;GP05:^9Z'AFK^3R':2-5>N2PJOW+A=1?Z%$Q#%DS7
MA"SS1Y/EFTW*[T(LX\+=_YVB\#\ 0-W[5IZ5/))HC5T9L>SV5QZHE0JI?58"
M[.WR?(<]^XOM0J*%B]MH'C1HRVPL-+RTD/J7M!7EULV0W.\ZYXCCS:<>H5*%
M2_< PZT+IR:=!(CO')LEF+=A0IC!3BYL5RJCJ%]1A8TQ&%6CW:8JHK"QO:Z=
M;HH+#EY>C(^Z2Y3,]6B,A=,Y%!(K+6>$-.?[R-]V@TI73-?;(*>;SO:T*.!3
M0?3LK8H@3P%70H4*%U(013(*A18?^6ZA _(3]#K$62<#C.QF@K6EH+FRVANC
M%&O[<N.DQ[W5''.1B<9'!=NRN6+:)K:)AJ4\.'*J,;]L(RD1:V^X\7!D5S(%
M*,NZ=] ATR'I\Y@S>SU)L.Q]618;FLQF%*4?*]OA$^'JG8%UW@GX\%:9IZG&
M:O<,1=];V!(WZ/^U]]5A577=O@LI"4%*6E(:!)04V'0(2+<*THT@(0AL04%!
M&D')38>4Y*9#NKN[2T Z]]YWB_H>W_=[OW.^>\ZYS[WG>>X?ZUGK66N..<8:
MLWYCCCGG\+=="IZ64_5^#,D3W,0G=G-2>JN-B_(*FIL?P_SYBZ_*R$N^K%RF
M751%%G^2(.YH/HZBG;EV"BC9FO0;S-H[S6KO6B0XC0F_1"@N,10'8/LV\TJ<
M/K_@%=I@0<U)J=A=<'5/9/DZG&#* O(&^3T*$ $7MN:_T%ZN[G2T(VX/*Z)U
MA$C>$2?\P]^B62JTS9DWH*@=H! KV!M#;D\]_()@4"C7;Q>]?2BM-$)1E\3,
ME$B^CNWEPV=OD*7DL;7Q_"[*@)I6R68 U\'DBX#(3O?K=UAR[OX(<I@2Y?=*
MFE[,]HVEJ/>S?6]1,$5B^?J%\K,G;L_L''#-!5<C,53="!]&]AVT"QXUWX$3
ML>^<SCN<"IR,)A]B[QU'3#5.2EBZOM<A10!84<<7WZ 7<1??S\[N.(<_-X K
MP^^"+8SO>=-MS?TK:5R@UOHD.-??GQ8FI"V2.>Y[4X.Q$\L-(#=FE ES&O#0
MWLZR"+49R7G'T$0I_Y:7=5UQX8W)75*H7\] (++IS_/6(KNA&PC@N!,<S'S!
MI(-LK2V3\%.'W718PMNOM;OGSZGS2)K!7\S "$#$KFXG&@%0@.9YZY!4_+/?
MB6C&QT(Z=_ =4$NSJ!7J JJ3-*7G.A-UHD[!5!9PU(>AO^>9%=<,S3@24N)V
MT)V6)2GTU8S?'_4Y&]1S =,)?[OWB3WP^Y\B /CS2? L)_)?_\35\)(1#=1G
M8DARY4:YC2/;:0>OA@A<JQ4!_"EA>^V0>5VM@)-=B"3F6760<4EF])##;%^,
M,7V9*%=2L7K9)PHZK$[/EZM4D-61"F6:)H\WL65[TJ-)",#9<W$7 =#T5 :+
M)!>J<)K*='H6F3P]#4UW'&WL\8_@>SUT*/.)):4B^'+?J;GV'8.HMX)Z6.:@
M>GX!AE-O/CZ=<FR+DJE\^?=;['W4P:.3Y!>.VJPU86'("N1_&08'ETUZ%*WI
M^AU?,IJZO1!PYKR&UHNG$,O*,2J!CP+;:P^:U[>"O(4RRHPY?I'\[T?"1%Y"
M53NG;!ZD,)_2VS :$VT7 [)#=H,XH?$1H:)<U9=RHL5:!;_W4E:*\ H$,'-W
MD?E&&E32>J.KZ28E-,0L>F1C9:J5_;XO[VL&WBU;#(W1?%$/X_A$:JC\UWE2
M4HR9[A'Y^5O\.X_=B*!NZBH/M6M(H"-L-;.',&_3<\$CGB??NDNK"9NIN]OP
ML:"RM[ ">9L#"SIG11^HU%B.3>#@L.1%6S')OV<KB7,BQD6I)S$/C!G)YK.Z
M%RS+;I02R$Y_&6LOR>">R_O[])2-,:AN4[)8%^79:S]0<W)%B?\>]P>L&HFV
MI2 J@J$7A""*V$# ^E,*F@SV)VZ #-#(^GOML$\\238V):+AEZ@B:^WQ-FQ$
M%H.=X79H1THI+IW=)@6$]P'#>O JYF:(2JVU1[;]K<_3.;#^4[52<"6(S86$
M@?+R@;_@6&[Y 3*WQ^BZQ*>^-#,M G8]WHY[<%$0!<0:69F\M4CZ3+"_ZHZ=
MAN\R*SF0@QXZB>YJ##N3JE7I]'EKEM]\7Z(9I(1_GUN4U3()K?X@BRITZZI.
M=XOQLV63'2<(OU=QZ F);A:9P&0*G0G[<JTN;,ZI''4RW]LW=DHI#G4@"/^^
M/BLN,H.FZF]3'O[YQSJ\X03 U<'L^FT;I\"1!+T!MU>%O('10;XC/3,=M[E&
M;@6#QZF],VMNV%4.JR2L.LV*\22J[*UK#-V(\RLZ?4=19O#VS(7O&M2U]?N@
MH,[]?:\T5@]3V4V'#S'RDT&G$ ;/NM%OV1OD4/>1<VE3]S>NVTEV#E4[\=[D
MV=FUODC5AGVY+#*?8M'Z?;>ML&OEK1_V"F["ZX)55+]0]I1/96'LEA2H\X<@
M>YU!XE$UHO_&2FZ09QG4'& ;F5CJYX4 ;JE((H#/_.D((/6K3=KWK8 FH<-U
MPF*M-#G>+L:!0,&1(,Q@/_6KXQET]<=6P?]9WWL+B]X:E#%$T,PJ[A4NP7=K
M[1/PU;Y:MXXM'CKT1#1$Y<6G%;#LIU-"LL1,3+U0YEZ@:%MUNMXJ-+S,4>XR
M6:Z:O!ER"-V83:"YS+Q0!K"8U9.V&^5I%]A).=7< SVO$WCPJF!>^Y*M\X>O
M.;9^R\_?)%R?2E#8)T5=4\$<BRW6ZGMT_R_2A4?!+PF\0D#:%QO-Q"@_N&HA
M*^&6(/X'.C$E2$TOSCYSYV#V)@) X4O62C.##_LHY9,UTA&$5C8ZF4(<PT.S
M,ZF;FL^IO/-.^R^5D4.L3OYG\<5)+OFX/&[IH#-/DF,$W?$,<I+K\JJCZ/LT
MX:Y=J$$5RK;M$',&^8@ SK(/2-6\_R26O\Z?<E=%QWG'TG54$:+ P]J("B]8
M<OBX>P*N__1#1:0<*0M==RHC>;!)4VDX3\3&VL]\OG?MX?^!1G_P&+IQI 9+
MV21HI]G!T(4<0NCW!"] V'5:6X%Q<9^+[H2SX.;UXS7/O7 [BU2V;6K\5[+\
M-['_I<]B["X!4%;&1:JADG^Z'A53X*\MQT9CB'Z@I'TGGV2"A?39U7H.N3+Y
M7(/?FYW^1$\<K"#UX9A[K4IBG&=W5=G^>KB.RH>$9UM>7NCLXV.]#C<FYG'Y
MW2)S(T0<A=E0Z&0XEA6YV\@8Q)(6^=A.$H>;W^65SD9ZFNBN\+Q,CB<D7EI*
M%**]+FK]ZOE='S2UZ89;I26]'/S'VK76+&8-Z@)!0<MO,FN42?W2 DH:CL;:
M!COL/AJ$W_/KT>B:_D(5#J46/,X_IJ(N 4,@%ZC$&Y'Z)Y\F#LL,]&;NW?6V
MI:6'PP2^3M4)H()F)ILMU_7?"]?&D!P65;9R?>5XB8'&HXYW9XJBX<T74NV1
M/)*R@F7A2:\(<NW)]V\KS'N[.V]BR/*$Q"PY6+G:9:[WZT?BC?D/79<V417S
M^[@Z*S*B-4(M<\Z<=W$$SSLY)<%[<=Y<R9)2'BQY&5<1VF=U!/<:Y&TMY]+F
M]R0:],.(=5%$#Z;>H95YBKT3QO4LL74-S*!24QP"[\];X<AJ5F!SGWL%8R<T
MQ [83@O?)B?46[88[W2W?VV']BI$+_3B:A_&>&TI@0IM(K_!4Z5)2D<EES;J
MDW5I:-GG>XS'W"T=5>./Q:\^7&06+7+4S'/&,5"T::-WO_\H6W9*APUO&Z7U
M7"[?:I2"PXU4_0&7/;U%^*V).&YJ<11_S2.R5A7;/M20"B,H)VYD[@L))CFC
MZW.RWD=>MPQ',NPT5-3G"_)\E.PQS$Z?#8KLZO7.&\@&T4]-MURQO44MJV-K
M\ZI52;(NYJB9'8R);A&RL"T+U>ZBD^<0\G0A0\5S$FI?#7F/TM_LXB 22G6G
ME:'EZ48(EL9@^&1RMHU8JRQT<)6P?L"4/1^+[-Y4Q=H](I\M_=_.>-D[P[DZ
MO*WDH^=[)?S.GCS@F;3(Z*.% *"V(B-!"JSA!O8-#G2,%XT^4$CYM"C;\/"G
M1U\*VW31PQDIO=0:\8=ES O\\U+J7HQQ,?N[AJ=-^?)TVO=^VS]^N\JHBI%>
MTZ2CO=MK/[\0+L6.MY"69;ME4E@<. %XEK]G6UJ"Y/T(9T?V;D&9OS_=]^A4
M9&TEC%M^[*5 /!ZF*C=^^=V=$T5GE5,8 FA3@9,H5].9>=T]%@!9^BJ8AP<R
MY/-4SQUL<X.1$!I]$+1:,PL[JKM0]L 6!)5,PPV7GGC4$'*!OQBD@'MWX)+@
M;ZEPPFDB.!B\1X0 _#20X)A4"8F[C\''$PA@%PF/<3+ O2_JSK? )[&>Y30K
M'P[W<$:^OH-\BUZ#[)\C@##(!0N2""J- ""S%Z^1:/][2*/?&--\\UV'[,_L
MP,\-X4PA#_'W%<].T3==I4<?LP\HL2]98P>OT-V:][2;$<"O&@KRV='X3;;<
M20BJ+L=]8YML@RYQS;94U*?MYS7^*O,:?Q&+TE/] M2FD^<5'HX9M)WGL(+_
MKDJ#G;@7EU3$""9JDS/(MWE-2[SL(Q9/ETHC?F/=_,.[-\EK:^IBV74#&ZAR
M?:V>DZ&%MG[++[[_+2HDOI-CO#+A@93@E^PCFL7865)<^I#0F3V80MK&;-L,
M$C*V"/LF.2& B>L^]&@\0CR0ZE967]$W0F>!B4DNS&I^KVFS L7->MD45#[L
M-H"^4=@X\GK\ 5J*S&VT>.4CR@RX$O"[K#U\V_4X2?0)L*9F:85:N\ 0PQ:(
MA OSK\,?_5V?\'W6(T%Y[Z^]L6CR5'3_U0%&1A:SME5>8%,1^OMH$P3 T=)"
M^6;1YV3H8 P)9-.X+P^Z,N*RJ+A&+QP :#W.XB_ G!4"2;)9^Z*SB[;SH%VC
MI?-! 'I[MT&#WS(JWR;^(OH7+]0X)*J*R$P&CU&J(X#^([X!G7_HSU-X:06Y
MDF"6*$,:GF,(H+8NX:8M>-:PYR6UC$!WZ/GF:?]**^SP8NU_W'?:P2.OF(MD
M6D.QAZ<)SU;XP;BK-\=R^+0[3"W)XJ+BCHNN3?/L0SM/G"_86N-HCD?W,SG'
MHANS,DX+$8 76%CD1V9T(2EQ/QCLF\#/X,XH&$G7)YEC&=E7FT-OYWLVM\['
M6TSRF7^:Z7EW)=SY,_R(IRK?V^44?!,2K/N#X@PG:X.U]E*F4'[03L&JO,E?
MF0#".?)$Y_I3X<PQ2XHEH57!_:MB,)Z3(?@E54[U.BP=&Y8MSB/O67!I!52"
MZ[-;'7F'B6<O,Y2[%#^-YQ\TI.6\Y=LLDDR?L5(?63##9W*IK^$7Y/UYQ''I
MD.C3L\MU@M[$9SC9UH$.E[FD7J89(/NSR.+7I]$$;KP8;B>B3O= 7:YC1IJQ
M\CDDV@N634=UZ^PWS1@L5[M.*9>/#A' R^$?-,I?7[]14_ZA _<?OROUUS(;
MUA^CK:P>H^)Y[S#=E_!N<)+LXIG&3]WX8BT*D#)LL3,QHCJHW%YZ+ H#4]B8
M,^G]N3S\A?\D>!_J/^KV7TV0KJ,MJ(UV3@'H_YUU81K1BFNV$FXBCL71_1(@
M!R4Q01X>ORO(Y=C*71I23FTE&6@S3MRB-=FK'4B/T8P_8D:7>FIYY5[+M5TY
M23/:5RD;C 2SQR-\F;?/5A' \Q'T6'?ON]]BO5>7ORVOP1JC0P,XQ#:IEKWP
MTQTZ?UC>P#\S<OZ]B_;OS-4"TV0CH\*[4MUA6_:9J_;>;PH6M5F1T/_S+UM+
MPIGL2]4-?C%33X5!RA:54:I03\W#QP<8/E+2 Z'\=TI55!*\'1J1J)_U@%3U
MLK_[9*%9K'A4'/&$JC.$YJ73G8:<*/6@U$I"JZ\DJ!CGSM(<9I[03IIJ/)W+
MQ12:AX_JX0.O3Y7D \5O]>)T>-:%&IY@I4$Q=/\X.1='^<NX9W.P 6>3EW!L
M8LXXBX$,#I&D@$!;*Z-G*P(854FJC$8FE+H\^C3.+<&A1%;NHYO]!L;(>>UI
MZWQL;%(YT&VM)+/+^KW'U-D38#[UYA,5Z).0(58GNXPPQ.V_GR_ AE)MQSX4
MG%I0=]"LK"H.E%<TR6"%F04@QT;Z/="'>2345OE%\?NE>03>##TO15>Q@)<C
M@"IQ4LN_V?S('K_KD\CB//F61AW[0V#$.PPAS:>:52B4T3CKK<QYSB[M)V./
M[^DRVNKWM74SVF1T.O$25(2E9;]>,B(X?BF:A1*VC1R;=[Y,+D8P(1\\SGDZ
MFF/PXTP:F"/DG*QG _)7"OL=MNT,.V/Y;E$"<ZM]PY;'X"]>\\&[I\H(X"H,
MKLHUG=E=N$@NV)JA,C32/,0SY5ZH0J%(24A.+8&9.#<\&!$TE)8?21QIE>;8
MF6L-59OXR&6^G\_%%+PU'T+;3RPIN=R"M=9T=I.M23\_Y=O:J+*S9TYFH)"N
M= KO@[D.C]H%\0: TZ$[W>H85_\%I97B=87GFJNHJ%D'"^^MRMB%E<JT%W3K
ML6@#W%A0 =00;O::!4N^-! ZLL*C;F\^(WG@U>.@/,QGL$A&JBYOSRG6I\ZR
M.$U.N#41]UD8_$*4W:%Q-&)V37M_JHOIXY)\@^L>UB(95<@;*HMT%5AD)G$X
MN'C+M:,A[>;]^;8>K,7(]HN-+M56!\)F-"MB:^ZL0(!&G)WM,%OSG6IPZ=?
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MF;#78;SO&K6&U[*Y%007S"%!6R4RP!?H[$JS:_'L#:\UW#S1//AS!TZT16J
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MM%E4E)ZUH8XEVF2EO"2@$EXR=9)CDY,*.2CYOW^JZW_718,8_U]02P,$%
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MLB@#4*D8D"Q59=M#E"89Y6'BPFZ=HTV-TNI]VT;:H!'7C8^Z$;8C(6^X#7]
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MDT,*0,E"_8UC 4@49XJE*D49M_G&#YX\M>]Z(UQ@I+/[J@_AZOZ2+P)AZ-,
M._VM/]F3NA[Y3 O)?[I;/O^L[ZF^4/V7[8=Y^*11/L:3"C0?X.D+>D>ZF'2M
MCZOE<RZD^.7E]T**MXNWBV=9F*2'6[[.G\O5?T:24% .,8 $<0"-MX<J%@.&
M:!K&!",JL6,8C.704XR1*7-5'VO93;VM'YZ*TG-M0L5K#0*Z4<$YT,%V5JRC
M( ; >H00B3*_]&,;YM\;F#?"![?G8>X3+>&(F+]0"MN!QXZS< 3D2!"&ZQ-\
M5-<U11YFDDLH(8V A$IJ!L,$X"R1@*2QWC5(&%%I95*<'F)JML6VAFN5M]*K
MJ\D1).T(YS)\!B:6@_*V1KZA:M>V=1^D.FTYP!7KS[85[*XPNW-EOT];DX>2
M19$O%W3^J]3K7QI#KH1$@(0< 2AB!%@&0Y#%(DY3;:^$RND@:G^ J7W66K[_
M+?DZ>* +6M<Q*LHNKS)0TO'K/@#3[MN^!**!O^RV:(&1S=]7?4IK3]_TP>-'
M_:)/*;?_/9^\KG?6S>-*WNMU*7^6U5&4-A(^J"_TVRP2D80<4T!BH0!,3+=>
M&(4@E"@C/&$TX<AEN]$QUM3V%SNB]HB3[H+5[A/W!-; 7_LN3CO1U#>!V3TL
M5: EOAD\M-H"+G\Y.B='&CM/YYS*1W)USM[BWD'TG=XQW)6'UGIS(6^_Y<5,
M<:50%E$ 54P -#Z+JI%HDL5)&L8PH=*VD>CAXZ=F$6PE-+ME&7PU0EJ>TIX
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M@,%CMD8W"KY2-DZ,,F[>1K>J!\D;9RZ_@ FJ\A+OEXOZ$YBIF&.4)!RHA#
M%0T!PW$,D*!)F,:I3!+DS /[HTR3!1;+!6B8@)82]R"! T =*. 2F$8A@$K
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M^=3P.G/I\UQQ9 W&/WF\SA0=/9N\DBC7"71I25R'1& 8"\*B!'!I,@<1I(!
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M[HFI0T+N*SEU$!G'35 =$N:#)-5!![M63Y;'O-[KOEU4LLVRC*0PH@HPDL0
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MB8G_2B($6,HA0 DFL10L$I'5RG1VI*DM*3NR;D^9'9)I.G'M)G:O: W,R+M
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M;2C%\:Y^ELJFH-!OFJ^>5F4$4K'YX?_,-9NM^'U3V%%%G.L-(0&4T@1  2.
M4Y8 Q40D11:J"'$7P\5I]*G9,:WB81M)RVW'^]O_<K-?W";!SIP9#-J!^:<+
M58^%-B^"R9.UXS;VJ,9/+UCV;:%^#^F9;$N+>[VA,W^8U/]G.C>#;?M1'O_]
MQ^4\YR^S&$4)5Y* D#"A:2W$@$1)!!A!<02U-0614XN$2X29&LL9(6^J8(*6
MK.4769TME[/JF+5[R639T=]84S P&Y:X&ZSW)V"G+W#'595&P=?ZST$: OO
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MM;S?QW;;%7YO&VWG@?NM4I]DL=8[=1-G:4SEIAHJ94QB%0.IH *0IQ%@"1:
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M4%THGF828*Y9'>])4HH EGE>(DIRZ5:DX.C)8UO7-<8EM77N"2?[<'7/_JM
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MAM)FZF7#L()-U\!TI.)TU<-ZAONQY=RTM6HKAKZ=SIY-"Q.(9%&4:0F$*#*
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M!21";[0=M/(ZVVZGNWIV$^[,Y:][;KH3[%B599RHC&9E7D!0,,0 9E(#KI0
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M^G'%9[5FT[F2[]C2BGJM;H5X?GRNA&;?*CT5T_5$L"S%FJ0@5P4$N, %H*1
M !6,:8@48L)+0^-RDV-CCAT+$UF;Z$<;#BB7F14>(AG(($( 0T8!P;D"S%!T
M7E!8%%RV ;&#XKP?^?K? &DWG@[[ED:FZ];8I+4V^647R<;@\Z'!WK3MCDX@
M]G9H<% 2=P?@D,L][NQSF"O$\MF&HE9)RU4MB+OYI^7BJWG=VH"4">-$<"R$
M\?HT 3@M%2"VYA3/5)YAR#$C'B>[#BV.D-"MS8G8,=IN5#PU9ON<9[H [G(
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M<=XI_4^_172/87!;!L<%-S*!VGIGE8IJ:[Y=M/YB>V"6HK^>E%V-(ES1'\1
MJ\@>!@RZ#NP/T.%*[HHG^:_%WDS7+[=+Q=XLI)I@:M9;)5,@%UP!S H%>$$1
M()+E)4E140BG&/G#!X^-K*QMB34NL=:YK[3VP+J\O.H+0>P3#+?>>ZVC3G6U
MU^)I[T&#K9A.F;^[3#KY^YZ)A;4 O)G=6JU6QK%DL_=*;4L0B+P@6F= 2+-
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M-7L>ODSIQ)Q8YS)*QR&;%(@-9<'+*, &1(48N(K-7X0\3,K8=RN#P*:%V'M
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MIUK?)SU"RKA%%2<XM%JHH ,D;;?'JQD%U+5C#.T%80J6$AD(3D&!8LE#R+J
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MHG89+7'Z9[W.7O4Z>\'J%/4Z^\BX YP_W%/J"G?.60\\>09*%CI_;5YQF>[
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MMY7ZC ^FEZ%J[VXV(S>,]-E+ 3G'.MPJ6?#,(PB.PDEODM;=^)]]B9NH@IT
MX:=7Q@/@=K >_CE,/_AMC:MUY]KX=_HOUK=KG&916BXYB<_P4,THUNF+ID V
M%$V'J)#'Z;B\N[1U?OU^";IX!-BF72#S+&=^'R1XRYE:A$&Q"T(0AC@C.*M-
MI,0>U$JZ$%U*>3)J>)>VSO,0+T$-CP#;_FKH-VJX&%89UAZ%[G5Q6\;W X>*
MB8(7(<%)I:HL39TT1QPJ(6H;!->YF\ZU_<F;:)7T)6GD<9!["4IY/XP7TD3K
M!8-8! >5G (OI(>D,D,5&-.RFWVUH]P:^RO+OB2%/ 9N1]X:WRS25'3Q7F/(
M$-Z_)HMR6]Q[1]#:F9R4!\OY4(JFZV!_LFT\<*VY8\&<O&+EM"R8Z UT,NG6
MT>#X,O*QS[)O9J7&5/M8./?$*:<X>)<59"=CBME'W[Z,MP.Z+SZ+.Y[B=&@$
M]D+QB\L /\^^J NWI@20 E,=XBLA6($5"0ZC9E+EUB4MW1 _40_^HBS!F'B^
MZ$#@;EKP><8A8\)8ZZ"P.B6A1 ^^OJE)S+PP+K@99QQ-#\1??!;[ @S!F'B^
M:$/PO8_]_NB'![BF@K/&&P4D?[H)JJ)K?ZZOF_LPV*B$P.DDXO:A_.+3YA=@
M D9#\D7K_QYWJ6B%8=&F6CZ3B6=2 WKIP*ABG)2.N>;U[3W0??$9^@O0_9%0
MW#2[_^B<B>T/ZI?:V/VW__E_4$L#!!0    ( "1#J%8*,QM?V2,  +O$   9
M    :W)Y<RTR,#(S,#,S,65X,3 Q<G-U+FAT;>T]:7/;1I;?]U?T.+49J8JZ
M?<H>5S$2;7,B4UZ2LM>?MII D^P8!!@<HCF_?M_1W6B $"4E3D0FGIK($@GT
M\?K=5[_ZQ_GEV?#SAXZ8YK-(?+CZZ:)[)A[M'1Q\.CD[.#@?GHMWP_<7XO'^
MX9$8IC+.=*Z36$8'!YW>(_%HFN?STX.#Q6*QOSC93]+)P;!_@$,]/HB2)%/[
M81X^>OT*/X&?2H:O_^O5/_;VQ'D2%#,5YR)(E<Q5*(I,QQ/Q*539%[&W9YXZ
M2^;+5$^FN3@^/#X1GY+TB[Z6_'VN\TB]MN.\.N"_7QW0)*]&2;A\_2K4UT*'
M_WJD'S\]>G%R_.SY\<EA\/C)>"R#X&3TY/CH1!X='STY"?[O"!9Y (_S.UF^
MC-2_'LUTO#=5./_IL^-Y_G*APWQZ>G1X^-^/*L_EZFN^)R,]B4]IM?#M.(&]
MF:^#)$K2TQ\.Z7\O\9N]L9SI:'GZSZ&>J4STU$+TDYF,_]G* ,)[F4KUF!_,
M]'_4Z=$13$Y_+LQJ8)Q(Q\JNCI?4^3K5(YV+H\/]HU<'^+S=T\K.YC(, =Y[
MD1KGI\>/]T^>S''5N1Q%RCXS2M)0I7NP^DC.,W5J?WD9ZFP>R>6ICFD-]-++
MF4PG *Y1DN?)[!2&>WFMTEP',C*0(2#QUP:0SU_L/WM\@K#,4_@OM!,;,.\3
MF _R</6[%\_W7QS>_#7LWWUW0&.G]@$+L!/>;RA@5]E<QO]Z=/*H!IS30W%$
M3Y7C'-!>FS"ELOOCQ[!]#RD"0%"5?G.L.+P35OS<_SP8MB_$3]W+8>?L74MT
M>V?[0$]'ST3WPZ48#"_/?L;/.KUA]V-'?+AH]UZ-8*_XGT&B/W_9#+U0!4DJ
MD=^<%C'@(C[UZ'7O<M@]ZXC+-Z+?&0S[W;-AY]QLXZK7'8KVIW;_O(K_-Y[4
MT?'\VU-K?8./&\_E+3#37*D??WA^?/3L)0PK9TK(.!3M,$Q5EOWXPY/G+W_\
MX>CI8<///^=DFA:^[F1N6^WF'L9W.'^'\^^ ,R^\PC,W]PP^)X78R:=*(.LY
M/GSI,:+CHY>[8BJOE1@I%8L)?1,"5Q)R(=-0)&/15UF>Z@ _'N1)\$5<Q3K/
M*@/V!U>9':TELF+TBPIRD2<"GP%!.,N(SP5)')(RF>&X^53##A/0&-2-TX@V
MK<*?B]\H9\.O?DZ762XC\9-.<A5,0>+%@2_Q:#SX#*2RAJU^B&3<$A(6!8ID
M"!..TV0F<@ YK1G_]6?$Q\OY<"/XY;KUMB>I4J3L^N.X3QW@99[+8 HC3%6J
M\H36- :E*UED^P(&C$ JB 2&2!<Z4V*>)M<Z-(_KN.6!5\<5>&93&45\KOA,
MAI)FIF2,&C?,D4]!41>A&@.JA/PN0V5_\Y&9(=PK9B.5_D69R\;!_!P,-J11
M@OUWH/\Y0/\(# ;I]2R9 =,(F)_@27P_@#_G (8)RA3F-"2A2,K])6&_1>K,
MNOU:DAF@4"TB]7"G@K ':V[3@?GH]:"JK-5MU#,80,=%4F1BH-)KU"U0 2*=
M1$1ZIG/)"EVF<E!=TGQ:4T5822D5(JL^L0Y&BA20E5AHT%>,GG0-IVA4)!Q,
M!G#4H00."$_!^/@.*TEXU)DYZHJF5<<#JW!MW)DT.W"&L),B1C" =D;@87T.
M/Q& ]7(4+45R#2<@ 1)%*I9*IF(.DR4APRB!(?$;_'5,$*N.=VT E+#J=Z.H
MX<,N!_/>4Z"YPM<Q*-1I)M,E#I0J.09]%";+=21PR=5I22'E#[9 TSPO4M*7
MXZ60!:C,*;P;BDCA)@"J<I0AK!B)'6#&)4Z#HNTT=DL4#EWY1$?P2Y'-V0IA
MV.'K]3F$^AHH%<*0]I1I'J IL7.R*V:PE2E:#!\;5L$3I2HKP 8HYN;$ZW2.
M5H2.B9;MVRN+0%P ,Z5(8^06F6$'AG$ ZLP14@DB95]%Y.+O ![D2UC8T$,R
M2Y0-JQSA3G.&QFAI5A%/2BQF8&6PRBW GRZ#6ETC-9D-U.$>3&4\48@>8,#F
MP&7)%.W,YE&R5(!;YSH%[@Q A?\#+\Z**(<!$.@$;&+#YDV8X;;W6G6 !\S>
MZ12)N]S ;U?.KF3W<@2<:!M.HW( 8I$4$2 9J!$SRY)H\W  ,K!D(&,$%GHT
M@-?!;P9J<9(SM)C/^</R@)DW(J$ /)<2X+< 4/:L#88HF7E\(S268 ._N(/J
M,$;N '@+<B)+0/SK.(@*C+R(4$FD\A00-Y,C'3';J%#0'>?0)3-#S\Y]9FPU
MB"Q23$:T]+'2^'&5X;%#B%@LPC"K08,XI<$>,Y@&&1MJ6!T(<;=2(K6DR,5<
M+F>&7^"Z@4 S$""LZM:4M"W I>$*?Z\Y!TE 9M8E.%!,>D='%HRH)CHJLHQ4
M O#3.>K_BB/4EF*!USE^BJB1)M$JD!Z(_?3$I^ZPUQD,Q*=WG7[G\DVK(C>M
M7FSQAE0E]54%!>&<Y]LC?$-]&CZ5N:=NI(1M .,)ZH9Q*4/OX(%ME="V*W$Z
M^\UXYH?*YPDG"IRF*/Q!*[PQ>&[0\K!\!32,)(*-KKSRK<_J^'?%+([N;C?[
M/Z<N%CV7$[4W E[T98^4O5,9+>0R>W2O'(1;YEQE WDRYYU7<P".GCX86VCT
MU[=P1U*< _HL$)<#0^. (+<Q.MPAA> W9H<_+?\.T=R- ?<04X'^RA#?(@<=
MG,:[CGC;;_>&G8YHG_W<N_QTT3E_VQF(=N]<M-_V._#K\%U[*/!!D%T#,7C7
MOK@0'SN#(?""-P*^@K];XK)W\5F<7_6[O;?T[(=.OWMYCHD@WA1&&1R(L\O>
ML-N[NL3Q.OV/E#+2%^V!N(2G^Y^Z@XX8?.B<==]TSV#TS^)#__)C][QS+E >
M@WS>Z5WBDOJ75V_?T03MLR'.]5,'YW_7[7?.6^8/GOH<GQJ8+>!49_]SU:7%
MPG[ZL$D<^*IWWNGOH@WL0>7-51_7M!XZL)QW.!@L#7X9X-^PIQ8O#9][W^D!
MO&!B@LU%NV?@"(!X X-??;CL569M]SZ+?O?MNR&J(N\PF0;  5N^A/4,K_H=
M3J2AK1A8MH==&./.\&[!&OMF$=TA+'S8Z<-*.K@%G/Q3^S-/W30<K\SLQOS!
M$Y]=OO^ K\-W_<Y%&P&/N4O#S[CT3^^Z9Y4![;FZ50WP,5C)^VX/WKTKZB .
MPIS#[GO8%BT:IL=_+Z^&XJQ]-8"/\<3J7_$IU<Z[<LYTN%>]"]0%_8?> :JV
MQ:=^=SCL]$3G_8>+R\]XQ.5AE\"S(,&=T9^]8;_=_]QJW-U@V!["S@"%VCC$
MQ<666 Y6%Y;!ESA91"J<P/BI"I2>&SL@2.;+BJFPHKP:K]4\51G\E;'.# ^
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MT0\- \ <%39<%V"YIJ!V;FQZLCW86'$WTFPFNQH?3OA)4B0A/^DE0\^,QG^
M<C *!A\QR#*,E==+7[;"MGBR3:13K;E:K7UZ6#+JWKD,S%4]97_M^BRBO&K>
M6,W[HK["=C-TQI463-4%M9BJ2OH#^L9 4$5)/,$<KL!9FQAZ)W.*@<R@=7XR
M6"Y:#? 1<A7TQI%W5>R4 (>9#,LI)T.^!QJIL47,7AG&+MY?F70QU5C9BX64
M]?KAW2V0I$^WB1W(K^IA)>?FG^?FN8YN.5%QH0VSVP"=R&,Y103:///$2),A
MR7G5H+T 4\"_B9,#H\@1+4%5+WTU;IB;34\T8R<R#=FS;=PK_%P]2P_^J;87
M@!F_(.?!\7!!-O\Z7JYSRYBDXA1ULC4+ TCTC+?+7TC<O)(9K83EF<DX=QE4
M=,ZP5%P';];Z_"@(X N5^K)O6!]S<!BZJ?F$T16S ICOKP5E-DONN>!Y!)I,
M,6_GOH\$CQL-_\J.,6TII/QA2OK3G/=$X15R5J+-YD!.HC9/BR O4E4N%#X%
MB5($)H53&WG;I$H@7")+']O ?3;.[[6.^WPH-9M/'O(]O)@1XH.M14!,Y#+P
M=7XLE[AGD=>I4QEI--@,)<JMO74SDV@YG0A#M12W9:55H<87M:CSAFH)]#Z0
M=8;!S:O]P;ZOQ^(461)PVGY6I))ZQBCJU,%..OFU5:J5G-E?,&$;&U!^W4L-
MV7GDY$=N47)\3Y#BGR=;EB"U,>S*I_I+AV?5:)$S## V+=.4BD/&5M@TN+K1
M^)D5,R%GC-0F,HX(VSP?=V$Q3A#.W.802\6LVP;NK_]H[D\CGNI<1CJXKSQX
MNO_D&8+FIR4K!/YI>)Z;AP!<+\F1'Y?Y&X;)/]L)=OTLZ1;F6<R1L6>L@K+2
MT2[#<A=RT6HHWD(90._E=5< I6>3H+$-ORIR!+ZPDL+FS6,C71O7=$X^%VTA
MGUJS?M4465I,L?1H)=Z:%>.Q#K2)Z#"588F6'6(FOS*-E3N_F;Z,7G>O=] "
M&$ER4ZZ$35,2B69C(%74M62A9F%(6N(.\@CU58+8 ^E7%:"D-)(,W?4%9Y,&
MF!&JPF0@+].$7:(9J(R13-GP:*UV7>/H;(2H 'IW$1G]W_ LN\@R7ZH:R;=Q
M?!P:]5PJB,1F;/3V%- 6_<34@@M0:TG@X'E!!_FE /LB9"<WP+T=FZ(G-D!,
M=8HY9$(L%9%7.",$2TR=F7'B.%?73(;JID9=6 2F.9<JJY0_-58QNLA\N2H\
MBQ$-O\"C8^M#4BB^@1M7AH,=ON':PGM09KVXS-)=5B.\5L4_G09(9B86N5*O
M=S\:_;UT6)%R]Z# ]34G#AW,W*4GSL8A;EQ,G6CLXM:NJ$W(!!_;DD2W/*\:
M;]G4[6_5#/;28FP6#(6J?=HV!7QA:&X7<A3MJ>(M]@,XS8'R,6]F4@0[S:5N
M# ]=(GY%PW<GBB&45(\P V]+VMCMZ(U6*T[VGQNMXFRJ@B\M.*O4-.G"H!_@
MRR79-.^QOO2!K<IVSO8?AJD19\CY1 &W,3+^G2>[8H275.''5 ^Y8]GE6"W0
MN^'X0_6QQH2E"J>$@=48\Z1P_C483>XIS+?:GU JM77T8&I872&7RU)[6<<-
MUDQ7S>>JD3K60#(EKC.O]3HNN7[JG:^[0*5I&2)UL1EK$<NJ4, MA]3GLB5V
MEKN5K!II4]#@! +$1.0O#78$16=W_K/K%[1R134RL;D*>(C5"R*:CG4+V$==
MM\8]("9.$N*W==Z^PMFC+&%19([U%@0>X6&,40%VG70)AS(O\-0"\LF9 +&?
M-$676NBME"D<SRB)"]9*,@6'2]J.<99DN_5#;2XTQK=__.'QLY?-O6F-SH)Y
MBZW55H,>>GM2YHZC4PGH6.J(0V9.+Y& ;K,:H:!TE57Y9WSI87&+[WR-N&Y>
M)[U:<Z*C+ERUT3$K')<74)HE97R9+%;''YG?4=]B+G&E8R;5,5<QC#"C/B&V
MQ/B.2TG0J9PEI?N-7&M58PV+"6+C1G,=!NXX@;0\#"AK"VCVV18%)0=Y,M]S
MXI[3D!]:SG=CSH0AVPU=L-2B !3UNNE4)B21G6MWL=K:OM;MPU8:I9YKHBZH
M.)L4[(,TF:>876!=MQE S,U5MKWG2(DU%-',<>N1$YI9$W>B_ ;ZHV(OF6<S
M>C-9H!,B*-@6AX>Y50-&JRHK AJ3;LK<%H>H\1C5"I-IC6.E>/1A/4+D[?*N
M>[/+=JUI@%5FOM:P7KQL0V[>\RTBW@ZWJ?;*SIX\?RG>4C=9A#P8[1L0E;ZA
MB9-/EI2J JR^,(%$TW];NN^-N*#^,@VQ8Q,YI0* F<Q1O'GMNK)B#I2E0MN3
MQNNV91I@Z6J\-RO;VK!C9E5:U9)>[[B<ENEJXY(39TG("JL,\5H&2F%JOMC#
MI3BB-VN>H\ID.@F-C0"GO!YJ/="@3]42_8;4W<?;8=F,F(XB-:'FNLL*1ZIW
M*Z:5H4? YCGBAQ1YPS]<-:E-R)JPTF&XE(D1!M/$U'["TR+%&AF2^-SU/9!%
MIGP_9N7: S,K#N/[[_R$S'LLTX#?))_A?L,B]]I]&!0$& ZX%PS.6S92,D_Y
M$J:"Z-3LQMF:#'$=16K" <DB5C&(KD"Q P:'XFUX9:.F(!&U:_B*C.!48:<D
M U/4]0CMS442_%4Y[!8PX1=;Q(3/DE(^;@"W#>2<50(JF*V6ES4P7BX(ABEM
M\WT@?["EM+M I%+^:HI\I2F:<<$1T_C)O%^J"U16XW?]@T5VF']1GJ3GW75M
MZ0Q7P9LN .A, WCS>($Q UY-I>0E*E*@'<OBS)^KS]DAL/HA<_8'4J)5?I)2
MXV&?)"X]#AV9NMS/%I"I\3VY=8H@4C*-EM:A[WFNMX#>C@XWA^!.;B.X=K5I
M))Y\MX)D#^VF!(%@&U_:D@%4;*I)9+76ERN44I4DGO:T*E/\NQIF:,BO9/)Q
M!6<M,MH4#QI.32/-PJZ!/ M-VVD,4+FEC'5LJ-*6*^!1H;(%:LYV6 )'&]19
MY%:B^$C-2!'>GUP+TG]C ](A-B#= +ED57?O)@S*M"HT\'A.02'?+B@Z&*TE
MOQ0H<X0Y!<D::IGI-XB]'W&,*(*56Y%8S1 [U^Q+ /K 0AP49$XCI"@"ZWI$
M#%RK$\G@2U7?Q/@PWNMF7."\(]Q?=5LM#M"ZX3FD3H/:?B'&86E!QEM@XK8[
MKVJZ8V]E-7CK-%7724!7T%%WVI8= JM=V:"@&E5.L##,XWMN&O]\_#TW[;=1
M/:5O4%2"S&";&,Z]6M$ YI*:Q)AP2Q/FY9[*MLB(D-KG$#4&X9%T!?\?KM\6
MWZ7PH=T?=O&"@(O!I>C\[X=^9S"XP&[ZV!BL;.H/CWX6[]H?Z=J#]VWS^_!2
MM,6_K_J?Q;#?;5]@3WU\97!U]@Y^=(<MO.: NOSWL7/^6:=SWNV]?4!1]>@U
MEI+167L=)1JZBGLMKYFE58O)D$E3!H6.KV6DPP9[6%.^ *GS'.H+6$E?<1 1
M#R6<6#&<?:^+S<<R"1>&$\8*BR7IBLR$G:[,P]&=ZCL@>)7(LK?+NC[:H+X[
MMRHVFQ&2:,?<ZS=P&5N$GJ7,1/\>)TTY+)N 1(S]Q*S2G"Y-:>>RB9;F!4J;
M8BU9N@8O2Y-.%2J2H$0Y+GP^HF"_\6]Q=@X9HD$RB>D*5/5U3KW?9U)'Q"0U
M14FXN!.IS!^Z43^B-V&>,DA/G^SH*ME9/U_3&+N<YR5@EAR$(E](@*%/6-M<
MZK!E6]27=&E<7R0S,%4(Z<^TL<=H_Q1C&SP5>1#0[T#>3%(D;3("#^*_1VS!
M"2+7.-P_JM7\@=4E;0.E;U"WC%LI_4+&DP(PXZ&CC]40%]_J8;I!UVP+([Y,
M6W73 EK8T@^#,=P 'V-JD;EV 7W>H//P;GTW=2>>8/8GUVX9!U7Y(@8(3&XO
MB"]J(I.7[FW[KGFJU?0A9Z2BQRI-(N?%*IUPR"5,>AW0>C7[<QNP?8/Z:MPN
MUR25U6U&+]!N;'*%K7>J(4_%SWKU;WT 36OCKFG?EN+B1Z\=A]#5].]KL([C
M7*8Z6JY<P\!:<)E C9HJR*Z8,*IE*C_MY0Y6UVW9YJ M[P9S%)/EW;OUJ&&9
M;MG(*ZHY^S=$=@$U7FP#:FQ<Y2>C1AE; :!:G." ;A($,N-4;(I2VDM#N .=
M;7:18SYWP<%%EC2N7YJ1:F)<$">B:5AU:KH\PGZM2*FU?[,9/U+P&7V@Z.XN
M:H$7+2UJS&6V-7@0;!(>,(N0U.<Q,$9L/=>@=GHVR<C6GAA78JWD8J7U\'8<
M3KA)AU,2:3U5H[P%R91'^DS>$?&V %UM$M!+H7EWH)<1;,L:2QY(]>EE:;?+
M+:R/;O)6TUI(G&QNU,3+-TVW@WK*D,DU=..@<>!Z%=T\8VE0(/%/]=Q+(RS%
M\[:@TGAS4.GI_N&1+V1-R-_F-<1).F.AJ;XBI\6JA-H-2YSP[GR8MG.35S75
MG"@?R"@H3!B+G-PV3;Y%M_5-8M/*P,MA;U''C1CSL.#@%3<8M_X;FUQO4N]Q
M!=AL:L]^;R4#+MXL'85 ZDS8A8K&Z+AQ4M^KT;2#LU(98X,03K4W ;%JERF9
M5:$$L&E5PG:F@\-"<H4@*@;5_E?U>H:56K5M0?7)YJ"Z%5654HF5N[(, : 7
MXH8<_<;S<%>7&36UEFIX!_:\\&HD70H$NT^XB#7V>6%2.BZM=EMB&+/(DA?_
M)3!INGF8Q-%CTCNO950X3&'WQM+=X4#E946,C@.V#0,9FY.&0P[Y;@TZ+?0K
MXUV/6W,J?WA1Y_T[0W#)D=?=L-*4&CAW$$D](YF&!!"YEM-UR1;*F9RXO -N
MN<4.\6I#2SLX9P7!-X4E[@I6V$=LY][ Q$]N;J#-_7Y*/_SJM'=H6MEP8>AJ
MY?-.+02Y +:8)2B1N1MQM9X)N]W#@QA4&)LF0I$<P9>84KQK963C(4SLS3_-
MWC4_2P-[,LBL5E!O.]W6UD_P<:%R/F!WM2>='!$4*(W4#6%=*6%M%+QH.\&[
M3#"Z9/O3CAE7*$JZDOM"-W?BE.Q\AI]X[R@H-'8R/UNGO%"S&@_S 6$'I;25
MT.^'Z?1W:F/.EX,K]063G56XK.8/-&']MG"97S:2RY1:!.+S;R+.G7M15JMQ
MV!5'%C&:\M:-TB.9\!42-DV$R:_B*=DQ515RG8NS3.KG+M.[G@GGI=Z[4H'R
MHMT51<OV@VWHR.JZH!M)24D)(;MG91F&GL.9)AB&C4-B"+QO"[J%K4%O:OE*
MFCM#G?.CI1T-%FZ2H3%55<7<$]:F1?MV 3_OWR+@IMYEEC->5Z;[YV'-']K.
M]PY=?"V_7\]R_F9I=4^^I]7]1HGP97,D@F\-N.M]C!O%T85IV-@2KL0),\-C
M:J\HPVO2![ YJZZWBOABW\8\EAF&KDRI:S6-_NYV9I(VOD#J*%./\>IX35>9
MDP&+W0)=(=H<S+"Z0HUOVI91<.PFR0=59>SL>:/?%0U'EPOEX1$E#U40*</B
MZ=^*&Z:[2UYBG<DW;<CEV(9$B VZ)>'61(ASF4ML&'LM@X?MH;WYY_K')S#\
MGE92-CHS]+.GF.355TPE NMK:>X<DK.1GJ!N%_&5#,J[.!:V8[K;M;"(D55X
MTY. -$EJFY0FL0[*J#9?/7>#*EEF4R*N2;^-V*T%DB-C>\\2,I*SREU>ZT)%
MU982-]GO-B[D%%';/!![Y6'S15P$V^=&D>5F3UQ''LO)O9G=-N#Y'YZ-\?OP
MO+R1SN(Y\3/RK#1TL[[))^Z"@50/@7V&C!NT1%B-B>4S4^@XPD(H;Z!;0TU-
MD^*5RRV8#:_ZLCFQN#X@JOD4$_BY2UK+76<YTF#'M59:8I>DA]=NF<LC<9GV
M?=L0RJ8D4[#@EV0DR O#_J;R@DGN"Y;0;6&9+0.HICV!44;M1C 9!8RX-B>@
M5'(P:XY-ZW'DS!0,O<'"(_R-;Z1IE7?3X&Z\*XAUW B\L;S&D-:WHUJ^TMG8
MW"@);??F;:#2#<R564N3I&G8Q!C_7B][^\14IZ%--\\RG;ETR/+.5:.GND,V
M\5FY6I-,YUSI7D+<M]I+M)%O "7HN?8;C]#*34*?O3KO!A2ESGLI]\E34:86
M*();U<+"<@+SFGVKK,PJ,XQ)9LY9/^/>&>8:\]PUQK4YR#>LY2Y[]MLB8H4%
M^NLD,+/,,PZ0=9G<4U,IX!I_E!=?W@"\$6?#H5I_@\!D_]&T@'.C$N@B17>.
M?R_(M:IW@FUN?FMEO:D52$Q/76]E?&LZ^>@)SRJO[Y@9HZ6YEK0,M^TR,.[/
M8DHO:8L6!, CY0IC+21Q?"7+0>T6;<NUD<?DLC]>;[D%BRK4S8V98[XK'IUU
M^"\Z)_S2+K=.?Y$>[7[;]=6PO%7-K[W6P!49Y@[]RUZ[S6I !O+25M)05626
MF5!:.9 V34O+C5,:\,PJW 0U"J"/4=?&=!# L#"5"Z.+&]W<WE5O,C@"F94=
M?8(DRULU"O-J:;X1L7D 1?UE@4&Z%H.6%L_>);MZ_&MLE\^49AH.-?F 3,X6
M-6&TQZMJA_O&5C;ZAV'*6FD>O+4G*)V^*^$*LTCC]K#)-TWKK8;(;N67!NR_
M'=#WT#78D@=M;A*?!G0E.'^B8]0"3T^>_@GJ2'/A;:=W3K6R;_N=SOM.;WA_
M!:K!$_SW==$__6TN^H-1$B[AGVD^BU[_/U!+ P04    "  D0ZA6"&&W;O$E
M  "CU@  &0   &MR>7,M,C R,S S,S%E>#$P,G!S=2YH=&WM/6ESVT:6W_=7
M8)W:&:F*NGW*'E?1$FUQ(DM>BK+'G[::0)/L& 0X.$1Q?OV^HR^ ("4E<40F
MGIK($@GT\?K=5[_Y[]/+D_[73YU@7$SBX-/UN_/N2?!D9V_OR]')WMYI_S0X
MZW\\#Y[N[A\$_4PDN2I4FHAX;Z]S\21X,BZ*Z?'>WFPVVYT=[:;9:*_?V\.A
MGN[%:9K+W:B(GKQ]@Y_ 3RFBM__UYK]W=H+3-"PG,BF",).BD%%0YBH9!5\B
MF7\+=G;T4R?I=)ZIT;@(#O</CX(O:?9-W0C^OE!%+-^:<=[L\=]O]FB2-X,T
MFK]]$ZF;0$7_>*)>O10'+PZ?'0R/GH5/Y2!Z)8?#5Z_"Z*D8/(L.!Z_^[P 6
MN0>/\SMY,8_E/YY,5+(SECC_\8O#:?%ZIJ)B?'RPO_\_3RK/%?*VV!&Q&B7'
MM%KX=IC"WO3781JGV?%/^_2_U_C-SE!,5#P__GM?360>7,A9T$LG(OE[*P<(
M[^0R4T-^,%?_D<<'!S Y_3G3JX%Q8I5(LSI>4N=VK :J" [V=P_?[.'S9D\+
M.YN** )X[\1R6!P?/MT]>C;%51=B$$OSS"#-(IGMP.IC,<WEL?GE=:3R:2SF
MQRJA-=!+KR<B&P&X!FE1I)-C&.[UC<P*%8I80X: Q%]K0+Y\M?OBZ1'"LLC@
MO\A,K,&\2V#>*Z+%[UZ]W'VUO_SK_=T#^]T>C9V9!PS CGB_40"[RJ<B^<>3
MHR<UX!SO!P?TE!MGC_;:A"F5W1\^A>U[2!$"@LKL=\>*_7MAQ<^]KU?]]GGP
MKGO9[YR<M8+NQ<DNT-/!BZ#[Z3*XZE^>_(R?=2[ZW<^=X--Y^^+- /:*_VDD
M^N.7S="+9)AF OG-<9D +N)33]Y>7/:[)YW@\GWPJ=-[?]G[V(;%[[QK7W5.
M@U[GJM_KGO3A5][8]46W'[2_M'NG58I8>G8'A]/?GW[K6W[:>%(?@+T64O[M
MIY>'!R]>P[!B(@.11$$[BC*9YW_[Z=G+UW_[Z>#Y?L///^:LFA:^ZJSN6NWZ
M'L8/./^ \V^ ,R^\PD77]PR^IF6P58QE@*SG</^UQX@.#UYO!V-Q(X.!E$DP
MHF\BX$J!F(DL"M)A,)79,,U@$:'<&8@<ONW)O,A4B ]>%6GX+;A.5)%7INA=
M7>=F_%:0EX-?9%@$11K@,R L)SEQOC!-(E(X<YRI&"O8<PI:A<0_/WD3OUL^
M<="FE?JS\QAN?OSJYVR>%R(.WJFTD.$8Y&02^G*2QH//0)8K ,>G6"2M0, R
M0?V,8,)AEDZ" HZ%=H'_^C/BXVX^W!I^^; =M$>9E*0T^R/;3^UQB:(0X1A&
M&,M,%BFM<@C*6SK+=P,8, 99$J0P1#93N0RF67JC(OVX2EK>$:BD O-\+.*8
ML0&?R5$^3:1(4'.'.8HQ*/Q!)(> 8!&_RW#:77\28 A?E).!S/ZD+&GM8'X*
MAA_2,<'^!]#_0"4S0-#_@/@? _%^BF*%60NB.XN^/R7L-TCK6;7?SR"$4:9=
MH10M8_EXIX*P!Z-OW8'YY.U558.KF[(G,(!*RK3,@RN9W: R@3H0*2%!K":J
M$*SEY;( 724KQC7=@[42IP%9#8K4,/P-R2J8*5!0M&)T Z>H=2(<3(1PU!&J
M6O 4C(_OL%:$1WVCC]PIG!L"^+[9NLBDKT?#RL:!\)5SM[>J9NH]<6*><+HD
MP%F0.JMU^^9!S*$N#- *9F,5CGDYDS(OP(X Q;%0^5"ATIQF[O!@U7@,NT$'
MU%<X,E3'8SIMS37A48$#A"DHGO@HJIFP<\":J<A0FYB*.;V XT[+; H**5D.
M_4R*O,SFH%^/RIAP#1 QI'\/=I_NOVKO'&X-MK<.MQ^BJ[ZNN%&?6:^? E:2
M%,<[!R\?#2T.=A_1>5<!R\'^+CF7E^ 9$%GPF/RU/S;X*!@=R,ZLF&;!AU3$
M-=:TGH+:1 #:CPG1W:"[!(2M ,@2>!( <16D6\3+DK1PC()8/!N4L.],YE/$
M(.#7CNL/D)UG0ZD*?+Q,-'_8RN0(S NV>8>-PJGI^!<8VC:9T?K;2*)]K!)F
M)(,Y"Z<(/E%@OHN"N!JPJF9$FLGZ]G:#/P?7.5P[KM,@F-:!XRPL2_M6*L*1
MU!3$=2W24QQ)Q$.#A83[*5,%?C>7 L@K2=2-S'(!PL['=S+Y2)S7AT5?7A3I
ML.[*27*)TO^.*9K4@KI";;2##7 ,G989N;>2>2#*8IQF\&X4Q!*=8+!Y,<AE
M8M33Q5,U:J4/3& CUN5FE-Q< \9#@Q(.B!R+8@C,AEZOSQK(VU#**&<]3Z41
MSP,Z<K!UM!U,8'-C=/G=;UT\-2!&"=I5.=5G7F>6/N/3;R\L"[$LDT69)8A?
MN9Y=FP8GZ62*T"11T),Q1?\[8!X4<UBJ3QQUK&E8[0!A4#"<-!N.93("!-?/
M,AAS6.T&X%J702YOM,[;!/]P+)*11,0!];@ >XK\SIW)-$[G$O#P5&5 UP!<
M^#^<=U[&!9(FT?E<&USZ39CAKO=:=8"';,A)HZPOLZR6GJ'3HL0@O9&;<"J5
M@PAF:1E'=2,$@  'X50(X*D - QL@"4#OVGHH= GJ)4 Q;@R+ ^8>R,2*L!S
M&1W !@#*G+7&%+"X/#X2:6=O _^XA[, [3G$7S3C4C#X51+&)2F D11([1D@
M<"X&*F8V4J&D>\ZA''/3END=,RX]$3]G"$Q08KG'&;(ZD)M+LXCT >Z[5X"?
MIG%9++[R>Y_OX6\*U1[<WP_H_QS;I)RI&,F= 4#ZVPX)NV,1S\0\?_*@9*P[
MYEQ'@G$H"\8%D(PU6IJMFIH$]7"R91TIXB95S(J!N**T'!0M0F,:$1]B=TS=
M,'&:P1C4$PKUBG"L@'Z U97%$NT&GT665GF>HYND2N!6ZU87:02:*^H]JLE$
M1@JH+IX["B11DL+4QJ5#7'6. B@'U8EMWYJ[<0-X9']!?ZG%ODDUS$W$V_JH
M#JRU'(-L435%0<"A9-.47&"4I&DD$<ARJR\@R\O2> . U+T(OG3[%YVKJ^#+
M6:?7N7S?JJB.QOEK4(HBTO)6AB51B1>Q)E1$I[&SQZVS%)VD,AB!$I(E3GV\
M1^Y!RQV$68EU3-\)W2*=<GY@-07SX/FC0;LQ\:&%?%0$IR"T9@BL4.,7@&/S
M=OAN_E=(G5L;</<Q$_O/#/$-"G/":9QU@@^]]D6_TPG:)S]?7'XY[YQ^Z%P%
M[8O3H/VAUX%?^V?M?H / G.\"J[.VN?GP>?.51]XP?L OH*_6\'EQ?G7X/2Z
MU[WX0,]^ZO2ZEZ>8A^M-H17LJ^#D\J+?O;B^Q/$ZO<^4L=L+VE?!)3S=^]*]
MZ@17GSHGW??=$QC]:_"I=_FY>]HY#9#A@P#8NKC$)?4NKS^<T03MDS[.]:Z#
M\Y]U>YW3EOZ#IS[%IZ[T%G"JD_^][M)B83\]V"0.?'UQVNEMHY_!@\K[ZQZN
M:35T8#EG.!@L#7ZYPK]A3RU>&C[WL7,!\(*)"3;G[0L-1P#$>QC\^M/E1676
M]L77H-?]<-9'67>&F<L #MCR):RG?]WK<-8R;47#LMWOPACWAG<+UMC3B^CV
M8>']3@]6TL$MX.1?VE]YZJ;A>&5Z-_H/GOCD\N,G?!V^ZW7.VPAX3!WO?\6E
M?SGKGE0&-.=J5W6%C\%*/G8OX-W[H@[B(,S9[WZ$;=&B87K\]_*Z'YRTKZ_@
M8SRQ^E=\2K7SKIPS'>[UQ3DJ&_Y#9X"J[>!+K]OO=RZ"SL=/YY=?\8C=83O@
M&9#@SNC/BWZOW?O::MS=5;_=AYT!"K5QB//S#5#(^IZR)<)O23J+932"\3,9
M2C75.FB83N<5-75!.]*>P6DF<_A+QW/1>PVFX)@L<%J^$IGS)#F%S%.-T8TE
MTR';&O@[:&\B#.64!C4JMM.L4=?6*VL<CX<S"\;?M2_2J9BXV1LE9U4-<U5>
M@E;35:;=.&CFX3AC00FTZ10#864"YA]Y]P>%T'J]B&YTBFN8EDDN8UBJ0@,O
MU5HNNB'J:NZPC,%^(G$&ZER"7N$XKID3]UQX?>\:OOBL/C,<^M\E^GOTR HK
M7.!<.8^#]6X7#\./V/^!"T_OJTP[(PD0)HUOG)9>C;4U^""MX;1OSMVIZ-7=
M#<N,G*)F>VR&@655HK,RUN-0X$1@V(-Q_1=,)B@R!7KSJMD/'CX[&-1J.*_8
M.^1$(^/7&G/X-0 %+&%RN'.!"'P1J5 47F"!@;PA+,;L=R+(N1%@TCB<NPPB
ME8> 6PH=<:"[P:X14I&,Z4"68W4#<M$?0!44_BKS8 O+VO"X;F0\Y^>]E&U;
MIVB3U6LN!T1(0I(L351(V= YLK-,$GDTN_"!9B3[Y*<":^34% UW+V&Z:=35
M1)D:X-E9+.775\P8B9G:9F^UZ31<Y\YZSE>MM1AG:3D:$TM+=O!D$0#>>#G8
MEW(2 #C$(%;YF.H'(CAE8!I">;9W)30$IYI%-.D<5I2K$?MEJX^N%6(WU]_5
MP@=1*MEIQN(*]PH835 C/,9@ 9=6("<!.+_:#R(QMVZT2M(TO@T (7\:AW;(
MS4XL&H@(.6>83B8@8Y@KU!"WXDST#X#<<GJ!M54M"0L.) 6-\5QMH$3[+R.D
M17)>DI^&A]6+6>YM,3*\F@]8EQ35N@B;>>*6 -B6,Z]H@G&K\G0^IM .$,YD
M6H L;>#$ ->G!X<[SUX^A_^.]FE">[(\1=XX1\6C&Z*D *[#=)"@'RJ10^1V
M7$1BGD]T# +.$(.8POCT[., DUC)L@(Q,XF-,</N-\L_VJAI6O^=KY$A+N5Y
MS2]N<1+8"SPK6;?!QZ4B&B&E%94)CT=AOJ"8PI>@Q"J95]18*P/NY=P[VG_4
M@HKH3^AX>0Q8+EO3%0BB/R60'^3=^HM%. \W+,*YI"'%CS/U?A[]%<ZT(7OT
M=QCG1W^+[]G?XD%=+9P[<OUUNS^J)J%1,E:C8R\Q.WC5(7!"JZX[>=QL^N;*
M]%;0')VMY-]Z&C$7XVBO 97QYW7'P*H6 (F8N*RT[U6"WU0IN6@!&D]/+7'"
M.8# ^OI.A?5)W6JMNU<7C9"5#016M0A8T5G %%7AT:O$'+ZMX$?3/I-#^!TF
MVPW:E(O(A5))FNS<I.2&1<<S+GI"E5&\?1X6GM0V.SK?P!#&O*%!FG[[)N44
M7[6559Q"(?]=JAL1:Y=6BOZ?LB ?-&5^CF&9VGEE<R_*W(V..X4)38ZPJ:W@
M'@.)108:AZ:DM)=2H+M[@$&#O*Q8N8$:>AE&7%%62[OAI*6@T+W'.",;K+^"
M?4^XH"+#8K5AF40F\^B;2J+=Q?8)IM_!8O>$ADX(C2T4S'.ZE8)KN^ [C=>?
MO?]1Q1^_!WN_DD412VX<]ZB\??V/=4MLK\VY/MU]12W9+A--IWF*D9&\$FM"
M1S[0,Z; A2!.MDS-"U,5TOC6T?XV.56WO0I@"KQ-IS&\A$WP3+[R8M;CEE@@
M;98]V[:L@C#MOGGP5:&Z)8P\,*]PKP9?3E;<M#8*XAB@6&2;6]KW-9B;%ZC\
M@WWUDQ1U"&S7-R1',6>*$@_5K[.?F=1\RO#VOD)Y [(!O\Q(5$Q(>%DVON#=
MUX$=%]/91@D")Z4%>5*5_^3XX^ FI<YK![1W5#Z@%M2">G$?>7'=NX6X)>08
MIS%)JW0 %@W7HN_"D=BD?E@>5T)E)JT50>1]JZ%A(Y:FKR7(RKS4%1@+3/W]
M?;)V"0!1ZE4,SE?D[Z[ 3KLVEU&,M%$1B3DQQJBYK$/E-K)Y"&QA ]S)6X-U
M8EY'3Q$0?J03$R&R&\E)"]SI%/"$5)JZ=HZ_AR(?^^J6I6\*EV*L+.!P.-)+
M8UVKC>UYKU)XN:$B3/>IXF50F57AD4[+Z9BYP32G2,-;AC_ 9HC4X)DP31*-
M0#:_P\L#IW1VWNDTQ>DHO([O:]) OE&'@4]@Q)<(C!N FT<;I"^=*HPE)<PP
M/K,!T2,^^,CZDU;'<5E<4T4H0,82,$*-@F0GL9F =7-6]T.4\BHNJM% 0DE2
MU!,P:F:)S/*QFMKZ<#TR: \ZM)K6Z*;ROI896#0'B%V1GSH$Z)Z(-*SO#C<]
M/@X_W2 <IL((X%C6%8!"_I'1UQG%1%MSSJ/2B2-DRV,8W\AFT%$ 1_4V,M:L
M1FH(RL*4HJ3P[7@^1=.4<)+:+3A#U7\1LPY4CD9\Q-E; >?= 'O6KZ#:09X$
MPF.MI\1B1HZ.2.8AT0\- \ <E"8V':8E22$ .YO=; LWENX.%+L(;)$@9[>E
M&9*0G^&5H^=*X3] .1CRA8\89#DFAM1KC#;"KGJV2:13+=I<+)Y\9#+JWKN0
MU-:7Y0^K*?UU!7J/5PE'I%?-DJRYGN0M;#='3Z2SQ*K^MYEIN6(=:YB2$L1I
M,L*,Q=":VIAH0F8A SE?:+^$E@-\A&P%79'D?@ZV',!A)LUSW&3(^$ EU=:4
MWBO#V&:W5":=C17V",!2['I'@DTP59YO$C\0M_)Q1>?ZG^?Z^<WN.-'@7&EF
MMP9*D<=RRAC4>>:)L2)+DJL(L =4KO!OXN3 * I$2]#5G<_)#K/<]D0[UN\0
M10XB?JZ>DXH>F4K#$ICQ&W*>A8XZ\U6.)9U"GZ%2MF)A (D+[;7S%Y(TKV1"
M*V%YINLK;+X@G3,L%=?!FS4.3XJ ^$*EONPEZV,.#D,W-9+1RF)> O/]=TEY
M_(*[MW@N@29;S-NY[R3!XT;+O[)C3-+33C%,<56<Y4>Q)7*^HM%F04ZBMLC*
ML"@SZ18*GX)$*4.=L*RTO&U2)1 NL:&/3> ^:^?X6IGRX#2;+Q[R/;Z8"8)/
MIO(&,9$+[E<YLFR:JD%>JT[EI-%@>Z6X, ;7<B;1LCH1QJDI:,U*JT2-+VY1
M#Q_9"M#]0.891G:O=Z]V6S_:DNB?3S<LP6MM>(?3RQ%'\S3D*J>\S 2U.I/4
M-(K=O.*VY>P2CAF4+!FT%T'<[F2:;WO\V,][0-7#I_I+^U@UZF4- PS,BRRC
M4BC3]Z3)UXW&SZ2<!&+":])I <OGXSY.V@O"=0H<)*J8=9O _=7WYOXTXK$J
M1*S"A\J#Y[O/7B!HWLU9(?!/PW/=/ ;@+M("^;%+7M%,_L56N.W7!+0PR62*
MC#UG%925CK8++)Z+6:NA5!%E +U7U%T!5(Q @L:T&:S($?C"2 I3)8*W;9CX
MK/7RV7 +.=6:]:NFT-)LC(5V"W'CO!P.5:AT2,>$'\NI&6(B;IG&W,Z7TY?6
MZQ[T#EH W'EZ,?";D4C4&P,N(V\$\R0#0](2MY!'R%L!7 N85U6 DM)(,G3;
M=P U:8 YH2K>=R/F6<H^T1Q4QEAD;'BT%CL[<GPY1E3(;.-IJR";1;IDL6H:
M@TEBP*%1SZ7R7VSX2&^/ 6W144S-_ "UY@0.GA=TD%]*L"\B]G(#W-N)+O%C
M T378NE#)L22,;F%<T*P5%=5:B>.=75-1"27M?S#DD?%B61YI=BOL6;79ABX
M5>%9#&CX&1X=6Q^"4@H:N'%E.(RE<R7M RBS7DIIZ"ZO$5ZKXJ#.0B0S'8Q<
MJ$Y]&(W^5CJL2+D'4.#J"BN+#GINYXDS@8BEBZD3C5G<RA6U"9G@8U. :Y?G
MU9[.F_J'+IK!7DZ020&B6+5/V[I<U?6\-13MJ>*<?^$T!TI/7<ZD"'8JKW9U
M-HA?T?#MB6(,)5,#3,+8D$:86VJMU8JCW9=:JS@9R_!;"\XJT^W0,.H'^'))
M*NE'K*9^9*NR7;#]AW%JQ!ER/E'$;8B,?^O9=C# &W'Q8ZK^W3+L<BAGZ-VP
M_*'Z6&/B5853PL!RB/E>./\*C";W%.:-[8XHU]PX>C OKJZ0B[G37E9Q@Q73
M5?/2:J2.%;],B:O,:[6*2ZZ>>NMV&Z@T<S%2&YLQ!HVH"@7<<D0=<UO!UGR[
MDE8C3"H=WI:!F(C\I<&.H/#LUG^V_?)M[A^ 3&PJ0QYB\5ZYIF/= /91UZUQ
M#XB)HY3X;9VW+W#V.$]9%.ECO0.!!W@80U2 ;?]NPJ'<"SRUJ+DE$2#>04/1
MI19Z*T4&QS-(DY*UDES"X9*VHVW=?+M^J,UE]?CVWWYZ^N)U<[=KK;-@_F5K
ML:FCA]Z>E+GGZ%3P/!0JYI"9U4L$H-ND1B@H7455_FE?>E3>X3M?(:Z;UTFO
MUISHJ M7;73,8,3EA90N2BE?.H77\D?F=]0;G0NZZ9A)=2QD B-,J"N.*:B_
MYU)2="KGJ7._D6NM:JQA)46BO2"VG\8])Q"&AP%E;0#-OMB@H.15D4YWK+CG
MI-?'EO/=A%-AR'9##QHUY !%O6XZN8PDLG/-+A:OPZKUMC&E6)GGFJ@+*DXG
M!?L@2Z<99A<8SUL.$+-SN:NR.%)B#$4T<^QZQ(AF5L2=*+^!_JC82_K9G-Y,
M9^B$"$NVQ>%A;DR"T:K*BH#&A)VR,)4Q<CA$M4)GC.-8&1Y]5(\0>;N\[][,
MLFTC)F"5N:\UK!8OFY"<]W*#B+?#C>Z]FCN\IN4#->=%R(/1O@91Z24MRWRR
MI%058/6E#B3J#O["?J_%!753:H@=Z\@IE3!,1('BS6M.EY=3H"P9F0Y,7F\Y
MW>Y-5>.]N6OBQ(Z916E5RWJ]YW):NH>3S4Z<I!$KK"+"RV$HA:GY,D";XXC>
MK&F!*I/NFS74 ISR>JC11H,^5<OTZU,O*V^'KK<S'456-I<SX$CUYL^T,O0(
MF$1'_) B;_B'+;<U"5DC5CHTE](QPG"<ZN)8>#K(L-:')#[?&Q&*,I>^'[-R
MD8J>%8?Q_7=^1N8#EJG!KY//<+]167C-;30*X@4QW/D(YW5MP_13OH2I(/I
M^K8F0US%L1QQ0+),9 *B*Y3L@,&A>!M>S:PN/4'M&KXB(SB3V!=,PQ1U/5>B
M8KYRPVX $WZU04SX)'7R<0VX;2BFK!)0M7"U3*Z!\7(U-$QIKN\ \@=;2MDK
MB2J%3KK"6>BJ&1L<T6W.]/M.7:"Z&K_')2RRP_R+\B0][ZYMPJBY"MZ9 T!G
M&LCA/$J,&?!J*C4O<9D![1@6I_]<?,X,@>4/N;4_D!*-\I,ZC8=]DKCT)+)D
M:G,_\:(\[7NRZPS"6(HLGAN'ON>YW@!Z.]A?'X([NHO@VM46J7CRW0J2/;:;
M$@2":?-J:@90L:DFD=4:O2Y02E62>-K3HDSQ;\68H"&_D,G'E:BUR&A3/*@_
MUFUC2[,&\BPT;:<Q0.6J)56BJ=+4*^!1H;(%:LYF6 (':]1ZY4ZB^$RM=Q'>
M7VS#W7]BN]T^MMM= [ED5'?O8A%*E"D5ENV&' A,2='!:"WYI4"9(\PI2=90
M@UB_'?+#B&- $:S"B,1JAMBI8E\"T =6XJ @LQHA11%8UR-BX&*=6(3?JOHF
MQH?Q,DGM N<=X?ZJVVIQ@-8.SR%U&M0T2]$.RQ\Y:?SSV8^<M%]'>H;FF 98
M.AC2J9I*0P^U:P2KLDS>I!@1GG,S[Y89 NNEV2*E*F?.T-'2A](W*"I!9K!)
M#.?.Q&@ <TE-JDVXN0[S<@=Q4V1$:_(Y1(U!>"1=6?[CM2CCFT,^M7O]+EZ'
M<7YU&73^]:G7N;HZQ[LCL)>:N\("'OT:G+4_TR4?']OZ]_YET [^>=W[&O1[
MW?8YWB"!KUQ=GYS!CVZ_A9=ZT)T6/;PGXJ33.>U>?'A$4?7D+9:2T5E[G3$:
M>NA[#=X9(ZO%9,BD*8-")3<B5E&#/:PH7X#4>0[UA:RD+SB(B(<23BP8SK[7
MQ>1CZ80+C<B)Q&I)O*BW2-GIRCP<W:F^ X)7B2Q[LZSK@S5J.G2G8K,>(8EV
MPIVM0YNQ1>CI6![Z]SAIRF+9"'AEXB=F.7/:F=+691//]0N4-L5:LK"-:N8Z
MG2J2)+R)<FSX?$#!?NW?XNP<,D3#=)30Q<OR=DHW'4R$BHE)*HJ2<'$G4ID_
M=*-^1&_"/"Y(3Y]LJ2K9&3]?TQC;G.<5P"P%R&.^?@-#G["VJ5!X!2)?R.#H
M4KN^2&9@JA#2G[ZT :/]8XQM\%3D04"_ WDS29$TR0@\B/\>L04KB&R;?/^H
M%O,'%I>T"92^1NTR[J3T<Y&,2L",QXX^5D-<?(>-[GU>LRVT^-*7".B&YX')
MW-<8P]<]8$PMUI>,H,\;=![>K>^F[B0CS/[DVBWMH'(O8H! Y_:"^*(N,H5S
M;YMW]5.MI@\Y(Q4]5ED:6R^6<\(AE]#I=4#KU>S/3<#V-6JL<;=<$U16MQ[-
M4KN)SA4VWJF&/!4_Z]6_XP0T+8H[KC]^K%]Q\9.WED.H:OKW#1CF22$R%<\7
M+AUA+=@E4*.F"K(K(8QJZ<I/<Y6)T75;IC,J^B1 >R;'-HI)=WMW/6KHTBT;
M>44U9W])9!=0X]4FH,;:57XR:KC8"@#5X 0'=-,P%#FG8E.4TER1PSWT3+.+
M O.Y2PXNLJ2Q#=.T5 ,SGC@13<.J4]-5*>9K24JM^9O->+[*&C^0=%,=-?&+
MYP8UIB+?&#P(UPD/F$4(ZE<9:B.VGFM0.SV39&1J3[0KL59RL=!W>3,.)UJG
MPW%$6D_5<'=^Z?)(G\E;(MX4H,MU KH3FO<'NHM@&];H>"#5I[O*7)M;6!]=
MYZUFM9 XV=RHB;LW=;>#>LJ0SC6TXZ!Q8'L5+9_1&11(_&,U]=((G7C>%%0:
MK@\J/=_=/_"%K [YF[R&!'O$DM"4M\AIL2JA=I\8)[Q;'Z;IW.15334GRH<B
M#DL=QB(GMTF3;]'=E*-$MS+P<MA;U'$CP3PL.'C)W=6-_\8DU^O4>UP!-IO:
M,=\;R8"+UTM'(9!9$W8FXR$Z;JS4]VHTS>"L5";8((13[75 K-IE2N15* %L
M6I6PG>[@,!-<(8B*0;7_5;V>8:%6;5-0?;0^J&Y$5:548N%F.$T Z(58DJ/?
M>![VHCZMIM92#>_!GF=>C:1-@6#W"1>Q)CXO3)WCTFBW#L.813I>_*? I/'Z
M81('_TCOO!%Q:3&%W1MS>X$%E9>5"3H.V#8,1:)/&@XYXHM%Z+30KXPWFV[,
MJ7SWHLZ'=X;@DB.ONV&E*S5P[C 6:D(R#0D@MCVGZY(M$A,QLF%C;KG%#O%J
M1TLS.&<%P3>E(>X*5IA'3.O>4,=/EG?0YGX_S@^_..T]FE8V7(^[6/F\50M!
MSH MYBE*9&Y'7*UGPJ[]\" &%8:ZB5 L!O EIA1O&QG9> @C<S52LW?-#[)C
M3P:1UPKJ3:O;VOH)/C94S@=L+[*EDR." J61NB&L*B6LC8+7RJ=XD0M&ETR#
MVB'C"D5)%W)?Z)Y:G)*=S_ 3;]D%A<9,YF?KN.MCJ_$P'Q!F4,HZB/Q^F%9_
MIS[FDJ6"_(;)SC*:5_,'FK!^4[C,+VO)99P6 0@!G!#;30@5EYP]O^RVA0^I
MB//Z30OK>>MGYW:L!GC1U6.ZY;?]HDCL(O K^>#6@YA8JW'8!9\A\?0MJJ"=
MIMF"0 "@<JO)2"?K+2("EW>@Z<SW>H\5H%2T[=T"XSS**5]B8M)\F'U6/%U;
MNBI&K')1NZ(,;A.^[9G@KG3"M2T1@ Z<28E(CA]%QEJO9+VV3*W=0F,3K]"^
MF1QTJ_M"NU U% )[XF[.)G7==!5NZ.MKF^EK?8M26R)V\@N7S# %W$PQF)]$
M)%88^@8K9J:305/C8++_&*$XRUZ8T0!@.J4>$YYA7]19V"37^]8E/^]?1F&G
MWF;!-5Q5[/T;">)'?B7_?/XCO_+7L>@'<-3OVE7\'LW$#6O>%,WGV_IH/K[5
M:Z_CTNY""WC=F+05V%(^K(!(J NDB&Y([\4FQ*K>$N6;>1OSM288HM4EW=5R
MD?O[4]*L\04RNY@O:>^EUUR8>2T(@0W C'A],,/HQ#7"-*W1X-AU,AN:A-C!
M=FE\ 1TD-N?/PR-*DJL@4HY- GXM;N@N1H7#.IU7W9"SM D)/VMT'<B="3^G
MHA#8&/E&A(_;*W[]S_7[)^K\EI9I)@K9][,$F>3E+:;,J2*>Z\NUQ&2@1JA]
MQGSUB/1ND(;MZ"Z.+2S695-']]X@79?:@V5IHD*7O<%712Y1=EW6,.*:\-OE
MW5D(/- ^IDE*SJ"\<FG=JI!HM77*,C^5B7]:3<<TR<2>D-AD%!?!?BBM*7%3
M,^Z7D(C1@YG=)N#Y=\\Z^FUX[JY>-'A._(P\B U=VY?%?FS0F^I^L)^6=O<[
MA%4)&<9<T#O @C]OH#M#JDV3XMWK+9@-[[0SN=^X/B"JZ1@+5;@;8,O>63M0
M8&FV%CIW.]+#^^7T9:^X3/.^:7QF4N\I*/9+.@C(V\A^57<A+/>_2^E:O-R4
MNU33^T#KI[8ZF'0%5D*;$ZTJN<8U![[QK',&%H:88>$Q_L8W+[7<'4RX&^^>
M<94T F\H;M"M\?M1+=_;KKT"* E-E_)-H-(US E;29.D:9@$,/\".W/+REAE
MD2FKR'.5V[1?=T>RUE/M(>L\!+%8>T_G7.G20]RWVC.WD6\ ):BI\AOLT,IU
MXJJY(W()BE*'R8S[0<HXES,4P:UJ :V;0+]FWG(5B"Z3GF3FE/4S[A&#8X&%
M5]@&T";7?LE:[K-GO_TG5A*A7U, ,\L]XP!9E\ZQUA4QML&-N^%U"? &G/6)
M:OT2@<D.BG$)YT:E_F6&_@+__IL;6>]XW-SDV<AZ71.3ZM[1WLIF8Q6..19%
M>%9Y?4O/&,_U_;LNK+S-P'@XBW$NZA8M"(!'RA7&%$GB^$J6A=H=VI:]+@'=
MN]]?;[D#BRK4S0W(DYAZ.*,W"/]%YX1?PFC7Z2_2H]W?=WTU+&]5\\AO%'!%
MAKE%?]=3NED-R$%>FHHQJO[-<QTR=@,IW9S7;9S2W2=&X2:H4:+($'5M3'L"
M#(LR,=.ZN-;-.3+0,IE*H<A=YZHPS8M6C<*\FK'?B=@\@*+^,L-@=(M!2XMG
M[Y)9/?XU-,MG2M.-M9I\0#HWD9J-FN.5M<-];RIX_</0(1&:!V^G"IU7<2%6
MI!>IW1XFR:QIO=50\)W\4H/]UP/Z ;H&6_*@S8V28[RU56;\B4I0"SP^>OX'
MJ"/-!>:=BU.J"?_0ZW0^=B[Z]]W4OEUQ@X_]KQO\>+'QP8]%5'TLS/S76?==
MM^_"YO?7Z7^@I/?SY:]#R;U!&LWAGW$QB=_^/U!+ P04    "  D0ZA6AX^R
M)]<'  "H*0  %@   &MR>7,M,C R,S S,S%E>#,Q,2YH=&WM6FMSV[82_7Y_
M!2K/39T9/:B7'[+C&5M6)IJF=FHK3?OI#DBN)(PI@@5 R;J__AX E"5;=N,V
M22W[)C.120"[V,4>GET0//SA]+P[^/U#CXW-)&$?/IZ\[W=9J5*K?6IV:[73
MP2E[-_CY/6M5@SH;*)YJ881,>5*K]<Y*K#0V)NO4:K/9K#IK5J4:U087-:NJ
M54NDU%2-35PZ.K0M^"4>'_WK\(=*A9W**)]0:EBDB!N*6:Y%.F*?8M)7K%(I
M1G5E-E=B-#:L$32:[)-45V+*?;\1)J&CA9[#FK\_K+E)#D,9SX\.8S%E(GY3
M$JV=G;#9W(G#QOY>J]%JA2W:;]7#O8#OQ?6]H/V?.HRL8;B7T6:>T)O21*25
M,=GY.ZU&=;>=F8.9B,VX4P^"?Y?<T*/#H4P-YE.0]Y=>S9HR0]>FPA,Q2CO.
MI9(7771',I&JLQ6X?P>VIS+D$Y',.S\.Q(0T.Z,9NY 3GOY8U@A#19,20S]0
MB_\2;()Y[G96F P]B4AIX4*]88WN78]%* QKUJOUVQ:O.L[5"+X;F4$*:E=L
MC[#8I+ZY\;OW&M_M70SZ;_O=XT'__(R=OV7==_W>6];[K=?]..C_VD,3>GL7
M#SJV*8Y\^'AQ^?'X;, &Y^RRUW7N-(.&=6GPKL<NCR].CL]ZEY7SW][W?F?'
MW8'M:01!X[$A>R)T]<OL)R7TF%U6_47*TS*+2!DQG#,SYN;55GOOX#%>[&/"
MC,<Q:*&2T-!TFCL+)(HT1O Z%=OR1([6JPL?_OG9;R]+8Z_:MLO09V,^):9H
M*F@&0C5CH=DO.5= >3)G%Y1)99A,V5NI)J^VZCO!03VH_.*OY!#AFFO#$W8B
MI*%H7&;]-*HB6OLO(%J-C8O6"=>($:(QF;.K5,X2BD=4]D%3/E2QA FI1(K$
M#%RDC*=SEJ=&Y00/D#1=_D3D.)O@3@D$;\@C-"DF)Z!X(_VXM0$I1:0U5W,[
M9,*O"/.NZ-1HBV$,IDQ<\L4<=D D%)(MAJ40AR4Q*38;BVC,=&Y_EO(S4E0H
ML0Y,A$Z0E6V"GPDSAH,ZH\@9:/5F,$W&<',*L9B%\]5E>"$(;#X?!!+*+KM@
MMGLH0."1!<XRNF4 $8(8J%;Z13H$KW!;'.(Z2O(8XD#02BC+0)^P7)0! !:[
M%M-)L@1G@0OMC%BJ!OYC5W66[8@\P0 @4@(V;CKM[(DXLLXPD3.]@*NBD= &
M):MAW#9ZNV%E>05U>F',FK4O!'BMC0/>X%9L7FWM->J[![H 5%$J6*J0PZ'
M[;9^[0+79UR1@PA"+L*$;"@9 9=A@D+#2MAA$S"E94M['PL=)5+GD+,<JF3B
ML9(I&5&,9LVV 8V8@#4?_]YU-.;IB-@QZ.DB3T@7F;+)*_7V-KWVMU!2M+=C
MWUYT6)/N8@\3VLS\]PN?W<8&X8EO#I[VJ\&N78=3TBCH$4"7ACX?]++-D!'/
M]>-%;*H*"4@I9O+)3^8*"D D4Z$=/6$4>-/JL:7NDMA6R5%1@@N@L\A^2ZB4
M"^*TG0(D!UNT3$3L]L<Z#[6(!5?".B!\CG;$G5I-N;9YTSU#VB591V;8@,,@
M[(R=4(9:4$1YPBT'PRUGQ#+_0L)G\]4B!%<AV8&@2<A3_/=I<:-@'&X.C M:
M[$UYDKM0VYC0<(A,**:4HE);SV@WK/D(Z/K;^Y.<@S $ 3OM4VDH<_.P!8]Y
MN/C-:+)UPO#S-1X+%[6(>QS)KP3L<6"S$SQ_P$6; [@;WO3!7 >%W6@4>=#U
MW(L\85^?I+X\LT!@-K0K59O7Y3D&7"BC*%<V]"O$<X_6B=0&[?;E#'3I"(K^
M\'M8MOV R! 8QJ;BSNC"<)2%Y/9(=ON4YC=VO?96C;F^86F0(G>8I]AE"+<>
M7,L4!<8<.Z$K2HH-TYWQY2]>HB_#^4;5F^W-P?F7UION?4J\>$C*2Y:RI+D*
MU"5A6:@].NKE]1+@QCJ.,L!(Y=G5CG$-4#G!SMX0_4E*""57CG=C ?N<DFW
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MFW61SWPU6/SZ;QC=UY1'_P-02P,$%     @ )$.H5FWE_:?"!P  @RD  !8
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MT6IO7+2.N4:,$(W)G%UF<I92=$%5'S3E0Q5)F)!)Y$B,P$7&>#9G16940?
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M<RTR,#(S,#,S,5]D968N>&UL4$L! A0#%     @ )$.H5B<2W7%+L   9.,
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M P!K<GES+3(P,C,P,S,Q97@S,C$N:'1M4$L%!@     ,  P )@,  &#6 P
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
